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ABSTRACT 
Jason H. Melehani: Mechanisms and consequences of Staphylococcus aureus Leukocidin AB-
mediated activation of the host NLRP3 inflammasome 
(Under the direction of Joseph A. Duncan) 
The NLRP3 inflammasome is a critical innate immune sensor implicated in the 
pathogenesis of dozens of infectious and non-infectious diseases. Activation of the NLRP3 
inflammasome causes IL-1β and IL-18 secretion and necrotic cell death. Staphylococcus aureus 
is a common cause of infections in humans. S. aureus produces a family of pore-forming toxins 
that are cytotoxic to human immune cells. One recently discovered pore-forming toxin, 
Leukocidin AB, is the focus of studies herein. 
 Leukocidin AB is a human-specific, pore-forming toxin that binds CD11b to initiate pore 
formation. In order to characterize the mechanism of Leukocidin AB cytotoxicity and determine 
its significance, we evaluated the effects of Leukocidin AB on primary human monocytes and 
THP1 monocytic cells. Leukocidin AB was one of the most potent toxins in killing primary human 
monocytes. In THP1 cells, knockdown of NLRP3 or ASC by shRNA diminished Leukocidin AB-
induced cytotoxicity and prevented secretion of IL-1β and IL-18. We also characterized the 
NLRP3 inflammasome in bacterial survival during phagocytosis. When S. aureus was 
phagocytosed by THP1 cells, LukAB triggered IL-1β secretion and cell death. shRNA-mediated 
depletion of NLRP3 or ASC suppressed IL-1β secretion but had no effect on Leukocidin AB-
induced cell death. These data suggest that a separate mechanism is responsible for triggering 
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cell death when Leukocidin AB binds CD11b on the phagosome membrane instead of the 
plasma membrane.  
We also initiated studies to characterize the role of kinases and phosphorylation in the 
response to Leukocidin AB. Using multiplex inhibitor bead chromatography and quantitative 
mass spectrometry, we identified eight kinases that rapidly decrease in activity during 
Leukocidin AB exposure. We demonstrated a role for Death-Associated Protein Kinase in the 
response to Leukocidin AB by showing that its inhibition suppressed Leukocidin AB-induced 
cytokine secretion and cytotoxicity. And finally, we used a novel transfection method for 
overexpressing mutant proteins in THP1 cells to show that the NLRP3 S198D/S201D mutant 
could spontaneously activate NLRP3 inflammasome signaling. 
In total, these studies make significant contributions to the understanding of S. aureus 
pathogenesis and the regulation of innate immune NLRP3 inflammasome signaling in response 
to a human specific, S. aureus pore-forming toxin. 
 
 
 
 
 
 
 
 v 
 
To my dear family, friends, and mentors for their unwavering support   
 vi 
 
ACKNOWLEDGEMENTS 
 I would like to acknowledge and thank the directors of the UNC Medical Scientist 
Training Program past and present, the faculty of the Pharmacology Department with whom I 
interacted, the members of my thesis committee, the numerous faculty and staff at the 
University of North Carolina with whom I worked with, my collaborators at the University of 
North Carolina Chapel Hill and New York University, my colleagues in the Duncan Lab, my 
colleagues in the Medical Scientist Training Program and Pharmacology Graduate Program, the 
Infectious Disease Society of America for funding support, and my family and friends. 
 vii 
 
TABLE OF CONTENTS 
 
LIST OF TABLES .............................................................................................................................. xiii 
LIST OF FIGURES ............................................................................................................................ xiv 
LIST OF ABREVIATIONS.................................................................................................................. xvi 
CHAPTER 1: Discovery, activation and regulation of the NLRP3 inflammasome ........................... 1 
1.1 A general overview of NLRP3 inflammasome form and function ...................................... 1 
1.2 Clinical relevance of NLRP3 inflammasome signaling ........................................................ 3 
1.3 Interleukin-1β-driven monogenic hyperinflammatory fever disorders 
are caused by mutations in the NLRP3 inflammasome pathway ................................. 4 
1.4 The NLRP3 inflammasome is a master innate immune sensor .......................................... 7 
1.5 Cautions in interpreting NLRP3 inflammasome research................................................... 8 
 1.5.1 Studies frequently overlook important outcomes of NLRP3 inflammasome 
activity ..................................................................................................................... 8 
 1.5.2 Dozens of activators and regulators complicate a comprehensive 
model for NLRP3 inflammasome activation ......................................................... 11 
1.5.3 Commonly used Caspase 1 knockout mice are also Caspase 11 deficient .............. 12 
1.6 Priming the NLRP3 inflammasome for activation ............................................................. 13 
 1.6.1 Pattern-recognition receptor signaling upregulates transcription of 
NLRP3 inflammasome components ...................................................................... 13 
 1.6.2 Negative feedback loops respond to prolonged priming to reign in 
NLRP3 inflammasome signaling ............................................................................ 18 
 1.6.3 Kinase-mediated post-translational priming regulates NLRP3 
inflammasome activity .......................................................................................... 22 
 1.6.4 Caspase 8 contributes to transcriptional and post-translational NLRP3 
inflammasome priming ......................................................................................... 25
 viii 
 
 1.6.5 Multiple ubiquitination signals regulate NLRP3 inflammasome priming and 
protein degradation .............................................................................................. 28 
1.6.6 Post-transcriptional regulation of NLRP3 inflammasome mRNA stability .............. 32 
1.6.7 NLRP3 inflammasome signaling without priming .................................................... 33 
1.7 Critical features of NLRP3 inflammasome activation ....................................................... 34 
 1.7.1 Potassium efflux is a universal requirement for NLRP3 inflammasome 
formation .............................................................................................................. 35 
1.7.2 Mitochondrial disruption triggers ROS production ................................................. 37 
1.7.3 Lysosome dysfunction liberates the cysteine protease Cathepsin B ...................... 43 
1.7.4 Endoplasmic reticulum dysfunction disrupts protein folding ................................. 47 
1.7.5 Calcium acts as a second messenger ....................................................................... 49 
1.7.6 Ubiquitination acts as a platform for regulator binding .......................................... 58 
1.7.7 Phosphorylation controls inflammasome oligomerization ..................................... 62 
1.7.7.1 Syk kinase couples C-type lectin domain family members to  
NLRP3 inflammasome signaling ...................................................................... 62 
1.7.7.2 RIPK1/RIPK3- and NLRP3-dependent necrosis overlap .................................. 65 
1.7.7.3 Kinases have a wide ranging role in regulating the NLRP3 inflammasome ... 68 
1.8 Canonical inflammasome activators: nigericin, ATP and monosodium urate ................. 74 
1.8.1 Nigericin is a potassium ionophore that activates the NLRP3 inflammasome ....... 75 
1.8.2 Extracellular ATP triggers NLRP3 activation by binding P2RX7 ............................... 85 
1.8.3 Monosodium urate disrupts lysosomes to trigger the NLRP3 inflammasome ....... 97 
1.9 Consequences of NLRP3 inflammasome signaling in pulmonary diseases .................... 105 
1.9.1 The NLRP3 inflammasome is a sentinel in pulmonary infections.......................... 108 
1.9.1.1 NLRP3 inflammasome activation helps clear respiratory viruses ................ 108 
1.9.1.2 The NLRP3 inflammasome is differentially required for clearing 
extracellular and intracellular bacterial infections ....................................... 110 
1.9.1.3 The NLRP3 inflammasome responds to acute and chronic  
fungal infections............................................................................................ 113 
 ix 
 
 1.9.2 Chronic obstructive pulmonary disease is influenced by long term NLRP3 
inflammasome stimulation ................................................................................. 115 
1.9.3 NLRP3 may contribute to airway hyperreactivity in asthma, allergy  
and obesity .......................................................................................................... 117 
1.9.4 The NLRP3 inflammasome is critically activated in acute lung injury ................... 122 
1.9.5 The NLRP3 inflammasome drives fibrotic changes in pulmonary fibrosis ............ 126 
 1.9.6 NLRP3 inflammasome signaling may predict risk of bronchopulmonary 
dysplasia in preterm infants ............................................................................... 129 
1.10 Concluding remarks ...................................................................................................... 130 
REFERENCES  ......................................................................................................................... 131 
CHAPTER 2: Inflammasome activation mediates tissue-specific pathogenesis in  
Staphylococcus aureus infection ..................................................................................... 154 
2.1 Introduction .................................................................................................................... 154 
2.2 S. aureus factors that activate inflammasomes .............................................................. 155 
2.3 Inflammasomes that are activated by S. aureus ............................................................ 160 
2.4 The role of inflammasomes in S. aureus infections ........................................................ 169 
2.4.1 The NLRP3 inflammasome responds to hemolysins to control S. aureus  
dermal infections ................................................................................................ 169 
2.4.2 S. aureus hijacks the NLRP3 inflammasome to exacerbate lung infection  
pathology ............................................................................................................ 173 
 2.4.3 Microglia activate NLRP3 in vitro but depend on AIM2 for survival in  
S. aureus brain abscesses .................................................................................... 177 
2.4.4 IL-1β signaling is critical in soft tissue infections ................................................... 179 
2.5 How host inflammasomes can affect other immune processes .................................... 179 
2.6 Integrating inflammasome studies to improve patient care .......................................... 182 
REFERENCES .......................................................................................................................... 184 
CHAPTER 3: Staphylococcus aureus Leukocidin A/B (LukAB) kills human monocytes by  
co-opting host NLRP3 and ASC when extracellular, but not intracellular ...................... 192 
3.1 Introduction .................................................................................................................... 192 
 x 
 
3.2 Materials and Methods ................................................................................................... 195 
3.2.1 Ethics statement .................................................................................................... 195 
3.2.2 Mammalian cell lines ............................................................................................. 195 
3.2.3 Purifying primary CD14+ human monocytes ......................................................... 196 
3.2.4 Bacterial strains, culture conditions and generating mutants .............................. 196 
3.2.5 Purifying toxins form S. aureus .............................................................................. 197 
3.2.6 Collecting culture filtrates ...................................................................................... 197 
3.2.7 Transmission electron microscopy ........................................................................ 198 
3.2.8 Evaluating cell death by lactate dehydrogenase release ...................................... 198 
3.2.9 Evaluating cell death by propidium iodide staining ............................................... 199 
3.2.10 Measuring cytokine secretion by AlphaLISA ........................................................ 199 
3.2.11 Measuring Caspase 1 activation with FLICA ........................................................ 200 
3.2.12 Immunoblot analysis ............................................................................................ 200 
3.2.13 Measuring THP1 surface CD11b levels ................................................................ 201 
3.2.14 Evaluating infection assays by flow cytometry .................................................... 201 
3.3 Results ............................................................................................................................. 205 
3.3.1 S. aureus kills human monocytes in a LukAB dependent manner ........................ 205 
3.3.2 LukAB kills human monocytes by engaging its cellular receptor .......................... 209 
3.3.3 LukAB-induced cell death displays necrotic features ............................................ 213 
3.3.4 LukAB induces activation of Caspase 1 in human monocytes ............................... 217 
3.3.5 NLRP3 and ASC are necessary for LukAB-induced cytokine 
secretion and necrotic cell death ....................................................................... 220 
3.3.6 Caspase 1 is required for LukAB-induced cytokine secretion ................................ 223 
3.3.7 LukAB promotes S. aureus escape from within human monocytes 
independent of NLRP3 or ASC, but dependent on CD11b ................................. 226 
3.4 Discussion ........................................................................................................................ 230 
REFERENCES .......................................................................................................................... 234 
 xi 
 
CHAPTER 4: Novel approaches to studying kinase-dependent regulation of  
the NLRP3 inflammasome .............................................................................................. 239 
4.1 Introduction .................................................................................................................... 239 
4.2 Materials and Methods ................................................................................................... 242 
4.2.1 Mammalian cell lines ............................................................................................. 242 
4.2.2 Purifying LukAB from S. aureus .............................................................................. 243 
4.2.3 Evaluating cell death by propidium iodide staining ............................................... 243 
4.2.4 Measuring cytokine secretion by AlphaLISA .......................................................... 244 
4.2.5 Measuring Caspase 1 activation with FLICA .......................................................... 244 
4.2.6 Multiplex inhibitor bead chromatography ............................................................ 244 
4.2.7 iTRAQ labeling ........................................................................................................ 245 
4.2.8 Mass spectrometry ................................................................................................ 245 
4.2.9 Exploratory statistical analysis of MIB/MS results ................................................ 246 
4.2.10 DAPK inhibition experiments ............................................................................... 246 
4.2.11 Site directed mutagenesis of NLRP3 .................................................................... 246 
4.2.12 Cloning of NLRP3 mutants into T7 expression vector ......................................... 247 
4.2.13 In vitro transcription of capped and poly-adenylated mRNA .............................. 247 
4.2.14 Transfection of mRNA into THP1 cells ................................................................. 248 
4.3 Results ............................................................................................................................. 248 
4.3.1 LukAB causes rapid NLRP3 inflammasome activation and cell death ................... 248 
4.3.2 MIB/MS identifies 344 kinases expressed in THP1 cells ........................................ 252 
4.3.3 Eight kinases are modulated in response to LukAB intoxication ........................... 252 
4.3.4 Inhibiting DAPK suppresses LukAB cytotoxicity and IL-1β and IL-18 secretion ..... 255 
4.3.5 mRNA transfection of NLRP3 S198D/201D into THP1 cells causes 
spontaneous IL-18 secretion not seen in S198D single mutant ......................... 256 
4.4 Discussion ........................................................................................................................ 259 
REFERENCES .......................................................................................................................... 264 
 xii 
 
CHAPTER 5: Concluding thoughts and future directions ............................................................ 267 
APPENDIX A: Functional amyloid signaling via the inflammasome, necrosome and  
signalosome: new therapeutic targets in heart failure .................................................. 271 
A.1 Abstract ........................................................................................................................... 271 
A.2 Introduction .................................................................................................................... 272  
A.3 Misfolded proteins in cardiac disease ............................................................................ 272 
A.4 Protein folding, preamyloid oligomers, and aggregation ............................................... 275 
A.5 Protein aggregates, proteotoxicity, and heart failure .................................................... 278 
A.6 How endogenous systems prevent protein misfolding .................................................. 281 
A.7 Pharmacological chaperone therapies ........................................................................... 282 
A.8 Amyloid proteins, heart failure, and activation of the inflammasome .......................... 295 
A.9 Amyloid proteins, heart failure, and activation of “functional  
amyloid”: Necrosome ............................................................................................... 299 
A.10 The COP9 signalosome enhances protein degradation to reduce 
the misfolded protein burden .................................................................................. 300 
A.11 Summary: The structural continuum between functional and pathological 
amyloids and the significance in heart failure .......................................................... 304 
REFERENCES .......................................................................................................................... 308 
 
 
 
 
 xiii 
 
LIST OF TABLES 
Table 1.1 – Kinases analyzed in NLRP3 inflammasome research ................................................74 
Table 3.1 – Staphylococcus aureus strains ..................................................................................203 
Table A.1 – Clinical studies investigating tafamidis and siRNA TTR in 
transthyretin-associated (amyloid) cardiomyopathy ........................................................285 
Table A.2 – Clinical studies investigating doxycycline in transthyretin-associated 
(amyloid) cardiomyopathy ...............................................................................................291 
Table A.3 – Clinical studies investigating ECGG in primary cardiac amyloidosis 
and Alzheimer’s disease ..................................................................................................293 
Table A.4 – Proteins forming amyloid as part of their functional role in cellular 
responses to the environment ...........................................................................................307 
 
 
 
 
  
 xiv 
 
LIST OF FIGURES 
Figure 1.1 – TLR signaling triggers NLRP3 inflammasome transcriptional priming ...................17 
Figure 1.2 – Negative feedback loops limit NLRP3 inflammasome priming ...............................21 
Figure 1.3 – Kinases in non-transcriptional priming of the NLRP3 inflammasome .....................24 
Figure 1.4 – Caspase 8 is critical for transcriptional and post-translational NLRP3 
inflammasome priming ......................................................................................................27 
Figure 1.5 – Ubiquitination regulates NLRP3 protein levels and activity .....................................31 
Figure 1.6 – Accumulation of mitochondrial damage activates the NLRP3 inflammasome ........42 
Figure 1.7 – Lysosomal disruption contributes to NLRP3 inflammasome signaling ....................46 
Figure 1.8 – TLR signaling may shift TAK1 between priming and NLRP3  
inflammasome roles .........................................................................................................103 
Figure 2.1 – S. aureus pathogen-associated molecular patterns and virulence factors 
activate inflammasome priming and signaling ................................................................156 
Figure 2.2 – NLRP3, NLRC5, NLRP7, AIM2 and other inflammasome-like signaling 
is activated in response to S. aureus.................................................................................161 
Figure 2.3 – NLRP3 inflammasome signaling plays unique rolls in skin and lung infections....176 
Figure 2.4 – Inflammasome signaling upregulates γδ-T cells and a TH17 response ..................181 
Figure 3.1 - Staphylococcus aureus LukAB induces cell death in human monocytic cells ........207 
Figure 3.2 – LukAB recognizes CD11b on human monocytes to potently induce cell death .....211 
Figure 3.3 – LukAB induces necrotic cell death and secretion of pro-inflammatory  
cytokines IL-1β and IL-18 ...............................................................................................215 
Figure 3.4 – LukAB is a potent activator of Caspase 1 ...............................................................218 
Figure 3.5 – LukAB activates the NLRP3 inflammasome leading to cell death  
and cytokine secretion......................................................................................................221 
Figure 3.6 – NLRP3 and ASC contribute to S. aureus culture filtrate-mediated 
cytokine secretion and THP1 cell death...........................................................................222 
Figure 3.7 – Media supplementation with KCl inhibits LukAB-mediated FLICA-1 
activation and cell death...................................................................................................223 
Figure 3.8 – Genetic or pharmacologic disruption of Caspase 1 blocks LukAB-induced  
cytokine secretion but not cell death ................................................................................224 
 xv 
 
Figure 3.9 – LukAB produced by extracellular or phagocytized S. aureus kills 
human monocytes ............................................................................................................228 
Figure 4.1 – LukAB intoxication leads to rapid NLRP3 inflammasome activation, 
mitochondrial depolarization and cell death ....................................................................250 
Figure 4.2 – Mitochondrial depolarization is not blocked by extracellular potassium 
or shRNA-mediated depletion of NLRP3 or ASC ...........................................................251 
Figure 4.3 – Kinome analysis by MIB/MS identifies 344 kinases, 8 of which are 
significant changed at 10 separate time points ................................................................254 
Figure 4.4 – DAPK inhibition blocks LukAB-mediated IL-1β and IL-18 secretion 
and cell death in THP1 cells ............................................................................................255 
Figure 4.5 – GFP mRNA transfection efficiency is high and well tolerated in THP1 cells ........258 
Figure 4.6 – Phosphomimetic mutation of NLRP3 S198 and S201 leads to  
spontaneous NLRP3 inflammasome activity ...................................................................259 
Figure A.1 – Native, non-native, aggregates, and amyloid protein structures and 
the stressors that drive them .............................................................................................276 
Figure A.2 – Protein aggregate and amyloid stimulate cellular dysfunction ...............................280 
Figure A.3 – The NLRP3 inflammasome is an amyloid-like fibrillar cytokine-processing 
platform, which senses amyloid and contributes to worsening heart failure ...................296 
Figure A.4 – Cullin-RING ubiquitin ligase (CRL) activity is regulated via 
neddylation and deneddylation ........................................................................................303 
Figure A.5 – Targeting pathological and functional aggregates in heart failure .........................305 
 
 
 
 
 
 
 
  
 xvi 
 
LIST OF ABBREVIATIONS 
 2-APB   2-aminoethoxydiphenyl borate 
 3-MA   3-methyladenine 
 ADAM10  A disintegrin and metalloprotease 10 
 ADCY   Adenylate cyclase 
 AIM2   Absent in melanoma 2 
 AL   Amyloid light-chain amyloidosis 
 ALI   Acute lung injury 
 ANOVA  Analysis of variance 
 AQP   Aquaporin 
 ASC   Apoptosis-associated speck-like protein 
 BAL   Bronchoalveolar lavage 
 BLM   Bleomycin 
 BMDC  Bone marrow dendritic cells 
 BMDM  Bone marrow-derived macrophages 
 BPD   Bronchopulmonary dysplasia 
 BSA   Bovine serum albumin 
 BTK   Bruton’s tyrosine kinase 
 C5aR   Complement component 5a receptor 1 
 CA-MRSA  Community-acquired methicillin-resistant S. aureus 
 CaM   Ca2+/Calmodulin domain 
 cAMP   Cyclic AMP 
 CANTOS  Canakinumab anti-inflammatory thrombosis outcomes study 
 CaOx   Calcium oxalate 
 CAPS   Cryopyrin-associated periodic syndromes 
 xvii 
 
 CARD   Caspase activation and recruitment domain 
 CAS   Casamino acids 
 CASR   Calcium sensing receptor 
 CCCP   Cyanide m-chlorophenyl hydrazine 
 CCR   C-C motif receptor 
 CD11b   Cluster of differentiation 11b 
 CFR   Code of Federal Regulations 
 CHOP   C/EPB homologous protein 
 CINCA  Chronic infantile neurological cutaneous and articular syndrome 
 Cm   Chloramphenicol 
 COP9   Constitutive photomorphogenesis mutant 9 
 COPD   Chronic obstructive pulmonary disease 
 CR3   Complement receptor 3 
 CREB   Cyclic AMP-responsive element-binding protein 
 CRL   Cullin-RING-ligase 
 CS   Cyclic stretching 
 CSN   COP9 signalosome 
 CTSB   Cathepsin B 
 CXCR   CXC chemokine receptor 
 DAPK   Death-associated protein kinase 
 DPI   Diphenyliodonium 
 dsRNA  Double-stranded RNA 
 DUB   Deubiquitinating enzyme 
 EGCG   (-)-epigallocatechin-3-gallate 
 ER   Endoplasmic reticulum 
 xviii 
 
 FACS   Fluorescence-activated cell sorting 
 FADD   Fas-associated protein with death domain 
 FAP   Familial amyloidotic polyneuropathy 
 FBS   Fetal bovine serum 
 FCAS   Familial cold autoinflammatory syndrome 
 FEV1   Forced expiratory volume, 1 second 
 FLICA-1  FLICA-FMK Alexa Fluor 660 
 FMK   Fluoromethyl ketone 
 GFP   Green fluorescent protein 
 HALI   Hyperoxic acute lung injury 
 HBSS   Hank’s balanced salt solution 
 HDAC   Histone deacetylase 
 HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
 HIES   Hyper IgE Syndrome 
 HIF1α   Hypoxia-inducible factor 1-alpha 
 HKSA   Heat-killed S. aureus 
 Hla   Alpha hemolysin 
 Hlb   Beta hemolysin 
 Hld   Delta hemolysin 
 HlgAB   Gamma hemolysin AB 
 HlgCB   Gamma hemolysin CB 
 HMGB1  High mobility group box 1 protein 
 HRP   Horseradish peroxidase 
 HSP   Heat shock protein 
 HV   High tidal volume 
 xix 
 
 IAP   Inhibitor of apoptosis proteins 
 IFN   Interferon 
 IKBKE  Inhibitor of NF-κB kinase subunit epsilon 
 IL   Interleukin 
 iNOS   Inducible nitric oxide synthase 
 IRAK   IL-1 receptor-associated kinase 
IRB   Institutional review board 
 IP3   Inositol 1,4,5-trisphosphate 
 LAC   Los Angeles County 
 LDH   Lactate dehydrogenase 
 LLMe   Leu-Leu-OMe 
 LLO   Listeriolysin 
 LOF   Loss of function 
 LRR   Leucine-rich repeat 
 LT   Lethal toxin 
 LTA   Lipoteichoic acid 
 LUBAC  Linear ubiquitin chain assembly complex 
 LukAB  Leukocidin AB 
 LukED  Leukocidin ED 
 LV   Low tidal volume 
 MAC   Membrane attack complex 
 Mac-1   Macrophage-1 antigen 
 MAPK   Mitogen-activated protein kinase 
 MAVS   Mitochondrial antiviral signaling 
 MCU   Mitochondrial calcium uniporter 
 xx 
 
 Mdm2   Mouse double minute 2 homolog 
 MDP   Muramyl dipeptide 
 MOI   Multiplicity of infection 
 MRSA   Methicillin-resistant S. aureus 
 MSU   Monosodium urate 
 mtDNA  Mitochondrial DNA 
 MVK   Mevalonate kinase 
 MWS   Muckle-Wells syndrome 
 NAC   N-acetylcysteine 
 NOX2   NADPH oxidase 2 
 Nec-1   Necrostatin-1 
 NHS   Normal human serum 
 NLRP3  NLR family, pyrin domain containing 3 
 NO   Nitric oxide 
 NOD   Nucleotide-binding oligomerization domain 
 NSA   Necrosulfonamide 
 NTA   Nickel-nitrilotriacetic acid 
 OVA   Ovalbumin 
 p53   Tumor protein 53 
 PAK   p21-activated kinase 
 PAMP   Pathogen-associated molecular pattern 
 PARP   Poly(ADP-ribose) polymerase 
 PBMC   Peripheral blood mononuclear cell 
 PBS   Phosphate buffered saline 
 PDE   Phosphodiesterase 
 xxi 
 
 PFT   Pore-forming toxin 
 PGAM5  Phosphoglycerate mutase family member 5 
 PGN   Peptidoglycan 
 PI   Propidium iodide 
 PKR   RNA-dependent protein kinase 
 PLC   Phospholipase C 
 PML   Promyelocytic leukemia protein 
 PMN   Polymorphonuclear cell 
 Poly-Q19  Poly-glutamine (19 repeats) 
 Poly-Q83  Poly-glutamine (83 repeats) 
 PP2A   Protein phosphatase 2A 
 PRR   Pattern recognition receptor 
 PSM   Phenol-soluble modulin 
 PVL   Panton-Valentine leukocidin 
 PYD   Pyrin domain 
 RA   Rheumatoid arthritis 
 RHIMs  RIP homotypic interaction motifs 
 RIPK   Receptor interacting protein kinase 
 ROS   Reactive oxygen species 
 RPMI   Roswell Park Memorial Institute 
 SAA   Serum amyloid A 
 SDS   Sodium dodecyl sulfate 
 SERCA  Sarco/endoplasmic reticulum Ca2+ ATPase 
 shRNA  Short hairpin RNA 
 siRNA   Small interfering RNA 
 xxii 
 
 SNAP   S-nitroso-N-acetylpenicillamine 
 SOCE   Store-operated Ca2+ entry 
 STIM   Stromal interaction molecule 
 Syk   Spleen tyrosine kinase 
 TAB   TAK-1 binding protein 
 TBS   Tris-buffered saline 
 TRIM33  Tripartite motif 33 
 TRPM2  Transient receptor potential cation channel subfamily M 
 TRX   Thioredoxin 
 TSB   Tryptic soy broth 
 TTR   Transthyretin 
 TXNIP  Thioredoxin-interacting protein 
 TUDCA  Tauroursodeoxycholic acid 
 UNC   University of North Carolina 
 UPR   Unfolded protein response 
 UTR   Untranslated region 
 VILI   Ventilator-induced lung injury 
 XIAP   X-linked inhibitor of apoptosis protein 
 XOR   Xanthine oxidoreductase 
 
 
 
 
 
 1 
 
Chapter 1. Discovery, activation and regulation of the NLRP3 inflammasome 
 
1.1 A general overview of NLRP3 inflammasome form and function 
The NLRP3 inflammasome is the most well characterized of a recently discovered family 
of sensors that activate Caspase 1 to initiate immune signaling. NLR proteins [1] (ex. 
Nucleotide-binding domain and leucine-rich repeat containing, pyrin-domain 3 – NLRP3) 
respond to pathogens and cellular stresses known as danger signals. Upon activation, NLR 
proteins interact with Caspase 1, either directly in those that contain a Caspase Activation and 
Recruitment Domain (CARD), such as in the NLRC family, or indirectly through pyrin-pyrin 
domain (PYD) interactions with Apoptosis-associated speck-like protein containing a CARD 
(ASC) [2]. Activation of Caspase 1 leads to proteolytic processing of critical inflammatory 
signals, including interleukin-1β (IL-1β) and interleukin-18 (IL-18), to their mature form. 
Additionally, activation of inflammasomes, and NLRP3 in particular, can cause necrotic-type 
cell death. This cell death has been referred to as pyroptosis or pyronecrosis, largely depending 
on the requirement for Caspase 1. However, the use of these terms in the literature is sometimes 
inexact so they will be avoided here. 
Activation of inflammasomes is also often times preceded by a “priming” step (or signal 
1). Toll-like receptor (TLR) signaling primes inflammasome activation by: (1) upregulating NF-
κB-dependent transcription of inflammasome components and pro-IL-1β and (2) initiating a 
series of post-translational modifications of inflammasome components and their regulators. In
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some cells, usually those with high levels of expression of inflammasome components, 
such as THP1 cells, this step can be bypassed, though usually without IL-1β secretion. 
Hundreds of unique agents activate the NLRP3 inflammasome. Because of the large number 
of different activating agents, a detailed comprehensive model of inflammasome activation has 
yet to emerge. Instead, the field is littered with disparate findings pertaining to different 
activators that are rarely confirmed system-wide. In this introduction I will summarize the 
current state (as of the end of 2015) of the NLRP3 inflammasome field. I will start by discussing 
the discovery of the NLRP3 inflammasome as the cause of heritable IL-1β-driven 
hyperinflammatory periodic fever disorders. Then, I will review the dominant hypotheses of how 
the NLRP3 inflammasome is regulated across different activators. Following that, I will discuss 
how each of these hypotheses fit in with each one another by reviewing the requirements for the 
three classical NLRP3 agonists: nigericin, extracellular ATP and monosodium urate (MSU). And 
lastly, I will highlight the role of NLRP3 in infectious and non-infectious pulmonary diseases, a 
personal and professional interest of mine, to demonstrate the wide ranging effects of the NLRP3 
inflammasome. My dissertation research will follow. This will include: 
 a comprehensive literature review of S. aureus and inflammasome interactions with a 
focus on the unique tissue specific roles of different inflammasomes 
 primary research comparing the cytotoxicity of S. aureus exotoxins in killing human 
monocytes and identifying that Leukocidin AB (LukAB) activates the NLRP3 
inflammasome 
 primary research on the role of kinases broadly and DAPK specifically in regulating 
NLRP3 inflammasome activity in response to LukAB 
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 a review of novel therapeutic targets in heart failure, including specifics on a role for the 
NLRP3 inflammasome (this previously published paper will be included as an appendix)  
At the end, I will conclude with my thoughts on significance of my work and the future of 
NLRP3 inflammasome research. 
 
1.2 Clinical relevance of NLRP3 inflammasome signaling 
The NLRP3 inflammasome is increasingly being recognized as a source of pathology in a 
wide range of infectious and non-infectious diseases, and at the same time, critical for clearing 
many infections. Staphylococcus aureus is a highly drug-resistant and clinically important 
pathogen responsible for a growing number of skin and lung infections. Early research into the 
interaction between S. aureus and inflammasomes has revealed interesting insights into the 
pathogenesis of infections. In pneumonia, S. aureus pore-forming toxins (PFTs) such as alpha-
hemolysin (Hla) activate the NLRP3 inflammasome leading to severe lung damage and death. In 
dermatitis, S. aureus PFTs and phenol-soluble modulins (PSMs) activate the NLRP3 
inflammasome allowing the bacteria to infiltrate the keratinocyte barrier but also promote 
bacterial clearance by neutrophils. Additionally, the NLRP3 inflammasome is activated in 
human monocytes in response to PFTs that were only recently discovered because of their 
specificity for human cells over mice. As a deeper understanding of S. aureus-inflammasome 
interactions begins to emerge, the inflammasome signaling node may become an attractive target 
for clinical intervention to treat infections or reduce inflammation-associated tissue damage in 
conjunction with antibiotics. 
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1.3 Interleukin-1β-driven monogenic hyperinflammatory fever disorders are caused by 
mutations in the NLRP3 inflammasome pathway 
NLRP3 (also referred to in early literature as CIAS1, PYPAF1, NALP3 and Cryopyrin) 
was identified as a critical protein in inflammation when it was found to be the causal gene 
mutated in familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome 
(MWS) [3]. Shortly thereafter, NLRP3 was also show to be mutated in chronic infantile 
neurological cutaneous and articular (CINCA) syndrome (also known as neonatal-onset 
multisystem inflammatory disease [NOMID]) [4]. Mutations in NLRP3 have been confirmed in 
dozens of patients with these diseases [5], now collectively known as Cryopyrin-Associated 
Periodic Syndromes (CAPS) or Cryopyrinopathies. 
FCAS is an autosomal-dominant systemic hyperinflammatory disease in which patients 
experience recurrent episodes of rash, arthralgia, fever and conjunctivitis after exposure to cold 
[6-8]. MWS is also an autosomal-dominant syndrome of periodic fevers, rash, arthralgia, 
sensorineural hearing loss, and sometimes amyloidosis [9,10]. CINCA syndrome is a severe 
early onset chronic inflammatory disease characterized by cutaneous symptoms, central nervous 
system involvement and arthropathy [11-13]. The mutations in NLRP3 that cause these three 
diseases are sometimes overlapping, suggesting that secondary modifying factors contribute to 
their distinct presentations. However, such modifying factors have yet to be identified.  
Insight into the function of NLRP3 quickly followed discovery of CAPS causing 
mutations. A mammalian two-hybrid screen showed that ASC interacts with NLRP3 and co-
expression of NLRP3 and ASC resulted in the formation of distinct cytoplasmic loci [14]. ASC 
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was also found to interact directly with pro-Caspase 1 [15] and, in conjunction with NLRP3, 
formed an IL-1β processing inflammasome [16].  
When NLRP3 with common disease-associated mutations (R260W, D303N, and E637G) 
was expressed in THP1 cells, these mutants constitutively associated with ASC and induced 
spontaneous IL-1β secretion, whereas wildtype NLRP3 did not [16,17]. Macrophages from 
MWS patients also spontaneously secreted active IL-1β [16]. Monocytes from patients with 
FCAS were cold sensitive and responded to incubation at 32°C by secreting IL-1β [18], 
mimicking the sensitivity of FCAS patients generally. Knockin mice expressing the D301N 
NLRP3 mutation (the ortholog of D303N in humans) exhibited widespread neutrophilia and high 
levels of serum inflammatory markers. They also exhibited skeletal abnormalities seen in 
CINCA patients including knee joint deformity, growth retardation and severe postnatal 
osteopenia resulting from increased osteoclastogenesis, accelerated bone resorption and loss of 
chondrocytes [19]. 
Early hints that IL-1β dysregulation may drive pathology in CAPS led to therapeutic 
trials of the recombinant human IL-1-receptor (IL-1R) antagonist anakinra (brand name: 
Kineret). Anakinra led to a dramatic, rapid, and sustained resolution of symptoms in patients 
with MWS [20] that has been reproduced in hundreds of patients [21], including patients with 
FCAS [22] and CINCA [23]. The clinical experience with anakinra has become the basis for 
clinical guidelines [24]. Clinical trials have also shown success with Rilonacept, an IL-1 Trap 
that acts as a long-acting and potent inhibitor of IL-1β, in patients with FCAS and MWS [25,26]. 
A third IL-1β disrupting therapy, Canakinumab, a human anti-IL-1β monoclonal antibody, has 
also been used successfully [27].  
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Additional periodic fever syndromes have been identified with casual genes that relate to 
inflammasome signaling providing greater insight into the activity and regulation of the NLRP3 
inflammasome-IL-1β signaling axis. Sterile Multifocal Osteomyelitis with Periostitis and 
Pustulosis (OMPP) [28,29] is caused by a deficiency in the IL-1R antagonist (IL1-RN) that leads 
to unopposed IL-1β signaling and life-threatening systemic inflammation [30]. Familial 
Mediterranean Fever (FMF) is an autosomal recessive disorder caused by mutations in the 
MEFV gene that encodes for Pyrin [31]. Pyrin negatively regulates the NLRP3 inflammasome 
by disrupting the interaction between NLRP3 and ASC, and thus, when mutated, leads to 
increased inflammasome activation [32]. Hyper-IgD and Periodic Fever Syndrome is caused by 
mutations in mevalonate kinase (MVK) [33,34] that disrupt autophagy, which is thought to 
negatively regulate the NLRP3 inflammasome and IL-1β secretion, leading to a 
hyperinflammatory state [35]. Pyogenic Sterile Arthritis, Pyoderma Gangrenosum, and Acne 
(also known as PAPA Syndrome - PAPAS) [36], is caused by mutation in the PSTPIP1 gene 
[37]. PSTPIP1 binds to Pyrin and disease-associated mutations exert a dominant-negative effect 
on Pyrin leading to increased IL-1β production in patients [38]. 
It is interesting to note that in all Mendelian disorders affecting the NLRP3 
inflammasome pathology results from increased activation of this pathway, not decreased. This 
makes the NLRP3 inflammasome fairly unique among critical immune signaling pathways in 
that outright disease resulting from absent NLRP3 inflammasome signaling has not yet been 
identified. It is likely that low or absent function NLRP3 alleles do exist in the human 
population, but their susceptibility to infection may be so minimal so as to not be easily 
recognizable. 
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1.4 The NLRP3 inflammasome is a master innate immune sensor 
Activation of the NLRP3 inflammasome typically proceeds in two stages. First, a 
“priming” step upregulates transcription and translation of inflammasome components and pro-
IL-1β through the well-studied TLR-NF-κB signaling pathway. Additionally, priming prepares 
the NLRP3 inflammasome for activation through a series of post-translational modifications. 
Second, Caspase 1 catalytic activity is triggered through NLRP3 inflammasome oligomerization 
leading to processing of cytokines to their mature form for secretion and necrotic cell death. In 
the absence of priming, cells that constitutively express NLRP3 inflammasome components can 
trigger IL-18 secretion and cell death, without IL-1β secretion. However, the physiologic 
significance of this partial activation is still unclear. 
Early functional studies of the NLRP3 inflammasome drew comparisons to the Toll-like 
receptor system, a family of pattern recognition receptors (PRRs) for sensing pathogen-
associated molecular patterns (PAMPs). While other NLR proteins detect a narrow range of 
PAMPs (ex. NLRC4 binds flagellin and NLRP1 binds muramyl dipeptide - MDP), NLRP3 is 
activated by hundreds of pathogen-associated molecules, endogenous danger signals, and 
environmental and man-made pollutants. The only common feature of these NLRP3-activating 
molecules identified thus far is that their activity is inhibited by increasing the extracellular 
concentration of potassium. As such, the NLRP3 inflammasome would be more accurately 
placed in a category of its own – as a master innate immune sensor – to distinguish its high 
degree of promiscuity from the PRRs that sense a narrow range of molecules.  
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As a result of this promiscuity, the NLRP3 inflammasome research field is full of gaps. 
Before discussing the NLRP3 inflammasome in more detail, the reader will be warned in section 
1.5 of these gaps and how they hamper generalizability of important data.  
 
1.5 Cautions in interpreting NLRP3 inflammasome research 
 Research on the NLRP3 inflammasome has been expanding rapidly with each passing 
year and with no signs of slowing down. A search of “NLRP3” on PubMed at the end of 2015 
returned 2182 results, of which, nearly half, 1035 (47.4%), were published in 2014 or 2015. 
Because NLRP3 inflammasome research is still a nascent field, many new discoveries are 
disjointed and little effort is made to integrate new findings into a coherent and comprehensive 
model for NLRP3 inflammasome activity. This issue has been exacerbated by the large number 
of different activating stimuli. Below, as a brief aside, I will highlight some of the common faults 
in the field in order to prepare the reader for some of the unfortunate confusion and shortcomings 
that exist in the data. 
 
1.5.1 Studies frequently overlook important outcomes of NLRP3 inflammasome activity  
 The vast majority of research on the NLRP3 inflammasome focuses on two readouts of 
NLRP3 activity: cleavage of pro-Caspase 1 into its active form and secretion of mature IL-1β. As 
previously mentioned, activation of the NLRP3 inflammasome actually triggers Caspase 1 
activation, IL-1β and IL-18 secretion, and necrotic cell death. These are also only the most well-
known outcomes. Activation of Caspase 1 is also thought to result in processing and secretion of 
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IL-33 [39] and cleavage of possibly up to 41 other cellular proteins including glycolytic enzymes 
[40].  
While activation of Caspase 1 and maturation of IL-1β are appropriate readouts for 
NLRP3 inflammasome activation, ignoring these other downstream events is certain to result in 
faulty assumptions and missed opportunities. For example, the secreted Listeria monocytogenes 
(Lm) p60 protein activated the NLRP3 inflammasome to trigger IL-1β and IL-18 secretion but 
not cell death. Diphenyliodonium (DPI) treatment to block production of reactive oxygen species 
(ROS) blocked secretion of IL-1β but not IL-18. Additionally, Caspase 11 deficient mice failed 
to secrete IL-1β in response to Lm p60 but IL-18 secretion was fully intact [41]. Of course, it 
would be unreasonable to evaluate forty different targets of Caspase 1 cleavage, but by more 
rigorously evaluating downstream results of NLRP3 inflammasome activity this one study 
demonstrated at least two unique aspects of Lm p60 that would have otherwise been 
unappreciated. First, that Lm p60-induced NLRP3-dependent IL-1β and IL-18 secretion are 
regulated by separate mechanisms, and second, that NLRP3 inflammasome activation in 
response to Lm p60 does not cause cell death. 
Numerous studies also support a larger role for Caspase 1 beyond IL-1β signaling 
(reviewed [42]). Interestingly, despite early studies establishing a role for Caspase 1 in NLRP3-
mediated cell death, many have since demonstrated NLRP3-dependent, Caspase 1-independent 
cell death, most notably the pore-forming toxins of S. aureus [43-45]. By just measuring IL-1β 
secretion, studies miss an opportunity to characterize the mechanism of NLRP3-mediated cell 
death in their system. My work, detailed in Chapter 3, also serves as an example showing that 
even when the NLRP3 inflammasome is activated, other pathways may contribute to the 
phenotype observed. S. aureus LukAB binding to CD11b on the phagosomal membrane 
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activated NLRP3 and killed THP1 cells. shRNA-mediated depletion of NLRP3 blocked LukAB-
induced IL-1β secretion but did not diminish LukAB-induced cell death, suggesting that a 
NLRP3-independent cell death pathway is responsible [45]. 
Most importantly, though, when studies of the NLRP3 inflammasome focus exclusively 
on IL-1β, there exists a potential to do harm to patients. As mentioned previously, disruption of 
IL-1β signaling has successfully been used as a treatment for CAPS. However, evidence from 
mouse models suggests that both IL-18 and cytokine-independent processes play an important 
role in disease pathogenesis as well. Expression of NLRP3-activating mutations A352V or 
L353P (commonly associated with MWS and FCAS respectively) in mice resulted in neonatal or 
perinatal lethality. Breeding each mutation onto an IL-1R knockout background resulted in an 
incomplete phenotypic rescue. The A352V MWS mutation combined with IL-1R knockout mice 
still had a diminished growth rate and limited cutaneous inflammation when compared to the 
parental strain mice. The L353 FACS mutation combined with IL-1R knockout was more severe 
with eighty percent of mice dying by 35 days after birth [46]. These data raised the possibility of 
non-IL-1β-mediated effects in CAPS. 
The MWS and FCAS mutations were also crossed onto an IL-18 receptor (IL-18R) 
knockout background in a subsequent study. FCAS IL-18R knockout mice had equivalent 
survival to FCAS IL-1R knockouts and MWS IL-18R knockout mice had vastly improved 
survival compared to MWS IL-1R knockouts. Knockout of Caspase 1 was completely protective 
against the FCAS mutation. However, knockout of both IL-1R and IL-18R does not fully protect 
against the lethality of the FCAS mutation. These data suggest that there are IL-1β- and IL-18-
independent processes resulting from Caspase 1 activation that are important for disease 
pathogenesis in this mouse model [47]. Of course, the generalizability of discoveries in mice to 
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humans is not exact. While there have not been widespread reports of treatment failure with anti-
IL-1 therapy in CAPS, these studies point to a theoretical shortcoming that must be investigated 
further. 
 
1.5.2 Dozens of activators and regulators complicate a comprehensive model for NLRP3 
inflammasome activation 
Studies of the NLRP3 inflammasome typically focus on identifying new activators or 
new regulators of NLRP3 inflammasome signaling. Mechanistic discoveries are being made 
across a wide range of cellular processes including organelle perturbation, calcium signaling, 
ubiquitinating enzymes and kinases. The breadth of these discoveries has created tremendous 
difficulty in relating these discoveries to one another. Additionally, because new regulators are 
often identified with only a small subset of activators, it is not clear that each regulatory element 
is critical across the range of all NLRP3 activating molecules. 
Compounding this difficulty, studies usually only validate mechanistic discoveries across 
activators using a narrow range of assays, rather than the full extent used to prove the original 
requirement. For example, in a typical publication, one that shows a role for Xanthine 
oxidoreductase (XOR) in regulating the NLRP3 inflammasome in response to crystalline 
activators, only one experiment using an inhibitor of XOR in ATP- and nigericin-induced IL-1β 
secretion is shown to extend the regulatory role of XOR to those activators. This was presented 
as sufficient evidence in light of the experiments on crystalline activators to substantiate an 
argument for a general requirement for XOR in NLRP3 inflammasome activation [48]. 
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Additionally, this makes it unlikely that future research will comprehensively address those 
claims because of the “first to publish” mentality. 
In some cases, when a well-studied protein or molecule is found to regulate the NLRP3 
inflammasome, the data provide no mechanistic hints except to rule out involvement of 
previously characterized pathways. One example of this is a study that showed the anti-
inflammatory eicosanoid 15-deoxy-delta-12,14-PGJ2 (15d-PGJ2) inhibits inflammasomes, 
including the NLRP3 inflammasome, but not through its known actions on PPARγ, NRF2, or 
COX-1 [49]. While these studies are important starting points, they must be followed up on in 
order to avoid creating too many holes in the field. 
 
1.5.3 Commonly used Caspase 1 knockout mice are also Caspase 11 deficient 
Caspase 1 activation is the most immediate result of NLRP3 inflammasome activation. 
The Caspase 1 knockout mouse strain commonly used in published studies in the field was 
produced using strain 129 embryonic stem cells. Strain 129 mice harbor a mutation in the 
Caspase 11 locus that attenuates Caspase 11 expression and segregates with Caspase 1 because 
of close proximity in the genome, approximately 1,500 base pairs. As such, the C57BL/6 
Caspase 1 knockout mouse first published in Li et al in 1995 [50] was determined to be deficient 
in both Caspase 1 and Caspase 11 activity in 2011 [51]. Unfortunately, many studies that 
preceded this discovery, and even some that have followed it, have not been clarified to 
determine the role of Caspase 1 and Caspase 11 separately. Caspase 11 activating stimuli are 
now commonly referred to as non-canonical inflammasome stimuli, but the failure to recognize 
the loss of Caspase 11 activity in these mice makes it difficult to appreciate the unique roles of 
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these two Caspases. When possible, in the discussion below, these mice will be called “Caspase 
1/Caspase 11 deficient” to highlight this important distinction. 
 
1.6 Priming the NLRP3 inflammasome for activation 
Priming of the NLRP3 inflammasome is often required for the full complement of 
NLRP3 inflammasome activity. Classically, priming involves transcriptional upregulation of 
NLRP3 inflammasome components and pro-IL-1β through NF-κB signaling. It has more 
recently been expanded to include non-transcriptional events including post-translational 
modifications that enhance eventual NLRP3 inflammasome activity. In this section, I will review 
current data on priming of the NLRP3 inflammasome. 
 
1.6.1 Pattern-recognition receptor signaling upregulates transcription of NLRP3 
inflammasome components 
Toll-like receptor ligand binding activated NF-κB leading to transcriptional upregulation 
of pro-IL-1β and components of the NLRP3 inflammasome. Ligand binding to plasma 
membrane-based TLR2 or LTR4, or endosomal membrane-based TLR3 or TLR7, are all 
sufficient to induce priming of the NLRP3 inflammasome. TLR4 binding to LPS signaled 
through two adapters, MyD88 and TRIF. Macrophages deficient in MyD88 or TRIF responded 
normally to LPS priming but macrophages deficient in both MyD88 and TRIF did not, 
suggesting that these two downstream adaptors can compensate for each other [52]. IRAK4, a 
kinase required for NF-κB activation downstream of MyD88, is also required for priming by 
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TLR ligands that signal exclusively through MyD88 [52]. Bay11-7082, an inhibitor of IκB-α 
phosphorylation and NF-κB signaling [53], and cycloheximide, an inhibitor of protein synthesis, 
both blocked transcriptional priming [52]. 
RNA from both Gram-positive and Gram-negative bacteria can prime NLRP3 
inflammasome activity in bone marrow-derived macrophages (BMDM) and bone marrow 
dendritic cells (BMDC). This response was independent of established nucleic acid sensing 
endosomal TLRs, including TLR3, 7 and 9, and the TLR-adaptor TRIF. Bacterial RNA-based 
priming required UNC93B, an endoplasmic reticulum protein that has a known role in delivery 
of TLRs to the endosome, and MyD88. Knockout of UNC93B or TLR2/3/7/9 had no impact on 
LPS-induced priming but blocked R848, CpG or polyI:C induced priming, as would be expected 
for these ligands. These data suggest that there is a yet unidentified intracellular nucleic acid 
receptor involved in bacteria RNA-mediated NLRP3 inflammasome priming that signals through 
MyD88 [54]. Despite the Toll-like receptor system being very well studied, this study highlights 
the importance of thoroughly evaluating the role of previously worked out pathways in the 
context of NLRP3 inflammasome priming.  
NOD2, the intracellular receptor for muramyl dipeptide, a component of peptidoglycan, 
also promoted transcriptional priming of the NLRP3 inflammasome through a receptor 
interacting protein kinase 2 (RIPK2)-dependent mechanism [52]. TNFR1 or TNFR2 binding to 
TNF-α was also sufficient for transcriptional priming of the NLRP3 inflammasome as loss of 
both these receptors blocked priming by TNF-α [52,55]. Likewise, exposure to IL-1α or IL-1β 
induced a lower levels of transcription as compared to TNF-α, but was sufficient to prime the 
NLRP3 inflammasome for ATP-induced Caspase 1 activation [55]. 
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Interestingly, whereas murine macrophages required priming for NLRP3 inflammasome 
activation, transcriptional priming was not required for AIM2 or NLRC4 activation in response 
to poly(dA:dT) and Flagellin, respectively. Cycloheximide had no effect on AIM2 or NLRC4 
activation but significantly reduced NLRP3-dependent Caspase 1 activation in response to LPS 
and nigericin. The AIM2 inflammasome is an ASC- and Caspase 1-containing inflammasome, 
suggesting that neither of these components are critically regulated by transcriptional priming. 
Transcriptional priming was necessary for transcription and translation of NLRP3, as constitutive 
expression of NLRP3 from an exogenous promoter was able to overcome the priming 
requirement [56]. In a second study, while constitutive expression of NLRP3 in BMDM was able 
to overcome the requirement for priming, LPS-induced priming still enhanced Caspase 1 
activation further, suggesting that other factors may also be induced or modified by priming [57]. 
DPI, an inhibitor of Flavin-containing cofactors that blocks NOX2-dependent ROS 
production, and N-acetylcysteine (NAC), an ROS scavenger, both blocked induction of NLRP3 
and IL-1β mRNA. Treatment of macrophages with DPI or NAC prior to LPS exposure 
suppressed IL-1β secretion but had no effect on IL-1β secretion when DPI was added after 
priming of the NLRP3 inflammasome was complete [56,58]. DPI treatment blocked 
phosphorylation of IκB-α and prevented downstream NF-κB activation [58]. Constitutive 
expression of NLRP3 from an exogenous promoter overcame sensitivity to DPI, further 
supporting the notion that DPI was blocking transcriptional priming [56]. It is important to note 
that in this series of experiments, DPI and NAC both also affected LPS-induced TNF-α secretion 
[56], consistent with a role for ROS in NF-κB-dependent transcriptional priming. 
In addition to activation of NF-κB, TLR signaling activates MAPK signaling pathways 
leading to nuclear translocation of cyclic AMP (cAMP)-responsive element-binding protein 
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(CREB) and activator protein 1 (AP1) [59]. Inhibitors of MAPK signaling, including the MEK1 
inhibitor PD98059 and the JNK1/2 inhibitor SP600125, but not the p38 inhibitor SB203580, 
blocked the LPS-induced increases in NLRP3 expression. The JAK2 inhibitor AG490 and the 
PI3-kinase inhibitors LY294002 and wortmannin also inhibited LPS-induced upregulation of 
NLRP3 protein [58]. This collection of inhibitor experiments suggests that multiple signaling 
paths downstream from TLRs all coordinate to promote induction of NLRP3 mRNA during LPS 
priming. 
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Figure 1.1. TLR signaling triggers NLRP3 inflammasome transcriptional priming. This 
figure summarizes the discussion in section 1.6.1. LPS binding to TLR4 trigged activation of 
both TRIF and MyD88 which compensated for each other to transduce signaling through IκB-α 
to activate NF-κB. Signaling through MyD88 also required IRAK4. Treatment of cells with the 
NOX2 inhibitor DPI, the ROS scavenger NAC, or the IκB-α inhibitor Bay11-7082 all blocked 
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transcriptional priming. MAPK and PI3K inhibitors blocked transcription of NLRP3 from the 
endogenous locus. Use of cyclohexamide demonstrated a requirement for transcriptional priming 
by blocking all protein translation. Solid lines represent direct interactions and dotted lines 
represent indirect interactions. Only relationships investigated in the context of NLRP3 
inflammasome priming are including, not all previously known TLR signaling components. 
Other pattern recognition receptors, such as NOD2 binding to MDP, and immune receptors such 
as TNFR binding to TNF-α can trigger transcriptional priming. A requirement for a new bacterial 
RNA sensor was also identified, demonstrating the importance of comprehensively evaluating 
these well-studied pathways in the context of NLRP3 inflammasome signaling. Solid lines 
represent direct interactions and dotted lines represent indirect interactions.  
 
1.6.2 Negative feedback loops respond to prolonged priming to reign in NLRP3 
inflammasome signaling 
Activation of the NLRP3 inflammasome and secretion of inflammatory mediators 
dramatically changes tissue structure and physiology. Just as the activation of the NLRP3 
inflammasome is critical for defense against many pathogens, it must be carefully regulated to 
avoid detrimental effects of inflammation. In this section, I will focus on mechanisms that 
translate prolonged TLR signaling into decreases in NLRP3 inflammasome activity.  
NLRP3 inflammasome transcriptional priming seems to integrate signals into time-
sensitive negative feedback loops. Murine macrophages stimulated with LPS for 12 hours 
secreted significantly less IL-18 in response to ATP and nigericin as compared to murine 
macrophages stimulated with LPS for 4 hours. In an inducible nitric oxide synthase (iNOS) 
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knockout strain, IL-18 secretion was nearly equivalent in both four and twelve hour-long LPS 
incubations. Long-term (twelve hour) stimulation of macrophages with LPS induced type I 
interferon (IFN) production leading to upregulation of iNOS and nitric oxide (NO) synthesis. 
Endogenous NO and the NO donor S-nitroso-N-acetylpenicillamine (SNAP) inhibited the 
NLRP3 inflammasome. S-nitrosylation of NLRP3 and Caspase 1 was detected in long-term LPS-
treated cells and was proposed, but not confirmed, to be responsible for iNOS-dependent 
suppression of NLRP3 inflammasome activity [60]. A second study investigating the 
immunopathology of tuberculosis showed that IFN-γ, a type II IFN, suppressed IL-1β secretion 
in an iNOS-dependent manner. They also observed s-nitrosylation of NLRP3 and Caspase 1 and 
demonstrated that ascorbate, a reducing agent, reversed the modification and release inhibition of 
IL-1Β secretion in a dose dependent manner [61]. 
Long term stimulation of macrophages with LPS also required inhibitor of NF-κB kinase 
subunit epsilon (IKBKE) for negative feedback control of NLRP3 inflammasome priming. Loss 
of IKBKE enhanced LPS-induced NLRP3 and IL-1β mRNA transcription in both a four-hour 
and twenty four-hour LPS exposure. Ultimately, this led to IKBKE deficient cells secreting more 
IL-1β relative to wildtype controls. Similar results were seen in adipose tissues [62]. IKBKE is 
also involved in activating production of type I IFNs in response to viral infections, suggesting 
the possibility that IKBKE could upregulate iNOS as well. However, the exact mechanism by 
which IKBKE decreased NLRP3 and IL-1β mRNA remains unexplored. 
A study on hemorrhagic shock highlights how multiple different signals can be integrated 
to balance NLRP3 inflammasome priming. Mice subjected to hemorrhagic shock then given LPS 
intratracheally experienced an increase in NLRP3 expression, Caspase 1 activation and IL-1β 
secretion in the lung. Pro-IL-1β mRNA levels were equivalent in sham operation mice treated 
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with LPS as in hemorrhagic shock mice, but IL-1β secretion was much higher in hemorrhagic 
shock, leading to the suggestion that hemorrhagic shock induces a NLRP3 inflammasome 
modifying factor. Hemorrhagic shock suppressed IL-10 secretion and these mice had lower 
levels of Pyrin, a negative regulator of the NLRP3 inflammasome. Blocking IL-10 with an 
antibody in sham treated mice decreased Pyrin expression and increased IL-1β secretion, while 
administering IL-10 exogenously to hemorrhagic shock treated mice increased Pyrin expression 
and decreased IL-1β secretion. Knockdown of Pyrin in mouse lung vascular endothelial cells 
(MLVECs) led to an increase in IL-1β secretion that could not be blocked by administration of 
exogenous IL-10 [63]. The ability of IL-10 to suppress NLRP3 inflammasome activity during 
chronic LPS stimulation was confirmed in a subsequent study of LPS and ATP-treated BMDMs. 
In this setting, IL-10 decreased expression of NLRP3 leading to decreased Caspase 1 activation 
and IL-1β secretion in response to LPS and ATP [64]. 
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Figure 1.2. Negative feedback loops limit NLRP3 inflammasome priming. This figure 
summarizes the discussion from section 1.6.2. Long term stimulation of cells with LPS leads to 
production of iNOS which regulates NLRP3 inflammasome signaling through production of 
nitric oxide and s-nitrosylation of NLRP3. IKBKE also negatively regulates NLRP3 
inflammasome signaling in long term LPS exposures. Solid lines represent direct interactions 
and dotted lines represent indirect interactions. Only relationships investigated in the context of 
NLRP3 inflammasome priming are including.  
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1.6.3 Kinase-mediated post-translational priming regulates NLRP3 inflammasome activity 
Careful time course analysis of shorter than typical priming exposure followed by ATP 
treatment demonstrated unique outcomes that depended on the TLR signal adapter used. 
Specifically, priming with Pam3CSK4, a TLR2 ligand that signals through MyD88, resulted in 
biphasic activation of Caspase 1, with levels of active Caspase 1 higher at 10 minutes and 180 
minutes of Pam3CSK4 stimulation and lower following 30 minutes and 60 minutes. Priming 
with poly I:C, a TLR3 ligand that signals through TRIF, induced maximal Caspase 1 activation 
following 30 and 60 minutes of poly I:C stimulation and almost none seen at 10 minutes and 180 
minutes. In contrast, when priming with LPS, a TLR4 agonist that signals through MyD88 and 
TRIF, robust Caspase 1 activation was observed at all four time points. Interestingly, knockout 
of MyD88 or TRIF led to LPS-induced priming that mirrored Pam3CSK4 or poly I:C, depending 
on the signaling adaptor present. Cells treated with just ATP did not activate Caspase 1 [65].  
These priming adaptations are more rapid than one would expect for transcriptional 
changes. Actinomycin D, an inhibitor of RNA chain elongation, was used to test for a 
requirement for transcription directly. Actinomycin D treatment had no effect on Pam3CSK4-, 
poly I:C- or LPS-induced priming of Caspase 1 activation at any time point but blocked 
upregulation of NLRP3 and pro-IL-1β. IRAK1 and IRAK4 were critically required for NLRP3 
inflammasome priming during a 10-minute exposure of Pam3CSK4 or LPS. Loss of IRAK1 or 
IRAK4 resulted in decreased ASC oligomer formation during simultaneous treatment with 
Pam3CSK4 and ATP. NLRP3 and IRAK1 co-immunoprecipitated together in macrophages and 
the interaction appeared to be enhanced by Pam3CSK4 treatment [65]. A subsequent study 
confirmed these findings, showing that simultaneous exposure to LPS and ATP induced IRAK1 
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and NLRP3 inflammasome co-localization leading to IRAK1-, NLRP3-, and Caspase 1-
dependent IL-18 secretion and cell death [66]. 
NOX2- and proteasome-dependent phosphorylation of ERK was also required for post-
translational priming of the NLRP3 inflammasome in human monocytes. Co-stimulation with 
LPS and ATP triggered Caspase 1 activation and IL-18 secretion from human monocytes in as 
little as 5 minutes whereas ATP treatment alone was insufficient. LPS induced phosphorylation 
of ERK, but ATP did not. Treatment of monocytes with U0126, an inhibitor of MEK1/2 that 
prevents phosphorylation of ERK, blocked IL-18 secretion in response to rapid LPS and ATP 
exposure. siRNA specifically targeting ERK1, but not ERK2, confirmed this finding. ERK was 
phosphorylated in response to LPS and treatment with MG132 or bortezemib, both inhibitors of 
the proteasome, blocked ERK phosphorylation, Caspase 1 activation and IL-18 secretion. 
Treatment of cells with DPI to block ROS production also suppressed ERK1/2 phosphorylation 
and IL-18 secretion. The deubiquitinating (DUB) enzyme inhibitors G5 and WP1130 blocked 
IL-18 secretion but had no effect on ERK1/2 phosphorylation, suggesting that they acted 
downstream or separately from this pathway. Wortmannin, a PI3K inhibitor, SB203580, a p38 
MAPK inhibitor, and SP600125, a JNK inhibitor, had no effect on IL-18 secretion. Loss of 
NLRP3 or Caspase 1 also had no effect on ERK phosphorylation in response to LPS [67]. The 
requirement for proteasome activity strongly suggests that priming of the NLRP3 inflammasome 
initiated destruction of some factor that blocked ERK phosphorylation, though the identity of the 
proteasome target is still unknown.  
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Figure 1.3. Kinases in non-transcriptional priming of the NLRP3 inflammasome. This 
figure summarizes the discussion in section 1.6.3. Rapid priming by Pam3CSK4 binding to TLR 
2 trigged MyD88-dependent activation of IRAK1. IRAK1 co-immunoprecipitated with the 
NLRP3 inflammasome and this association was enhanced by Pam3CSK4 priming. IRAK1 
promoted ASC oligomerization. LPS binding to TLR4 promoted activation of MEK1/2 and 
phosphorylation of ERK1 leading to rapid inflammasome priming. Inhibition of MEK1/2 with 
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U1026, NOX2 with DPI or the proteasome with MG132 or bortezemib, suppressed ERK 
phosphorylation and IL-18 secretion. The DUB inhibitors G5 and WP1130 had no effect on ERK 
phosphorylation, but blocked IL-18 secretion. Solid lines represent direct interactions and dotted 
lines represent indirect interactions. Only relationships investigated in the context of NLRP3 
inflammasome priming are including.  
 
1.6.4 Caspase 8 contributes to transcriptional and post-translational NLRP3 inflammasome 
priming 
 Caspase 8 played a bifunctional roll in priming the NLRP3 inflammasome through both 
transcriptional and post-translational means. Previous research has noted that deletion of Fas-
associated protein with death domain (FADD), the activator of Caspase 8, leads to defects in 
myeloid cell differentiation [68]. Differentiation can be normalized with additional deletion of 
RIPK3, allowing for the study of FADD and Caspase 8 in BMDMs. LPS-primed and ATP or 
nigericin-stimulated BMDMs required TLR4, TRIF, MyD88 and FADD for Caspase 8 
maturation. Deletion of Caspase 8 resulted in decreased ATP- and nigericin-induced Caspase 1 
activation, IL-1β secretion and cell death, suggesting that Caspase 8 regulates NLRP3 
inflammasome activity [69,70]. Deletion of FADD significantly decreased LPS induction of 
NLRP3 and pro-IL-1β mRNA. Similar results were observed with Caspase 8 deletion as well 
[69]. 
Interestingly, Caspase 8 maturation also required NLRP3 and ASC, but not Caspase 1 or 
Caspase 11, suggesting a possible interaction between Caspase 8 and the core of the NLRP3 
inflammasome. Confocal immunofluorescene showed significant co-localization of Caspase 1 
 26 
 
and Caspase 8 in LPS and ATP-stimulated macrophages. Pharmacologic inhibition of Caspase 8 
with Ac-IETD-fmk was equally as effective in suppressing Caspase 1 activation in response to 
LPS and ATP when used both as a pretreatment and following LPS priming [69]. Activation of 
the NLRP3 inflammasome as measured by dsRNA also required Caspase 8 but, contrary to the 
previous study, could not be blocked by another Caspase inhibitor, the pan Caspase inhibitor 
OMe-zVAD-fmk [71]. 
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Figure 1.4. Caspase 8 is critical for transcriptional and post-translational NLRP3 
inflammasome priming. This figure summarizes the discussion in section 1.6.4. Caspase 8 
maturation in response to LPS stimulation required TLR4, TRIF, MyD88, FADD, NLRP3 and 
ASC. Caspase 8 co-localized with Caspase 1 in BMDM stimulated with LPS plus ATP. Loss of 
Caspase 8 impacted both production of NLRP3 and IL-1β mRNA and Caspase 1 activation, 
suggesting a dual role in NLRP3 inflammasome priming. Solid lines represent direct interactions 
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and dotted lines represent indirect interactions. Only relationships investigated in the context of 
NLRP3 inflammasome priming are including.  
 
1.6.5 Multiple ubiquitination signals regulate NLRP3 inflammasome priming and protein 
degradation 
 TLR receptor signaling also primes the NLRP3 inflammasome through ubiquitination 
and degradation of the NLRP3 inflammasome and its regulators. It was noted that NLRP3 
protein levels increased in response to LPS priming in U937 human monocytic cells even in the 
presence of cycloheximide, a protein translation inhibitor. Blocking protein degradation with the 
proteasome inhibitor MG132, but not the lysosomal inhibitor leupeptin, prevented steady-state 
degradation of NLRP3 in untreated cells, leading to increased NLRP3 protein levels. These data 
suggest that the ubiquitin-proteasome targeting of NLRP3 is regulated by TLR priming to 
control the half-life of NLRP3.  
FBXL2 catalyzed NLRP3 ubiquitination in vitro, and interacted with NLRP3 when 
overexpressed in cells. LPS treatment decreased the interaction between FBXL2 and NLRP3 and 
also decreased ubiquitination of NLRP3. Additionally, depletion of FBXL2 by siRNA in human 
macrophages led to increased levels of NLRP3. Mutation of NLRP3 lysine 689 to arginine 
blocked ubiquitination, suggesting that K689 was the ubiquitin acceptor site [72]. 
 FBXO3 is an E3 ligase subunit that regulates activity of FBXL2 when FBXL2 is 
phosphorylated GSKβ [73]. The FBXO3 inhibitor BC-1215 increased FBXL2 levels and 
decreased NLRP3 levels. Importantly, this FBXO3 inhibitor opposed LPS-induced 
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accumulations in NLRP3 but had no effect on mutant K689R NLRP3, suggesting that FBXO3 
was responsible for degrading FBXL2 leading to increased NLRP3 protein levels [72]. 
 A loss-of-function (LOF) polymorphism was identified in FBXO3 (V221I) that has an 
allele frequency of 6.2% in European Caucasians. Peripheral blood mononuclear cells (PBMCs) 
from patients carrying the LOF allele produced less IL-1β when treated with LPS. Mice injected 
with a lentivirus encoding for wildtype FBXO3, but not FBXO3 V221I, had increased cellular 
infiltration and lung damage in response to Pseudomonas aeruginosa pneumonia, suggesting 
increased activity from the NLRP3 inflammasome [73]. The discovery of a naturally occurring 
allele that would result in decreased NLRP3 inflammasome activity is particularly interesting. 
Mendelian disorders of NLRP3 are the result of activating mutations, but now with a reasonably 
abundant allele causing decreased NLRP3 activity, it would be interesting to compare patient 
outcomes in NLRP3-driven processes such as S. aureus pneumonia or acute lung injury. 
However, this would not be a perfect correlation with NLRP3 activity as FBXO3 and FBXL2 
also regulate TRAF [73]. 
 Deubiquitination of NLRP3 is also required for LPS-mediated priming. The general DUB 
enzyme inhibitors PR-619 and WP1130 blocked deubiquitination of NLRP3 in response to LPS. 
Similarly, treatment with ROS scavenging NAC or mitochondrial ROS specific Mito-TEMPO 
inhibited LPS-induced deubiquitination of NLRP3. ROS scavenging blocked LPS plus ATP-
induced Caspase 1 activation, but not Caspase 1 activation resulting from ATP treatment alone, 
suggesting a relationship between TLR signaling, ROS production and deubiquitination-
mediated priming. This deubiquitination did not result in accumulation of NLRP3, suggesting 
that ubiquitin is acting to suppress NLRP3 activity in this case and not acting to target NLRP3 
for degradation [74].  
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 The linear ubiquitin chain assembly complex (LUBAC) plays a role in priming of the 
NLRP3 inflammasome. Knockout of Sharpin, one of the three components of the LUBAC - 
along with HOIP and HOIL-1, in BMDMs leads to defective pro-IL-1β synthesis in response to 
LPS stimulation. Loss of Sharpin decreases LPS-induced NF-κB activation, phosphorylation of 
ERK and phosphorylation of p38 MAPK [75]. The exact point of intersection between the 
LUBAC and LPS-induced priming is unclear, but the broad effects on these downstream 
activators suggests it is relatively early in the signaling pathway. 
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Figure 1.5. Ubiquitination regulates NLRP3 protein levels and activity. This figure 
summarizes the discussion in section 1.6.5. LPS priming triggered numerous changes through 
ubiquitination-deubiquitination. First, LPS activated FBXO3 to prevent FBXL2 mediated 
ubiquitination and proteasomal degradation of NLRP3. Treatment with the FBXO3 inhibitor BC-
1215 opposed LPS-induced activation of FBXO3. Treatment with the proteasome inhibitor 
MG132 increased NLRP3 protein levels. LPS also activated deubiquitinating enzymes that 
regulated NLRP3 activity rather than abundance. Treatment with NAC and Mito-TEMPO to 
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suppress ROS blocked deubiquitination of NLRP3. Additionally, the deubiquitinating enzyme 
inhibitors PR-619 and WP1130 blocked LPS-mediated priming of NLRP3 by preventing 
deubiquitination of NLRP3. Lastly, LPS treatment required Sharpin for full NF-κB signaling, 
ERK phosphorylation and p38 MAPK phosphorylation. “P” and “U” indicate the post-
translational modifications phosphorylation and ubiquitination, respectively. The color of the “P” 
and “U” reflects the effect of the post-translational modification: green is activating, yellow is 
inhibiting, and red is targeted for degradation. Solid lines represent direct interactions and dotted 
lines represent indirect interactions. 
 
1.6.6 Post-transcriptional regulation of NLRP3 inflammasome mRNA stability 
 While TLR-induced priming upregulated transcription, other mechanisms exists to 
facilitate tight control of NLRP3 inflammasome mRNA. The myeloid-specific microRNA miR-
223 was a critical regulator of NLRP3 inflammasome expression. miR-223 interacted with the 3’ 
untranslated region (UTR) of NLRP3 transcripts to target them for degradation. Overexpression 
of miR-223 led to decreased NLRP3 protein levels and sequestration of miR-223, by expression 
of GFP with a 3’ UTR containing multiple miR-223 binding sites, led to increased NLRP3 
protein levels. The consequence of these changes in NLRP3 protein levels carry through to 
differences in IL-1β secretion as well. miR223 is not induced during priming, however. It has 
been suggested to act as a threshold regulator of transcriptional priming – requiring a strong 
enough activating signal to overcome endogenous miR-223-mediated repression [76,77]. 
 Interestingly, Epstein-Barr virus (EBV) produced a microRNA that binds to the same site 
as miR-223. EBV miR-BART15 decreased NLRP3 protein levels leading to decreased IL-1β 
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secretion. When EBV-infected B cells and THP1 cells were cultured in the same media divided 
by a 3-μm pore-containing filter, miR-BART15 was secreted from infected B cells via exosomes 
that were ultimately taken up by the THP1 cells leading to decreased NLRP3 protein levels and 
inhibition of IL-1β secretion [77]. 
 
1.6.7 NLRP3 inflammasome signaling without priming 
THP1 cells are able to activate the NLRP3 inflammasome independent of priming. This 
is thought to be the result of sufficiently high expression of NLRP3, ASC and pro-Caspase 1, 
allowing THP1 cells to respond to NLRP3-activating stimuli without priming. In this case, 
NLRP3 inflammasome activation led to secretion of IL-18 and necrotic cell death without IL-1β 
secretion. THP1 cells are a human leukemic cell line established from a patient with monocytic 
leukemia [78], so it is unclear how relevant this response is to physiologically normal cells. 
However, in experiments presented in Chapter 3, I have found that primary human CD14+ 
monocytes responded to LukAB stimulation with production of IL-18 and necrotic cell death, 
even in the absence of priming, similar to THP1 cells.  
There are likely to be differences in the wide range of phagocytic cell phenotypes, 
including not just dendritic cells vs monocytes and macrophages, but alveolar macrophages of 
the lung versus Kupffer cells of the liver and Langerhans dendritic cells versus plasmacytoid 
dendritic cells, for example. The Immunological Genome Project [79], an effort to catalog gene 
expression profiles across a wide range of immune cells using microarrays, suggested that tissue-
specific phenotypes may influence NLRP3 inflammasome activity. Expression of NLRP3 was 
highest in Langerhans dendritic cells in the skin but was nearly 10-fold lower in spleen 
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plasmacytoid dendritic cells. Classical monocytes and bone marrow neutrophils expressed an 
intermediate level of NLRP3. IL-1β transcripts follow the same pattern [79]. Research into 
tissue-specific cell type differences may reveal important distinctions in NLRP3 inflammasome 
priming which may be important in establishing the best models to study tissue-specific 
infections.  
If priming-independent NLRP3 inflammasome activation is physiologic, then it presents 
the possibility of temporally regulating NLRP3-dependent signaling events. Exposure to most 
infectious pathogens likely results in both priming and NLRP3 inflammasome activation, but 
because transcriptional upregulation is a slower process than post-translational proteolytic 
processing, IL-18 signaling may initiate an immediate response that is only later followed by 
secretion of IL-1β.  
 
1.7 Critical features of NLRP3 inflammasome activation 
 As mentioned previously, because of the large number of different activating molecules, 
it has been difficult for the field to converge on a core set of features required for NLRP3 
inflammasome activation. Currently though, there are a few overarching hypotheses outlining the 
necessary cellular changes that promote NLRP3 inflammasome activation. The most well 
established and universal requirement in NLRP3 inflammasome activation is a requirement for 
potassium efflux. Following that, a substantial amount of evidence points to a role for 
mitochondrial disruption and reactive oxygen species production for most, but not all NLRP3 
agonists. Additional key features include lysosomal disruption, endoplasmic reticulum 
disruption, calcium signaling, ubiquitination, and phosphorylation.  
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Different activators rely upon these processes to different extents to activate the NLRP3 
inflammasome and this might explain why such a wide range of unique molecules activate 
NLRP3 as compared to other inflammasomes. Additionally, multiple processes are at probably at 
play at the same time, but the details of connections between them have not yet been uncovered. 
While the convergence point of all these changes is NLRP3 inflammasome activation, there is no 
satisfying explanation for how so many different pathways can result in formation of this 
complex. 
Below, I will briefly describe each of the previously mentioned critical signaling 
pathways to NLRP3 inflammasome activation and the evidence supporting them. I will focus on 
the most significant studies and highlight the activating molecules used and the endogenous 
regulators that have been implicated. During this discussion it will become obvious to the reader 
(and at the same time be entirely disappointing) of how little is known about the requirement for 
certain regulators across a wide range of activators. Following this discussion, in section 1.8, I 
will focus on the three most popular canonical activators of NLRP3 inflammasome signaling, 
ATP, nigericin and MSU, and attempt to outline how each of the features discussed in section 
1.7 come together to mediate the response to each of these three activators. Unfortunately, 
because of space and time limitations, I will not be able to touch on all endogenous regulators or 
all NLRP3 agonists. 
 
1.7.1 Potassium efflux is a universal requirement for NLRP3 inflammasome formation 
 Potassium efflux appears to be the only absolute requirement for activation of the NLRP3 
inflammasome, subsequent cytokine processing and cell death [80]. In mouse macrophages and 
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human monocytes, NLRP3-dependent Caspase 1 activation and IL-1β secretion in response to 
R837, MSU, PGN, nigericin, ATP, and E. coli was blocked by addition of KCl to the media [81]. 
Since this early discovery, inhibition of NLRP3 inflammasome activation by increasing 
extracellular potassium has been demonstrated with nearly every activator including the 
particulates alum [82], silica and asbestos [83]; malarial hemozoin [84]; S. aureus pore-forming 
toxins [43,45]; and more. In fact, this author is unaware of and was unable to find any NLRP3 
agonists that were not suppressed by extracellular potassium.  
Unfortunately, little is known about why potassium efflux is critical in NLRP3 
inflammasome activation. The simplest, and perhaps best explanation is that oligomerization of 
ASC is sensitive to decreases in potassium concentration. When THP1 cells were lysed then 
incubated at 30°C for 60 minutes, spontaneous ASC oligomerization occurred leading to Caspase 
1 activation and pro-IL-1β processing [85]. Furthermore, increasing the concentration of 
potassium in these lysates blocked spontaneous ASC oligomerization in vitro [86]. 
However, despite all the NLRP3 agonists that are blocked by potassium efflux inhibition, 
potassium efflux is not a defining feature of the NLRP3 inflammasome. Treatment of murine 
macrophages with lethal toxin (LT) from Bacillus anthracis activated the NLRP1 inflammasome 
and was responsive to potassium efflux inhibition [81]. Activation of the NLRC4 inflammasome 
by Pseudomonas aeruginosa can be blocked by increased extracellular potassium as well [87]. 
Alternatively, potassium efflux is not required for Salmonella typhimurium-induced activation of 
IPAF1 inflammasome signaling [81] or dsDNA-induced activation of AIM2 inflammasome 
signaling [80]. So in addition to potassium efflux, other signals must help differentiate NLRP3 
activating stimuli from NLRP1- and NLRC4-activating stimuli. There is likely more to the story 
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of potassium efflux than its effect on ASC as the AIM2 and IPAF1 inflammasomes contain ASC 
but are not potassium-responsive. 
 
1.7.2 Mitochondrial disruption triggers ROS production 
 Mitochondria intersect with NLRP3 inflammasome signaling in numerous different ways. 
First, the earliest discovered and most direct, is that mitochondrial production of ROS led to 
NLRP3 inflammasome activation. Both NAC, an ROS scavenger, and DPI, an inhibitor of 
NOX2-dependent ROS production, inhibited NLRP3-dependent Caspase 1 activation and IL-1β 
secretion in response to numerous different activators [81,88-91]. Loss of NLRP3 does not 
impact ROS production, supporting the notion that ROS production is upstream of NLRP3 
inflammasome activation [92]. However, not all NLRP3 agonists depend on ROS. Both nigericin 
and gramicidin acted independently of ROS [80], as did linezolid [93]. 
 Thioredoxin-interacting protein (TXNIP) is an ROS-sensor that regulates the NLRP3 
inflammasome. TXNIP natively interacts with thioredoxin (TRX). When ROS are produced in 
the cell, TXNIP and TRX dissociate and TXNIP interacts with the NLRP3 inflammasome. This 
interaction is essential for inflammasome formation as loss of TXNIP led to dramatically 
decreased MSU-induced IL-1β secretion [94].  
 ROS production has also been tied to calcium signaling leading to NLRP3 inflammasome 
activation. ROS production trigged opening of the calcium channel transient receptor cation 
channel subfamily M member 2 (TRPM2). This occurred because ROS activated poly(ADP-
ribose) polymerase (PARP) and TRPM2 is a ADP-ribose gated channel [95]. Alum and silica 
triggered calcium fluxes that were blocked by knockout of TRPM2, treatment with DPI to block 
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ROS production, or treatment with DPQ, an inhibitor of PARP. All three of these interventions 
led to a decreased alum-, silica- and MSU-mediated IL-1β secretion [96]. 
 Accumulation of damaged mitochondria, and failure to appropriately clear them, may led 
to increased ROS production. BMDCs from RIPK2 knockout mice were defective in autophagy 
of mitochondria. Influenza infection of RIPK2-deficient BMDCs led to hyperactivation of 
Caspase 1 and decreased LC3-II levels, a marker of autophagy, as compared to BMDCs from the 
parental mouse strain. Deficiency in RIPK2 caused accumulation of damaged mitochondria and 
extremely elevated levels of ROS production. This is because RIPK2 phosphorylated ULK1 to 
induce autophagy. Loss of ULK1 mimicked the accumulation of damaged mitochondria and 
Caspase 1 hyperactive seen upon influenza infection in RIPK2 deficient cells. The autophagy 
defect resulting from RIPK2 deficiency can be rescued by rapamycin treatment to induced 
autophagy downstream of RIPK2 leading to more subdued Caspase 1 activation levels and 
increased LC3-II [97]. The γ-aminobutyric acid A receptor-associated protein (Gabarap) also 
played a role in clearing damaged mitochondria. Gabarap deficiency led to accumulation of 
damaged mitochondria and ROS production during LPS plus ATP treatment of macrophages. 
Ultimately, Gabarap deficiency led to increased Caspase 1 activation and IL-1β and IL-18 
secretion [98]. 
 Mitochondrial homeostasis requires a delicate balance of mitochondrial fission and 
fusion, mechanisms by which new mitochondria are created and old mitochondria are recycled, 
respectively. As would be expected based off the studies implicating autophagy discussed above, 
both mitochondrial fission and fusion are important in NLRP3 inflammasome activation.  
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The protonophore carbonyl cyanide m-chlorophenyl hydrazine (CCCP) can chemically 
induce mitochondrial fission and inhibited ATP and nigericin-induced NLRP3 inflammasome 
formation. Knockdown of dynamin-related protein 1 (DRP1) caused elongation of mitochondrial 
as a result of defective fission. In turn, DRP1 deficiency caused increased Caspase 1 activation 
and IL-1β secretion in BMDMs treated with LPS plus ATP or just ATP alone. Loss of DRP1 led 
to enhanced phosphorylation of ERK, and inhibition of MEK with U1026 blocked IL-1β 
secretion in DRP1-deficient cells [99]. Although the authors do not propose a mechanism by 
which ERK might be regulating NLRP3 inflammasome activity, it appears from their data that it 
might be through priming, as pro-IL-1β production seems to be decreased in U1026 treated cells. 
This would be consistent with a previously discussed report that found a roll for ERK1 in 
NLRP3 inflammasome priming [67]. If that is the case, it appears DRP1-mediated fission is 
important for both priming and activation of the inflammasome. 
On the other end, mitofusin 2, a mediator of mitochondrial fusion, interacted with NLRP3 
upon loss of mitochondrial membrane polarization after infection with influenza virus. 
Knockdown of mitofusin 2 reduced IL-1β secretion following infection without significantly 
affecting pro-IL-1β production [100]. 
The mitochondria might serve as a scaffold for inflammasome assembly and regulation in 
order to tightly couple mitochondrial homeostasis and NLRP3 inflammasome activation. The 
mitochondria are an important site of negative regulators of NLPR3 too. During NLRP3 
inflammasome activation, both small heterodimer partner (SHP) and NLRP3 are recruited to 
mitochondria where SHP interacted with NLRP3 to block association of NLRP3 and ASC. As 
such, SHP blocked Caspase 1 activation and IL-1β secretion in cells stimulated with ATP, 
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nigericin or dsRNA. Loss of SHP further disrupted mitochondrial integrity during ATP 
stimulation and ultimately led to mtDNA translocating to the cytosol [101]. 
Perturbation of mitochondrial homeostasis by NLRP3 agonists led to decreased 
intracellular NAD+. Addition of NAD+ to cells blocked nigericin-, ATP-, silica- and MSU-
induced NLRP3 inflammasome activation. Decreased NAD+ concentrations led to inactivation of 
the NAD+-dependent α-tubulin deacetylase sirtuin 2 and accumulation of acetylated α-tubulin. 
shRNA-mediated depletion of MEC-17, an acetyltransferase for α-tubulin, decreased IL-1β 
secretion, suggesting acetylated α-tubulin accumulation was critical for NLRP3 inflammasome 
activation. Acetylated α-tubulin caused dynein-dependent rearrangement of mitochondria and 
endoplasmic reticulum so that they approximated each other. Disruption of dynein activity with 
ciliobrevin-D or microtubule dynamics with colchicine, nocodazole or podophyllotoxin all 
decreased IL-1β secretion from a broad range of agonists. These features were all unique to 
NLRP3 agonists, as flagellin and dsDNA-induced IL-1β secretion was unaffected [102]. This 
study, because of its use of a wide range of different agonists and its comprehensive analysis, in 
particular, is one of the best pieces of evidence demonstrating the scaffolding role of 
mitochondria in spatially regulating NLRP3 inflammasome activation. 
 This juxtaposition of NLRP3 and mitochondria might be arranged because the 
mitochondria is the source of two different ligands that trigged NLRP3 inflammasome 
activation. Mitochondrial cardiolipin, a specialized lipid found in the mitochondrial inner 
membrane, bound directly to NLRP3. Cardiolipin-containing liposomes were sufficient to 
activate NLRP3 inflammasome formation. Knockdown of cardiolipin synthesis with siRNA 
targeting cardiolipin synthase decreased linezolid-, silica- and ATP-induced IL-1β secretion. The 
authors propose that cardiolipin is at the intersection of ROS-dependent and ROS-independent 
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signaling pathways, because silica and ATP required ROS and linezolid did not, that converge to 
damage mitochondria and activate the NLRP3 inflammasome [93]. 
 The other NLRP3 ligand identified is oxidized mitochondrial DNA (mtDNA). 
Mitochondrial ROS production led to oxidation of mtDNA. ATP-induced mitochondrial 
dysfunction caused release of oxidized mtDNA into the cytosol. Oxidized mtDNA co-localized 
with the activated NLRP3 inflammasome when expressed and activated in 293 cells. 
Transfection of oxidized mtDNA directly is sufficient to induce IL-1β secretion from LPS-
primed BMDMs [103]. Oxidized mtDNA is thought to translocate from damaged mitochondria 
into the cytosol. Depletion of autophagic proteins LC3B and Beclin 1 led to accumulation of 
damaged mitochondria and increased cytosolic mtDNA in response to ATP treatment. Disruption 
of autophagy increased Caspase 1 activation and IL-1β secretion. Interestingly, culturing cells in 
low levels of ethidium bromide blocks replication of mitochondrial DNA, allowing one to 
culture cells free of mitochondrial DNA after several passages. Loss of mitochondrial DNA 
severely limited LPS plus ATP-induced Caspase 1 activation [104].  
Damage to the mitochondria is also a consequence of NLRP3 inflammasome activation. 
Expression of NLRP3 Y570C, a CAPS-associated mutation, in THP1 cells caused a decrease in 
mitochondrial membrane polarization. Pretreatment of cells with the Cathepsin B (CTSB) 
inhibitor CA-074-Me completely blocked the decrease [105]. The Caspase 1 inhibitor VX-765 
and deletion of Caspase 1 and Caspase 11 can block ATP and CAPS mutation-induced damage 
to mitochondria and ROS production, suggesting these features may also be important 
downstream of inflammasome activation. Interestingly, Parkin, a critical protein in promoting 
mitophagy, was cleaved by Caspase 1 leading to inhibition of mitophagy [106]. These data 
suggest a possible positive feedback cycle to amplify NLRP3 inflammasome signaling.  
 42 
 
 
Figure 1.6. Accumulation of mitochondrial damage activates the NLRP3 inflammasome. 
This figure summarizes the discussion in section 1.7.2. All pathways were combined for the 
purpose of comparison and brevity. Concurrence of different pathways has not been established. 
Tan circles indicate proteins that oppose NLRP3 inflammasome activation. Purple circles 
indicate proteins that promote NLRP3 inflammasome activation. Solid lines represent direct 
interactions and dotted lines represent indirect interactions. My hypothesis is that accumulated 
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damage to mitochondria is central in these NLRP3 inflammasome activating pathways. Low 
NAD+ concentration decreased activity of Sirtuin 2, an α-Tubulin deacetylase. Accumulation of 
acetylated α-Tubulin resulted in dynein-dependent microtubules rearrangement of mitochondria, 
binding of NLRP3 and activation of the NLRP3 inflammasome. Loss of MEC-17, an α-Tubulin 
acetyltransferase, prevented microtubule and dynein-dependent rearrangement. Oxidized 
mtDNA and cardiolipin both bound directly to NLRP3 and promoted NLRP3 inflammasome 
activation. ROS production activated PARP and led to production of ADP-ribose. ADP-ribose 
opened the Ca2+ channel TRPM2 which was required for NLRP3 inflammasome activation. 
ROS production blocked the association of TRX and TXNIP and allowed TXNIP to interact with 
NLRP3 promoting NLRP3 inflammasome formation. Functional autophagy opposed NLRP3 
inflammasome activation. RIPK2 phosphorylated ULK1, a requirement for autophagy. 
Rapamycin treatment bypassed loss of RIPK2 to promote autophagy. Loss of Gabarap prevented 
autophagy through an unknown mechanism. Loss of DRP resulted in defective mitochondrial 
fission and NLRP3 inflammasome activation. SHP associated with the mitochondria and 
inhibited NLRP3 inflammasome formation. Activation of the NLRP3 inflammasome resulted in 
Caspase 1- and CTSB-dependent mitochondrial ROS production and damage.   
 
1.7.3 Lysosome dysfunction liberates the cysteine protease Cathepsin B 
 Early studies of NLRP3 inflammasome activation reported a critical requirement for 
CTSB activation. Expression of NLRP3 Y570C, a CAPS-associated mutation, in THP1 cells 
caused lysosomal leakage as measured by staining with the lysosome-accumulating dye acridine 
orange. Inhibition of CTSB with CA-074-Me eliminated lysosomal leakage in the NLRP3 
mutant [105], a very unusual discovery given that CTSB is a protease that is activated inside 
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lysosomes normally. Inhibition of CTSB also blocked NLRP3 induced cell death [105], 
suggesting that CTSB leakage and activation might be driving necrosis. The requirement for 
CTSB in CAPS-associated mutant-mediated cell death has been confirmed in a subsequent study 
[107]. CTSB is also required for pathogen and particulate matter-associated NLRP3-induced cell 
death [107-109]. 
 Bafilomycin A is an inhibitor of the vacuolar H+-ATPase in lysosomes that prevents 
acidification of lysosomes. Bafilomycin treatment of macrophages blocked both acidification of 
lysosomes, as measured with the lysomotropic pH sensitive dye lysosensor green, and 
suppressed lysosomal proteolytic function. This inhibition led to a decrease in silica-mediated 
IL-1β release but had no effect on ATP treatment. In this setting, activation of CTSB preceded 
NLRP3 activation, as mature CTSB was still detected in NLRP3 knockout cells [108]. During 
Neisseria gonorhoeae infection of macrophages, the same effect was seen: inhibition of CTSB, 
but not Cathepsin L, blocked NLRP3-dependent IL-1β secretion and LDH release, a marker for 
cell death [109]. The requirement for CTSB in CAPS-associated mutants and in the activation of 
wildtype NLRP3 suggests that CTSB plays an amplifying role by acting on both ends of the 
NLRP3 inflammasome pathway. 
 The commonly used CTSB inhibitor CA-074-Me inhibits cathepsins family proteins 
more broadly at concentrations commonly used in NLRP3 inflammasome studies [110]. This 
broad inhibition of cathepsins turns out to be the real requirement for blocking NLRP3 
inflammasome activation. Genetic disruption of individual cathepsins B, C, L, S, or X had no 
effect on silica-induced IL-1β secretion. Only by deleting all five cathepsins could an effect be 
seen [110]. Interestingly, a newly described broad cathepsin inhibitor, K777 [111], potently 
 45 
 
blocked IL-1β secretion even in the absence of these five cathepsins [110], suggesting that there 
are still more cathepsins at play or that the inhibitor had additional off-target effects.  
 Once cathepsins are activated and released into the cytosol, their mechanism of action 
leading to NLRP3 activation is not well understood. One suggestion is that lysosome rupture 
leads to a cascade of kinase signaling that activates the NLRP3 inflammasome. Treatment of 
THP1 cells with Leu-Leu-OMe (LLME), a direct lysosome disrupting peptide, activated TAK1 
(MAP3K7) leading to phosphorylation of JNK. Inhibiting cathepsins with CA-074-Me or 
bafilomycin A blocked phosphorylation of JNK. The TAK1 inhibitor, 5-Z-oxozeaenol, or 
siRNA-mediated knockdown of TAK1 blocked LLME-induced JNK phosphorylation. These 
inhibitory effects decreased activation of Caspase 1 in response to LLMe and MSU [112]. 
Interestingly, 5-Z-oxozeaenol prevented ATP-induced Caspase 1 activation, even though ATP 
has not previously been shown to activate cathepsins [112,113]. This finding suggests that TAK1 
may be a common transducer of signaling to activate the NLRP3 inflammasome by both 
lysosome-dependent and -independent mechanisms. TAK1 and JNK phosphorylation in response 
to LLME was also blocked by chelation of intracellular calcium using BAPTA-AM [112], but 
the exact role of calcium was unclear. 
 Although the ties between cathepsin leak and NLRP3 inflammasome signaling are still 
not well established, activation of such a broad range of cathepsins is likely to have a profound 
effect on cells. Given the fact that Ca-074-Me blocked downstream TAK1 phosphorylation in 
response to LLMe, it would be interesting to examine the effects of cathepsins on protein 
phosphatases, and whether inhibition of protein phosphatases is sufficient to bypass inhibition of 
cathepsin activation. 
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Figure 1.7 Lysosomal disruption contributes to NLRP3 inflammasome signaling. This 
figure summarizes the discussion from section 1.7.3. Numerous NLRP3 inflammasome 
activating agents disrupted lysosomes and caused release of cathepsins into the cytosol. 
Inhibition of Vacuolar H+-ATPase with Bafilomycin A or of cathepsins with CA-074-Me and 
K777 prevented NLRP3 inflammasome activation. In a study investigating LLMe, Cathepsin 
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release triggered TAK1-JNK signaling leading to NLRP3 inflammasome activation. Solid lines 
represent direct interactions and dotted lines represent indirect interactions. 
 
1.7.4 Endoplasmic reticulum dysfunction disrupts protein folding 
 The endoplasmic reticulum (ER) has also been proposed as central to NLRP3 
inflammasome activation. Induction of ER stress directly using brefeldin A (BFA), which 
reversibly blocks protein transport from the ER to the Golgi, thapsigargin, which blocks ER 
SERCA pumps and depletes ER calcium stores, or tunicamycin, which blocks GlcNAc-1-
phosphate transferase and prevents glycoprotein synthesis, led to IL-1β secretion in primary 
human macrophages. NLRP3 deficient cells or cells incubated in high potassium media did not 
secrete IL-1β in response to these ER stress triggers. Disruption of the unfolded protein response 
(UPR) by depleting IRE1 had no effect on BFA-induced IL-1β secretion, depletion of PERK had 
no effect on tunicamycin-induced IL-1β secretion and deletion of ATF6a had no effect on 
thapsigargin- or tunicamycin-induced IL-1β secretion [114]. These data suggest that ER stress-
mediated NLRP3 inflammasome activation in this setting is independent of the well-studied UPR 
pathway. However, the incomplete analysis of treatments and effectors made it likely something 
could be missed, as we will see below. 
 Alternate mechanisms of NLRP3 activation might, however, triggered the UPR to 
activate the NLRP3 inflammasome. Silver nanoparticles of 15 nanometers (AgNP15) induced 
ER stress in THP1 monocytes and ultimately NLRP3 inflammasome-dependent Caspase 1 
activation, IL-1β secretion and cell death. During AgNP15 treatment, ATF6, an ER stress sensor, 
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was rapidly degraded. Blocking ATF6 degradation with the Site-2 protease inhibitor 1,10-
phenanthroline completely blocked AgNP15-induced NLRP3 inflammasome activation [115].  
 A few studies have found links between ER stress and mitochondrial disruption. ER 
stress-induced by thapsigargin caused IRE1 activation leading to upregulation of TXNIP by 
depleting the TXNIP mRNA regulator miR-17. As seen before with mitochondria, TXNIP is 
involved in activation of the NLRP3 inflammasome, and as such, thapsigargin-induced TXNIP 
upregulation led to NLRP3-dependent IL-1β secretion in THP1 cells [116,117]. Inhibition of 
IRE1 with STF-083010 was sufficient to block thapsigargin-induced IL-1β secretion, but not 
ATP-induced IL-1β secretion [117]. 
In BMDMs infected with Brucella abortus strain RB51, NLRP3 was activated leading to 
Caspase 1-dependent IL-1β secretion. Treatment of cells with the chemical chaperone 
tauroursodeoxycholic acid (TUDCA) to facilitate protein folding and alleviate ER stress or 4μ8c, 
an inhibitor of IRE1, blocked RB51-induced IL-1β secretion but had no effect on LPS plus ATP-
induced IL-1β secretion. IRE1 upregulated TXNIP expression, as seen in previous studies. 
NLRP3 caused mitochondrial stress independent of ASC by activating Caspase 2-dependent 
cleavage and activation of Bid. Knockdown of Bid in BMDM prevented RB51-induced 
mitochondrial disruption, Caspase 1 activation and IL-1β secretion [118].  
 However, not all inflammasome activators trigger ER stress. Notably, MSU and R837, a 
NLRP3 inflammasome-activating anti-viral compound, did not induce CHOP activation, a 
marker for ER stress [114]. Therefore, ER stress-induced NLRP3 activation may be an 
uncommon requirement for only a unique set of activating molecules. 
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 The ER has also been proposed to be a critical source for calcium signaling leading to 
NLRP3 inflammasome activation. That will be discussed in the next section. 
 
1.7.5 Calcium acts a second messenger  
 Another less prominent but still common regulatory schema controlling NLRP3 
inflammasome activity is the mobilization of calcium ions (Ca2+). Evidence suggesting a role for 
Ca2+ began to emerge around the same time the NLRP3 inflammasome was discovered. 
 IL-1β does not have a signal sequence and is not secreted through the classical ER-Golgi 
route. Drugs that blocked intracellular transport of IL-6, TNF-α and other secreted proteins had 
no effect on IL-1β secretion [119]. BAPTA-AM, an intracellular calcium chelator, inhibited 
ATP-induced IL-1β processing and secretion. To test the opposite condition, 100μM ATP (sub-
P2RX7 activating) and 1μM thapsigargin were used to mobilize calcium. Cells treated with 
thapsigargin or thapsigargin and ATP secreted significantly less IL-1β in response to both ATP 
and nigericin. Thapsigargin is an inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase 
(SERCA), the channel that opposes Ca2+ leak from the ER. By blocking SERCA, thapsigargin 
increased intracellular Ca2+ concentration. Increased intracellular Ca2+ concentration was not 
sufficient to induced IL-1β secretion and premature depletion of Ca2+ from the ER blocked IL-1β 
secretion. Coordinated Ca2+ ER flux and cytoplasmic potassium depletion were together required 
for effective IL-1β secretion [120]. 
 Ca2+-dependent NLRP3 inflammasome activation extends beyond classical NLRP3 
agonists. Cholesterol-dependent cytolysins, exotoxins secreted by many Gram-positive bacteria 
that bind cholesterol to form pores in eukaryotic cell membranes, activated the NLRP3 
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inflammasome in a Ca2+-dependent manner as BAPTA-AM treatment suppressed IL-1β 
secretion. This study also confirmed that BAPTA-AM treatment can block ATP- and nigericin-
induced IL-1β secretion [121]. 
 Rhinovirus ion channel protein 2B (P2B) triggered the NLRP3 inflammasome in a Ca2+-
dependent manner. Expression of P2B in bronchial cells caused an increase in cytosolic Ca2+ and 
thapsigargin pretreatment reduced the P2B-dependent increase in Ca2+ suggesting that they both 
pulled from the same source – the ER. Further supporting that notion, P2B and NLRP3 co-
localized at the Golgi and disruption of the Golgi with the fungal metabolite brefeldin A (BFA) 
caused a redistribution of P2B and blocked NLRP3 inflammasome activation by rhinovirus. 
However, BFA did not have the same effect on ATP-induced IL-1β secretion, suggesting that 
this mechanism may be unique to Golgi targeted proteins. Lastly, as was done in previous 
studies, BAPTA-AM treatment of rhinovirus infected cells caused a significant decrease in IL-1β 
secretion, further implicating Ca2+ in this process [122]. 
 Similarly, encephalomyocarditis virus (EMCV) viroporin 2B activates the NLRP3 
inflammasome and localized to the Golgi where it caused an increase in intracellular Ca2+ 
concentration. EMCV-induced IL-1β secretion was blocked by BAPTA-AM treatment, but not 
suppression of mitochondrial ROS or inhibition of Cathepsin B with Ca-074 Me [123]. This may 
be a common theme in picornaviruses as multiple others, including coxsackievirus, polio virus, 
hepatitis A virus, enterovirus, and foot-and-mouth disease virus, all produce similar 2B proteins 
that localize to the Golgi or ER or effect Golgi and ER integrity [124].  
 One study on keratinocytes suggests that Ca2+ plays a role in activation of the NLRP3 
inflammasome here too. Keratinocytes secreted IL-1β in a NLRP1- and NLRP3-dependent 
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manner in response to UVB irradiation. UVB irradiation caused an increase in intracellular Ca2+ 
concentration that when blocked with BAPTA-AM suppressed IL-1β secretion. An extracellular 
Ca2+ chelator was not effective in blocking IL-1β secretion, adding to evidence suggesting an 
intracellular source of Ca2+ flux [125]. 
 The emerging mechanism describing how increases in intracellular Ca2+ activate the 
NLRP3 inflammasome is complex and may differ depending on the type of stimulus used. A few 
studies have begun to detail this complexity. 
 Multiple calcium release inhibitors including the two SERCA inhibitors thapsigargin and 
XeC, the Phospholipase C (PLC) inhibitor U73122, and the Inositol 1,4,5-trisphosphate receptor 
(IP3R) inhibitor 2-aminoethoxydiphenyl borate (2-APB) blocked ATP-, nigericin-, MSU- and 
LLMe-induced calcium mobilization and IL-1β secretion [126,127]. Knockdown of IP3R had the 
same effect [127]. 
 Loss of the murine calcium sensing receptor (CASR) also suppressed ATP-induced 
Caspase 1 activation and IL-1β secretion and demonstrated the potential of extracellular Ca2+ to 
activate the NLRP3 inflammasome [127]. CASR interacted with both PLC and adenylate cyclase 
(ADCY), the protein responsible for generation of cAMP, and both pathways remained intact 
and responsive to direct activation in a CASR-deficient background. The PLC agonist m-
3M3FBS, the ADCY inhibitor KH7, and knockdown of ADCY3, ADCY6, ADCY7 or ADCY9 
led to spontaneous IL-1β secretion, suggesting that both arms of this calcium-sensitive pathway 
are critical for controlling NLRP3 inflammasome activity [127]. 
 Increasing cAMP concentrations by activating ADCY with NKH477 or forskolin or 
decreasing cAMP hydrolysis by inhibiting phosphodiesterase (PDE) 4 with Ro-20-1724, (r)-(-)-
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rolipram, or zardaverine suppressed IL-1β secretion and ASC oligomerization induced by ATP. 
cAMP bound directly to NLRP3 and binding was decreased with CAPS-associated NLRP3 
mutations suggesting that the spontaneous activation of these mutations may be due to decreased 
cAMP binding. Furthermore, activating ADCY or inhibiting PDE4 to increase cAMP 
concentrations suppressed IL-1β secretion from PBMCs isolated from CAPS patients with 
NLRP3 mutations. Treatment with 2-APB or BAPTA also decreased IL-1β secretion from these 
cells [127].  
A separate study confirmed that increased concentrations of extracellular Ca2+ can 
activate the NLRP3 inflammasome, but came up with a different mechanism of action. Inhibition 
of CASR with Calhex231 and GPRC6A with NPS2143 separately blocked IL-1β secretion in 
response to extracellular Ca2+ but had no effect on ATP-induced NLRP3 inflammasome 
activation [128]. This is in contrast to the previously discussed study on CASR that showed a 
role for CASR in ATP-induced NLRP3 inflammasome activation. That studied made use of a 
CASR knockout though [127], raising the possibility that Calhex231 is not acting specifically on 
CASR in the presently discussed study. The requirement for CASR in extracellular Ca2+-
mediated inflammasome activation in the current study is further supported by siRNA-mediated 
depletion of CASR that caused disruption of IL-1β secretion, not just the inhibitor [128]. 
Unlike in the previous study of ATP-induced Ca2+ mobilization, cAMP had no role in 
extracellular Ca2+ mediated-IL-1β secretion as treatment with forskolin, the ADCY activator, and 
SQ22536, an ADCY inhibitor, had no effect. Additionally, apyrase treatment to consume 
extracellular ATP had no effect on IL-1β secretion. Exposure of monocytes to necrotic cells 
(induced by 7-BIO treatment) caused IL-1β secretion that was suppressed by Calhex231 and 
GPRC6A knockout, suggesting that necrotic cells can act as a physiologic source of increased 
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extracellular calcium. In vivo, injection of aluminum ions, another agonist of GPRC6A, caused 
footpad swelling and IL-1β secretion that was not seen in GPRC6A deficient or Caspase 1 
deficient mice [128]. 
The discrepancy in whether cAMP production through ADCY activation with forskolin 
regulates the NLRP3 inflammasome in the two studies of CASR might be explained by the dose 
of forskolin used. In the study that found an effect, the dose of forskolin to achieve suppression 
of IL-1β secretion was between 50 and 500μM [127] whereas the study that purported no effect 
only used concentrations as high as 20μM [128]. Strangely though, direct measurement of cAMP 
in both studies suggests that the dose used caused an increase in cAMP concentration of 
comparable magnitude. It is also possible that there is a difference in sensitivity of murine 
BMDMs and human monocytes to cAMP-mediated NLRP3 inflammasome regulation. 
 C/EPB homologous protein (CHOP) regulates ER Ca2+ release through IP3R and was 
required for NLRP3 inflammasome activation in response to ATP stimulation. XeC did not 
further reduce IL-1β secretion in a CHOP deficient background suggesting that CHOP and IP3R 
are part of the same pathway. Calcium flux also led to production of mitochondrial ROS that was 
blocked by each of the aforementioned inhibitors used in this study. Lastly, potassium efflux was 
required for ATP-mediated Ca2+ flux [126].  
Sublytic concentrations of the complement-mediated membrane attack complex (MAC) 
can activate the NLRP3 inflammasome. Pretreatment with BAPTA-AM, XeC or 2-APB 
suppressed MAC-induced IL-1Β secretion, as seen before with other stimuli. Additionally, the 
FDA-approved Ryanodine receptor inhibitor dantrolene also reduced MAC-triggered increases 
in cytosolic Ca2+ and IL-1β secretion. Released Ca2+ was found to accumulate in the 
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mitochondria using the Rhod2-AM probe and knockdown of the mitochondrial calcium uniporter 
(MCU) reduced both mitochondrial calcium uptake and IL-1β secretion, possibly providing a 
link between Ca2+ mobilization and mitochondrial ROS production [129].  
Another recent study has linked Ca2+ mobilization and mitochondrial dysfunction through 
the MCU. Pseudomonas aeruginosa flagellin activated the NLRP3 inflammasome in IB3-1 cells, 
bronchial epithelial cells derived from a patient with cystic fibrosis. Treatment with purified 
flagellin induced MCU transport of Ca2+ into the mitochondria leading to ROS production. 
Depletion of MCU in IB3-1 and CFTRΔ508-expressing human primary cells blocked Ca2+ 
accumulation in the mitochondria and decreased IL-1β secretion. Mutation of CFTR in cystic 
fibrosis has been shown to enhance cytosolic and mitochondria Ca2+ mobilization, setting these 
cells up to be particularly sensitive to this mode of NLRP3 activation [130]. This study, in 
addition to the previously discussed study implicating MCU, raise the possibility that MCU may 
be a common tie between Ca2+ and mitochondria dysfunction in NLRP3 inflammasome 
signaling. 
Reliance on phagocytosis-mediated NLRP3 activation can turn the relationship between 
Ca2+ mobilization and mitochondrial ROS production around. In this study, charged liposomes 
were used to activate the NLRP3 inflammasome and induce IL-1β secretion. Liposome-mediated 
NLRP3 activation required phagocytosis and could be blocked by cytochalasin D, much like 
alum-induced activation, but not like ATP-induced activation. These liposomes caused an 
increase in intracellular Ca2+ that was not seen when Ca2+ was removed from the media. It was 
discovered that liposome-, silica- and alum-mediated Ca2+ flux required TRPM2 as Ca2+ flux 
was blocked by TRPM2 knockout. TRPM2 is an ADP-ribose and Ca2+ gated channel and as such 
was blocked by inhibition of PARP with DPQ to prevent ADP-ribose accumulation. 
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Additionally, treatment with the antioxidant DPI to suppress ROS generation also blocked Ca2+ 
flux. Loss of TRPM2 suppressed Caspase 1 activation and IL-1 β secretion in response to 
liposomes, alum, silica and MSU and in MSU-induced peritonitis, but did not affect ROS 
generation, suggesting that ROS is upstream of TRPM2 [96].  
Activation of the NLRP3 inflammasome by lysosome rupture triggered by LLME 
required Ca2+-dependent TAK1-JNK signaling. While lysosome rupture was discussed in section 
1.7.3, and kinase signaling will be discussed in more detail in section 1.7.7, the requirement for 
Ca2+ signaling will be discussed here. The intracellular calcium chelator BAPTA-AM, but not 
extracellular calcium chelators, suppressed TAK1-JNK signaling suggesting that lysosome 
rupture releases calcium ions that activate TAK1-JNK. The authors claim that the 
Ca2+/calmodulin-dependent protein kinase II (CaMKII) inhibitor KN-93 suppressed LLME-
induced TAK1-JNK signaling, however the effect is rather hard to appreciate. Additionally, KN-
93 and its inactive derivative KN-92 both suppressed Caspase 1 activation and IL-1β secretion in 
response to LLME, although KN-92 to a lesser extent than KN-93 [112]. This observation is not 
consistent with CaMKII regulating NLRP3 inflammasome activation, a fact that is overlooked 
by the authors. KN-93 and KN-92 also exert CaMKII-independent effects through inhibition of 
L-type and N-type calcium channels at doses substantially lower than those used to show an 
effect on the NLRP3 inflammasome. The structurally unrelated CaMKII inhibitor AIP does not 
exert these effects and would be an easy means to test for this off-target effect [131]. Another 
kinase, death associated protein kinase (DAPK), contains a calcium/calmodulin-regulatory 
(CaM) domain and has been implicated in regulating the NLRP3 inflammasome. However, in 
the one study investigating DAPK, calcium studies were not conducted [132].  
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Ca2+ release from the ER causes opening of store-operated Ca2+ release-activated Ca2+ 
(CRAC) channels in the plasma membrane via the interaction of stromal interaction molecule 
(STIM) 1 and STIM2. This allows ORAI1, the pore-forming subunit of the CRAC channel, to 
open and results in store-operated Ca2+ entry (SOCE). To study the role of SOCE in innate 
immunity, STIM1 and STIM2 conditional knockout mice were generated. BMDMs from 
STIM1-deficient and STIM2-deficient mice secreted equivalent levels of IL-1β in response to 
ATP and MSU as wildtype BMDMs despite slight decreases in Ca2+ mobilization. Although 
SOCE was not required, Ca2+ inhibitors used previously including BAPTA and 2-APB were 
confirmed to block ATP-induced IL-1β secretion [133].  
Despite this evidence for Ca2+ signaling playing an important role in regulating the 
NLRP3 inflammasome, multiple studies contradict these findings. 
The calcium ionophore ionomycin increased cytoplasmic calcium concentrations by 
triggering influx of extracellular calcium and release of ER calcium stores but did not trigger IL-
1β secretion in BMDCs [134] or BMDMs [126], suggesting that calcium flux is not sufficient for 
NLRP3 inflammasome activation. 
Nigericin-induced increases in cytosolic Ca2+ concentration, but these Ca2+ currents 
actually appeared to occur downstream of the NLRP3 inflammasome as loss of NLRP3 and 
Caspase 1 in BMDCs suppressed Ca2+ mobilization. Incubation of BMDCs in calcium-deficient 
media prevented both ATP- and nigericin-induced increases in the cytosolic Ca2+ concentration 
but has no effect on their ability to stimulate IL-1β secretion. LLME-induced IL-1β secretion 
was actually enhanced by culture in calcium-deficient media and LLME-induced calcium 
currents were observed to be NLRP3 inflammasome dependent. Thapsigargin treatment of 
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BMDCs caused an increase in intracellular Ca2+ that required calcium-containing media. The 
authors of this study reason that, while thapsigargin blocks SERCA activity, it also induced 
oligomerization of STIM family sensors in the ER that opened OraI family store-operated Ca2+ 
influx channels within juxtaposed domains of the plasma membrane. These channels facilitated 
Ca2+ influx to offset the loss of intracellular Ca2+ and replenish ER Ca2+. Thapsigargin treatment 
in calcium-depleted media, in order to isolate ER Ca2+ disruption, also had no effect on 
nigericin- or ATP-induced IL-1β secretion. Unfortunately, only a small number of confirmatory 
experiments were conducted in BMDMs. Treatment of BMDMs with ATP or nigericin in 
calcium-depleted media or thapsigargin pretreatment did not decrease IL-1β secretion [134].  
Interestingly, BAPTA-AM treatment suppressed nigericin-induced IL-1β secretion in 
BMDCs treated in calcium-deficient media. The authors reasons that since there was no 
observable increase in intracellular Ca2+ in nigericin-treated cells incubated in calcium-deficient 
media, the suppressive activity of BAPTA must have been the result of some other change. 
Similarly, treatment of BMDCs with 2-APB, the IP3R inhibitor, caused complete suppression of 
nigericin-induced IL-1β secretion. Rather than suppressing Ca2+ mobilization, as would be 
expected with an IP3R inhibitor, the intracellular Ca2+ concentration was increased dramatically, 
in both 2-APB and 2-APB plus nigericin treated cells and this was not observed with nigericin 
treatment alone [134]. While this study was very thorough and convincing, it was conducted 
almost entirely using BMDCs and not BMDMs as is more commonly used. This difference 
makes it difficult to compare directly between this and previously discussed studies. 
Overall, the majority of conflicting findings in these studies pertain to responses seen 
with pharmacologic manipulation. Numerous knockouts and knockdowns have been made to 
substantiate findings and provide additional strength to experiments involving pharmacologic 
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manipulations. More widespread use of genetic approaches will continue to provide confidence 
in the role of calcium in regulating NLRP3 inflammasome activity. Surprisingly, the finding that 
loss of MCU protects mitochondria from MAC-mediated dysregulation has been largely 
overlooked by subsequent studies, but I feel it is an area worth investigating further. 
 
1.7.6 Ubiquitination acts as a platform for regulator binding 
 Classically, ubiquitination plays a role in regulating protein turnover by targeting proteins 
for proteasomal degradation [135,136]. However, ubiquitination, mainly by the LUBAC, is also 
now being appreciated as a non-proteasomal regulator of the NLRP3 inflammasome. 
  The LUBAC is required for NLRP3 inflammasome activation in response to a wide 
variety of triggers. BMDM deficient in HOIL-1L, a component of the LUBAC, have decreased 
IL-1β secretion in response to nigericin, ATP, silica, MSU, and dsDNA, an activator of the 
AIM2 inflammasome. Upon treatment of BMDMs with nigericin, linear ubiquitin-specific 
antibody staining co-localized with ASC foci in an HOIL-1L-dependent manner. This linear 
ubiquitin chain is bound directly to ASC. In vivo, HOIL-1L is required for both NLRP3-
dependent MDP-induced peritonitis and LPS-induced septicemia demonstrating that linear 
ubiquitination of NLRP3 is an important regulator of NLRP3 activity [137]. Sharpin, another 
component of the LUBAC, is also required for NLRP3 inflammasome activation as loss of 
Sharpin expression almost completely eliminated ATP-induced IL-1β and IL-18 secretion and 
LDH release [75]. Strangely, while loss of Sharpin expression reduced cytokine secretion in 
response to nigericin, alum, flagellin and dsDNA, it had no effect on LDH release [138]. The 
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difference is unexpected and may suggest that ATP-induced cell death has a unique requirement 
for Sharpin. 
Deubiquitination is also necessary to release baseline inhibition of NLRP3 to promote 
NLRP3 inflammasome activation. The small molecule DUB enzyme inhibitor G5 increased 
ubiquitination of the NACHT and LLR domains and blocked ATP-, nigericin-, silica and LLMe-
induced IL-1β secretion. BRCC3 was identified through a series of co-immunoprecipitation, 
overexpression, and knockdown experiments to screen cellular DUBs as a critical DUB in 
NLRP3 inflammasome activation [139]. 
Steady-state ubiquitination may serve as a platform for negative regulators of the NLRP3 
inflammasome. HDAC6, a negative regulator of the NLRP3 inflammasome, bound directly to 
NLRP3 through its Binder of Ubiquitin Zinc finger (Buz) domain. Loss of HDAC6 caused 
increased ASC oligomerization, Caspase 1 activation and IL-1β secretion in response to ATP and 
nigericin. Treatment with the DUB enzyme inhibitor PR619 caused increased NLRP3 
ubiquitination, as expected, and also suppressed ATP-induced IL-1β secretion in an HDAC6-
dependent manner [140]. At this point, it remains unclear how HDAC6 binding to NLRP3 
suppressed NLRP3 inflammasome activity. 
 Ubiquitination also regulated the NLRP3 inflammasome indirectly. Tripartite motif 33 
(TRIM33), like most proteins in the TRIM family, is a E3 ubiquitin ligase that interacts with E2 
ubiquitin-conjugating enzymes via their RING domain and transfers ubiquitin from E1 ubiquitin 
activating enzymes [141,142]. TRIM33 interacted with DHX33, the cytosolic dsRNA sensor for 
the NLRP3 inflammasome [143], and induced K63-linked ubiquitination of DHX33 K218 upon 
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dsRNA stimulation. This ubiquitination promoted interaction between DHX33 and NLRP3. As a 
result, TRIM33 was essential for dsRNA-induced NLRP3 inflammasome activation [144]. 
 A20, a ubiquitin-modifying enzyme that inhibits NF-κB, also regulated the NLRP3 
inflammasome. A20 deficient macrophages treated with LPS alone spontaneously secreted IL-1β 
and IL-18, and dramatically increased IL-1β secretion when additionally stimulated with ATP. 
This effect was dependent on RIPK3 and RIPK1. A20 associated with pro-IL-1β in a complex 
including Caspase 1, Caspase 8, RIPK1 and RIPK3. Pro-IL-1β was found to be ubiquitinated 
with K63-linked ubiquitin chains and poly-ubiquitin at pro-IL-1β K133 before activation of the 
NLRP3 inflammasome as blocking potassium efflux had no effect on the ubiquitination status of 
pro-IL-1β. Overexpression of A20 suppressed K63-linked ubiquitination of pro-IL-1β and 
decreased Caspase 1 activation. Similarly, a pro-IL-1β K133R mutation resulted in decreased IL-
1β secretion [145].  
 Ubiquitination is also hijacked by pathogens to trigger NLRP3 inflammasome activation. 
Shigella flexneri, the cause of the food borne illness Shigellosis, injects invasion plasmid antigen 
H (IpaH) 7.8, an E3 ubiquitin ligase, through its type 3 secretion system into the host cytosol. 
The presence of IpaH7.8 during infection of macrophages caused NLRP3- and NLRP4-
dependent Caspase 1 activation, IL-1β and IL-18 secretion and LDH release. Treatment of cells 
with the ubiquitin-proteasome inhibitor MG132 blocked IpaH7.8-mediated cell death, 
implicating the E3 ligase activity of IpaH7.8 in this process. IpaH7.8 interacted with GLMN, a 
Cullin ring ligase inhibitor [146,147], hinting at a role for GLMN in NLRP3 inflammasome 
activation. Upon stimulation with LPS and ATP, GLMN localized in specks, similar to the 
NLRP3 inflammasome, and sometimes but not always co-localized with Caspase 1. IpaH7.8 
forced this localization. Heterozygosity of GLMN (deletion was embryonic lethal) in murine 
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BMDMs led to increased IL-1Β secretion and cell death in response to Shigella infection that 
required IpaH7.8. A similar role of GLMN in suppressing NLRP3 inflammasome activation was 
also seen for LPS and ATP treatment [148]. Exactly how GLMN regulates the NLRP3 
inflammasome is unknown, but the authors of this paper suggest that it may be through inhibiting 
an E3 ubiquitin ligase that activates the NLRP3 inflammasome. Numerous other bacteria, such 
as enteropathogenic Escherichia coli and Legionella pneumophila, produce virulence factors that 
hijack the human ubiquitination system too [149]. Further research may uncover other 
pathogenic ubiquitin-manipulating NLRP3 inflammasome-activating factors 
 Ubiquitin targeting NLRP3 for degradation is also an important regulator of NLRP3 
inflammasome activity. Dopamine binding to the DRD1 receptor trigged production of cAMP 
that binds to NLRP3 and promotes K48-linked polyubiquitination of NLRP3 by the E3 ligase 
MARCH7. As such, dopamine stimulation of BMDMs decreased IL-1β and IL-18 secretion 
induced by MSU, nigericin, ATP and alum. Loss of MARCH7 blocked dopamine-mediated 
NLRP3 inflammasome repression. Interestingly, the autophagy inhibitor 3-methyladenine (3-
MA) blocked dopamine-induced NLRP3 degradation but the proteasome inhibitor MG132 did 
not. Dopamine-DRD1 signaling also suppressed inflammation in a variety of models including 
nigericin-induced neuroinflammation, LPS-induced systemic inflammation and MSU-induced 
peritoneal inflammation [150].  
Each of these regulatory mechanisms is probably relied upon to a different extent in 
different tissues. For example, colonic macrophages suppressed NLRP3 and pro-IL-1β through 
ubiquitination and proteasomal degradation, as inhibition with MG-132 dramatically increased 
NLRP3 and pro-IL-1β protein levels in these macrophages, but not in BMDMs [151]. Further 
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regulatory differences will be discovered as more cell types and tissue types continue to be 
investigated. 
 
1.7.7 Phosphorylation controls inflammasome oligomerization 
 Numerous kinases have been identified that regulate the NLRP3 inflammasome in 
response to a wide range of stimuli. However, the exact mechanism of action for most of these 
kinases remains unknown. NLRP3 inflammasome-regulating kinases are an important area of 
study because the druggability of kinases [152] makes them viable targets for modulating 
NLRP3 inflammasome activity. 
  
1.7.7.1 Syk kinase couples C-type lectin domain family members to NLRP3 inflammasome 
signaling 
The first identified and most well studied NLRP3 inflammasome-regulating kinase is 
Spleen tyrosine kinase (Syk). Syk coupled the detection of fungal molecular patterns by Dectin1 
(also known as CLEC7A) to NLRP3 inflammasome activation [90,153]. Specifically, Dectin-1 
bound to beta-glucans, polysaccharides in fungal cell walls, including curdlan, glucan from 
baker’s yeast, paramylon and zymosan [153]. Pharmacological inhibition or genetic depletion of 
Syk completely blocked NLRP3-dependent Caspase 1 activation and IL-1β and IL-18 secretion 
in response to Candida albicans [90] and beta-glucans [153]. Additionally, activation of NLRP3 
by beta-glucans was blocked by cytochalasin D, an inhibitor of phagocytosis, CA-074-Me, an 
inhibitor of CTSB, butylated hydroxyanisole (BHA), an antioxidant, and extracellular potassium 
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[153]. Loss of NLRP3 increased susceptibility of mice to C. albicans infection, suggesting that 
the Dectin1-Syk-NLRP3 pathway is critical for generating a productive immune response [90]. 
Syk activation has also been shown to be required for NLRP3 inflammasome activation in 
response to Aspergillus fumigatus [154], acapsular Cryptococcus neoformans [155], and 
Malassezia yeasts [156], a cause of pityriasis versicolor. 
 Beyond detection of fungal pathogens, the role of Syk in NLRP3 inflammasome 
activation is mixed. Soluble schistosomal egg antigens (SEA) from Schistosoma mansoni bound 
to Dectin-2 (also known as CLEC6A) and activated Syk to induce NLRP3 inflammasome 
activation. Unlike Dectin-1/Syk recognition of fungal molecules, this response was not sensitive 
to inhibition by cytochalasin D but did require ROS and potassium efflux. Mice lacking ASC or 
NLRP3 infected with S. mansoni showed decreased immunopathology including smaller 
granulomas with no significant difference in parasite burden [157] suggesting that NLRP3 
inflammasome activation is a detrimental immune response in this setting. 
 Evidence also suggests that Syk may play a role in NRLP3 inflammasome activation in 
response to dengue virus. NLRP3-dependent Caspase 1 activation, IL-1β and IL-18 secretion and 
cell death were observed in dengue virus infected macrophages [158]. Treatment with an 
antibody to block CLEC5A, a C-type lectin critical for dengue hemorrhagic fever [159] and 
Japanese encephalitis virus infection [160], inhibited NLRP3 inflammasome activation [158]. 
Activation of the NLRP3 inflammasome by dengue virus could be blocked by preventing 
potassium efflux, CTSB activation and Syk activation [158].  
Dectin-1, Dectin-2 and CLEC5A are all C-type lectin domain family members, remarked 
for their similarity to the calcium-dependent carbohydrate binding domain from Mannose-
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binding lectin [161]. A variety of other C-type lectin domain family members coupled to Syk and 
bound to molecules that can stimulate an inflammasome-like response [162] but a direct 
connection to NLRP3 has yet to be investigated. Ligands for CLEC9A are exposed upon cell 
death and CLEC9A is required for cross-presentation of dead cell-associated antigens by 
dendritic cells [163]. CLEC9A binding to dead cell-associated antigens is also required for 
development of IFN-γ positive cells [163], a process that can be initiated and enhanced by IL-18 
and IL-1β [164,165]. Macrophage-inducible C-type lectin (Mincle) bound SAP130, a component 
of small nuclear ribonucleoprotein released by dying cells [166], and also detected Malassezia 
[167], a Syk-dependent NLRP3 inflammasome-activating fungi [156]. Syk activation is also 
required to activate the NLRP3 inflammasome in response to DAP12-dependent (a C-type lectin-
associated protein that also binds CLEC5A [159,160]), and DAP12-independent haptens that 
cause allergic contact dermatitis [168]. It has been postulated that these haptens are causing cell 
death leading to CLEC9A or Mincle-mediated Syk activation of the NLRP3 inflammasome, 
however direct evidence is lacking. 
Additionally, Syk may play a larger role in NLRP3 inflammasome activation than is 
suggested by the previously discussed data on C-type lectin domain family members. Inhibition 
of Syk diminished Alum- [169], MSU-, ATP- and nigericin-induced Caspase 1 activation and 
IL-1β secretion [170]. Interestingly, early evidence suggests that NLRP3 inflammasome 
regulation by Syk is cell type specific. For example, in murine BMDCs, Syk was not required for 
nigericin-induced NLRP3 inflammasome activation [90] but was critical in murine BMDM and 
the U937 human macrophage cell line [171].  
The Src family kinase Lyn appeared responsible for Syk activation in response to 
hemozoin (Hz), an inorganic crystal formed by Plasmodium during the heme detoxification 
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process. Lyn was activated by Hz and pharmacologic inhibition of Lyn or genetic disruption 
blocked Hz-induced Syk phosphorylation and NLRP3-dependent IL-1β secretion. However, this 
effect was not seen with MSU, suggesting that Lyn was specifically involved downstream of a 
Hz receptor. Hz-induced NLRP3 inflammasome activation was also dependent on phagocytosis, 
ROS production, potassium efflux and CTSB activation [84].  
Syk appeared to regulate the NLRP3 inflammasome through direct phosphorylation of 
ASC [170]. ASC was phosphorylated during NLRP3 inflammasome activation in a Syk-
dependent manner and inhibition of Syk prevented ASC speck formation [170,171]. ASC 
tyrosine residues at position 146 and 187 were phosphorylated by Syk and were required for 
Syk-dependent ASC oligomerization and IL-1β secretion [170].  
 
1.7.7.2 RIPK1/RIPK3- and NLRP3-dependent necrosis overlap 
RIPK1 and RIPK3 are additional well characterized kinases implicated in regulating the 
NLRP3 inflammasome. RIPK1 and RIPK3 form a necrosis-induced signaling node originally 
characterized in TNF-α-induced necrosis [172-174]. The RIPK1/RIPK3 complex bound MLKL 
and RIPK3 phosphorylated MLKL at threonine 357 and serine 358. Blocking this 
phosphorylation step by knocking down MLKL or through necrosulfonamide (NSA) treatment 
prevented necrosis [175,176]. RIPK3 also phosphorylated Phosphoglycerate mutase family 
member 5 (PGAM5), a mitochondrial protein phosphatase [177]. PGAM5 activated DRP1, a 
GTPase involved in mitochondrial fission, by dephosphorylating the serine 637 residue causing 
mitochondrial dysregulation and ultimately NLRP3 dependent cell death [177]. However, a 
variety of studies with conflicting results have produced confusion as to whether certain 
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pathogens and molecules activate RIPK1- and RIPK3-dependent NLRP3 inflammasome 
signaling. 
In one report, double-stranded RNA (dsRNA) viruses including vesicular stomatitis virus 
(VSV), Sendai virus and influenza virus all induced Caspase 1 activation and IL-1β and IL-18 
secretion in murine BMDMs in a RIPK3- and NLRP3-dependent fashion. RIPK3 activation in 
response to these RNA viruses led to RIPK1 activation, mitochondrial damage, activation and 
translocation of DRP1 to mitochondria, and ultimately NRLP3 inflammasome activation. dsRNA 
was sufficient to induce each of these changes and activated the NLRP3 inflammasome in a 
RIPK1-, RIPK3-, DRP1-dependent manner. Interestingly, dsRNA viruses induced RIPK1-, 
RIPK3-, MLKL- and PGAM5-dependent, and NLRP3-independent cell death, suggesting that 
RIPK1/RIPK3 signaling diverges to promote inflammatory signaling and necrosis separately 
[178]. This signaling was also specific to dsRNA viruses as DNA viruses including adenovirus 
or herpes simplex virus (HSV), as well as classic NLRP3 agonists including ATP, MSU, alum 
and nigericin, were RIPK3-independent [178].  
However, in two sequential reports, RIPK3 was not required for VSV-induced NLRP3 
inflammasome activation [71,179]. PGAM5 knockout mice were generated and both 
macrophages and dendritic cells demonstrated defective IL-1β secretion in response to NLRP3 
agonists including VSV, nigericin, ATP, and silica. RIPK3 deficiency did not mirror the IL-1β 
secretion defect seen in PGAM5 knockout mice, suggesting PGAM5 is activated through a 
separate pathway under these conditions [179]. 
Caspase 8 is also thought to play a significant role in determining the fate of RIPK1 and 
RIPK3 signaling. Caspase 8 can cleave RIPK1 [180], so Caspase 8 deficient cells essentially 
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have RIPK1/RIPK3 upregulated signaling. In Caspase 8 deficient dendritic cells, NLRP3 
inflammasome-priming agents alone were sufficient to induce secretion of IL-1β and IL-18 in a 
RIPK1-, RIPK3-, MLKL- and PGAM5-dependent manner. Deletion of NLRP3 or ASC in the 
Caspase 8 deficient background blocked this hypersensitivity to NLRP3 inflammasome priming 
[181]. Similarly, inhibitor of apoptosis proteins (IAPs) promoted ubiquitination of RIPK1 and 
RIPK3 to prevent NLRP3 inflammasome hyperactivation in response to priming agents. In the 
absence of IAPs, the NLRP3 inflammasome is activated in a Caspase 8-dependent and MLKL-
independent or MLKL-dependent manner, depending on the presence or absence of Caspase 8 
[182]. 
The role of RIPK1 and RIPK3 signaling in the context of bacterial infection is much 
more clear. Human neutrophils infected with USA300 strain community-acquired methicillin-
resistant Staphylococcus aureus (CA-MRSA) underwent necrosis in a Necrostatin-1 (Nec-1)-
sensitive manner, implicating RIPK1 signaling in this process [183]. S. aureus also triggered 
RIPK3- and MLKL-dependent cell death in THP1 cells and mouse alveolar macrophages, and 
triggered Nec-1- and NSA-sensitive cell death in primary human macrophages. S. aureus 
cytolytic PFTs, including Hla, LukAB and PVL, were required to induced this cell death. S. 
aureus-mediated RIPK3 activation led to IL-1β secretion as RIPK3 deficient mice had less 
cytokine production and improved bacterial clearance when challenged with S. aureus 
pneumonia [184].  
Serratia marcescens, Streptococcus pneumoniae, Listeria monocytogenes, and 
uropathogenic Escherichia coli (UPEC) all induced RIPK1-, RIPK3- and MLKL-dependent cell 
death through production of pore-forming toxins. Inhibition of RIPK1 with necrostatin-5 
improved survival in a mouse model of S. marcescens hemorrhagic pneumonia [185]. 
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As more data is collected on RIPK1/RIPK3-dependent cell death, the division with 
NLRP3-dependent cell death begins to blur. For example, both S. aureus [43] and UPEC [186] 
have been shown to induce NLRP3-dependent cell death. Carefully tailoring the exact conditions 
initiating necrotic cell death signaling is extremely important for understanding the contribution 
of these various pathways. For example, S. aureus LukAB induced NLRP3-dependent cell death 
when binding the plasma membrane of human monocytes, but when S. aureus was phagocytosed 
and LukAB binds to the phagosomal membrane, the NLRP3 inflammasome was still activated 
but necrotic cell death occurred independent of NLRP3 (Chapter 3, Figure 9) [45]. 
 
1.7.7.3 Kinases have a wide ranging role in regulating the NLRP3 inflammasome  
 About a dozen other kinases have been implicated in regulating the NLRP3 
inflammasome but have only preliminary evidence supporting their involvement – that evidence 
will be reviewed here.  
RIPK2 acted outside of the RIPK1/RIPK3 signaling complex to influence NLRP3 
inflammasome activation. RIPK2 deficiency caused defective mitochondrial autophagy leading 
to accumulation of damaged mitochondria and ROS and ultimately NLRP3 inflammasome 
activation. RIPK2 promoted autophagy by phosphorylating ULK1, and ULK1 deficiency 
similarly caused increased mitochondrial ROS and Caspase 1 activation. RIPK2 deficient mice 
were unusually susceptible to influenza A viral infection and subsequent disruption of IL-18, by 
deletion or antibody-mediated blockade, led to improved infection clearance and survival [97]. In 
contrast, deficiency of RIPK2 had no impact on ATP-induced IL-1β and IL-18 secretion [2], 
suggesting RIPK2 is not a universal requirement for NLRP3 inflammasome activation. 
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DAPK appeared necessary for Caspase 1 activation and IL-1β production, but its kinase 
activity may be dispensable. DAPK deficient murine BMDMs and THP1 cells showed decreased 
IL-1β production and Caspase 1 activation in response to MSU, nigericin, ATP and alum. 
Overexpression of DAPK and the kinase-dead mutant, DAPK K42A, led to increased Caspase 1 
activation and IL-1β production. When expressed in 293T cells, DAPK and NLRP3 interacted 
through DAPK ankyrin repeats and death domain and NLRP3 leucine-rich repeat (LRR) motif 
[132]. While the authors suggest that DAPK plays a scaffolding role for the NLRP3 
inflammasome, overexpression experiments with kinase-dead mutants were conducted in THP1 
cells that expressed wildtype DAPK and it remains possible that wildtype DAPK function was 
not blocked by co-expression of mutant DAPK allowing it to promote NLRP3 inflammasome 
activation, necessitating only a minimal requirement for DAPK kinase activity. Expressing 
kinase-dead mutants in DAPK deficient cells or using DAPK kinase activity inhibitors would 
provide greater strength to the authors’ argument. 
Activation of the NLRP3 inflammasome required NEK7, a cell cycle regulating kinase of 
the “never in mitosis gene a” (NIMA)-related family, forcing cell division and inflammasome 
activation to be non-overlapping processes temporally. Loss of NEK7 resulted in decreased IL-
1β and IL-18 secretion and LDH release in response to nigericin [187], ATP, and alum, and 
decreased IL-1β and IL-18 secretion alone in response to E. coli and C. rodentium [188]. NEK7 
bound directly to the LRR domain of NLRP3 to promote NLRP3 inflammasome formation. 
Kinase-dead NEK7 K64M successfully rescued the secretion of IL-1β in response to nigericin or 
ATP in NEK7 deficient peritoneal macrophages, suggesting that kinase activity was not 
important. Interestingly, the association between NEK7 and NLRP3 was diminished during 
mitosis and cells arrested in mitosis by RO-3306 treatment had decreased IL-1β secretion in 
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response to nigericin that was restored upon RO-3306 release [188]. This was the first 
demonstration of a cell cycle effect on NLRP3 inflammasome activation and may suggest a role 
for other cell cycle regulating kinases in NLRP3 inflammasome activation. 
RNA-dependent protein kinase (PKR, also known as EIF2AK2) autophosphorylation was 
induced by NLRP3 inflammasome agonists including dsRNA, ATP, MSU, and alum, as well as 
NLRP1, NLRC4 and AIM2 agonists. PKR interacted with NLRP3 and this interaction was 
enhanced upon stimulation of the NLRP3 inflammasome. PKR also interacted with NLRP1, 
NLRC4 and AIM2. Loss of PKR blocked NLRP3-dependent Caspase 1 activation, IL-1β 
secretion and HMGB1 release, a marker of necrotic cell death. Loss of PKR kinase activity 
(PKR K296R) also blocked Caspase 1 activation [189]. A second study has also confirmed that 
PKR inhibition blocked alum-induced Caspase 1 activation and IL-1β secretion [169]. 
Interestingly, activation of PKR in response to ATP required potassium efflux, a feature not 
typically seen in the activation of AIM2 inflammasomes [189]. How PKR is activated in 
response to diverse stimuli and regulates multiple inflammasomes remains an open question.  
Bruton’s tyrosine kinase (BTK) also physically interacted with NLRP3 and ASC to 
regulate the NLRP3 inflammasome. The BTK TK domain bound the ASC pyrin domain and 
both BTK SH2/3 and TK domains bound to the NLRP3 NACHT and LRR domains. Inhibitors of 
BTK, including Ibrutinib, an FDA approved BTK inhibitor for the treatment of B-cell 
malignancies, blocked alum-, MSU-, nigericin-, ATP and LLMe-induced Caspase 1 activation 
and IL-1β secretion but not dsDNA-induced AIM2 inflammasome activation [169]. 
 IL-1 receptor-associated kinases (IRAKs) played a role in NLRP3 inflammasome 
activation by signaling through MyD88. When a TLR agonist such as LPS and an NLRP3 
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agonist such as ATP were added together, Caspase 1 was activated in an IRAK-4 and IRAK-1-
dependent manner that required kinase activity of both enzymes. However, when LPS and ATP 
were added sequentially, with ample time for LPS to prime the NLRP3 inflammasome, IRAK-4 
and IRAK-1 were not required. Loss of both IRAK-1 and IRAK-2 together compromised ATP-
induced Caspase 1 activation in both immediate activation and primed cells. IRAK-1 associated 
with ASC upon stimulation of the NLRP3 inflammasome. This immediate response triggered 
through simultaneous exposure was important for IL-18 processing and secretion and necrotic 
cell death. This type of exposure is likely to mimic early exposure to pathogens, as most 
pathogens express both TLR-binding ligands that act as priming molecules and NLRP3 
inflammasome activating molecules, and indeed, infection of BMDMs with L. monocytogenes 
activated Caspase 1, HMGB1 release and necrotic cell death in an IRAK-1 and IRAK-4-
dependent manner [65,66]. 
Inhibitor of nuclear factor κ-B kinase subunit α (IKK-α) was a negative regulator of 
ASC-dependent inflammasomes including NLRP3. In resting macrophages, IKK-α bound ASC 
to sequester it in the nucleus. IKK-i facilitated translocation of IKK-α and ASC from the nucleus 
to the perinuclear area during NLRP3 inflammasome activation by ATP. Mutation of ASC serine 
16 or serine 193 to alanine disrupted IKK-α-mediated regulation of ASC and mutation of ASC 
serine 58 to alanine disrupted IKK-i-mediated regulation of ASC. Loss of IKK-i, IKK-α or IKK-
α kinase activity (K44A) caused NLRP3 inflammasome hyperactivation in response to both 
priming agents alone and classical NLRP3 activators. Protein phosphatase 2A (PP2A) interacted 
with IKK-α following treatment with LPS and ATP. Inhibition of PP2A by okadaic acid blocked 
this interaction and blocked dissociation of ASC and IKK-α suggesting that phosphatase activity 
was responsible for opposing the suppressive activity of IKK-α in regulating the NLRP3 
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inflammasome. Furthermore, knockdown and inhibition of PP2A disrupted Caspase 1 activation 
[190].  
JNK, a stress-responsive mitogen-activated protein kinase (MAPK), was required for 
NLRP3 inflammasome activation in response to nigericin and dsRNA. Loss of JNK blocked 
Caspase 1 activation and IL-18 secretion by blocking ASC aggregation. JNK was required for 
ASC phosphorylation but a JNK-dependent ASC phosphorylation site was not identified, leaving 
it open as to whether JNK phosphorylated ASC directly [171]. JNK also was critical for 
lysosome rupture-induced NLRP3 inflammasome activation. Upon treatment with LLME or 
MSU, activation of JNK led to Caspase 1 activation and IL-1β secretion. Treatment with the 
TAK1 (also known as MAP3K7) inhibitor 5-Z-Oxozeaenol [113] or TAK1 siRNA blocked JNK 
activation in this setting. TAK1-JNK signaling helped promote ASC oligomerization and was 
dependent on intracellular Ca2+ signaling, as discussed above [112].  
Mitochondrial ROS triggered signaling through PI3K-AKT-ERK1/2 during ATP-induced 
NLRP3 inflammasome activation. Treatment of macrophages with NAC or the PI3K inhibitors 
blocked phosphorylation of AKT and ERK1/2. The ERK1/2 inhibitor PD98056 blocked ATP-
induced Caspase 1 activation as well. However, this study was unusual in that its ATP treatments 
lasted for 6-12 hours and, as such, raised the possibility that what we are seeing is engagement of 
a long-term feedback mechanism and not a direct requirement of NLRP3 inflammasome 
activation [88]. However, two additional studies have shown that AKT inhibitors can block 
NLRP3 inflammasome signaling. In one, treatment of macrophages with the AKT inhibitor 
AKTx blocked ATP- and nigericin-induced IL-1β secretion [48]. In the second, treatment with 
AKT inhibitor IV blocked Caspase 1 activation during a 30 minute ATP treatment in LPS-
primed THP1 cells [113]. 
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Numerous phosphorylation sites on ASC have been identified and implicated in NLRP3 
inflammasome activity. These include the previously mentioned S16 and S193 that were 
required for interaction with IKK-α [190], S58 that was required for interaction with IKK-i 
[190], Y146 and Y187 that were phosphorylated by Syk [170], as well as ASC Y144, S58, T125, 
T151, T152 and S153 [171], as disruption of any of these caused aberrant NLRP3 inflammasome 
activation. 
Thus far, little direct evidence of NLRP3 or Caspase 1 phosphorylation has been 
produced, though early evidence suggests that NLRP3 and Caspase 1 are also regulated by 
phosphorylation. H. pylori induced NLRP3 inflammasome activation [191] and H. pylori LPS 
activated Caspase 1 and IL-1β secretion [192]. Interestingly, H. pylori LPS induced direct 
interaction between p21-activated kinase (PAK) 1 and Caspase 1 that required Caspase 1 S376. 
PAK1 was able to phosphorylate recombinant Caspase 1 but not the S376A mutant and LPS-
induced Caspase 1 activation was blocked in cells transfected with the S376A mutant [192]. 
Additionally, NLRC4 was phosphorylated by PKCδ at S533 and depletion of PKCδ attenuated 
Caspase 1 activation and IL-1β secretion in response to S. typhimurium. NLRC4 S533A was 
unable to recruit pro-Caspase 1 and did not form visible specks [193]. NLRC4 contains a CARD 
allowing it to interact directly with pro-Caspase 1 without requiring the adapter ASC raising the 
possibility that phosphorylation of NLRC4 is more akin to ASC phosphorylation than NLRP3 
phosphorylation, however, amino acid 533 lies between the NACHT and LRR domains raising 
the possibility that a corresponding residue in NLRP3 is similarly phosphorylated. 
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Table 1.1. Kinases analyzed in NLRP3 inflammasome research 
ATK BTK DAPK ERK1/2 IKK-α 
IKK-i IRAK1 IRAK2 IRAK4 JNK 
Lyn NEK7 PAK1 PI3K PKR 
RIPK1 RIPK2 RIPK3 Syk TAK1 
 
1.8 Canonical inflammasome activators: nigericin, ATP and monosodium urate 
After carefully reviewing the most well studied mechanisms of NLRP3 inflammasome 
activation, the lack of cohesion between studies resulting from the diversity of activating stimuli 
is now probably apparent to the reader. In this section, I will look specifically at the three most 
well studied NLRP3-activating molecules: nigericin, extracellular ATP and MSU. Each classical 
activator is thought to provoke a unique series of changes that leads to NLRP3 inflammasome 
activation: nigericin is a mitochondria-disrupting ionophore [194], extracellular ATP triggers 
P2RX7 causing potassium efflux [195], and MSU causes lysosome dysfunction [196]. Many 
critical regulatory elements in NLRP3 inflammasome signaling have been characterized using 
one of these activating molecules. Although the initial insults differ, the resultant signaling 
pathways have some overlap. In the subsections of 1.8, I will review the requirements for 
NLRP3 inflammasome activation in response to each of these three well-studied activators.  
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1.8.1 Nigericin is a potassium ionophore that activates the NLRP3 Inflammasome 
Incubation of murine macrophages and human peripheral blood monocytes with the 
bacterial toxin nigericin, a potassium/proton ionophore produced by Streptomyces hygroscopicus 
[197,198], led to proteolytic processing of the 35-kDa pro-IL-1β and release of the 17-kDa active 
form [199]. Cells treated with nigericin experienced rapid and complete loss of the preloaded 
potassium analog 86Rb+, whereas cells treated with valinomycin, a potassium ionophore that 
does not stimulate IL-1β processing, caused only a partial depletion of the radiolabeled cation. 
Nigericin-stimulated IL-1β processing was inhibited in cells grown in medium containing KCl 
rather than NaCl [200]. Caspase 1 (originally called interferon-converting enzyme – ICE) was 
responsible for nigericin-induced IL-1β processing and activation [201]. In THP1 cells, nigericin 
induced Caspase 1 activation and IL-18 secretion without LPS priming [202]. 
With this information in hand, and the discovery of NLRP3 as an activator of Caspase 1, 
nigericin was shortly thereafter demonstrated to activate the NLRP3 inflammasome. Nigericin 
activated Caspase 1 through the NLRP3 inflammasome followed by processing and secretion of 
mature IL-1β and IL-18, as genetic deletion of NLRP3 or ASC in macrophages disrupted this 
response [203]. Complementation of Caspase 1 deficient cells with a non-cleavable or 
catalytically inactive mutant of Caspase 1 also disrupted IL-1β secretion in response to nigericin 
[204]. Nigericin-induced Caspase 1 cleavage can be prevented by blocking potassium efflux 
[80]. Caspase 11 was not required for nigericin-mediated NLRP3 inflammasome signaling [51]. 
Nigericin-induced NLRP3-dependent IL-1β and IL-18 secretion also extended beyond the 
periphery and was triggered in microglia [205]. 
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In addition to IL-1β and IL-18 secretion, nigericin induced Caspase 1-independent and 
CTSB-dependent cell death. Treatment of cells with nigericin caused rapid lysosomal leakage 
and translocation of CTSB to the cytoplasm. Both pharmacologic intervention, including the 
CTSB inhibitor CA-074-Me, and genetic disruption, including transformation with an 
endogenous cathepsin inhibitor cystatin A or antisense CTSB cDNA, blocked nigericin-induced 
cell death, and interestingly, IL-18 secretion [202]. Nigericin-induced cell death has also been 
shown to be NLRP3-dependent [206]. Nigericin-induced NLRP3-dependent cell death has been 
observed in non-immune cells including primary renal tubular epithelial cells [207]. 
In the absence of Caspase 1 and Caspase 11, prolonged treatment of BMDCs with 
nigericin triggered NLRP3-inflammasome dependent Caspase 8 activation and Caspase 8-
dependent IL-1β secretion. Caspase 8 also was required for nigericin-induced cell death in this 
setting [208]. The precise role of Caspase 8 in responding to nigericin in wildtype cells, though, 
is unclear.  
Further characterization of nigericin-induced NLRP3 inflammasome activation has 
proceeded in a piecemeal fashion largely as a comparator for other NLRP3-activating stimuli or 
to test for endogenous regulators of NLRP3 inflammasome activity.  
Inhibition of Syk with R406, Syk inhibitor I, or BAY 61-3606, or knockdown of Syk 
expression blocked nigericin-induced IL-1β and IL-18 secretion from peritoneal macrophages. 
Similarly, inhibition of JNK with SP600125 or TAT-TI-JIP153-163, or knockout of MAPK8 or 
MAPK9, the genes encoding for JNK1 and JNK2, also blocked nigericin-induced IL-1β and IL-
18 secretion. Similar results were also obtained in mouse BMDMs and the U937 human 
macrophages cell line. Decreased cytokine secretion resulted from decreased ASC speck 
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formation and Caspase 1 activation. Treatment of macrophages with nigericin induced 
phosphorylation of Syk and JNK but Syk inhibitors did not block phosphorylation of JNK, 
placing these two kinases into separate pathways. Overexpression of Syk or JNK resulted in 
phosphorylation of ASC that was blocked by a Y144F substitution, suggesting that this is the site 
targeted by these kinases. However, in vitro kinase assays using purified Syk or JNK and amino 
acids 139-150 of ASC did not consume ATP and could not confirm phosphorylation at Y144 
[171]. Interestingly, two reports on BMDCs found Syk is not required in nigericin-induced 
NLRP3 inflammasome activation, pointing to cell type specific signaling [90,171]. 
Other kinases, such as NIMA-related kinase 7 (NEK7), which plays a role in nucleating 
microtubules at centrosomes during mitosis, have been implicated in NLRP3 inflammasome 
activation. Disruption of NEK7 by CRISPER/Cas9 protected macrophages from nigericin-
induced cell death. Murine macrophages deficient in NEK7 had a largely blunted NLRP3 
inflammasome response suggesting that NEK7 acted upstream of NLRP3 [187], however the 
precise mechanism has not been elucidated. BTK interacted with NLRP3 and ASC during 
nigericin treatment and was required for nigericin-induced ASC oligomerization [169]. The 
TAK1 inhibitor 5-Z-oxozeaenol blocked nigericin-induced Caspase 1 activation [113]. The AKT 
inhibitor AKTx also blocked nigericin-induced IL-1β secretion [48]. Lastly, DAPK was required 
for nigericin-induced IL-1β secretion. However, little is known about how the regulating 
modality of these kinases overlaps during nigericin-induced NLRP3 inflammasome activation 
[132]. 
The mitochondrial protein phosphatase PGAM5 promoted nigericin-induced NLRP3 
inflammasome activation. Deletion of PGAM5 diminished IL-1β secretion, but not cell death, in 
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response to nigericin in BMDMs but not BMDCs. Nigericin-induced ASC oligomerization was 
blocked by PGAM5 deficiency [179].  
The production of ROS, and more specifically mitochondrial ROS that perturb 
mitochondrial function, have been proposed as a major requirement for NLRP3 inflammasome 
activation. This finding is typically established through two observations: (1) that mitochondrial 
oxygen consumption or mitochondrial membrane potential becomes disrupted and (2) that 
antioxidant treatment prevents NLRP3 inflammasome activation. 
Macrophages treated with nigericin showed a series of mitochondrial changes that can be 
separated into two groups, NLRP3-independent changes that are not suppressed by blocking 
potassium efflux and NLRP3-dependent changes that are suppressed by blocking potassium 
efflux.  
Nigericin reduced the mitochondrial oxygen consumption rate and decreased cellular 
ATP, observations that were unchanged during incubation with high extracellular potassium. 
However, NLRP3 inflammasome activation by nigericin led to loss of mitochondrial membrane 
integrity, as measured using MitoTracker Red, loss of mitochondrial DNA, as measured by 
PicoGreen staining, and loss of lysosome staining, as measured using the Lysotracker Green dye, 
suggesting either loss of lysosomal acidity or loss of lysosomal membrane integrity. Exposure of 
phosphatidyl-serine on the plasma membrane also occurred in an NLRP3 inflammasome-
dependent fashion. Neither nigericin-induced lysosome and mitochondria disruptions nor LDH 
release, a common measure of cell death, were blocked by the Caspase 1 inhibitor Ac-YVAD-
CMK [206]. Direct disruption of mitochondrial function using rotenone, an inhibitor of the 
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mitochondrial electron transport chain, was not sufficient to induce NLRP3 inflammasome 
activation and actually suppressed nigericin-induced Caspase 1 activation [209]. 
In one report, high doses of NAC, a potent antioxidant, or the NOX2 inhibitor DPI did 
not block nigericin-induced Caspase 1 cleavage [80]. Mito-Tempo, a mitochondria-specific ROS 
scavenger, delayed lysosomal membrane permeabilization and reduced mitochondrial membrane 
permeabilization. The authors also claimed that IL-1β secretion and LDH release after nigericin 
exposure was dampened by Mito-Tempo, but the change was unconvincing and the difference 
may have been called based on inappropriate statistical tests [206]. XOR has been implicated in 
contributing to crystalline-mediated ROS production and NLRP3 inflammasome activation and 
febuxostat, a XOR inhibitor, also decreased IL-1β secretion in response to nigericin, possibly 
implicating XOR as a source of ROS [48]. Although mitochondrial ROS are detected in nigericin 
treated macrophages, inhibitors of Syk or JNK do not impact their production [171].  
TRIM30 negatively regulated nigericin-induced NLRP3 activation through modulating 
ROS. Knockdown of TRIM30 increased nigericin-induced Caspase 1 activation and IL-1β 
production. Production of ROS, measured using CM-H2DCFDA labeling, was also increased in 
TRIM30 knockdown cells, and its increase was required for enhanced NLRP3 inflammasome 
activation as treatment with NAC blocked excess IL-1β production. Conversely, overexpression 
of TRIM30 attenuated ROS production and NLRP3 inflammasome activation [210]. 
Pinning down ROS-mediated effects can be extremely difficult as redox states of cells 
can differ even within the same cell types. TRIM30’s effect on IL-1β secretion was demonstrated 
in murine BMDMs, but the ROS studies and suppression by NAC in knockdown TRIM30 cells 
were performed using murine J774 macrophages, a cell line derived from a reticulum cell 
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sarcoma. Future studies using murine TRIM30 knockout cells would provide more convincing 
evidence for TRIM30 in suppressing ROS-induced NLRP3 inflammasome activation.  
Nigericin-induced NLRP3 inflammasome activation appeared to make use of the 
mitochondria as a scaffold for inflammasome assembly. Treatment of J774 cells with colchicine 
to disrupt microtubule dynamics blocked nigericin-induced IL-1β secretion. Nigericin induced 
microtubule-driven and dynein-dependent rearrangement of mitochondria that was critical for 
NLRP3 inflammasome activation. This resulted from decreased concentration of cellular NAD+ 
leading to increased acetylated α-tubulin, as discussed above [102]. SHP, which also binds 
NLRP3 at the mitochondria, inhibited nigericin-induced NLRP3 inflammasome activation [101]. 
Disruption of mitochondrial fission by knockdown of DRP1 increased nigericin-induced 
Caspase 1 activation and IL-1β secretion. CCCP, which induces mitochondria fission, attenuated 
nigericin-induced NLRP3 inflammasome activation in wild type treated cells. Mitochondrial 
fission appeared to block ASC oligomerization [99]. 
Another possible role for mitochondrial disruption in NLRP3 activation is through 
reduction in intracellular ATP. Artificial reduction of intracellular ATP by 2-deoxyglucose, a 
glycolysis inhibitor, caused mitochondrial membrane depolarization and IL-1β secretion via 
NLRP3 and Caspase 1 activation. Nigericin also lowered intracellular ATP through potassium 
and calcium-mediated mitochondrial dysfunction possibly leading to a positive feedback loop for 
enhanced NLRP3 inflammasome activation [211]. However, decreased cellular ATP in response 
to nigericin was unaffected by incubation with high extracellular potassium [206], putting these 
studies in conflict.  
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To summarize, current evidence suggests that nigericin damages mitochondria directly 
and NLRP3 inflammasome activation causes further damage, but the association between ROS 
production and NLRP3 inflammasome activation is weak. The suggestion made in Nomura et al. 
that ATP leakage might be involved in NLRP3 inflammasome activation is interesting in light of 
evidence that Pannexin 1, a membrane protein can act as a pore and associates with the ATP 
receptor P2RX7, is also required for nigericin-induced Caspase 1 processing and IL-1β secretion. 
Additionally, inhibition of Pannexin 1 did not block nigericin-induced potassium efflux, 
suggesting that Pannexin 1 is required downstream of this critical step [212]. Studies pointing to 
the mitochondria as a scaffold for inflammasome assembly during nigericin treatment are also 
compelling. 
NLRP3 is also regulated by ubiquitination. The small molecule deubiquitinase inhibitor 
G5 blocked nigericin-induced IL-1β secretion by inhibiting Caspase 1 activation. G5 treatment 
induced appearance of a high molecular weight NLRP3 that reacted with anti-K48 and anti-K63 
ubiquitin antibodies. The deubiquitinase BRCC3 co-immunoprecipitated with NLRP3 and was 
required for activation of the NLRP3 inflammasome [139]. In a separate study, histone 
deacetylase 6 (HDAC6) was found to negatively regulate nigericin-induced NLRP3 
inflammasome activation through binding to ubiquitinated NLRP3. Knockdown of HDAC6 by 
shRNA led to increase nigericin-induced Caspase 1 processing and IL-1β secretion without 
affecting mRNA levels through NF-κB activation. In 293T cells, HDAC6 co-
immunoprecipitated with NLRP3 and required the BUZ domain, a binder of ubiquitin zinc finger 
domain, for this association. Treatment of cells with PR619, a deubiquitinase inhibitor, enhanced 
association between HDAC6 and NLRP3 [140]. 
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The LUBAC used ubiquitin to promote nigericin-induced NLRP3 inflammasome 
signaling. Disruption of LUBAC by deletion of HOIL-1L decreased nigericin-induced ASC 
oligomerization and IL-1β secretion [137]. Similarly, deletion of Sharpin, another LUBAC 
component, eliminated nigericin-induced IL-1β and IL-18 secretion but had no effect on LDH 
release, raising the possibility that LUBAC does not regulate NLRP3-dependent cell death [138].  
Ubiquitin also promoted NLRP3 degradation to limit NLRP3 inflammasome signaling. 
Treating cells with dopamine signaled through DRD1 to activate the E3 ligase MARCH7. 
MARCH7 bound directly to the NLRP3 inflammasome and ubiquitinated it, targeting it for 
degradation. Treatment of cells with dopamine and nigericin decreased IL-1β secretion as 
compared to nigericin alone, and knockdown of MARCH7 by siRNA eliminated the dopamine-
mediated reduction in IL-1β secretion [150]. 
Calcium is a common second messenger in many signaling processes. Nigericin-induced 
IL-1β secretion but not LDH release was sensitive to inhibition by BAPTA-AM and thapsigargin 
[120]. The SERCA inhibitor XeC, the PLC inhibitor U73122, and the IP3R inhibitor 2-APB all 
blocked nigericin-induced Caspase 1 activation and IL-1β secretion [126]. Depletion of CASR 
by siRNA suppressed nigericin-induced IL-1Β secretion [127].  
However, the mechanism of action of BAPTA and 2-APB appeared to be dissociated 
from their canonical or expected effects on calcium homeostasis. Calcium perturbations resulting 
from nigericin treatment were actually NLRP3 inflammasome-dependent, rather than signaling 
events responsible for initiating NLRP3 inflammasome activation [80,134]. 
Disruption of ribosome function has also been proposed as a common initiator signal for 
NLRP3 inflammasome activation. Ribosomal function inhibitors including ricin, cycloheximide, 
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puromycin, pactamycin, and anisomycin caused NLRP3 inflammasome-dependent IL-1β 
secretion. Nigericin treatment also disrupted protein synthesis in a manner dependent on 
potassium efflux [213]. However, convincing evidence is currently lacking to place ribosomal 
dysfunction upstream of NLRP3 inflammasome activation and no clear mechanism has been 
proposed to link the two events.  
Loss of guanylate binding protein 5 (GBP5) dramatically decreased nigericin-induced 
ASC oligomerization, and IL-1β and IL-18 secretion. Tetrameric GBP5 associated with NLRP3 
by binding the NLRP3 pyrin domain but little is known about the mechanism of regulation [214]. 
β-arrestin 1, also promoted nigericin-induced NLRP3 activation, as loss of β-arrestin 1 decreased 
nigericin-induced Caspase 1 activation, IL-1β secretion and LDH release. β-arrestin 1 promoted 
NLRP3 self-oligomerization, an important step for NLRP3 inflammasome formation [215]. 
Again, few details have been ascertained about this interaction and regulation. 
A variety of NLRP3 inflammasome inhibiting and dampening agents have also been 
characterized using nigericin. Ethanol had a dose-dependent effect in suppressing nigericin-
induced IL-1β secretion without affecting potassium efflux. Ethanol blocked ASC speck 
formation [216]. Arsenic trioxide and sodium arsenite inhibited activation of multiple 
inflammasomes including NLRP1, NLRC4, and nigericin-induced NLRP3 through an unknown 
mechanism to suppress Caspase 1 cleavage and IL-1Β secretion [217]. Carbon monoxide, a 
gaseous molecule physiologically produced in cells and tissues during heme catabolism, 
inhibited IL-18 secretion in response to nigericin treatment [218]. Unsaturated fatty acids oleate 
and linoleate suppressed IL-1β secretion triggered by nigericin [219].  
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Additional endogenous factors implicated in NLRP3 inflammasome activation and 
regulation by other stimuli have no demonstrated role in nigericin-induced NLRP3 
inflammasome activation. Loss of RIPK3 in BMDMs did not impact nigericin-induced IL-1β 
signaling [178]. The proteasome inhibitor MG132 did not block Caspase 1 activation and cell 
death triggered by lipopolysaccharide and nigericin [220]. Mitochondrial antiviral signaling 
(MAVS), a common adaptor that induces NLRP3 activation in response to poly I:C, was not 
required for nigericin-mediated NLRP3 activation [221]. Promyelocytic leukemia protein (PML) 
was shown to increase and decrease NLRP3 inflammasome activation in separate conflicting 
studies [222,223], but loss of PML appeared to have no effect on nigericin-induced IL-1β 
secretion [217]. 
Much less is known about the mechanistic details of events downstream of nigericin-
induced NLRP3 inflammasome activation. Recently, Gasdermin D (GSDMD) was shown to be 
cleaved by Caspase 1 upon activation by nigericin. GSDMD cleavage was required for cell death 
and IL-1β secretion but not proteolytic maturation of IL-1β. Expression of the N-terminal 
proteolytic fragment of GSDMD triggered cell death and modifications such as tagging with 
Flag sequence disrupted this function. Pro-Caspase 1 was capable of processing GSDMD and 
ASC was not essential for GSDMD to function, so the means by which GSDMD is regulated to 
limit cell death is unclear [224].  
Lastly, on the organism level, elderly mice (8-9 month old) had decreased inflammasome 
activation in response to a mouse-adapted strain of influenza (HKx31 an H3N2 strain) but 
retained normal inflammasome activation in response to nigericin [225]. These data suggest that 
core NLRP3 inflammasome signaling remained intact during aging. Also, NLRP3 
inflammasome activation by nigericin was observed in miniature and domestic pigs - important 
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pre-clinical models for toxicology studies. Porcine PBMCs secreted IL-1β at lower doses of 
nigericin than mouse BMDMs, though no comparison was made to human cells [226]. 
There are many gaps in knowledge in nigericin-induced NLRP3 inflammasome 
signaling. For example, of the kinases that have been implicated in regulating the NLRP3 
inflammasome, only a small fraction have been evaluated in the context of nigericin. Very few 
studies have examined both cytokine secretion and cell death resulting from nigericin-induced 
NLRP3 activation. In the studies that have, though, we observed a role for Caspase 1 and 
Sharpin in cytokine secretion, but not cell death. Additionally, BAPTA-AM blocked IL-1β 
secretion but not nigericin-induced cell death. As is probably now clear, when examining the 
NLRP3 inflammasome signaling pathway from the context of a single activator, the landscape is 
littered with holes. We will continue our review of ATP and MSU now. 
 
1.8.2 Extracellular ATP triggers NLRP3 activation by binding P2RX7 
Extracellular ATP is another commonly used NLRP3 inflammasome activator. Even 
before the discovery of the NLRP3 inflammasome, it was realized that treatment of mouse 
peritoneal macrophages with extracellular ATP caused processing and secretion of IL-1β that 
was dependent on intracellular potassium depletion with longer incubations also causing cell 
death. ADP was less effective at inducing cytokine secretion and AMP, GTP and UTP were 
completely inactive in that regard [200]. In cells lacking P2RX7, ATP did not activate Caspase 1 
or cause IL-1β processing and secretion. This finding translated in vivo to mouse models 
including a LPS-septicemia model. ATP injection into LPS-primed wildtype mice caused IL-1β 
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secretion that was not seen in P2RX7 deficient mice [227]. ATP-binding to P2RX7 activated the 
Pannexin 1 channel leading to large pore formation and IL-1β secretion [228]. 
The discovery of the NLRP3 inflammasome tied together ATP binding P2RX7 and 
Pannexin 1-mediated potassium efflux with Caspase 1 activation and IL-1β secretion. ATP 
bound to its plasma membrane receptor, P2RX7, decreased intracellular K+ levels leading to 
NLRP3 inflammasome activation that resulted in Caspase 1 activation and IL-1β processing and 
secretion. Incubating cells in high extracellular potassium prior to ATP treatment blocked 
Caspase 1 activation and IL-1β secretion [80,203]. Deletion of Caspase 11 did not change ATP-
mediated IL-1β secretion [51]. ATP also caused NLRP3- and Caspase 1/Caspase 11-dependent 
necrotic cell death [80]. 
The steps between potassium efflux and inflammasome activation are less well 
understood. When macrophages that phagocytosed rhodamine-labeled MDP were treated with 
ATP, rapid redistribution of the labeled MDP from phagolysosomes to the cytoplasm, consistent 
with lysosome disruption, was observed. This lysosomal disruption also required Pannexin 1, 
suggesting it may be in line with the NLRP3 inflammasome signaling pathway [229]. Consistent 
with this lysosomal disruption, ATP binding to P2RX7 triggers cathepsin release in macrophages 
that was blocked by pre-incubation with a P2RX7 inhibitor [230]. However, treatment with the 
CTSB inhibitor CA-074-Me or bafilomycin to block lysosome acidification did not block ATP-
induced IL-1β secretion [108,231]. TAK1-JNK signaling has been implicated in responding to 
lysosome rupture in cells treated with LLME. Pretreatment of THP1 cells with the TAK1 
inhibitor 5-Z-oxozeaenol or the JNK inhibitor SP600125 blocked ATP-induced Caspase 1 
activation, however, this study did not look directly at whether ATP induced lysosome rupture. 
Additionally, LLMe-induced JNK phosphorylation was sensitivity to inhibition by CA-074-Me, 
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but this was not investigated for ATP [112]. A second study has confirmed that 5-Z-oxozeaenol 
inhibition of TAK1 blocked ATP-induced Caspase 1 activation [113]. These data show that ATP 
caused lysosome rupture but CTSB was not a critical component of signaling that rupture. It 
appears that TAK1 was necessary for ATP-induced NLRP3 inflammasome activation, but the 
partial responsiveness of JNK phosphorylation to CTSB inhibition would not be consistent with 
ATP requiring TAK1 but not CTSB. A focused study addressing these questions would help 
provide greater certainty than these piecemeal reports.  
Treatment of macrophages with LPS and ATP caused mitochondria to swell and 
disrupted mitochondrial cristae. This was worsened by loss of LC3B and Beclin 1, proteins 
important in autophagy. These autophagy-defective macrophages produced more mitochondrial 
ROS and had enhanced NLRP3 inflammasome activation. Quenching mitochondrial ROS with 
Mito-TEMPO, a scavenger specific for mitochondrial ROS, inhibited secretion of IL-1β in 
response to LPS and ATP in both wildtype and autophagy-defective macrophages [104]. 
Rotenone, a mitochondrial complex I inhibitor, induced mitochondrial ROS production [232] 
and enhanced Caspase 1 activation and IL-1β secretion when added to cells with LPS and ATP 
[104,209].  
Culturing cells in the presence of low levels of ethidium bromide inhibits replication of 
mtDNA and can produce cells lacking mitochondrial DNA altogether. Upon treatment with ATP, 
DNA can be found in the cytoplasm of wildtype but not mitochondrial DNA deficient J77A.1 
macrophages, suggesting that the DNA in the cytosol originated in the mitochondria. Treatment 
of cells with cyclosporine A, an inhibitor of the mitochondrial membrane permeability transition 
pore, blocked ATP-induced mtDNA translocation to the cytoplasm. Cyclosporine A also 
inhibited NLRP3 inflammasome activation in both wildtype and autophagy-defective 
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macrophages. Cytosolic mtDNA appeared to activate the NLRP3 inflammasome as treatment 
with DNase I, but not heat-inactivated DNase I, blocked ATP-induced inflammasome activation. 
Additionally, transfection of AIM2 deficient cells (a cytosolic double stranded DNA sensor) with 
mtDNA caused Caspase 1 activation [104]. Interestingly though, NLRP3 deficiency suppressed 
release of mtDNA into the cytosol, but not mitochondrial ROS production in response to 
treatment with LPS and ATP suggesting that mitochondrial ROS may be upstream of 
inflammasome activation, and mtDNA translocation may be downstream and play an amplifying 
role [104,209]. 
Treatment of macrophages with ATP resulted in rapid ROS-dependent PI3K activation, 
AKT phosphorylation and ERK1/2 phosphorylation. Pretreatment with NAC or the PI3K 
inhibitors LY294002 and wortmannin blocked AKT and ERK1/2 phosphorylation. The PI3K 
inhibitors and the ERK1/2 inhibitor PD98056 also completely blocked ATP-induced Caspase 1 
activation and IL-1β secretion, comparable to a direct Caspase 1 inhibitor. While this evidence 
suggests that ROS-PI3K-AKT-ERK1/2 signaling is required for ATP-mediated NLRP3 
activation, this study used unusually long ATP treatment times, 6 and 12 hours, when assaying 
Caspase 1 activation and IL-1β secretion. The inflammasome is typically activated on a time 
scale on the order of minutes, not hours, raising the possibility that other pathways are being 
recruited for Caspase 1 activation and cytokine secretion in this setting [88]. However, two 
additional studies have shown that inhibition of AKT, using AKTx or AKT inhibitor IV, blocked 
ATP-induced Caspase 1 activation and IL-1β secretion during shorter ATP exposures [48,113].  
Overexpression of Bcl2, an anti-apoptotic mitochondrial protein, suppressed ATP-
induced Caspase 1 activation and IL-1β secretion while helping to preserve mitochondrial 
polarization. Similarly, knockdown of Bcl2 enhanced ATP-induced IL-1β secretion and cell 
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death. In this very important study, mtDNA co-localized and immunoprecipitated specifically 
with NLRP3. NLRP3 bound directly to oxidized DNA to promote Caspase 1 activation and 
subsequent cytokine processing [103]. This was the first demonstration of a direct ligand for 
NLRP3. However, it remains unclear how it fits in with previous studies that showed mtDNA 
translocation to the cytosol required NLRP3, rather than activated it.  
XOR has been implicated in contributing to crystalline-mediated ROS production and 
NLRP3 inflammasome activation and Febuxostat, a XOR inhibitor, also decreased IL-1Β 
secretion in response to ATP [48]. XOR produces ROS as a byproduct of its enzymatic activity 
and may be a source of ROS production during ATP treatment.  
The γ-aminobutyric acid A receptor-associated protein (Gabarap), which functions in γ-
aminobutyric acid A receptor trafficking and postsynaptic localization in neurons, has also been 
implicated in regulating mitochondrial-based NLRP3 inflammasome activation. Gabarap 
deficient macrophages treated with LPS and ATP had defective clearance of damaged 
mitochondria resulting in more mitochondrial ROS and mtDNA release into the cytosol. 
Additionally, ATP-induced Caspase 1 activation and IL-1β and IL-18 secretion were increased in 
Gabarap deficient macrophages [98]. 
Knockdown of TRIM30 enhanced ATP-induced Caspase 1 activation and production of 
IL-1β in BMDMs by increasing cellular ROS production. Treatment of TRIM30-depleted cells 
with NAC or DPI before ATP stimulation opposed the increased NLRP3 inflammasome activity 
by suppressing ROS. Overexpression of TRIM30 also attenuated ROS production and opposed 
ATP-induced NLRP3 inflammasome activation [210].  
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While the evidence supporting a role for ROS in ATP-induced NLRP3 inflammasome 
activation is generally strong, there have been occasional conflicting findings. For example, in 
one study, pretreatment of LPS-primed ATP-stimulated BMDMs with NAC or DPI was unable 
to specifically suppress Caspase 1 activation [80]. 
The evidence for calcium mobilization in the activation of the NLRP3 inflammasome in 
response to ATP is also somewhat conflicted. Incubation in calcium free media blocked 
extracellular calcium entry and attenuated ATP-induced Caspase 1 activation and IL-1β secretion 
in one study [126] but had no effect in another [134]. ATP-induced IL-1β secretion was also 
suppressed by BAPTA-AM, an intracellular calcium chelator [120,127,233].  
Treatment of LPS-primed BMDMs with thapsigargin, an inhibitor of SERCA pumps and 
agonist of plasma membrane calcium channels that increases cytoplasmic calcium 
concentrations, has produced conflicting results. Thapsigargin treatment attenuated ATP-induced 
Caspase 1 activation and IL-1β secretion in two studies [120,126]. In cells treated with 
thapsigargin alone, without additional NLRP3 stimulus, thapsigargin activated Caspase 1 and IL-
1β secretion in one study [127] and had no effect in another [120]. And to further complicate 
things, in a study using thapsigargin-treated LPS-primed BMDCs and macrophages, increased 
cytoplasmic calcium concentration was only observed when cells were in calcium-containing 
media and not calcium-free media suggesting that thapsigargin was causing calcium influx from 
the extracellular environment and not depletion of ER calcium stores. In comparison to the two 
previous studies, thapsigargin treatment in calcium-free media did not induce IL-1β secretion on 
its own and did not change ATP-induced IL-1β secretion. However, when the TLR2 ligand 
Pam3CSK4 or TNF-α were used to prime the dendritic cells, thapsigargin-treatment in calcium 
free media caused a modest but significant decrease in ATP-induced IL-1β secretion [134]. 
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Interpretation of these studies together is difficult, especially given the use of dendritic cells and 
not macrophages in one. This series of studies, however, nicely highlights how more care needs 
to be taken in the field to replicate previous work to confirm or refute existing data and design 
new experiments to be more easily comparable. 
Macrophages deficient in the murine CASR did not activate Caspase 1 or secrete IL-1β in 
response to ATP [127]. Interestingly, the synthetic CASR agonist R568 produced sustained 
calcium influx and led to barely detectable ASC oligomerization but failed to induce Caspase 1 
activation or IL-1β secretion [134], suggesting that CASR is not sufficient for NLRP3 
inflammasome activation. It is also possible that a critical threshold of calcium signaling was not 
reached by R568-CASR binding as peak cytosolic calcium concentration reached with R568 was 
nearly 5-fold less than with ATP [134].  
Calcium mobilization or direct calcium binding usually leads to interaction of CASR with 
PLC at the plasma membrane [234]. Activated PLC hydrolyses phosphatidylinositol-4,5-
bisphosphate into diacyl glycerol (DAG) and IP3. DAG activates protein kinase C (PKC) and 
InsP3 binds to IP3R in the ER to increase cytosolic calcium. The PLC inhibitors U73122 and the 
SERCA inhibitor XeC attenuated ATP-mediated Ca2+ mobilization. Additionally, 2-APB, an 
inhibitor of store-operated calcium entry, a system for triggering extracellular calcium influx 
upon ER calcium depletion, also blocked calcium mobilization [126]. Edelfosine, another PLC 
inhibitor, U73122, XeC and 2-APB all also blocked ATP-induced Caspase 1 activation and IL-
1β processing [126,127]. Knockdown of IP3R also had the same suppressive effect [127]. m-
3M3FBS, a direct activator of PLC, caused IL-1β secretion in the absence of any other 
exogenous stimuli [127].  
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Interestingly, high extracellular potassium reduced ATP-mediated Ca2+ mobilization and 
U73122, XeC and 2-APB all reduced production of mitochondrial ROS, providing a link 
between Ca2+ mobilization and both of these NLRP3 inflammasome activation hypotheses [126]. 
CASR also interacted with and inhibited ADCY to reduce cellular cAMP levels. 
Increased cAMP levels, either through direct activation of ADCY and cAMP synthesis with 
NKH477 or forskolin or decreasing cAMP hydrolysis with PDE4 inhibitors Ro-20-1724, (R)-(-)-
rolipram, or zardaverine, suppressed ATP-induced IL-1β secretion. The ADCY inhibitor KH7 
induced dose-dependent secretion of IL-1β on its own in an NLRP3, ASC and Caspase 1-
dependent manner. Spontaneous inflammasome activation was also observed in BMDM upon 
knockdown of several ADCYs found in macrophages including ADCY3, ADCY6, ADCY7 and 
ADCY9 [127]. 
cAMP does not influence inflammasome activation through protein kinase A (PKA), its 
usual pairing, as PKA inhibitors and knockdown of PRKACA caused no change in ATP-induced 
NLRP3 activation. Instead, cAMP interacted with endogenous NLRP3 in pull down experiments. 
This binding occurred in the nucleotide-binding domain of NLRP3 but did not interfere with 
ATP binding to NLRP3 [127]. 
Deletion of CHOP, a transcription factor that can regulate ER calcium release through the 
IP3R, reduced ATP-induced calcium mobilization and IL-1β secretion. Treatment with the 
SERCA inhibitor XeC that suppresses IP3R signaling did not reduce IL-1β secretion any further 
in CHOP deficient cells suggesting that these two changes are acting on the same pathway [126]. 
Activation of the NLRP3 inflammasome also trigged necrotic cell death, though the 
effects of calcium signaling on this process are far less well studied. While treatment of cells 
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with BAPTA-AM decreased ATP-induced IL-1β secretion, it had no effect on ATP-induced 
LDH release. Incubation in calcium-free media actually increased ATP-induced LDH release 
[120] and propidium iodide staining in BMDCs but not macrophages [134]. Treatment with 
thapsigargin had no effect on ATP-induced LDH release [120] but reversed increases in 
propidium iodide staining seen during stimulation in calcium-free media [134]. 
Nitric oxide (NO) is an important short-lived signaling molecules in the immune system. 
It also inhibited NLRP3 inflammasome activation. SNAP, an NO donor, markedly inhibited 
NLRP3 inflammasome activation in response to ATP without a significant effect on 
mitochondrial reactive oxygen species. NO may act directly on NLRP3 as S-nitrosylation of 
NLRP3 was detected in macrophages treated with SNAP [60]. Endogenous NO derived from 
iNOS also negatively regulated NLRP3 inflammasome activity. Depletion of iNOS caused 
increased accumulation of dysfunctional mitochondria in response to ATP. iNOS deficiency or 
pharmacological inhibition of NO production enhanced NLRP3-dependent cytokine production 
in vivo which was prevented by NLRP3 deficiency [235]. 
Treatment of macrophages with ATP induced PKR autophosphorylation and PKR 
disruption blocked IL-1β and IL-18 secretion as well as HMGB1 release, a marker of cell death. 
PKR interacted with numerous inflammasomes including NLRP3, NLRP1, NLRC4 and AIM2, 
suggesting a broad role in regulating inflammasome activity [189]. 
LPS and ATP stimulation induced deubiquitination of NLRP3. LPS-induced 
deubiquitination of NLRP3 was sensitive to treatment with NAC and Mito-TEMPO while ATP-
induced deubiquitination was not [74]. 
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A variety of other proteins contributed to the regulation of ATP-mediated NLRP3 
inflammasome activation. mTORC1, a regulator of hexokinase 1 (HK1)-dependent glycolysis, 
controlled ATP-mediated activation of the NLRP3 inflammasome. Knockdown of mTORC1 or 
HK1 suppressed Caspase 1 activation and IL-1β secretion in response to ATP [236]. 
Acetylcholine, choline and phosphocholine signaling through the α7, α9, and α10 nicotinic 
acetylcholine receptors inhibited ATP-induced Caspase 1 activation and IL-1β with evidence 
suggesting they may have worked by preserving mitochondrial integrity [237,238]. Cellular 
FLICE-inhibitory protein (c-FLIP), an inhibitor of Caspase 8, also promoted Caspase 1 
activation and IL-1β secretion in response to ATP. c-FLIP associated with the NLRP3 
inflammasome and promoted NLRP3 mitochondrial localization [239].  
Other proteins implicated in NLRP3 inflammasome regulation in response to diverse 
stimuli do not play a role in ATP-mediated NLRP3 regulation. For example, MAVS, the 
common mitochondrial adaptor for antiviral signaling, induced NLRP3 activation in response to 
poly(I:C) but did not play a role in response to ATP [221]. 
The physiologic significance of extracellular ATP-mediated NLRP3 inflammasome 
signaling is apparent when one considers that necrotic cells release ATP. Pressure-disrupted B16 
mouse melanoma cells or complement-lysed 6F10 activated the NLRP3 inflammasome. When 
dying cells were fractionated, only isolated mitochondria were able to activate the NLRP3 
inflammasome. P2RX7-deficient macrophages had significantly disrupted NLRP3 
inflammasome activation in response to pressure-disrupted B16 cells, complement-lysed 6F10 
cells and isolated mitochondria. However, this response was not disrupted entirely suggesting 
that other ligand-receptor pairs contributed [240]. Dying tumor cells released ATP that acted on 
P2RX7 in dendritic cells to activate the NLRP3 inflammasome. Interestingly, this has 
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consequences for chemotherapy as well. The tumoricidal activity of oxaliplatin was dramatically 
decreased in tumors established in P2RX7 deficient, NLRP3 deficient or Caspase 1/Caspase 11 
deficient mice as compared to the parental mouse strain. Breast cancer patient data suggests 
these findings extend to humans as well. Anthracycline-treated breast cancer patients carrying a 
loss-of-function allele of P2RX7 developed metastatic disease more rapidly than individuals with 
normal alleles [241]. 
Extracellular ATP may also amplify the NLRP3 inflammasome response to crystalline 
molecules such as aluminum salt, silica, and uric acid. Crystalline-induced NLRP3 
inflammasome activation is diminished in cells treated with purinergic receptor and 
connexin/pannexin channel inhibitors including A740003, carbenoxolone and flufenamic acid. 
Addition of less than 1mM ATP, ADP and UTP to BMDMs did not promote IL-1β secretion 
independently, but enhanced IL-1β secretion in response to silica and alum [242]. Calcium 
oxalate (CaOx) crystals, a common cause of kidney stones and nephropathy, induced renal 
tubular damage, cytokine secretion, neutrophil recruitment and renal failure in an NLRP3 
inflammasome-dependent manner. CaOx-induced kidney damage was blocked by depletion of 
ATP with apyrase treatment, suggesting that ATP is important in amplifying the response to 
CaOx crystals [243]. Serum amyloid A (SAA) also formed particulate structures that activate the 
NLRP3 inflammasome. Similarly, inhibition of P2RX7 blocked SAA-induced IL-1β secretion 
[244]. 
Extracellular ATP has been implicated in triggering and amplifying inflammasome 
activation in response to a variety of pathogens. Entamoeba hystolytica binding to α5β1 integrin 
caused NLRP3 to relocate into the intercellular junction. Activation of α5β1 integrin induced 
ATP release through Pannexin 1 into the extracellular space. There, ATP trigged P2RX7 leading 
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to NLRP3 inflammasome activation [245]. Streptococcus pneumonia pore-forming toxin 
pneumolysin caused ATP-dependent IL-1β secretion. Inhibition of P2RX7 blocked 
pneumolysin-induced Caspase 1 activation and IL-1β secretion [246].  
Complement C3a binding to C3aR caused IL-1β secretion from LPS-stimulated human 
macrophages and dendritic cells. C3a controlled release of intracellular ATP into the 
extracellular space in an ERK1/2-dependent fashion, that subsequently triggered NLRP3 
inflammasome activation [247]. 
ATP is not always required and does not always amplify NLRP3 inflammasome 
activation. Heme activated the NLRP3 inflammasome in LPS-primed macrophages causing IL-
1β secretion. This response required mitochondrial ROS and potassium efflux but was 
independent of ATP release and P2RX7 signaling [248]. 
Extracellular ATP has also been implicated in pulmonary fibrosis. Fibrotic patients have 
elevated ATP content in bronchoalveolar lavage (BAL) fluid as compared with non-fibrotic 
individuals. In mice, airway administration of bleomycin (BLM), a model of idiopathic 
pulmonary fibrosis, caused an early increase in ATP in BAL fluid. Apyrase treatment to degrade 
ATP reduced BLM-induced inflammatory cell recruitment and lung IL-1β while treatment with 
ATPγS, a non-hydrolyzable form of ATP, enhanced inflammation. BLM-induced inflammation 
depended on P2RX7 and Pannexin 1 [249]. 
ATP played a critical role in contact hypersensitivity (CHS), a type of allergic reaction. 
Mice lacking P2RX7 were resistant to CHS and failed to induce sensitization to contact 
allergens. Similarly, treatment of wildtype mice with P2RX7 antagonists, apyrase or the IL-1R 
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antagonist prevented CHS and exogenous IL-1β administration restored CHS in P2RX7 deficient 
mice [250]. 
 Overall, the use of ATP as a model agonist for NLRP3 inflammasome activation and its 
direct relevance to numerous diseases has provided a large base of data to analyze ATP-induced 
NLRP3 inflammasome activation. Even with all we have to examine, though, there are still many 
gaps in our understanding of how ATP activates the NLRP3 inflammasome. The role for 
mitochondria is probably most well supported in the context of ATP stimulation than for any 
other agonist but the link between P2RX7 binding and mitochondrial damage is not clear. 
Mitochondria exchange potassium in the matrix with protons from the cytosol to concentrate a 
pool of protons for use in ATP synthesis [251]. Decreased extracellular potassium resulting from 
ATP stimulation may compromise mitochondrial respiration by limiting the exchange of 
potassium ions for protons and might be a connection worth investigating. 
 
1.8.3 Monosodium urate disrupts lysosomes to trigger the NLRP3 inflammasome  
MSU is the last of the three classic NLRP3 agonists. MSU is a crystalline particulate 
NLRP3 agonist [196]; a class of agonists that also includes silica [83,108], asbestos [83], 
aluminum hydroxide [108,252,253], basic calcium phosphate crystals (octacalcium phosphate, 
carbonate-substituted apatite, and hydroxyapatite) [254], fibrilar amyloid-beta [231] and others. 
This section will primarily focus on MSU but will also touch on these other crystalline 
particulate molecules. 
 It has long been known that patients with gout have elevated serum uric acid. As such, 
the treatment for gout has largely focused on inhibiting the breakdown of purines to uric acid 
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with xanthine oxidase inhibitors, such as allopurinol, or increasing the excretion of uric acid with 
uricosurics, such as probenecid. The recent discovery that MSU triggers the NLRP3 
inflammasome and promotes gouty inflammation through IL-1R signaling [196,255] has given 
patients with uncontrolled gout new options to reduce their inflammation and pain [256].  
The importance of MSU-induced NLRP3 inflammasome activation likely extends 
beyond gout. Release of uric acid from dying mammalian cells is sensed broadly by the immune 
system leading to NLRP3 inflammasome activation, dendritic cell maturation, and CD8+ T cell 
activation [257]. However, there is some debate on whether or not uric acid is a major 
contributor to this process [240,258]. 
MSU caused canonical Caspase 1 activation, IL-1β and IL-18 secretion and necrotic cell 
death and did not require Caspase 11 [51]. Particulate NLRP3 agonists are thought to act 
primarily through phagolysosome destabilization [108]. Inhibition of phagocytosis by blocking 
actin polymerization with cytochalasin D or latrunculin A caused a complete block of IL-1β 
secretion in particulate-stimulated phagocytes [83,108,254]. Blocking the H+-ATPase system, 
which is required for acidification of lysosomal compartments, with bafilomycin A blocked both 
formation of acidic lysosomes and prevented silica- and LLMe-induced IL-1β secretion 
[108,112]. Silica crystal treatment also activated CTSB, which was partly required for NLRP3 
inflammasome activation. Interestingly, disruption of the lysosome using a rapid hypertonic to 
hypotonic media switch or the lysomotropic reagent LLMe was sufficient for causing NLRP3 
inflammasome activation and IL-1β secretion [108]. Disruption of the lysosome by LLMe also 
activated TAK1-JNK signaling that was important for NLRP3 inflammasome activation, though 
this was discussed in more detail in a previous section on kinases [112].  
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 It has been suggested that exposure of MSU to the acidic environment of the lysosome 
causes dissociation of sodium that places osmotic pressure on lysosomes. Inhibition of lysosomal 
acidification with CQ and NH4Cl, or inhibition of aquaporins (AQP) with HgCl2 or phloretin, 
blocked MSU-induced IL-1β secretion. Similarly, knockdown of AQP0, AQP1, and AQP9 in 
THP1 cells resulted in decreased IL-1β secretion [259]. However, while sodium is a component 
of MSU, it is not typically associated with other particulate NLRP3 agonists. It would be 
important to test AQPs in the context of other particulate activators to better substantiate, or 
disprove, the osmotic pressure hypothesis. 
 Other studies have focused on the role of ROS in MSU-mediated NLRP3 inflammasome 
activation. THP1 cells treated with the antioxidants NAC or (2R,4R)-4-aminopyrrolidine-2,4-
dicarboxylate (APDC) blocked MSU-induced IL-1β secretion [84,108,254], suggesting that ROS 
production was necessary for NLRP3 inflammasome activation. Loss of the NADPH oxidase 
subunit p22phox also led to decreased IL-1β secretion and loss of the ROS detoxifying protein 
TRX caused an increase [83]. This is in contrast to claims made by authors of another study that 
MSU treatment did not trigger respiratory oxidative burst as loss of gp91phox, a subunit of the 
phagosomal NADPH-oxidase cytochrome b, did not affect MSU-induced Caspase 1 or IL-1β 
secretion [108]. However, this data is presented in a manner that frustrates comparisons between 
WT and gp91Phox knockout cells. Attempts to compare IL-1β secretion between mouse strains 
(and between graphs) but within the same treatment group appears to suggest that loss of 
gp91phox actually increased IL-1β secretion. Gp91phox and p22phox are the two components of 
the NOX2 complex so different outcomes of knocking down these two proteins would be 
unexpected. Analysis of gp91phox was performed in BMDM from knockout mice and analysis 
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of p22phox was performed using shRNA in human THP1 cells, so it is certainly possible that the 
depletion strategy, cell type or species influenced the different outcomes. 
 A second study has further supported the role of the TRX system in NLRP3 
inflammasome activation. TXNIP is triggered by ROS to dissociate from TRX and bind to 
NLRP3 in THP1 cells treated with MSU. Treatment with APDC to suppress ROS generation 
prevented dissociation of TRX and TXNIP and blocked association of TXNIP and NLRP3. 
Knockout of TXNIP in BMDMs or siRNA-depletion of TXNIP in THP1 cells suppressed MSU-
induced Caspase 1 activation and IL-1β secretion. Similar results were observed in a model of 
MSU-induced peritonitis [94]. The exact mechanism leading from TXNIP and NLRP3 binding 
to NLRP3 inflammasome activation remains unclear. 
 A variety of kinases have also been shown to regulate MSU-induced NLRP3 
inflammasome activation, though unfortunately without much integration of these findings with 
one another. Loss of DAPK in BMDM or THP1 cells led to a decrease in MSU-induced Caspase 
1 activation and IL-1β secretion. DAPK deficiency also reduced neutrophil infiltrations and IL-
1β secretion in a murine MSU-triggered peritonitis [132]. PKR is phosphorylated during 
exposure of BMDM to MSU. Knockout of PKR in BMDM eliminated MSU cytotoxicity and 
HMGB1 secretion, a marker of necrotic cell death [189]. NEK7, a kinase involved in cell cycle 
regulation, was also important in murine MSU-triggered peritonitis. Loss of NEK7 resulted in 
decreased peritoneal exudate cells, neutrophils and monocytes/macrophages in the peritoneum. 
The same result was seen in irradiated wildtype mice reconstituted with NEK7 deficient bone 
marrow treated with MSU. This decrease in infiltrating cells was accompanied by less IL-1β 
secretion and an improved clinical phenotype, reflecting less inflammation [188]. MSU 
treatment also induced phosphorylation of Syk and MSU-induced IL-1β secretion was blocked 
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by inhibition or genetic disruption of Syk [170]. However, MSU-induced phosphorylation of Syk 
in PMA-differentiated THP1 cells was not observed, suggesting a possible cell type or species 
difference [84]. The BTK inhibitor LFM-A13 and loss of BTK also prevented MSU-induced IL-
1β secretion [169].  
 Some kinases that have been implicated in regulating the NLRP3 inflammasome in 
response to other stimuli, such as Lyn [84] and RIPK3 [178], have not been required for MSU-
induced NLRP3 inflammasome activation. 
 One study utilized the human phospho-kinase array from R&D Systems to characterize 
MSU treatment of osteoblasts, a non-professional phagocyte. This screen is a semi-high 
throughput antibody based method of testing for kinase activation among a panel of 46 kinases. 
In this screen MSU treatment caused a significant increase in ERK1/2 T202/Y204, T185/Y187 
phosphorylation and a significant decrease in TOR phosphorylation. A few other kinases were 
trending towards significance but unfortunately further investigation of these changes was 
focused on vacuole formation and not NLRP3 inflammasome activation [260]. At the very least, 
this study demonstrates that a high throughput approach can detect differences in kinase activity 
resulting from treatment with an NLRP3 agonist. 
 As with other NLRP3 agonists, a variety of other regulators have been identified in a 
piecemeal fashion. While there are clear opportunities to try to unify separate lines of evidence, 
the necessary experiments have not been carried out.  
 TRIM30 is one of the few negative regulators of MSU-induced NLRP3 inflammasome 
activation that has been identified. Knockdown of TRIM30 by siRNA caused increased IL-1β 
secretion in response to MSU challenge in J774 cells. Similarly, overexpression of TRIM30 
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(under control of the enhancer of the cytomegalovirus intermediate-early gene and the promoter 
of chicken beta-actin [261]) in murine MSU-induced peritonitis caused decrease neutrophil 
infiltration and IL-1β secretion [210]. A previous study showed that, in response to TLR 
agonists, TRIM30 interacted with TAK-1 binding protein 2 (TAB2), TAB3, and TAK1 and 
promoted degradation of TAB2 and TAB3. This was not blocked by inhibitors of the ubiquitin-
proteasome pathway and TRIM30 could not undergo autoubiquitination, suggesting it lacks E3 
ligase activity. Downregulation of TAB2 was blocked by NH4Cl and chloroquine, both 
inhibitors of lysosomal protein degradation [261]. TAB2 and TAB3 are required for activation of 
TAK1 by TRAF6 in TLR signaling [262,263]. Interestingly, this suggests that priming with TLR 
ligands is opposed by the pathway leading to NLRP3 inflammasome activation because TRIM30 
promotes degradation of TAB2 and TAB3. However, TAK1 is activated in NLRP3 
inflammasome signaling [112], so this shift may allow TAK1 to come under control of a second 
pathway responsible for NLRP3 activation.  
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Figure 1.8. TLR signaling may shift TAK1 between priming and NLRP3 inflammasome 
roles. TRIM30 is a negative regulator of the NLRP3 inflammasome. However, treatment of cells 
with LPS recruits TRIM30 to interact with TAB2, TAB3 and TAK1 leading to degradation of 
TAB2 and TAB3. TAB2 and TAB3 are required for TRAF6 to activate TAK1 in canonical TLR-
NF-κB signaling. TRIM30-induced degradation of TAB2 and TAB3 may release TAK1 to 
activate the NLRP3 inflammasome, rather than NF-κB signaling. 
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 PML is required for MSU-induced Caspase 1 activation and IL-1β secretion. Loss of 
PML also led to reduced CTSB activation in response to MSU [223]. BMDM from β-arrestin1, 
the G protein-coupled receptor signaling regulator, knockout mice showed decreased Caspase 1 
activation, IL-1β secretion and LDH release in response to MSU. It was similarly important in 
MSU-induced peritonitis in these same mice, with loss of β-arrestin1 leading to decreased 
neutrophil infiltration and IL-1β secretion. β-arrestin1 interacted with NLRP3 when exogenously 
expressed in HEK293T cells and promoted NLRP3 self-oligomerization [215]. 
 Interestingly, xanthine oxidase activity is rapidly increased in response to MSU and other 
crystalline activators leading to production of both uric acid and ROS. Uricase treatment had no 
effect on IL-1β secretion in this setting, suggesting that uric acid production was not responsible 
for downstream NLRP3 inflammasome activation. Instead, XOR activity increased PI3K-AKT-
mTOR signaling and treatment with the XOR inhibitor febuxostat blocked phosphorylation of 
AKT and ROS production. Additionally, inhibitors of PI3K and AKT blocked MSU-induced IL-
1β secretion [48].  
 The intracellular concentration of ATP has been implicated in NLRP3 inflammasome 
signaling. MSU treatment of murine BMDMs caused a significant decrease in intracellular ATP 
concentration that coincided in time with IL-1β secretion [211]. This loss of ATP might lead to 
mitochondrial dysfunction as mitochondrial respiration is increased to replenish the diminished 
ATP stores. 
 As briefly mentioned above, MSU has been a popular agonist to study because of its easy 
application to in vivo study in the murine MSU-induced peritonitis model and its direct role in 
gout. Below, we will examine a few studies focusing on in vivo effects of MSU. 
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  Ventilator-induced lung injury (VILI) is thought to result from overly aggressive 
ventilation that causes mechanical stretch-induced inflammation and injury. In a recent study that 
modeled this cyclic stretching in isolated alveolar macrophages and in mice, the NLRP3 
inflammasome was identified as the source of IL-1β production. While ROS contributed to 
NLRP3 inflammasome activation, gp91phox was not required as was seen above with MSU 
stimulation. Uric acid concentrations were vastly increased in the media after the cyclic stretch 
protocol. Treatment of alveolar macrophages with allopurinol diminished uric acid production, 
ROS generation and NLRP3 inflammasome activation. In a mouse model of VILI, high tidal 
volumes induced NLRP3 activation in a time dependent manner. This led to an increase in trans-
alveolar protein permeability and lung edema. These consequences were reduced in mice 
pretreated with an IL-1β blocking antibody, supporting the NLRP3 etiology of these effects 
[264]. To better support the role for uric acid release in NLRP3 inflammasome activation in vivo, 
VILI should be assessed in mice treated with allopurinol, as was done for isolated macrophages, 
and uricase. Allopurinol inhibits XOR and might also reduce ROS independent of uric acid 
release, so uricase treatment would provide important supporting evidence by directly depleting 
uric acid levels. 
 Uric acid is liberated from hepatocytes during alcohol intoxication. This can be observed 
both in tissue culture and in human volunteers who when given alcohol experienced an increase 
in serum uric acid concentrations. This spike in uric acid concentration leads to increased IL-1β 
secretion in human PBMCs stimulated with hepatocyte conditioned media. The increase in IL-1β 
secretion in this setting was sensitive to uricase treatment, suggesting a causal role for uric acid. 
Most interestingly, NLRP3 knockout mice fed an alcohol containing diet to induce liver toxicity 
did not experience increased serum or liver IL-1β levels and were protected against liver damage 
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[265]. The authors try to connect the in vitro observation of ethanol-induced uric acid changes to 
the in vivo changes seen in ethanol fed mice. However, further experiments in mice to 
substantiate the role of uric acid are important to rule out a uric acid-independent effect of 
ethanol on the NLRP3 inflammasome. Even in this very same study, extracellular ATP was 
found to contribute to IL-1β secretion observed in vitro [265]. 
 NLRP3 may not be the only inflammasome-like pathway activated by uric acid exposure. 
In a mouse model of radiation damage, radiation exposure led to cell damage and a local 
inflammatory response. Whole body radiation caused an increase in serum uric acid levels and 
activation of Caspase 1. In mice treated with allopurinol or Caspase 1 knockout mice, radiation 
induced immune cell loss was blunted, however, the effect, while statistically significant, was 
not dramatic. Unexpectedly, NLRP3 knockout mice subjected to whole body radiation 
experienced the same extent of Caspase 1 activation and immune cell loss as the parental strain 
mice. However, serum IL-1β was reduced in both Caspase 1 and NLRP3 knockout mice [266]. 
This study raises two important points. First, this study suggests that uric acid might be 
activating Caspase 1 in an NLRP3-independent manner. Since the discovery that MSU activates 
the NLRP3 inflammasome, most studies have relied on Caspase 1 activation and IL-1β secretion 
as their assay readouts, without confirming that the effect they are seeing was the result of 
NLRP3 inflammasome activation specifically. Second, the use of allopurinol to reduce uric acid 
might not be free from off-target effects. While this study tried to tie together radiation damage, 
increased serum uric acid, and allopurinol inhibition of Caspase 1 activation, the potential for a 
uric acid-induced NLRP3-independent inflammasome effect must further be addressed using 
additional methods to reduce uric acid. 
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1.9 Consequences of NLRP3 inflammasome signaling in pulmonary diseases 
  There is an increasing amount of research linking NRLP3 inflammasome signaling to 
outcomes for both infectious and non-infectious diseases in mouse models. In chapter 2, the 
discussion will focus on the interaction between S. aureus and host inflammasomes. In 
particular, the role of TH17 cells will be highlighted as a critical component of the immune 
response against S. aureus that depends on NLRP3-dependent IL-1β signaling. Additionally, a 
portion of the publication included in Appendix A will highlight the importance of the NLRP3 
inflammasome to heart failure and how it might be targeted by novel drugs to improve heart 
failure outcomes.  
 Before concluding this introduction, I will briefly discuss the role of the NLRP3 
inflammasome in lung diseases – a particular interest of mine – in order to highlight the wide 
ranging role of the NLRP3 in both infectious and non-infectious diseases. I will not 
comprehensively detail the pathophysiology of every disease discussed, I will only highlight 
recent reports on the role of the NLRP3 inflammasome. The reader is cautioned against reading 
too much into these results given the incomplete discussion of disease pathophysiology. 
Additionally, since Staphylococcus aureus will be the focus of the body of this 
dissertation, it will be skipped over here and instead be included in Chapters 2, 3 and 4.  
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1.9.1 The NLRP3 inflammasome is a sentinel in pulmonary infections 
 Bacteria, viruses and fungi can all infect upper and lower respiratory airways. While the 
NLRP3 inflammasome is activated in response to nearly every lung pathogen investigated, the 
consequence of that activation differs substantially. 
 
1.9.1.1 NLRP3 inflammasome activation helps clear respiratory viruses 
 In influenza infection, mice lacking NLRP3 and Caspase 1 were more susceptible than 
the parental strain, with approximately 60% of knockout mice from both groups dying after two 
weeks compared to only 30% from the parental strain. Knockout of NLRP3 or Caspase 1 had 
wide ranging depressive effects on cytokine production during influenza infection. Decreases 
were seen in IL-1β, IL-18, TNF-α, IFN-α IL-6, KC and MIP-2, demonstrating a cascade of 
immune signaling defects emanating from the defective NLRP3 inflammasome response. 
Additionally, lymphocyte chemotaxis was defective, as BAL fluid from infected knockout mice 
had significantly fewer neutrophils and monocytic dendritic cells than the infected parental strain 
mice. Surprisingly, these mice had no observed general defect in IgM, IgA or IgG production or 
CD8+ T cell recruitment. They also had equivalent viral titers during the first week of infection. 
The increased mortality of the NLRP3 and Caspase 1 deficient mice appeared to result from 
uncontrolled pulmonary necrosis later in infection. Concentric layers of collagen were common 
in the distal airways and lung interstitium of both NLRP3 and Caspase 1 knockout mice and 
alveoli were occluded. This severely exacerbated lung pathology correlated with decreased blood 
oxygen partial pressure [267]. 
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 Elderly mice (15 months) infected with influenza experience a more severe disease 
course characterized by increased duration, higher viral burden, and higher mortality than in 
young (2-4 months) and middle-aged (8-9 months) mice. Elderly mice produce less IL-1β and 
IL-18 during the course of infection, suggesting that the NLRP3 inflammasome was 
compromised by aging in this setting. BMDCs demonstrated the same defect when infected ex 
vivo, and adoptive transfer of young dendritic cells to aged hosts partially rescued IL-1β 
secretion and improved their clinical progress, suggesting it is a cell intrinsic problem. Elderly 
influenza infected mice treated with nigericin have increased IL-1β secretion, decreased disease 
severity and dramatically improved survival [225]. Altogether, this data suggests that the ability 
of phagocytes sense influenza infections and transduce that signal into NLRP3 inflammasome 
activation is compromised, but NLRP3 inflammasome activation itself retains much of its 
youthful potential. 
 Respiratory syncytial virus (RSV) is a common cause of severe respiratory illness in 
children. NLRP3 inflammasome activation in response to RSV has been studied in tissue culture. 
NLRP3, ASC and Caspase 1 were all required for IL-1β secretion in response to RSV infection 
in BMDMs [268]. The RSV protein SH, a small hydrophobic protein that is classified as a 
viroporin and important for infectivity in vivo [269,270], is required for IL-1β secretion in 
infected lung epithelial cells as loss of SH completely eliminated the IL-1β response with no 
effect on IL-6 secretion [271]. However, the role of SH in activating the NLRP3 inflammasome 
has not been tested directly, nor has the role of NLRP3 been evaluated in the context of an actual 
respiratory RSV infection.  
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1.9.1.2 The NLRP3 inflammasome is differentially required for clearing extracellular and 
intracellular bacterial infections  
Streptococcus pneumoniae is one of the leading causes of pneumonia. Infection of mice 
with S. pneumoniae serotype 3 results in pneumonia typically without spreading to bacteremia 
[272]. NLRP3 deficient mice appeared to have a slight increase in infection severity with 
mortality generally occurring two days before the parental strain mice. The bacterial burden in 
the whole lung was slightly increased in NLRP3 deficient mice at 48 hours post infection, 
suggesting compromised control of bacteria. Surprisingly, no significant differences were 
recorded in BAL leukocytes or in IL-1β, IL-18, IL-10, IL-6, IFN-g or KC in BAL fluid. In this 
report, comparison of the concentration of serum albumin in BAL fluid to serum albumin in the 
serum was used as an indicator of damage to the lung vascular barrier. Mice deficient in NLRP3 
had increased serum albumin in BAL fluid at 24 hours compared to the parental strain mice but 
both strains were equivalent at 48 hours. Additionally, dynamic lung compliance was 
compromised in NLRP3 deficient mice reflecting increased lung edema [273]. Overall, the 
contribution of NLRP3 to infection course was not outstanding. A subsequent study on serotypes 
1 and 8 found that expression of non-hemolytic pneumolysin resulted in these serotypes being 
poor activators of IL-1β secretion [274]. This finding suggests that NLRP3 would be even less 
engaged in infections with these two serotypes, an important suggestion given that serotype 1 is 
the major cause of invasive disease worldwide. 
 Klebsiella pneumonia most often occurs in patients with weakened immune systems, 
typically as a result of aspiration. It is characterized by production of “red-currant jelly” sputum 
and is extremely aggressive. Mice infected intratracheally with Klebsiella pneumoniae develop a 
severe pulmonary infection that reflects human infection. Klebsiella infected mice lacking 
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NLRP3 or ASC had an exacerbated disease course and worse outcomes than the parental strain 
infected mice. In contrast to what was seen with influenza, mice lacking NLRP3 had severely 
attenuated airway inflammation as seen by H&E staining. However, the bacterial burden 
measured in BAL fluid and lung homogenates was equivalent to the parental strain infected 
mice. As is expected, NLRP3 deficient mice produced less IL-1β and had a lower burden of 
necrosis in vivo but had increased levels of IL-6 [275]. 
 Mycobacterium tuberculosis (Mtb) evades killing by alveolar macrophages to established 
infection of these cells. In tuberculosis, ESAT-6, a substrate of the ESX-1 secretion system 
implicated in membrane damage, was both necessary and sufficient for NLRP3-dependent 
Caspase 1 activation and IL-1β secretion [276]. Mice deficient in ASC, but not NLRP3 or 
Caspase 1, that were infected with aerosolized Mtb demonstrated a survival defect as compared 
to the parental strain mice but with no difference in bacterial burden or lung IL-1β detected. ASC 
deficient mice formed fewer granulomas and, despite a similar bacterial burden, were unable to 
contain bacteria within granulomas during chronic Mtb infection [277]. In a separate model for 
chronic tuberculosis, IFN-γ activation of macrophages suppressed IL-1β production by 
specifically inhibiting the NLRP3 inflammasome. Loss of IFN-γ led to increased IL-1β secretion, 
compromised infection control, increased neutrophil recruitment and tissue damage. IFN-γ 
induced iNOS and stimulated NO production leading to S-nitrosylation of the NLRP3 [61]. 
Overall, for Mtb, this early research suggests that the adaptive immune response must suppress 
the NLRP3 inflammasome to progress to the chronic phase of infection. In the chronic phase, 
ASC is required for granuloma formation independent of its role in activating Caspase 1. 
Chlamydophila pneumoniae is an intracellular bacterium that causes atypical pneumonia. 
C. pneumoniae-infected macrophages secreted IL-1β and IL-18 that was almost completely 
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absent upon deletion of NLRP3 or ASC. Infection of mice with C. pneumoniae intranasally 
resulted in pneumonia. Infected mice deficient in IL-1R had increased TNF-α, IL-6, and IL-12 at 
day 3 of infection but these cytokines were equivalent to the parental strain by day 5. At day 3 
and day 5, the infectious burden of both IL-1R deficient mice and the parental strain were 
equivalent, and nearly all mice cleared the infection by day 12. By histologic examination, IL-1R 
deficient mice had extensive proliferation of fibroblasts and decreased infiltration of neutrophils 
out to day 12. The IL-1R deficient mice had more significant fibrosis as observed by trichrome 
staining [278]. It would be additionally interesting to examine NLRP3 and IL-18 (or IL-18R) 
deficient mice in Chlamydophila pneumonia. Controlling this infection is known to depend 
heavily on IFN-γ signaling [279] and IL-18 is an important IFN-γ-inducing cytokine [280]. Early 
studies of Chlamydophila suggested that IL-18 is critical for induction of IFN-γ in response to 
infection too [281]. 
Burkholderia pseudomallei (previously known as Pseudomonas pseudomallei) is an 
intracellular bacterium that causes a lung infection called melioidosis endemic to southeast Asia 
and Australia. Mice deficient in ASC, Caspase 1, NLRC4 or NLRP3 were more susceptible to 
intranasal B. pseudomallei infection than the parental strain mice. Interestingly, NLRP3 deficient 
mice produced lower levels of IL-1β and IL-18, but NLRC4 deficient mice produced higher 
levels of IL-1β and IL-18. Cells from NLRC4 deficient mice did not undergo cell death and these 
mice had higher bacterial burdens whereas NLRP3 deficient mice were equivalent to the parental 
strain in bacterial burden. To determine how both enhanced and defective cytokine secretion 
could be detrimental, IL-1R and IL-18 knockout mice were examined. IL-1R knockout mice had 
improved survival during B. pseudomallei infection as compared to the parental strain whereas 
IL-18 knockout mice died extremely rapidly. Mice deficient in both IL-1R and IL-18 died at 
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similar rates to the IL-18 deficient mice, suggesting that IL-18 was a more significant 
determinant in infection outcomes. Daily injection of exogenous IFN-γ in IL-18 deficient mice 
provided complete protection, demonstrating that IL-18 was important for induction of IFN-γ. 
Surprisingly, daily injection of exogenous IL-1 receptor antagonist into wildtype mice protected 
mice from infection with a lethal dose of B. pseudomallei. The detrimental effect of IL-1β was 
the result of enhanced recruitment of neutrophils to the site of infection. Neutrophils did not 
undergo cell death in this setting and as such failed to limit replication of B. pseudomallei. 
Inhibition of neutrophil chemotaxis by injection of antileukinate, a CXCR2 antagonist, provided 
perfect protection in NLRC4 deficient mice [282]. The detailed work in this report nicely 
highlights how different inflammasomes can be activated in a single infection, and how the 
outcomes of inflammasome signaling – IL-1β, IL-18 and cell death – can each contribute to 
infection pathology or clearance in different ways. 
 
1.9.1.3 The NLRP3 inflammasome responds to acute and chronic fungal infections 
Although numerous fungi have been shown to activate the NLRP3 inflammasome, little 
research has been conducted to investigate the importance of the NLRP3 inflammasome in 
fungal pulmonary infections. Fungal pneumonia is almost entirely found in 
immunocompromised patients and includes a wide variety of infections like histoplasmosis, 
coccidioidomycosis, pneumocystis pneumonia, cryptococcosis, aspergillosis, and more. 
Paracoccidioides brasiliensis, the cause of paracoccidioidomycosis (PCM), activated the 
NLRP3 inflammasome leading to IL-1β and IL-18 secretion. NLRP3, ASC and Caspase 1 
knockout mice were more susceptible to infection than the parental strain mice. Loss of 
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inflammasome function compromised control of fungal growth and led to higher fungal burdens 
in the course of infection. Loss of NLRP3 inflammasome components did not affect the 
appearance of granulomas but must have affected their function given the compromised fungal 
control. To study the downstream effects of NLRP3 inflammasome activation, IL-1R knockout 
mice and IL-18 knockout mice were studied. Loss of IL-18 mimicked the survival defect seen in 
NLRP3 inflammasome deficient mice whereas IL-1R knockout mice had similar mortality to the 
parental strain. Loss of IL-18 resulted in aggressive dissemination of the fungus as fungal counts 
were dramatically increased in the lung, liver and spleen. Loss of IL-18 resulted in decreased 
IFN-γ production and injection of recombinant IL-18 improved infection control as seen by 
fungal burdens decreased to the level seen in the parental strain mice [283].  
To model aspergillosis, a fungal pneumonia caused by Aspergillus fumigatus, mice were 
administered A. fumigatus conidia intranasally. These mice experienced a pulmonary infection 
characterized by pulmonary neutrophilia, histologic lung damage and upregulation of 
chemotactic cytokines CXCL1 and CXCL2. Administration of IL-37 intraperitoneally prior to 
infection resulted in decreased neutrophil influx and lung damage in a dose-dependent fashion. 
IL-37 decreased Caspase 1 activation and IL-1β production during aspergillosis, and also 
decreased mRNA levels of IFN-g, IL-17A, TNF-α, and IL-6. IL-10 was increased with IL-37 
administration indicating that IL-37 tips the cytokine balance more towards an anti-inflammatory 
state. However, this anti-inflammatory state did not depend on IL-10 as the protective effect of 
IL-37 persisted in IL-10 deficient mice. To evaluate the importance of IL-37-dampened IL-1β 
signaling in aspergillosis, NLRP3 deficient mice were infected with A. fumigatus. NLRP3 
deficient mice had decreased IL-1β production, as expected, and showed decreased signs of 
neutrophil infiltration. By histology, lungs of NLRP3 deficient mice had more well preserved 
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architecture and less inflammatory cell infiltrates than the parental strain infected mice. IL-37 
had no additional benefit in NLRP3 deficient mice, suggesting that IL-37 downregulating 
NLRP3 activity is its primary mode of action. The protective effect of IL-37 required TIR-
8/SIGIRR [284], a negative regulator of TLR signaling [285]. However, it is not clear from this 
study alone whether TIR-8 is responsible for reduced NLRP3 inflammasome signaling or simply 
acts in a complementary manner to suppress NLRP3 inflammasome signaling. 
 
1.9.2 Chronic obstructive pulmonary disease is influenced by long term NLRP3 
inflammasome stimulation 
 Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease 
in the world. The primary cause of COPD is chronic exposure to tobacco smoke and pollution.  
 In order to study the role of acute inflammation in response to COPD-causing pollutants, 
mice were exposed to cigarette smoke for 3 days or 4 weeks and evaluated for pulmonary 
inflammation. Cigarette smoke caused a significant increase in IL-1α and IL-1β production in the 
lungs of parental strain mice. The numbers of immune cells recovered in BAL fluid and in total 
lung homogenates, including neutrophils, macrophages, dendritic cells, and both CD4+ and 
CD8+ T cells, were all decreased in IL-1R knockout mice exposed to cigarette smoke as 
compared to the parental strain. Treatment of parental strain mice with neutralizing IL-1α or IL-
1β antibodies significantly reduced the recruitment of neutrophils to the lungs. Loss of NLRP3 or 
Caspase 1 had no effect on cigarette smoke-induced leukocyte infiltration of the lung or IL-1α 
production, but completely eliminated IL-1β secretion [286]. The difference observed between 
an IL-1β neutralizing antibody, which decreased neutrophil infiltration, and depletion of NLRP3-
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mediated production of IL-1β, which had no effect on neutrophil infiltration is a somewhat 
perplexing finding. It is possible that the level of IL-1β required for neutrophil infiltration is 
below the limit of detection of the assay used. It is also possible that IL-1α production is 
increased to the extent necessary to compensate for the loss of IL-1β signaling at the IL-1R. To 
test this, the IL-1α neutralizing antibody should be tested in NLRP3 knockout mice to see if it 
blocks neutrophil infiltration into the lung.  
 A functional mouse model of chronic cigarette smoke exposure, in which mice were 
exposed to cigarette smoke for up to 12 months, was also used to study the role of NLRP3 in 
COPD. Pulmonary function tests included small animal plethysmography, pleural pressure 
measurements, transpulmonary pressure calculations, and pressure-volume curve assessments. 
Parental strain mice exposed to cigarette smoke (COPD mice) had significantly increased 
respiratory system resistance after 10 and 12 months of cigarette smoke exposure, whereas the 
NLRP3 deficient mice had the same resistance as unexposed mice. Similarly, respiratory system 
compliance was significantly decreased in COPD mice, whereas the NLRP3 deficient mice 
mimicked the unexposed mice again. Immune cell infiltrates in the BAL fluid and IL-18 and IL-
1β measured in the serum were nearly equivalent in unexposed and NLRP3 deficient mice and 
were significantly greater in COPD mice. Lung sections from COPD mice stained with H&E 
showed significant immune cell infiltration and destruction of normal alveolar architecture. Lung 
histology for the NLRP3 deficient mice was indistinguishable from control mice [287]. Unlike 
the rather acute exposure model seen above, this year long exposure showed a very significant 
role for the NLRP3 inflammasome in COPD. Although it is hard to say with complete certainty, 
this model probably more accurately reflects the physiologic experience of humans as COPD 
normally develops through decades of cigarette smoking or pollutant exposure. 
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 BAL fluid was collected from never-smokers, asymptomatic smokers, and patients with 
COPD of different severity for measurement of extracellular ATP. ATP levels were increased in 
all smokers over never-smoker subjects and ATP levels in COPD patients were negatively 
correlated with lung function as measured by the amount of air forcefully expired in 1 second 
(FEV1). Some patients with severe COPD had an extracellular ATP concentration recovered in 
BAL fluid as high as 600 nmol/mL BAL fluid, whereas normal subjects were closer to 5 
nmol/mL BAL fluid. Neutrophils and macrophages from patients with COPD were 
hyperresponsive to ATP stimulation, with neutrophils releasing more elastase and macrophages 
releasing more IL-1β and MMP-9 than healthy controls [288]. These data are very suggestive of 
NLRP3 inflammasome activation. If that is the case, the high extracellular ATP observed in 
COPD patients might be both the result of NLRP3 inflammasome activation and the cause, 
resulting in a positive feedback cycle that is exacerbated by smoke inhalation. 
 Although it would seem tempting to evaluate IL-1β disrupting therapies in patients with 
COPD, their increased risk for infection, even without cytokine antagonism, would be a major 
risk.  
  
1.9.3 NLRP3 may contribute to airway hyperreactivity in asthma, allergy, obesity 
 Airway hyperreactivity is a characteristic of asthma and other similar disorders in which 
airways are overly sensitivity to a constrictor trigger. This can be tested for directly in a clinical 
or laboratory setting using methacholine challenge [289]. Although mild asthma is most 
commonly associated with eosinophil and mast cell infiltrates and histamine production, patients 
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with severe asthma have a predominantly neutrophil infiltrate that causes tissue damage [290]. 
Research studies have tried to model both conditions. 
 Segmental allergen challenge of patients with asthma caused a significant increase in 
extracellular ATP recovered in BAL fluid from the allergen challenged segment versus a saline 
challenge segment after 24 hours. The same increase was observed in mice sensitized with 
ovalbumin (OVA) and alum and challenged 10 days later with OVA. Twenty-four hours after the 
challenge, the concentration of ATP was increased in the BAL fluid of OVA- but not PBS-
challenged mice. Administration of apyrase to the lung 30 minutes before OVA challenge greatly 
lowered the concentration of ATP in BAL fluid. This decrease was also accompanied by 
decreased inflammatory cell infiltrates and peribronchial inflammation. Inhibition of P2Rs with 
suramin prior to OVA challenge also decreased inflammatory cell infiltrates and peribronchial 
inflammation. To better appreciate the effect of extracellular ATP in this setting, ATPγS was 
administered to mice before OVA challenge. In this case, ATPγS dramatically increased 
inflammatory cell infiltrates and led to increased TH2 cytokine production, including IL-4, IL-5 
and IL-13 [291]. Although this study did not measure NLRP3 inflammasome activation, it is 
important in that it established the abundance of an NLRP3 agonist in the OVA plus alum model 
of airway hypersensitivity. 
 Allergic lung inflammation can also be induced by OVA sensitization without an 
adjuvant for one week followed by intranasal challenge with OVA. This model leads to a 
predominantly eosinophilic infiltrate and production of TH2 cytokines. In NLRP3 deficient mice 
challenged with OVA, cell infiltrates recovered in BAL fluid were almost entirely absent as 
compared to parental strain mice challenged with OVA. NLRP3 deficient mice had a significant 
reduction in lung IL-1β, IL-6, IL-33, CCL5, CCL11, and CCL17, and BAL recovered IL-5. 
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CCL5 and CCL11 are known to play a role in eosinophil influx into the lung, and CCL17, IL5, 
and IL-33 are all TH2 cytokines. Cellular infiltrates in the lungs were evaluated by histology and 
confirmed that NLRP3 deficient mice had less cellular infiltration and less mucus production. 
OVA challenge in IL-1R knockout, IL-1β knockout and IL-1α knockout mice showed the same 
results, that loss of IL-1 signaling decreased cellular infiltrates and TH2 cytokine production in 
this model. Increased levels of ATP were found in BAL fluid of OVA challenged mice, as was 
seen in the previous study that used OVA and alum sensitization, and may be the trigger for 
NLRP3 inflammasome activation [292].  
 However, another study of allergic airway disease in mice using alum-dependent and 
alum-independent OVA sensitization and acute and chronic house dust mite antigen exposure 
found no role for the NLRP3 inflammasome. Loss of NLRP3 did not impact inflammatory cell 
infiltration in BAL fluid or lung histology in any of the four sensitization modalities. It also did 
not impact airway resistance or tissue damping in the airways in response to methacholine [293]. 
This study points to the need for further investigation of NLRP3 in allergic airway diseases. 
Perhaps modifying factors exist, like the microbiome, as the authors of this study propose, that 
can explain the requirement for NLRP3 in previous studies and the lack in this one. 
  One possible explanation for how NLRP3 is able to so widely influence cytokine 
secretion comes from a study that has found NLRP3 acts separately from the inflammasome to 
activate transcription of a TH2 program. Differentiation of CD4+ cells to a TH2 phenotype is 
normally accompanied by production of IL-4, IL-5, and IL-13. In NLRP3 deficient T cells, 
production of these three TH2 cytokines and more were dramatically decreased. T cell IL-2 
induced STAT5-mediated NLRP3 mRNA transcription, as blocking IL-2 with an antibody or 
siRNA-mediated depletion of STAT5 prevented upregulation of NLRP3 transcripts. Loss of 
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ASC and Caspase 1 did not reproduce the defective cytokine secretion seen in TH2 cells, 
suggesting that NLRP3 was acting outside of its role in the inflammasome. Interestingly, in 
chromatin immunoprecipitation experiments, NLRP3 precipitated with hundreds of regions of 
DNA associated with transcription of TH2 phenotype genes including IL-4, IL-5 and IL-13. 
NLRP3 bound to a consensus motif of nGRRGGnRGAG, where ‘n’ is any nucleotide and ‘R’ is 
any purine. NLRP3 interacted with IRF4 to promote binding to TH2 promoters including IL-4 
[294].  
 From these data, it is apparent that NLRP3 directly influenced TH2 cell fate. Turning 
back to airway hyperreactivity, loss of NLRP3 in a model of OVA sanitization without alum 
followed by OVA challenge, as above, led to decreased leukocyte infiltration in the lungs and 
decreased mucus production. These effects were not observed in ASC and Caspase 1 deficient 
mice, suggesting that NLRP3 was acting outside of its role in the inflammasome. NLRP3 
deficient mice challenged with OVA produced less IL-4 and IL-5 than the parental strain mice. 
Transfer of NLRP3-containing T cells into NLRP3 deficient mice restored the OVA-induced 
airway inflammation and IL-4 and IL-5 production to the same level seen in parental strain mice 
[294]. This study is really quiet stunning. Even separate from the compelling analysis of allergic 
airway disease, this study further complicates the interpretation of NLRP3 deletion studies in 
whole animal models by demonstrating a diminished differentiation of TH2 cells in NLRP3 
deficient animals. This study points to a critical need for development of lineage specific 
knockouts of NLRP3 and a more thorough investigation of NLRP3 beyond its role in the NLRP3 
inflammasome. 
Obesity is often associated with the development of asthma. As such, mice fed a high-fat 
diet for 12 weeks became obesity and developed airway hyperreactivity. Knockout of Rag1, a 
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protein required for differentiation of B and T cells, had no effect on the development of obesity-
associated airway hyperreactivity. Instead, loss of IL-17 prevented the mice from developing 
airway hyperreactivity even in the context of obesity. Similarly, deletion of NLRP3 actually 
worsened obesity but protected mice from developing airway hyperreactivity. Parental strain 
mice with airway hyperreactivity had increased IL-1β, IL-6 and IL-23a mRNA in both adipose 
tissue and the lung. In these mice, IL-1β promoted development of innate lymphoid cells (ILC3 
cells) that produced IL-17A which was critical for airway hyperreactivity. Treatment of obese 
parental strain mice with the IL-1R antagonist prevented development of ILC3 cells and 
prevented airway hyperreactivity. Administration of IL-1β into Rag2 deficient mice had the 
opposite effect, leading to robust airway hyperreactivity [295].  
 Serum amyloid A (SAA) is increased in subjects with severe allergic asthma. Saa3 is 
expressed in the lungs of mice exposed to several mixed TH2/TH17-polarizing allergic 
sensitization regimens. SAA drove production of multiple pro-inflammatory cytokines and 
promoted NLRP3-dependent secretion of IL-1β by dendritic cells and macrophages. This IL-1β 
triggered naive CD4+ T cells to produce IL-17. On its own, SAA acted as an adjuvant to 
sensitize mice to inhaled OVA, but in IL-1R or NLRP3 deficient cells, it did not induce 
production of IL-17 or recruitment of eosinophils to the lung [296].  
 Overall, the variety of models used in these studies of allergic airway disease make 
understanding the relevance of their discoveries to human health more complicated. Each 
proposes to more accurately mirror the physiology seen in the human condition, but without any 
direct interventional studies in humans to corroborate these findings, it is hard to differentiate 
cause from effect. The NLRP3 inflammasome seems to play an interesting role in IL-17-
mediated allergic airway disease but its role in TH2 oriented diseases is still an open question. 
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The possibility of NLRP3 acting outside of the context of the inflammasome to influence the 
TH2 program is also an important discovery that needs additional follow up and may have 
widespread implications in other TH2-driven diseases such as atopy.  
 
1.9.4 The NLRP3 inflammasome is critically activated in acute lung injury 
 Acute lung injury (ALI) can result from a wide variety of different causes including 
hyperoxia, mechanical ventilation/stretch and more. ALI is characterized by extravasation of 
protein into alveoli resulting in high protein BAL fluid, pulmonary edema, and immune cell 
infiltration. 
 NLRP3 deficient and parental strain mice were exposed to 100% O2 for 48-72 hours to 
induce hyperoxic acute lung injury (HALI). Mice lacking NLRP3 had improved pathological 
scores indicating less damage to the lung resulting from hyperoxia. Recruitment of inflammatory 
cells, including macrophages and neutrophils, and secretion of IL-1β, TNF-α and MIP-2, but not 
IL-6, were all decreased in NLRP3 deficient mice as compared to the parental strain [297]. This 
hyperoxic damage was thought to cause ROS production leading to NLRP3 inflammasome 
activation, however, at this point, that is not well established. 
 P2RX7 knockout mice and the parental strain were exposed to 100% oxygen for 72 
hours. Knockout of P2RX7 increased survival during this trial. Hyperoxia caused an increase in 
BAL protein and infiltration of macrophages and neutrophils. Knockout of P2RX7 protected 
mice from hyperoxia-induced macrophage and neutrophil infiltration. Interestingly, IL-1β levels 
were substantially decreased in the P2RX7 mice as compared to the parental strain after 
hyperoxia. In cells exposed to hyperoxia ex vivo, P2RX7 exhibited substantially decreased 
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Caspase 1 activation, suggesting that hyperoxia caused release of ATP that triggered the NLRP3 
inflammasome [298]. Unfortunately, as we have seen in many other studies that suggest a role 
for extracellular ATP in activating the NLRP3 inflammasome, apyrase should have been used to 
definitively diminish extracellular ATP levels in the parental strain mice. 
 While NLRP3 mediates HALI, PTEN-induced putative kinase 1 (PINK1), an initiator of 
mitophagy, mediates protection from HALI. First, NLRP3, ASC and Caspase 1 deficient mice 
were confirmed to have improved survival after HALI as compared to the parental strain mice. 
Loss of inflammasome components resulted in decreased BAL fluid protein, immune cell and 
IL-1β recovery. NLRP3 deficient mice had increased PINK1 expression, both at baseline and 
following HALI as compared to the parental strain mice. Deletion of PINK1 sensitized mice to 
HALI, including worsening BAL parameters such as protein recovery, and even reversed the 
improved survival seen in NLRP3 deficient mice suggesting that PINK1 is critical for protection 
against HALI. Specific knockdown of PINK1 in lung endothelial cells had the same effect as 
global knockout [299]. As has been seen in many in vitro studies, functional autophagy and 
mitochondrial repair/recycling was critical for avoiding NLRP3 inflammasome activation. When 
PINK1 was deleted producing a defect in mitophagy, HALI likely over activated the NLRP3 
inflammasome, leading to greater cell death than see in the parental strain mice. 
 In a separate model of ALI induced by administration of LPS intratracheally, the NLRP3 
inflammasome was required for both albumin and IL-1β recovery in BAL fluid. Additionally, 
loss of NLRP3 or Caspase 1 diminished infiltration of neutrophils into the lungs. Depletion of 
macrophages by clodronate liposomes or neutrophils by treatment with a neutrophil depleting 
antibody limited IL-1β production in this model of ALI. Although neutrophils did not produce 
IL-1β when stimulated ex vivo, neutrophils were a source of extracellular histones that stimulated 
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NLRP3-dependent IL-1β secretion from macrophages. Histone release during ALI required both 
NLRP3 and Caspase 1, suggesting that it resulted from pyroptotic cell death [233]. 
Inhibition of P2RX7 with A438079 also blocked LPS-induced ALI in mice. A438079 
decreased neutrophil and protein recovery in BAL fluid of LPS treated mice. LPS-induced ALI 
resulted in IL-1β, IFN-γ and IL-17A production in lung tissue. Blocking P2RX7 with A438079 
decreased each of these cytokines, but had no effect on IL-10 secretion [300]. As before, while 
this picture of P2RX7-mediated production of IL-1β resembled activation of the NLRP3 
inflammasome, without direct experimental evidence we cannot be certain.  
Vimentin, an intermediate filament and component of the cytoskeleton is required for 
LPS-induced ALI in mice. Deletion of Vimentin improved survival, preserved alveolar 
architecture by lung histology, decreased lung edema, decreased protein content in BAL fluid 
and interestingly decreased Caspase 1 and IL-1β production. Alveolar macrophages from 
vimentin deficient mice exhibited a significant defect in NLRP3 inflammasome activation in 
response to LPS plus ATP, asbestos or MSU challenge ex vivo. Vimentin co-precipitated with 
both NLRP3 and Caspase 1 from human macrophage cell lysates and this association was 
enhanced following stimulation of cells with ATP [301]. These findings suggest that the NLRP3 
inflammasome is regulated by the cytoskeletal intermediate filament vimentin that potentially 
acts as a scaffold for NLRP3 inflammasome assembly. 
  Mice receiving high tidal volume (HV) ventilation experience ventilator-induced lung 
injury, just as humans do. Treatment with HV ventilation liberated more uric acid and IL-1β than 
treatment with low tidal volume (LV) ventilation. NLRP3 knockout mice exposed to HV 
ventilation experience less lung edema, protein in the BAL fluid, neutrophil infiltration, IL-1β 
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and IL-6 secretion than the parental strain, suggesting a role for NLRP3 in mediating HV 
ventilation lung damage. ASC knockout mice had less edema and neutrophil infiltration, but 
equivalent protein recovery and IL-1β secretion, an unexpected finding that might suggest 
another ASC-independent inflammasome compensates for the loss of ASC [302]. 
 Depletion of alveolar macrophages by administration of clodronate liposomes largely 
attenuated HV ventilation lung damage as measured by neutrophils and protein recovered in 
BAL fluid and by histology. Injection of BMDMs prior to the start of HV ventilation restored the 
pre-depletion phenotype. Interestingly, treatment of BMDMs with siRNA targeting ATG5 to 
block autophagy prior to reconstituting mice resulted in decreased BAL fluid neutrophil and 
protein recovery following HV ventilation. Immunoprecipitation of NLRP3 and co-precipitation 
of ASC and Caspase 1 was used to assess inflammasome activation following HV ventilation. 
Mice depleted of macrophages, or reconstituted with siATG5 treated macrophages had 
significantly less ASC and Caspase 1 associated with NLRP3 than mice that were not treated 
with clodronate liposomes or reconstituted with BMDMs receiving a scrambled siRNA [303]. 
Overall, this study suggests that the NLRP3 inflammasome is being activated in mice during HV 
ventilation and correlates with the severity of lung damage. This study is unusual in that it 
suggested blocking autophagy decreased, rather than increased NLRP3 inflammasome 
activation. 
 Mouse alveolar macrophages that undergo a cyclic stretching (CS) protocol ex vivo 
experienced significant cell death and IL-1β secretion. CS macrophage IL-1β production was 
Caspase 1 dependent, as it was blocked by the Caspase 1 inhibitor ac-YVAD-fmk and siRNA 
against Caspase 1. Depletion of NLRP3 by siRNA also greatly diminished CS-induced IL-1β 
production. NLRP3 activation appeared to be the result of mitochondrial ROS production as 
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treatment with rotenone exacerbated IL-1β production and treatment with SS-31, a ROS 
scavenger, significantly reduced IL-1β production. Similar results were seen in whole mouse 
lungs. Pretreatment with SS-31 or depletion of macrophages by liposomes diminished IL-1β 
production resulting from HV ventilation [264]. 
 Overall, the NLRP3 inflammasome appears sensitive to both mechanical-induced 
ventilator lung damage and hyperoxia-induced lung damage. However, these data would be more 
convincing if other inflammasomes were used as controls. In some instances, discrepancy 
between NLRP3 and ASC knockout mice in the severity of lung damage raises important 
questions about the involvement of other, non-ASC-containing inflammasome. 
 
1.9.5 The NLRP3 inflammasome drives fibrotic changes in pulmonary fibrosis 
 Pulmonary fibrosis occurs through widespread scarring in the lungs that stiffens lung 
tissue and increases the work of breathing. In most instances, the exact cause of pulmonary 
fibrosis is difficult to determine, resulting in classification as idiopathic pulmonary fibrosis. 
Without a clear cause, accurately recapitulating the mechanism of action in a mouse model is 
challenging, but many studies have focused in on bleomycin (BLM)-induced pulmonary fibrosis. 
BLM induces DNA strand breaks. Patients who receive BLM are at higher risk for pulmonary 
fibrosis and are cautioned against breathing high concentrations of oxygen, such as during some 
anesthesiology regimens, as it is believed that BLM treatment induces sensitivity to oxygen 
toxicity. 
  Patients with pulmonary fibrosis had increased ATP in BAL fluid as compared to healthy 
controls. Isolated lung epithelial cells from both human and mice released significant amounts of 
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ATP when challenged with BLM. In mice, administration of BLM led to an early increase in 
extracellular ATP, IL-1β production and neutrophil infiltration. Treatment of mice with apyrase 
opposed the changes seen with BLM, leading to less neutrophil infiltration and less IL-1β 
production. ATPγS treatment further exacerbated damage caused by BLM. The P2R family 
inhibitor suramin further implicated ATP in that blocking P2Rs similarly decreased neutrophil 
infiltration and IL-1β production in BLM-treated mice. Knockout of P2RX7 caused a significant 
reduction in these inflammatory markers as well, that is not further exacerbated by ATPγS 
administration. P2RX7 deficient mice had an improved clinical course and did not lose as much 
weight as the parental strain mice when treated with BLM. By histology, loss of P2RX7 reduced 
inflammatory cell infiltration and production of collagen in the lung [249]. Again, this pattern is 
highly suggestive of NLRP3 inflammasome-mediated IL-1β production, but without testing it 
directly, we are left with too many confounding possibilities to know for certain. 
 A subsequent study from this same group identified IL-1β, IL-23p19 and IL-17A as 
critical inflammatory mediators in BLM-induced pulmonary fibrosis. Administration of IL-1β 
without BLM caused a significant increase in IL-23p19 and IL-17A production and loss of the 
IL-1R diminished IL-17A production during BLM administration. Mice lacking IL-23p19 or IL-
17A receptor experienced significantly less neutrophil infiltration into the lung during BLM 
exposure and treatment with an anti-IL-17A neutralizing antibody, but not an anti-IL-17F 
neutralizing antibody, had the same effect. γδ-T cells were determined by flow cytometry to be 
the primary source of IL-17A production in this setting. Loss of IL-23p19, IL-17A or treatment 
with a IL-17A neutralizing antibody all dramatically improved lung architecture by histology 
[304]. Combined IL-17A and IL-23p19 knockouts would have been interesting to examine in 
this setting. IL-23p19 is thought to upregulate matrix metalloprotease MMP9 and IL-17A is a 
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proinflammatory cytokine involved in neutrophil recruitment, so loss of both cytokines together 
may have had a complementary effect. 
As was saw above with LPS-induced ALI, Vimentin was also required for BLM-induced 
pulmonary fibrosis in mice. Deletion of Vimentin preserved alveolar architecture by lung 
histology, decreased lung edema, decreased protein content in BAL fluid and, as seen in ALI, 
decreased Caspase 1 and IL-1β production. In the absence of vimentin, BLM-induced collagen 
deposition was significantly decreased as seen by Masson’s trichrome and Picro-Sirius red stains 
for collagen. Mice also had significantly improved lung elasticity as measured by quasi-static 
compliance and elastic modulus testing by atomic force microscopy [301]. These findings 
suggest that the NLRP3 inflammasome is regulated by the cytoskeletal intermediate filament 
Vimentin and that disruption of this interaction can dramatically improve clinical measures of 
BLM-induced fibrosis. 
 Epidemiologic evidence suggests that statin use could increase risk for development of 
interstitial lung disease, a type of pulmonary fibrosis. In mice treated with BLM, co-
administration of a statin increased markers of lung inflammation and fibrotic change, including 
IL-1β and IL-18 production and destruction of alveolar architecture as determined by histology. 
In isolated macrophages, treatment with pravastatin enhanced NLRP3 inflammasome activation 
in response to LPS plus ATP challenge as measured by Caspase 1 activation, IL-1β and IL-18 
secretion. Deletion of NLRP3 or Caspase 1 completely eliminated secretion of these cytokines. 
Statin pretreatment was thought to increase mitochondrial ROS production, leading to 
exacerbation of NLRP3 inflammasome activity [305]. In light of the difficulty in identifying a 
cause of pulmonary fibrosis in patients, this study is particularly interesting. It suggests that even 
commonly used medications might contribute to pulmonary fibrosis in the right setting. Further 
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investigation of modifying factors, particularly with a focus on ROS production, might prove 
fruitful in identifying individuals at risk for development of pulmonary fibrosis or might provide 
a point of intervention to limit disease progression.  
 
1.9.6 NLRP3 inflammasome signaling may predict risk of bronchopulmonary dysplasia in 
preterm infants 
 Lastly, the NLRP3 inflammasome played a major role in the development of 
bronchopulmonary dysplasia (BPD). BPD is a chronic lung disease that affects newborns and is 
thought to result from damage to the lungs from mechanical ventilation and long-term oxygen 
supplementation. Hyperoxia-exposed neonatal mice (BPD mice) developed lung damage 
characterized by larger alveolar spaces and simplification of distal lung architecture. In mice 
deficient of NLRP3, alveoli were well formed and more closely approximated normoxia exposed 
mice. BPD mice had significantly increased pulmonary IL-1β production that was completely 
absent with loss of NLRP3, suggesting a critical role for the NLRP3 inflammasome in BPD 
pathogenesis. Treatment with IL-1R antagonist every other day during hyperoxic exposure 
dramatically improved mouse lung histology and more closely mirrored the lung architecture of 
NLRP3 deficient mice and normoxia mice indicating that NLRP3-dependent IL-1β signaling is 
critical. Interestingly, in preterm infants intubated for respiratory failure, tracheal aspirate IL-1β 
content was negatively correlated with gestational age, with the most preterm infants having the 
highest levels of IL-1Β. Decreasing gestational age is an important risk factor for BPD. IL-1β 
content was also a predictor of death or BPD development in preterm infants and improved 
predictions made on the basis of gestational age alone [306].  
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Together, these data are very suggestive of a role for the NLRP3 inflammasome in the 
development and severity of BPD. Being able to predict which infants are at greatest risk of BPD 
is an important step for ultimately targeting preventive measures to the right patients. One could 
imagine that these patients would benefit from more tightly controlled respiratory settings or IL-
1β-targeted therapy. It would be interesting to see if therapeutic intervention in mice that develop 
a BPD-like phenotype could reverse disease course and improve survival or long-term lung 
function. While treating preterm infants, who are already at increased risk for infections, with 
anti-cytokine therapy would be risky, a small bump in the right direction might provide a 
sufficient benefit to diminish the effects of BPD. 
 
1.10 Concluding introduction 
 Throughout this introduction we examined the role of NLRP3 in heritable fever 
disorders, the complex system of regulation of NLRP3 inflammasome activation both by 
regulatory modality and agonist modality, and have seen the widespread significance of NLRP3 
in the pathogenesis of pulmonary diseases. Now, our focus will turn to the interaction between 
Staphylococcus aureus and inflammasomes generally. Following that review, we will turn to my 
dissertation research focused on elucidating the mechanism of S. aureus LukAB cytotoxicity and 
identifying critical kinases in mediating NLRP3 inflammasome activation in response to LukAB. 
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Chapter 2. Inflammasome activation mediates tissue-specific pathogenesis in 
Staphylococcus aureus infection1 
 
2.1 Introduction 
Staphylococcus aureus is a Gram-positive coccus that interacts with human hosts on a 
spectrum from quiet commensal to deadly pathogen. S. aureus is capable of infecting nearly 
every tissue in the body resulting in cellulitis, pneumonia, osteomyelitis, endocarditis, brain 
abscesses, bacteremia and more. S. aureus has a wide range factors that promote infection and 
each site of infection triggers a different response in the human host. In particular, the different 
patterns of inflammasome activation mediate tissue-specific pathogenesis in S. aureus infection. 
Although still a nascent field, understanding the unique host-pathogen interactions in each 
infection and the role of inflammasomes in mediating pathogenesis may lead to novel strategies 
for treating S. aureus infections. Reviews addressing S. aureus virulence and pathogenesis [1], as 
well as epidemiology and pathophysiology [2], have recently been published. This review will 
focus on S. aureus factors that activate inflammasomes and their impact on innate immune 
signaling and bacterial survival. 
 
 
 
                                                          
1 This chapter was submitted as an invited review for publication to the journal Current Topics in Microbiology and 
Immunology.  The citation was not available at time of submission. 
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2.2 S. aureus factors that activate inflammasomes 
S. aureus has numerous mechanisms to evade and subvert the immune system allowing it 
to produce infection broadly in immune-competent hosts. Many virulence factors, such as pore-
forming toxins (PFTs) and phenol-soluble modulins (PSMs), and common bacterial constituents, 
such as bacterial RNA, lipoproteins and lipoteichoic acid – a constituent of the Gram-positive 
cell wall, activate inflammasomes and will be discussed here (Figure 1).   
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Figure 2.1 S. aureus pathogen-associated molecular patterns and virulence factors activate 
inflammasome priming and signaling. Activation of inflammasome signaling typically 
proceeds in two steps. First, Toll-like receptors (TLR) engage pathogen-associated molecular 
patterns (PAMPs) to prime inflammasome signaling. S. aureus lipoteichoic acid (LTA), a major 
constituent of the cell wall of Gram-positive bacteria binds TLR2 (not pictured). TLR signaling 
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activates NF-κB-mediated transcription of pro-interleukin-1B (IL-1β) and also triggers post-
translational modifications of the inflammasome signaling pathway. Second, a wide variety of S. 
aureus factors, including pore-forming toxins (PFTs), peptidoglycan (PGN), phenol-soluble 
modulins (PSMs and Hld), activate inflammasome signaling. Each PFT requires a receptor, as 
seen in the center of the figure, to promote binding and pore formation. The NLRP3 
inflammasome is depicted as the primary example of inflammasome signaling in this setting. 
When activated, NLRP3 binds ASC through PYD-PYD interactions and ASC binds pro-Caspase 
1 through CARD-CARD interactions. Formation of the NLRP3 inflammasome complex causes 
activation of Caspase 1 that can process pro-IL-1β and pro-IL-18 for activation and secretion. 
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S. aureus PFTs (i.e., alpha-hemolysin [Hla], gamma-hemolysin [HlgAB, HlgCB], 
leukocidin AB [LukAB, also known as LukGH], leukocidin ED [LukED], and Panton-Valentine 
leukocidin [PVL, also known as LukFS]) are, in most cases, two-component toxins that initiate 
attack when one component recognizes and binds to a cell surface receptor inserting itself into 
the host cell membrane. This is followed by recruitment of the second component and additional 
pairs to complete a hexameric beta-barrel pore [3-6]. The notable exception to this pattern is Hla 
which forms a pore by binding to its receptor then forming a heptameric beta-barrel pore made 
up of only a single component [7,8]. Each of these toxins is cytotoxic to a range of cells based on 
expression of their cognate receptor: Hla and a disintegrin and metalloprotease 10 (ADAM10) 
[9]; HlgAB and CXCR1, CXCR2 and CCR2; HlgCB and C5aR and C5L2 [10]; LukAB and 
CD11b [11], LukED and CCR5 [12], CXCR1 and CXCR2 [13]; and PVL and C5aR [14]. Many 
of these toxin-receptor pairs lend a level of species specificity as well – murine neutrophils are 
partially resistant to HlgAB and HlgCB because CCR2 is the only compatible Hlg murine 
receptor [10], LukAB binds to human CD11b at a 1000-fold higher affinity than murine [11], 
and both rabbit and human neutrophils are susceptible to PVL while murine and java monkey 
neutrophils are resistant [15].  
Beta-hemolysin (Hlb) and delta-hemolysin (Hld) are similarly named but functionally 
distinct toxins that do not form a beta-barrel pore like the aforementioned toxins. Hlb is a 
hemolytic and cytotoxic sphingomyelinase [16,17]. Delta-hemolysin is a 26-amino acid 
membrane-damaging peptide that is classified as a phenol-soluble modulin [18]. 
Phenol-soluble modulins (PSMs – reviewed [19]) are cytotoxic and pro-inflammatory 
peptides produced by S. aureus [20]. S. aureus produces four PSMα peptides (PSMα1-PSMα4), 
two PSMβ peptides (PSMβ1 and PSMβ2), and delta-hemolysin (Hld). PSMs are sensed by 
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formyl peptide receptor 2 in human neutrophils [21]. PSMs have demonstrated roles in cytolysis, 
biofilm development, and immunomodulation and are thought to be partially responsible for the 
increased virulence of community-acquired S. aureus over hospital-acquired strains [22].  
Lipoteichoic acid (LTA) is a component of the bacterial wall in Gram-positive bacteria 
that is essential for bacterial growth, cell division and survival [23]. Likely because of this 
integral requirement for LTA, the innate immune system has many robust strategies for detecting 
and responding to LTA, including Toll-like receptor 2, Scavenger Receptor A [24,25], CD36 
[26], CD14 and soluble CD14 [27,28], Surfactant Protein D [29], Paired Ig-like Receptor B [30], 
and L-ficolin [31] (reviewed [32]). Having multiple methods for sensing LTA is probably 
important to fine tune the immune response to infections. For example, LTA binding to TLR2 
upregulates cytokine production through NF-κB signaling, while LTA binding to Paired Ig-like 
receptor B suppresses IL-6 and IL-1β secretion [30]. The same LTA found is S. aureus is also 
found in other members of the Frimicutes phylum, such as Bacillus subtilis and Listeria 
monocytogenes [33], that share a last common ancestor approximately 1.5 billion years ago 
[34,35]. As such, LTA likely evolved well before the establishment of multicellular life 
suggesting that multiple strategies of LTA sensing in humans is the result of selective pressures 
favoring LTA detection rather than evolution of LTA to manipulate immune signaling.  
Additionally, other integral bacterial components such as bacterial RNA [36,37], lipoproteins 
[38], and peptidoglycan [39,40] are important molecular patterns detected by the immune system 
through inflammasomes. 
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2.3 Inflammasomes that are activated by S. aureus 
A complex interplay of different inflammasomes activate during S. aureus infections 
(Figure 2). The first demonstration of inflammasome activation by S. aureus was the NLRP3 
inflammasome [41]. Activation of the NLRP3 inflammasome involves two steps: (1) a priming 
step that involves NF-kB-mediated upregulation of pro-IL-1β transcription and post-translational 
modifications of inflammasome components and (2) NLRP3 inflammasome oligomerization 
leading to Caspase 1 activation and secretion of mature IL-1β and IL-18 and pyroptosis. 
In the case of an S. aureus infection, TLR2 detects LTA to provide an initial priming signal 
[42,43]. In experiments, in addition to purified LTA [44], priming is typically triggered by heat-
killed S. aureus (HKSA) [45] or a xenobiotic TLR-ligand such as LPS. 
Numerous studies have since delineated the contribution of various S. aureus virulence 
factors to NLRP3 inflammasome activation. All six PFTs from S. aureus activate the NLRP3 
inflammasome in THP1 cells and primary human monocytes, leading to canonical cytokine 
processing and pyroptosis [38,44-46].   
Caspase 1 is critical for processing IL-1β and IL-18 for secretion and is classically 
required for pyroptosis. However, Caspase 1 is not required for Hla-, PVL- or LukAB-triggered 
pyroptosis as shown with all three toxins using a Caspase 1 inhibitor in human cells treated with 
the toxins and by Caspase 1/Caspase 11 knockout mouse macrophages treated with Hla [44-46].  
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Figure 2.2 NLRP3, NLRC5, NLRP7, AIM2 and other inflammasome-like signaling is 
activated in response to S. aureus. Priming of inflammasome signaling in response to S. aureus 
typically occurs when lipoteichoic acid (LTA) binds Toll-like receptor 2 (TLR2) leading to 
upregulation of NF-κB-mediated transcription. The most well studied inflammasome activated 
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by S. aureus is the NLRP3 inflammasome. Activation of the NLRP3 inflammasome occurs 
through pore-mediated and phagocytosis-mediated actions. PFTs and Hlb damage the plasma 
membrane and cause potassium efflux necessary for NLRP3 inflammasome activation. PVL 
signals through CTSB to activate inflammasome signaling. PVL, Hla and LukAB also promote 
Caspase 1-independent cell death. PFTs may also destabilize lysophagosomes. In particular, 
LukAB has been shown to bind CD11b on the phagosomal membrane to promote S. aureus 
escape. This triggers NLRP3-dependent cytokine secretion and NLRP3-independent cell death. 
Phagocytosis of particulate peptidoglycan (PGN), but not soluble PGN, also leads to NLRP3 
inflammasome activation. Lysophagosomal rupture is thought to lead to CTSB leakage into the 
cytoplasm, though this has not been shown directly with S. aureus.  
A variety of other inflammasomes have also been implicated in sensing S. aureus. 
NLRC5 binds to NLRP3 and enhances cytokine secretion. NLRP7 binds to ATP and promotes 
cytokine secretion as well. AIM2 plays an important role in detecting S. aureus in central 
nervous system infections. PSMs also trigger secretion of IL-1β and IL-18, but through a 
Caspase 1-independent mechanism. 
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S. aureus activation of the NLRP3 inflammasome with PFTs, Hla [45], LukAB [44], and 
PVL [46], requires potassium efflux. PVL also causes activation of Cathepsin B (CTSB) and 
inhibition of CTSB protease activity by CA-074, a small molecule inhibitor, blocks cell death 
[46]. CTSB is a lysosomal cysteine protease required for NLRP3 activation by disruption of 
lysophagosomes after ingestion of inflammation inducing particulate matter like silica [47]. 
CTSB is thought to spill into to the cytoplasm after lysophagosomal disruption, but the 
mechanism by which CTSB activates NLRP3 is unclear. It is also not known whether the 
requirement for CTSB in PVL-induced NLRP3 activation is toxin specific or common to all S. 
aureus PFTs. One possible explanation for how CTSB is liberated from lysophagosomes is that 
S. aureus PFTs can bind to their cognate receptor on phagosomal membranes. This binding 
promotes S. aureus escape from phagocytosis to enable survival [48]. Interestingly, the route of 
exposure (i.e., extracellular versus within a phagocytic vacuole) also seems to influence 
signaling in response to LukAB [44]. When LukAB interacts with CD11b at the plasma 
membrane, NLRP3 activation drives IL-1β and IL-18 secretion and causes cell death through 
pyroptosis. Alternatively, when LukAB expressed from phagocytosed S. aureus interact with 
CD11b on the phagocytic vacuole membrane, cell death becomes independent of NLRP3 
activation, while NLRP3 is still required for IL-1β and IL-18 secretion. It is not clear whether 
this separate cell death mechanism engaged by phagosome-localized LukAB is activated in 
addition to NLRP3-dependent pathways or if the NLRP3-dependent pathways activated by 
extracellular toxin are not activated by toxin in this setting [44].  
S. aureus can also trigger necroptosis, cell death dependent on RIPK1, RIPK3, and 
MLKL that can be blocked by necrostatin-1 and necrosulfonamide. Necrosulfonamide 
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diminished S. aureus- and purified Hla-induced IL-1β secretion suggesting this agent or the 
necroptotic pathway may tie in with inflammasome activation [49].  
While the cytotoxicity of PFTs has been demonstrated widely in primary human 
monocytes, macrophages, neutrophils and dendritic cells, most studies of PFTs and 
inflammasome activation have been carried out in THP-1 cells, mouse macrophages or human 
peripheral blood monocytes. While it is easy to assume that the cytotoxicity across all these 
primary human cell types is NLRP3-mediated, this has not been demonstrated directly 
[46,50,51].   
In primary human monocytes, the rank order potency of the PFTs is PVL and LukAB 
(tied), Hla and HlgCB (tied), HlgAB, then LukED [44]. The LukAB operon promoter is 
preferentially activated when USA300 strain S. aureus is exposed to human polymorphonuclear 
leukocytes (PMNs) [48]. Despite these hints at a prominent role for LukAB in S. aureus 
pathogenesis, the role of LukAB in infections has largely been overlooked because of its lack of 
effect in mice.  
New infection models are sorely needed to better appreciate the role of human-restricted 
PFTs in pathogenesis. As an example, a recently developed humanized NSG mouse model of S. 
aureus skin infections required one to two log lower inoculum to induce consistent skin lesions 
as compared with non-humanized mice. This model aided in studying the role of PVL in 
dermonecrosis. Blocking the PVL receptor, human C5aR, with PMX53 or an anti-C5aR antibody 
eliminated the enhanced cytotoxicity of PVL-positive S. aureus but also reduced recruitment of 
neutrophils and exacerbated the infection [52]. 
Also important to note, the PFT rank order potency is almost certainly different in other 
cells based on the abundance of cell surface receptors for each toxin which may vary with 
 165 
 
receptor gene polymorphisms. Further, binding affinities between toxins and receptors differ 
between species. For example, mouse bone marrow derived macrophages are resistant to purified 
Hla [45] and highly resistant PVL [46].  
Few other mechanistic details between PFT exposure and NLRP3 inflammasome 
activation have been determined. Many other host proteins have been implicated along the 
NLRP3 inflammasome signaling cascade with other triggers, but have yet to be confirmed for S. 
aureus. 
Particulate peptidoglycan (PGN), a component of the bacterial cell wall, can activate the 
NLRP3 inflammasome when internalized via phagocytosis [39,40].  The S. aureus enzyme PGN 
O-acetyltransferase A modifies PGN making the cell wall resistant to lysozyme digestion [53].  
S. aureus lacking O-acetyltransferase A lead to enhanced inflammasome activation and 
inflammation in vitro and in vivo when compared to S. aureus with the enzyme.  Loss of O-
acetyltransferase A in S. aureus decreased bacterial survival in co-culture with BMDMs and in 
murine skin infections.  However, skin lesion size was significantly increased in infections with 
O-acetyltransferase A-deficient S. aureus and treatment of mice with anti-IL-1β and IL-18 
antibodies eliminated this increase [40].   
Induction of S. aureus penicillin-binding protein 2A (encoded by the mecA gene) by 
beta-lactam treatment leads to a reduction in PGN cross-linking and enhanced PGN degradation.  
Phagocytosis and digestion of PGN from beta-lactam treated S. aureus caused NLRP3 
inflammasome activation and robust IL-1β secretion in BMDMs and when injected into mice.  
These effects are lost upon peptidoglycan solubilization by pretreatment with lysostaphin.  Mice 
infected subcutaneously with S. aureus then treated with nafacillin, a beta-lactam, had larger skin 
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lesions and more neutrophils in the lesion than PBS-treated mice.  Bacterial burden was lower in 
nafacillin-treated mice, suggesting that a hyperactive immune response caused the lesion [39]. 
The exact nature of PGN crosslinking that induces NLRP3 inflammasome activation has not 
been determined.  Mutanolysin, like lysozyme, cleaves the N-acetylmuramyl-β(1-4)-N-
acetylglucosamine linkages of PGN.  While pretreatment of purified PGN with mutanolysin or 
lysostaphin prevents NLRP3 activation, most methods for purifying PGN generate 
lysozyme/mutanolysin-sensitive PGN [40].  Therefore, the ability of lysozyme-sensitive PGN in 
O-acetyltransferase A-deficient S. aureus, but not mutanolysin predigested purified PGN, to 
induce NLRP3 inflammasome activation must depend upon the timing and location of lysozyme 
digestion.  The NLRP3 inflammasome is most likely activated by partially cross-linked PGN 
undergoing digestion in the phagosome.  This strategy could help phagocytes differentiate PGN 
digested by secreted lysozyme from bacteria-associated PGN to better assess the proximity and 
severity of a bacteria threat.  Consistent with that hypothesis, Muller et al. found that lysostaphin 
digestion of PGN could be titrated down to a point that promoted IL-1β secretion [39]. 
S. aureus Hlb-deficient mutants had no observable defect in inducing IL-1β and IL-18 
secretion in mouse macrophages. S. aureus lacking the combination of Hla, Hlb, and Hlg caused 
very little IL-1β and IL-18 secretion when compared to S. aureus lacking any pair of these 
hemolysins [38]. This finding suggests that Hla, Hlb, and Hlg may have a synergistic effect on 
mouse macrophages, though the mechanism of which is unclear. In a study that preceded the 
discovery of the NLRP3 inflammasome, purified Hlb triggered human monocytes to secrete IL-
1β and extracellular potassium suppressed this activity [16]. Suppression by extracellular 
potassium strongly suggests a role for the NLRP3 inflammasome in Hlb-induced IL-1β 
secretion, though this has not been directly demonstrated. These studies suggest that S. aureus 
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may have redundant mechanisms for activating the NLRP3 inflammasome. It is also possible 
that hemolysin production is context dependent and each hemolysin may be required in infection 
of separate tissues that has not been recapitulated in in vitro cell culture of immune cells. Hlb 
also limits production of IL-8, a potent neutrophil chemoattractant, by human endothelial cells 
[54] and as such, may play a dual role in establishing and promoting infection. 
Deletion of lipoprotein diacylglyceryl transferase (Δlgt), the protein responsible for 
catalyzing the first step of lipoprotein biosynthesis in S. aureus, was also used to explore 
secondary factors responsible for NLRP3 inflammasome activation.  Macrophages exposed to 
purified Hla and supernatant from Δlgt S. aureus exhibited decreased Caspase 1 processing and 
IL-1β secretion as compared to macrophages exposed to supernatant from the isogenic parental 
S. aureus strain [38].    
Other inflammasomes may interact with NLRP3 to enhance inflammatory signaling. In 
one instance, NLRC5 was shown to co-immunoprecipitate with NLRP3 and knockdown of 
NLRC5 in THP1 cells by shRNA led to dramatic reduction in IL-1β secretion in response to live 
S. aureus [55].  
Beyond NLRP3, NLRP7, a sensor of acylated lipopeptides, appears to play a role in 
response to S. aureus. Knockdown of NLRP7 in THP1 cells resulted in decreased S. aureus-
induced IL-1β secretion and increased intracellular bacteria following infection. However, loss 
of NLRP7 did not impact S. aureus-induced pyroptosis [56]. NLRP7 function requires ATP 
binding and hydrolysis as expression of a mutant NLRP7 defective in this process in THP1 cells 
led to decreased IL-1β secretion and pyroptosis, as measured by PI uptake, in response to S. 
aureus as compared to WT THP1 cells [57].  The role of NLRP7 in pyroptosis in these two 
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studies differed, both having used THP1 cells and live S. aureus, and the discrepancy remains 
unexplained. 
AIM2 may also detect S. aureus during central nervous system infections leading to IL-
1β production. S. aureus forms abscesses when injected intracranially into mice. Ultimately, the 
abscess is lethal to ASC knockout mice, but not NLRP3 knockout mice or the parental strain. To 
better understand why ASC, but not NLRP3, knockout mice succumb to infection, abscess 
homogenates were collected and analyzed with a multi-analyte microbead cytokine array. Loss 
of ASC dramatically decreased IL-1β, IL-6, CXCL1 and CXCL10 production, suggesting a 
defect in sensing and responding to S. aureus. Further investigation identified AIM2 as integral 
to the immune response against S. aureus in this brain abscess model as loss of AIM2 mirrored 
the cytokine secretion defect and mortality seen in ASC knockout mice [58]. 
Inflammasome-like or non-canonical inflammasome responses may also initiate an 
immune response against S. aureus. When purified, each of the seven S. aureus PSMs are 
sufficient to induce IL-18 secretion from human keratinocytes. S. aureus with all seven PSMs 
deleted induced lower levels of IL-18 and IL-1β secretion from keratinocytes. Unexpectedly, 
secretion of IL-18 or IL-1β from keratinocytes in response to live S. aureus could not be blocked 
by a panel of Caspase inhibitors [59]. 
While many studies of inflammasome activation by S. aureus have been conducted in in 
vitro cell culture using primary human monocytes as well as other cell types (THP1 cells, mouse 
macrophages, etc.), in natural infections, S. aureus and its secreted toxins interact with multiple 
cell types each with a unique capacity to sense and respond to the bacteria. This leads to the 
possibility that a variety of inflammasomes may be activated in different cell types over the 
course of an infection with variable effects on infection outcomes. To understand the role of 
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inflammasome activation in the natural course of infection, we turn our review to studies of S. 
aureus infection in animal models, primarily in mice. In most cases, mouse studies were carried 
out using only the C57BL/6 strain in which inflammasome components have been genetically 
deleted. Mice as a model for S. aureus infections have serious limitations as mice are relatively 
naturally resistant to S. aureus and non-responsive to many virulence factors that act specifically 
on human cells. These studies would benefit from incorporating more genetic diversity.  
 
2.4 The role of inflammasomes in S. aureus infections 
2.4.1 The NLRP3 inflammasome responds to hemolysins to control S. aureus dermal 
infections 
S. aureus is the number one cause of skin infections. These infections range in severity 
from pimples and boils to abscesses and cellulitis. Neutrophils are an important component of 
controlling these infections [60] as neutrophil functional defects, such as chronic granulomatous 
disease, result in susceptibility to invasive S. aureus cutaneous infections [61]. A mouse model 
for S. aureus skin infections has been developed [62] and adapted to study the role of 
inflammasomes in this setting [63-65]. 
Tissue biopsies were collected from mice injected subcutaneously with a variety of 
isogenic hemolysin knockout S. aureus strains. When Hla, Hlb, and Hlg were deleted together, 
secreted IL-1β and IL-18 were significantly decreased as compared to any single or double 
hemolysin knockout and the parental S. aureus strain. Subcutaneous injection of mice with 
individual deletions of NLRP3, ASC, or Caspase 1, did not elicit IL-18 secretion, demonstrating 
a role for the NLRP3 inflammasome in this setting [38].  
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Mice deficient in IL-1β develop larger lesions with higher bacterial burdens and reduced 
neutrophil recruitment following subcutaneous injection of S. aureus as compared to parental 
strain mice [63]. Adoptive transfer of IL-1β deficient bone marrow into irradiated parental strain 
mice mirrored the defect seen in wholly IL-1β deficient mice, suggesting that immune cells are a 
critical source of IL-1β in this model skin infection. In IL-1β deficient mice, recombinant active 
IL-1β helped to control infections and promote bacterial clearance [63].  
Using the same subcutaneous injection model, multispectral noninvasive imaging during 
infection revealed a strong functional and temporal association between neutrophil recruitment 
and IL-1β signaling. Adoptive transfer of IL-1β-expressing neutrophils into an IL-1β deficient 
host was sufficient to restore the impaired neutrophil abscess formation, suggesting neutrophils 
are the critical source of immune cell-derived IL-1β in this model. S. aureus induced IL-1β 
production during subcutaneous injection in mice in a Hla-dependent manner that required 
TLR2, NOD2, FPR1 and the NLRP3 inflammasome [64].  
Although these studies in mice have been done with direct inoculation of bacteria through 
the epidermal barrier, S. aureus can cause infection by invading through a human keratinocyte 
barrier. In an organotypic culture of human keratinocytes grown at an air-liquid interface on a 
dermal substitute matrix, S. aureus can be seen by microscopy to disrupt the apical keratinocyte 
layer. Hla triggers Caspase 1 and Calpain (Ca2+-dependent intracellular protease) activation 
leading to IL-1β secretion and pyroptosis. If Caspase 1 or Calpain are inhibited during this 
process, invasion efficiency is partially decreased [66].  
Patients with atopic dermatitis or psoriasis are commonly colonized with S. aureus; 
however, only those with atopic dermatitis suffer from increased risk of bacterial superinfections. 
Expression of NLRP3 and Caspase 1 by immunohistochemistry was reduced in skin in a cohort 
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of patients with lesional atopic dermatitis as compared to patients with psoriatic or healthy skin. 
Primary human keratinocytes from healthy skin downregulated NLRP3 and ASC expression in 
response to IL-4, IL-5 and IL-13 (cytokines abundant in atopic dermatitis) and upregulated 
NLRP3 in response to interferon-γ. Similar results were seen in isolated monocytes. As a result, 
Hla-mediated Caspase 1-dependent IL-1β secretion was impaired in monocytes from patients 
with atopic dermatitis compared to patients with psoriasis and healthy controls [67]. The 
significance of a monocyte defect in S. aureus dermatitis, and whether neutrophils exhibit the 
same defect, however, is unclear. If it holds true that a Th2 dominant immune response opposes 
NLRP3 inflammasome activation, this might explain epidemiologic data suggesting patients with 
asthma and other atopic diseases are at increased risk of infection [68]. 
PSMs also play a role in pathogenesis of S. aureus-induced skin inflammation. Primary 
human keratinocytes exposed to S. aureus with all seven PSMs knocked out by allelic 
replacement or start codon disruption secreted significantly less IL-1β, IL-18, and LDH, a 
marker of cell death, than keratinocytes exposed to wild type S. aureus. When purified, all PSMs 
triggered IL-18 release but only the four PSMαs and delta-toxin were cytotoxic. Interestingly, 
caspase inhibitors and extracellular potassium were unable to block cytokine secretion or 
cytotoxicity, suggesting that this combination of cell death and cytokine secretion that is 
normally associated with inflammasome activation of Caspase 1 is triggered by a Caspase 1-
independent process in keratinocytes that remains unidentified. In mice challenged 
epicutaneously with S. aureus and an isogenic mutant lacking PSM, the parental S. aureus strain 
triggered a predominantly neutrophil infiltrate and the PSM-deficient S. aureus did not. This 
difference in host neutrophil recruitment to infection site persisted in mice lacking IL-18, 
suggesting that PSM-mediated killing of keratinocytes led to release of chemoattractive factors 
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or that PSM themselves are chemoattractive [59]. Previous research has shown that blocking 
formyl peptide receptor 2, the receptor for S. aureus PSMs, blocked PSM-mediated leukocyte 
infiltration in a mouse air pouch and mouse peritoneal infection model, suggesting that PSMs 
themselves are chemoattractive [21].  
Currently though, the translatability of these models to the human condition remains an 
open question. Mouse skin differs significantly from human skin. Mouse epidermis is made up of 
only three cell layers and is less than 25 micrometers thick whereas human epidermis is usually 
6-10 cell layers and is greater than 50 micrometers thick. The epithelial turnover in mouse skin is 
faster and mouse skin regenerates without significant scarring. These differences and more are 
reviewed in Gudjonsson et al [69]. Considerable interest exists in humanized mouse models of 
skin infections and these have been deployed to study the human specific pathogen Neisseria 
meningitides [70]. Caution must be taken in interpreting results, however, given changes 
observed in skin grafts over time [71]. Additionally, mice with human skin grafts would still 
carry myeloid-derived cells from mice which may be a significant cause of differences seen in S. 
aureus susceptibility between human and mice. 
With those caveats in mind, current evidence suggests that S. aureus activates 
inflammasomes in keratinocytes to promote invasion and establish infection. PSMs that induce 
NLRP3-independent cell death in keratinocytes may provide a redundant mechanism to support 
invasion. Once infection is established, neutrophils are recruited and secrete IL-1β, probably 
through NLRP3 inflammasome activation, to promote clearance of S. aureus infections. If this 
holds true, therapeutic intervention to suppress inflammasome signaling may have a desirable 
effect in preventing invasion through keratinocytes but may unduly hinder clearance of already 
invaded S. aureus. 
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2.4.2 S. aureus hijacks the NLRP3 inflammasome to exacerbate lung infection pathology 
S. aureus pneumonia is a difficult disease to effectively treat. Even with proper 
antimicrobial therapy, S. aureus triggers a massive immune response that causes significant 
tissue destruction with substantial lethality. 
Hla is an essential virulence factor in mouse models of severe pneumonia. As in mouse 
skin infection models, S. aureus lacking Hla causes less lung pathology and death when 
delivered intranasally or intratracheally to the mouse lung when compared to S. aureus with an 
intact Hla gene. Blocking Hla with an antibody also promotes bacterial clearance from the lung, 
indicating that expression of Hla is important in the ability of the bacteria to cause lung infection 
[72,73]. Highly purified recombinant Hla, alone or in conjunction with HKSA, delivered 
intratracheally causes a clinical syndrome resembling S. aureus pulmonary infection in mice. 
Pathologic changes in the lung including destruction of normal alveolar architecture, tissue 
necrosis, hemorrhage, and inflammation are consistent with pathologic findings in human lungs 
with severe S. aureus pneumonia. This syndrome is largely abrogated when Hla is administered 
to mice lacking NLRP3. There was also no difference in bacterial burden or lung inflammation 
between wild type and NLRP3 null mice that were infected with S. aureus lacking Hla, 
suggesting Hla–induced activation of NLRP3 is a major cause of pneumonia pathology during S. 
aureus infection. Using an IL-1 receptor deficient mouse, it was shown that the pathogenesis of 
this severe inflammatory response and tissue destruction did not depend on IL-1β signaling [74]. 
These findings suggest that cell death and/or other Caspase 1-dependent cytokines downstream 
of NLRP3 activation were sufficient to cause severe lung pathology in the setting of S. aureus 
infection. 
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There is significant debate as to whether PVL is a critical virulence factor in pneumonia. 
Mice infected intranasally with PVL-expressing S. aureus experienced substantial neutrophil 
recruitment, inflammation in the lung parenchyma, bronchial epithelial damage, tissue necrosis 
and hemorrhage. These same effects were seen upon administration of both components of the 
purified PVL toxin but were absent in isogenic PVL-negative S. aureus or upon administration 
of a single component of the PVL toxin [75]. A second report replicated these findings, 
demonstrating that deletion of PVL from the LAC S. aureus strain improves Balb/c mouse 
survival following intranasal inoculation. Additionally, immunization against PVL showed a 
trend towards protection in subsequent S. aureus challenge by intranasal infection [76]. These 
results are in contrast to separate findings that deletion of PVL from the LAC S. aureus strain 
actually enhances virulence and decreases survival of Balb/c mice infected using the same 
protocol [77]. 
In primary human monocyte-derived macrophages, HKSA followed by administration of 
recombinant PVL induced secretion of high levels of IL-1β. IL-1β secretion was enhanced by co-
administration PVL and the PSMs Hld and PSMalpha3, the PFTs Hlg and LukED, and Hlb, 
greater than the sum of their parts [78]. PVL also triggered IL-1β secretion in human alveolar 
macrophages that goes on to stimulate the secretion of neutrophil attracting chemokines IL-8 and 
MCP-1 by A549 human lung epithelial cells in a mixed culture model. Blocking the IL-1 
receptor with IL-1R antagonist abolishes PVL-induced secretion of IL-8 and MCP-1 [78].  These 
data suggest that blockade of IL-1β signaling may diminish pathology in S. aureus pulmonary 
infection. However, a subsequent study in rabbits demonstrated that Anakinra, an IL-1 receptor 
antagonist, could block pathology induced by treatment with recombinant PVL and HKSA but 
not in live S. aureus infection. Furthermore, treatment of infected rabbits with Anakinra led to 
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increased bacterial burden in the lungs [79]. These data demonstrate that IL-1β secretion 
triggered by PVL plays a protective role in S. aureus pneumonia in rabbits, where the toxin is 
active. While these findings seem at odds with the apparent pathologic role of NLRP3 
inflammasome activation in mice with S. aureus pneumonia, it is worth noting that NLRP3-
dependent IL-1β production was not the primary driver of pathology in mice.  
Recently, S. aureus toxins were shown to induce necroptosis in the lung through 
RIPK1/RIPK3/MLKL signaling. In primary human macrophage co-culture with S. aureus, 
inhibitors of necroptosis, including necrostatin-1 and necrosulfonamide (NSA), or siRNA-
mediated knockdown of RIPK3 or MLKL blocked S. aureus-induced cell death. NSA also 
decreased purified Hla-induced THP1 cell death. In murine S. aureus pneumonia, blocking 
necroptosis with NSA or knockout of RIPK3 improved bacterial clearance. RIPK3 deficient 
mice had improved lung architecture and less disruption of the pulmonary barrier, resulting in 
less protein in bronchoalveolar lavage fluid. Interestingly, NSA pretreatment of THP1 cells 
exposed to S. aureus supernatants in culture or RIPK3 knockout in S. aureus pneumonia led to 
decreased IL-1β secretion, suggesting a possible link between necroptosis and inflammasome 
activation [49].  
Currently, there is strong evidence supporting the use of systemic corticosteroids in 
hospitalized patients with severe community acquired pneumonia [80]. Interestingly, a 
glucocorticosteroid-responsive negative regulatory element has been identified just upstream of 
the IL-1β transcription start site [81] and, as such, suppression of IL-1β production might be 
contributing to improved outcomes in these patients. However, conflicting results as to whether 
IL-1 signaling enhances or diminishes lung pathology will be important to clarify before targeted 
therapeutic immunosuppression is used clinically in the setting of severe S. aureus pneumonia. 
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Clinical trials of anakinra suggest patients with asthma or other pulmonary comorbidities might 
be at increased risk of infectious complications, though results were not statistically significant 
[82,83]. Suppression of necroptosis through RIPK3 inhibition may also be a viable strategy but 
understanding the contributions of necroptosis and NLRP3 inflammasome-mediated cell death to 
pathology and bacterial clearance is still in its infancy. 
A summary comparison of S. aureus skin and lung infections is depicted (Figure 3). 
 
 
Figure 2.3 NLRP3 inflammasome signaling plays unique rolls in skin and lung infections 
Skin and lung infections are modeled here as an example of the unique effects of 
inflammasome signaling on S. aureus infections.  
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When injected subcutaneously, S. aureus Hla, Hlb, and Hlg activate the NLRP3 
inflammasome leading to IL-1β and IL-18 secretion. NLRP3 activation in keratinocytes requires 
Caspase 1 and Calpain for IL-1β secretion and pyroptosis and promotes S. aureus invasion. 
PSMs also cause IL-1β and IL-18 secretion and cell death, though these are not blocked by 
potassium or Caspase inhibitors. IL-1β, primarily from bone marrow derived cells, is required for 
neutrophil recruitment and bacterial clearance. Loss of IL-18 does not impact that process. 
In the lung Hla causes hyperactivation of the NLRP3 inflammasome leading to tissue 
destruction, as loss of NLRP3 seems to improve pathology with no change in bacterial burden. 
Loss of the IL-1 receptor does not impact the infection suggesting that IL-1 signaling is not 
required. In contrast, a separate study has shown that PVL triggers IL-1β that leads to IL-8 and 
MCP-1 secretion from lung epithelial cells and loss of the IL-1 receptor decreases Th17 
activation. Hla, LukAB and PSMs also induce necroptosis, a RIPK1-, RIPK3-, MLKL-dependent 
cell death process. MLKL also plays a role in IL-1β secretion as loss of MLKL blocks Caspase 1 
activation. RIPK3 knockout in pneumonia improves S. aureus clearance. 
 
 
2.4.3 Microglia activate NLRP3 in vitro but depend on AIM2 for survival in S. aureus brain 
abscesses 
S. aureus can also cause brain abscesses usually as a complication of surgery, trauma or 
bacteremia. Microglia are immunologically competent cells in the brain activated early in the 
process of S. aureus abscess formation [84]. Exposure of primary microglia isolated from 
C57BL/6 mice to live S. aureus strain USA300 induced both IL-1β and IL-18 secretion. 
Microglia from mice lacking NLRP3 or ASC were deficient in IL-1β secretion but responded to 
live S. aureus with similar levels of IL-18 as wild type mice. Deletion of Hla or Hlg, but not 
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LukAB or LukED reduced Newman strain S. aureus-induced IL-1β secretion from microglia 
[85]. However, this is not surprising given the general resistance of mouse to LukAB [11] and 
the low level of expression of LukED [48] under the conditions the bacteria were cultured. 
Caspase 1 and CTSB inhibitors blocked S. aureus-induced microglial IL-1β secretion in these in 
vitro cell culture experiments. Consistent with a second pathway controlling IL-18 secretion in 
this setting, the CTSB inhibitor had no effect on IL-18 secretion [85].  
In a model of brain abscess, ASC and Caspase 1/11 knockout mice had earlier morality as 
compared to the parental strain. Unexpectedly, the survival of NLRP3 knockout mice was 
identical to the parental strain. Upon further investigation, loss of AIM2 mimicked the sensitivity 
to S. aureus infection seen in ASC deficient mice, suggesting that AIM2 is the primary 
inflammasome responsible for IL-1β production in an actual brain abscess. Besides IL-1β, other 
key inflammatory mediators, including IL-6, CXCL1, CXCL10, and CCL2 were significantly 
reduced in the CNS of AIM2 and ASC knockout mice [58]. Strangely, immune cell infiltrates, 
including neutrophils and macrophages, and other cytokines, such as IL-10, TNF-α and IFN-γ, 
were not changed between ASC knockout and the parental strain mice. Also, the bacterial burden 
of AIM2 knockout mice and the parental strain were equivalent in the first 18 hours of infection. 
Most AIM2 knockout mice that died were recorded as having died at approximately 20 hours 
post infection, leaving us without a satisfying explanation for why these mice suddenly 
succumbed to disease given the similarities in bacterial burden and immune cell infiltrates [58]. 
Previous studies of S. aureus brain abscesses have demonstrated damage to the blood-brain 
barrier [86] and impaired capillary perfusion and parenchymal cell death has been noted in soft 
tissue infections [87], both explanation that might be worth further investigation in this setting.  
The discrepancy of which inflammasome is activated between in vitro and in vivo results points 
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to the need to push mechanistic studies through the translational pipeline to differentiate possible 
effects from actual effects. Further investigation of AIM2 knockout microglia in vitro would be 
beneficial for characterizing the response seen in vivo. Also, study of AIM2 knockout mice in the 
context of other S. aureus infections would help determine if the role of AIM2 is 
brain/microglia-specific or is a general feature of the immune response to S. aureus. 
 
2.4.4 IL-1β signaling is critical in soft tissue infections 
Staphylococcus aureus is a common culprit in soft tissue and medical device infections. 
Patients with ulcers, commonly resulting from advanced complications of diabetes, deep injuries, 
recent surgery, or indwelling medical devices are particularly at risk. Recent work has 
demonstrated a differential effect of S. aureus strains in inducing inflammasome activation and 
IL-1β secretion in surgical site infections, with strain PS80 leading to substantially more IL-1β 
than SH1000. In this study, loss of NLRP3 did not completely diminish IL-1β secretion, 
suggesting a coordinated role with other inflammasomes. However, deletion of NLRP3 or IL-1R 
compromised control of bacterial burden in infected surgical wounds [88]. Little else has been 
done to characterize the role of inflammasome signaling in soft tissue infections, though it is 
tempting to assume these would be similar to dermal infections once S. aureus crosses the 
keratinocyte barrier. 
 
2.5 How host inflammasomes can affect other immune processes 
The Th17 response has emerged as a major focus of studies looking downstream of 
inflammasome activation (Figure 4). The most direct hint that IL-17-driven responses are critical 
for defense against S. aureus is seen in patients with hyper IgE syndrome (HIES). In HIES, 
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mutation in STAT3 causes impaired Th17 cell function and recurrent and severe S. aureus 
infections [89]. Similar impairments have been recapitulated in mouse models of S. aureus 
infection. 
NLRP3-mediated secretion of IL-1β by bone marrow dendritic cells promotes secretion 
of IL-17 by γδ-T cells, as loss of the IL-1 receptor limits this response. Importantly, the ability to 
control surgical site infections is enhanced by IL-1β stimulated γδ-T cells as bacterial burden is 
increased in δTCR deficient and IL-17R deficient mice [88]. In S. aureus cutaneous infections, 
loss of γδ-T cells led to larger skin lesions with higher bacterial counts as a result of impaired 
neutrophil recruitment. IL-17R-deficient mice had a similar phenotype. Treatment of γδ-T cell-
deficient mice with a single dose of recombinant IL-17 rescued the impaired immune response to 
S. aureus [90]. A population of CD44+ CD27- memory γδ-T cells that is expanded upon 
peritoneal infection of C57BL/6 mice with S. aureus produce high levels of IL-17 and promote 
bacterial clearance during reinfections. IL-1 signaling was not required for activation or 
expansion of memory γδ-T cells during reinfection [91]. γδ-T cells also play a prominent role in 
defense against S. aureus pneumonia. γδ-T cell-deficient mice had impaired neutrophil 
recruitment and an increased bacterial burden in the lung. However, the absence of γδ-T cells 
decreases lung pathology and improves survival [92], similar to studies with loss of NLRP3 [74]. 
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Figure 2.4 Inflammasome signaling upregulates γδ-T cells and a Th17 response 
NLRP3-mediated secretion of IL-1β in response to S. aureus signals through the IL-1R to 
promote development of γδ-T cells that secrete IL-17. γδ-T cells and IL-17 contribute to defense 
against S. aureus in multiple mouse models including surgical site infections, cutaneous 
infections, peritoneal infections, and pneumonia. Loss of γδ-T cells or the IL-17 receptor leads to 
impaired neutrophil recruitment and higher bacterial counts; treatment of γδ-T cell deficient mice 
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with IL-17 rescues the impaired immune response and treatment of IL-17R deficient mice with 
IL-1β does not. In humans, patients with hyper IgE syndrome have impaired Th17 cell function 
and contract recurrent and severe S. aureus infections. 
 
2.6 Integrating inflammasome studies to improve patient care 
Early evidence suggests that vaccines against PFTs may be beneficial in reducing virulence and 
severity of infections. In hospitalized patients with S. aureus infections, the risk of sepsis was 
significantly lower in those patients with higher levels of IgG against Hla, Hld, PVL, 
staphylococcal enterotoxin C-1 and PSMα3 [93]. Some children with culture-proven S. aureus 
infection developed anti-LukAB antibodies that potently neutralize cytotoxicity in vitro, 
suggesting that the toxin is produced in vivo and that it elicits a humoral response [94]. 
Immunization of mice with a mutant form of Hla that cannot form pores, Hla H35L, generates 
antigen-specific immunoglobulin G responses and affords protection against staphylococcal 
pneumonia. Additionally, transfer of Hla-specific antibodies or anti-Hla monoclonal antibodies 
also protects naïve animals against S. aureus challenge and prevents the injury of human lung 
epithelial cells during infection [72,73]. This is presumably the result of decreased NLRP3 
inflammasome activation in this setting, however, that has not been measured in vivo directly. 
Therapies targeting specific virulence factors may provide a useful adjuvant to antibiotic therapy. 
As recently declared in the Annals of Internal Medicine, many believe it is “time to change 
clinical practice” and recommend systemic administration of corticosteroids in patients with 
severe community acquired pneumonia. Theoretically, tailoring therapy more narrowly to reduce 
virulence and hyperactive immune responses without compromising bacterial clearance would 
provide further benefit over this broadly immunosuppressive therapy.  
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For understanding tissue-specific pathogenesis, we will need improved infection models that 
better recapitulate human tissues and immune cells to overcome the natural resistance of mice to 
S. aureus. Tissue-specific knockouts and bone marrow chimeras will also help differentiate 
tissue-driven immune responses from those of bone marrow origin. Ultimately, investigations 
into inflammasome-mediated responses to S. aureus infections may provide us with the 
therapeutic tools we need to push back against this growing threat. 
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Chapter 3. Staphylococcus aureus Leukocidin A/B (LukAB) kills human monocytes by co-
opting host NLRP3 and ASC when extracellular, but not intracellular2 
 
3.1 Introduction 
S. aureus is one of the most commonly identified causes of infection, and is responsible 
for a significant health and economic burden including approximately 100,000 life-threatening 
infections per year in the United States [1]. S. aureus can cause a variety of diseases that range 
from recurrent epidermal abscesses to life-threatening necrotizing pneumonias. To promote these 
infections, S. aureus produces many different virulence factors including several cytotoxic beta-
barrel pore-forming toxins such as: α-toxin (Hla), Leukocidin AB (LukAB), Leukocidin ED 
(LukED), Panton-Valentine leukocidin (PVL), and gamma hemolysins (HlgAB and HlgCB) [2,3]. 
Among these toxins, Hla and PVL are the most studied in vivo. In mouse studies, Hla has been 
implicated in enhancing virulence in numerous infectious models, including keratitis, mastitis, 
pneumonia, skin abscess, and lethal intraperitoneal infection [4-9]. In contrast, mouse models of 
keratitis, pneumonia, bone and muscle infections have demonstrated variable contributions to 
virulence by PVL [5,10-13]. Rabbit models of infection, however, highlight a clearer role of PVL 
in S. aureus virulence [14-17]. Rabbit neutrophils are significantly more susceptible to PVL than 
                                                          
2 This chapter previously appeared as an article in the journal Public Library of Science Pathogens. The original 
citation is as follows: Melehani J.H., James D.B.A., DuMont A.L., Torres V.J., Duncan J.A. Staphylococcus aureus 
Leukocidin A/B (LukAB) kills human monocytes via host NLRP3 and ASC when extracellular, but not intracellular. 
PLOS Pathog. 2015;11:e1004970. doi: 10.1371/journal.ppat.1004970. 
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mouse neutrophils [18], but remain relatively resistant to the toxin when compared to 
human neutrophils, which is due to the species selectivity of PVL towards its cellular receptor, 
C5aR [19].  
 The most recently identified S. aureus leukotoxin is LukAB (also known as LukGH) 
[20,21]. LukAB kills primary human neutrophils, monocytes, macrophages, and dendritic cells 
[20]. As with PVL, LukAB also exhibits species specificity towards human leukocytes [22,23] and 
most of its characterization has been performed on primary human neutrophils. LukAB binds to 
CD11b, a component of the CD11b/CD18 integrin (also known as αM/β2, CR3, or Mac-1), to 
target and kill human neutrophils [22]. A glutamic acid at position 323 within the unique C-
terminal region of the LukA subunit binds directly to the I-domain of human CD11b to promote 
cell binding and subsequent pore-mediated cell lysis [24]. Interestingly, sufficient differences exist 
between the mouse and human CD11b I-domain to render mouse leukocytes resistant to LukAB. 
Additionally, S. aureus escape from phagocytic killing by human neutrophils requires LukAB 
production, suggesting this toxin may play a unique and important role in bacterial survival and 
persistence [25].  
Host innate immune response to combat S. aureus involves a diverse set of pattern 
recognition/danger responsive receptors including the intracellular NOD-like Receptor (NLR) 
protein 3 (NLRP3) [26]. NLRP3, together with proteins ASC and Caspase 1, form a cytoplasmic 
oligomeric complex known as the NLRP3 inflammasome, which plays a critical role in initiating 
innate immune responses [27]. S. aureus and its secreted toxins Hla, HlgACB, and PVL have been 
all found to activate the NLRP3 inflammasome leading to activation of Caspase 1, secretion of 
Caspase 1-processed pro-inflammatory cytokines IL-1β and IL-18, and induction of necrotic cell 
death [26,28-31]. In a mouse skin infection model, neutrophil NLRP3 inflammasome activation 
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and IL-1β secretion promotes inflammation and abscess formation that accompany bacterial 
clearance [32]. This is in contrast to murine S. aureus pneumonia where the NLRP3-driven 
response is not required for bacterial clearance but instead exacerbates the severity of disease 
pathology [26,33].  
 Herein, we sought to investigate how S. aureus directly kills human monocytes and 
whether the NLRP3 inflammasome contributes to this process. We utilized THP1 human 
monocytic cells as a model and to determine the molecular mechanism of cell death. This cell line 
expresses high levels of NLRP3, ASC, pro-Caspase 1 and is also extensively used to study 
inflammasome activation [34]. We show that S. aureus employs LukAB as a predominant toxin to 
promote necrotic cell death in THP1 monocytes. We demonstrate that purified LukAB is sufficient 
to activate Caspase 1, induce secretion of IL-1β and IL-18, and cause necrotic cell death. 
Importantly, these finding were replicated in primary CD14+ human monocytes. Using shRNA 
knockdowns in THP1 monocytes, we confirmed that these responses were dependent on LukAB 
binding to its receptor CD11b, which leads to activation of the NLRP3 inflammasome. In contrast 
to LukAB binding to the host plasma membrane, LukAB secreted from within the phagosome of 
THP1 cells requires CD11b, but not ASC or NLRP3, to trigger cell death. Together these results 
provide a greater understanding of an important, yet previously underestimated, S. aureus 
virulence factor and the means by which this toxin targets and kills host monocytes. 
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3.2 Materials and Methods 
3.2.1 Ethics statement 
All protocols were conducted in accordance with National Institutes of Health guidelines 
for the care and use of human subjects. De-identified human blood packs were purchased from 
Gulf Coast Regional Blood Center or New York Blood Center. The use of the de-identified 
samples was reviewed by the UNC Office of Human Research Ethics, which determined that the 
proposed studies (Study #12-0024) do not constitute human subjects research as defined under 
federal regulations [45 CFR 46.102 (d or f) and 21 CFR 56.102(c)(e)(l)] and does not require 
further IRB approval. The New York City Blood Center obtained written informed consent from 
all participants involved in the study. This research was approved by the New York University 
School of Medicine institutional human subjects board. 
 
3.2.2 Mammalian cell lines 
THP1 cells (ATCC TIB-202) were maintained in Roswell Park Memorial Institute medium 
1640 (RPMI) medium (Cellgro) at 37°C with 5% CO2, where culture medium was supplemented 
with 10% heat-inactivated fetal bovine serum (FBS), penicillin (100 U/ml), and streptomycin (0.1 
mg/ml). Transduced THP1 cells were maintained in 1.3 μg/ml puromycin. All experiments utilized 
cells that 2 days prior reached a density of approximately 0.8 x 106 cells/ml before being split 1:2 
with fresh media. Prior to infections or intoxications, the desired volume of cells was removed, 
centrifuged and suspended in fresh RPMI media and equilibrated for 1 hr at 37°C with 5% CO2. 
Unless specified, experiments were carried out in either 96-well or 48-well flat-bottom tissue 
culture treated plates. All experiments were conducted within approximately 1 month of thawing 
frozen cell stocks.  
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3.2.3 Purifying primary CD14+ human monocytes 
Human blood from leukopacks was diluted 1:2 with 1x phosphate buffered saline (PBS) 
supplemented with 0.1% bovine serum albumin (BSA) and 2mM EDTA or Hank's Balanced Salt 
Solution (HBSS). Diluted blood was layered over Ficoll-Paque (GE Healthcare Life Sciences) and 
centrifuged for isolation of buffy coats. Purified buffy coats were washed, counted, concentrated 
by centrifugation and labeled with CD14+ magnetic beads (Miltenyi Biotec). Cells were then 
washed to remove excess beads and separated per manufacturer’s instructions on a magnetic 
column. Purified primary CD14+ human cells were suspended in RPMI media with 10% (FBS) 
for 1 hour prior to intoxication experiments. 
 
3.2.4 Bacterial strains, culture conditions and generating mutants 
S. aureus isolate Newman [35] was used in all experiments as the “wild-type” (WT) strain 
(unless stated). S. aureus was grown on tryptic soy broth (TSB) solidified with 1.5% agar at 37°C. 
S. aureus cultures were grown in TSB or in RPMI (Invitrogen) supplemented with 1% Casamino 
Acids (RPMI+CAS), with shaking at 180 rpm. When appropriate, RPMI+CAS was supplemented 
with chloramphenicol (Cm) at a final concentration of 10 μg/ml for purification of toxins from S. 
aureus. 
Bacterial strains are listed in Table 3.1. Generation of the S. aureus Newman ΔΔΔΔ 
(ΔlukAB, ΔlukED, Δhlg, Δhla) [VJT 31.57], and precursor strain S. aureus Newman 
ΔlukAB/ΔlukED/Δhlg [VJT 25.03] have been previously described [53]. To generate S. aureus 
Newman ΔlukAB/ΔlukED [VJT 25.50], a previous lukAB mutant [VJT 8.91] [20] was transduced 
with a phage encoding lukED::kan. To generate green fluorescent protein (GFP) S. aureus strains 
Newman and USA 300-BK18807, and respective isogenic lukAB mutant, were transformed with 
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pOS1-PsarA-sod RBS-sgfp, a plasmid that constitutively and robustly produces superfolded GFP 
[54]. 
 
3.2.5 Purifying toxins from S. aureus 
A construct to co-purify recombinant LukAB from S. aureus (pOS-1-PlukAB-sslukA-6His-
lukA-lukB) was generated as previously described [24] and transformed into Newman ΔΔΔΔ [53] 
to facilitate purification. This construct was also used to individually express toxin subunits from 
LukED, PVL, HlgABC [24]. Toxins were purified from S. aureus as previously described [24]. 
Briefly, strains were grown in TSB with 10 μg/ml chloramphenicol for 5 h at 37°C, 180 rpm, to 
an optical density at 600 nm (OD600) of approximately 1.5 (which represents 1 x 10
9 CFU/ml). The 
bacteria were then pelleted, and the supernatant was collected and filtered. Nickel-nitrilotriacetic 
acid (NTA) resin (Qiagen) was incubated with culture supernatant, washed, and eluted with 500 
mM imidazole. The protein was dialyzed in 1× Tris-buffered saline (TBS) plus 10% glycerol at 
4°C overnight and then stored at −80°C. 
 
3.2.6 Collecting culture filtrates 
Culture filtrates were collected essentially as described previously [25]. Briefly, three-
milliliter overnight cultures in RPMI+Cas were grown in 15-ml conical tubes held at a 45° angle 
and incubated at 37°C with shaking at 180 rpm. The following day, bacteria were subcultured at a 
1:100 dilution and grown as described above for 5 h. Bacteria were then pelleted by centrifugation 
at 4,000 rpm [3220 x g] and 4°C for 10 min. Supernatants containing exoproteins were collected, 
filtered using a 0.2-μm filter, and stored at −80°C.  
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3.2.7 Transmission electron microscopy 
THP1 cells were intoxicated with culture filtrates (10 % v/v) from WT S. aureus Newman, 
an isogenic lukAB-deficient mutant or culture media for 1 h at 37°C with 5% CO2. Cells were then 
fixed in 0.1 M sodium cacodylate buffer (pH 7.2), containing 2.5% glutaraldehyde and 2% 
paraformaldehyde for 2 h and post-fix stained with 1% osmium tetroxide for 1.5 h at room 
temperature, and en bloc stained with 1% uranyl acetate. The cells were dehydrated in ethanol then 
embedded in EMbed 812 (Electron Microscopy Sciences, Hatfield, PA). Semi-thin sections were 
cut at 1 µm and stained with 1% toluidine blue to evaluate the quality of preservation. Ultrathin 
sections (50 nm) were post stained with uranyl acetate and lead citrate and examined using Philips 
CM-12 electron microscope (FEI; Eindhoven, The Netherlands) and photographed with a Gatan 
(4 k × 2.7 k) digital camera (Gatan, Pleasanton, CA, USA). 
 
3.2.8 Evaluating cell death by lactate dehydrogenase (LDH) release 
For infection assays, S. aureus was cultured as described above for culture filtrate 
production then the bacterial pellet was washed twice with 5 ml of PBS. Bacteria were then 
normalized to an OD600 1.0, which represents approximately 1.0 X 10
9 CFU/ml using a Genesys 
20 spectrophotometer (Thermo Scientific). Normalized S. aureus cultures were used to infect 
THP1 cells, seeded at 1 X 105 cells/well, at a multiplicity of infection (MOI) of 50 in a final volume 
of 100 μl for 2 h at 37°C and 5% CO2. Controls for 100% viability were composed of THP1 cells 
without S. aureus, while controls for 100% THP1 lysis included the addition of Triton X-100 
(0.2%). Following infection, cells were pelleted by centrifugation at 1,500 rpm [450 x g] at 4°C 
for 5 min and lactate dehydrogenase (LDH) release was assayed as a measure of THP1 viability 
using the CytoTox-ONE homogeneous membrane integrity assay (Promega) per manufacturer 
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specifications. Briefly, 50 μl of culture supernatant was removed and added to wells containing 50 
μl of LDH reagent and incubated for an additional 10 min at RT. Fluorescence was measured using 
a PerkinElmer Envision 2103 multilabel reader (excitation, 555 nm; emission, 590 nm), and data 
were normalized to 100% THP1 lysis. 
 THP1 cells were intoxicated with titrations of S. aureus culture filtrates (vol/vol) for 4 h at 
37°C and 5% CO2. Controls for 100% viability were composed of cells with S. aureus growth 
medium (RPMI-CAS), while controls for 100% THP1 lysis included the addition of Triton X-100 
(0.2 %) in RPMI-CAS. THP1 viability was assayed by measuring LDH release as described above. 
 
3.2.9 Evaluating cell death by propidium iodide (PI) staining 
THP1 cells, seeded at 1 x 106 cells/mL in 300 μL/well, were intoxicated with culture 
filtrates or LukAB in the presence of propidium iodide (2.5 μg/mL) for 60 minutes. Cells were 
fixed with a combination formaldehyde and methanol solution supplied by ImmunoChemistry 
Technologies. Fluorescence was measured by flow cytometry using an Accuri C6 flow cytometer 
(BD Biosciences). 
 
3.2.10 Measuring cytokine secretion by AlphaLISA 
Culture supernatants from THP1 cells incubated with culture filtrates or LukAB were 
analyzed by alphaLISA for IL-1β, IL-18 and TNF-α according to the manufacturer’s protocol for 
short incubation (Perkin Elmer) with reduced volumes. Briefly, 1uL of each sample or standard 
was added to a separate well in a 384-well plate with 4uL of acceptor beads and cytokine antibody. 
After a 1-hour incubation at room temperature shielded from light, 5uL of streptavidin-conjugated 
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donor beads was added to each well for 30 minutes. Luminescence was measured on an EnSpire 
Multimode Plate Reader (Perkin Elmer). 
 
3.2.11 Measuring Caspase 1 activation with FLICA 
THP1 cells, seeded at 1 x 106 cells/mL in 300uL/well, were intoxicated with culture 
filtrates or LukAB in the presence of the Caspase 1 inhibiting peptide FLICA-FMK bound to Alexa 
Fluor 660 (FLICA-1) (1:100 dilution) for 60 minutes. Cells were washed once with 1x PBS and 
resuspended in 1x PBS plus 8% fixative solution supplied by ImmunoChemistry Technologies. 
Fluorescence was measured by flow cytometry using an Accuri C6 flow cytometer (BD 
Biosciences). 
 
3.2.12 Immunoblot Analysis 
THP1 cells were washed with 1x PBS and lysed with RIPA buffer (50mM Tris, pH 7.4, 
150mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40, protease inhibitor cocktail) for 
a concentration of 1 x 107 cell equivalents/mL. Lysate was spun at full speed in a mini centrifuge 
for 10 minutes at 4˚C. Lysate supernatant was mixed with Laemmli sample buffer and heated to 
95˚C for 5 minutes. Samples were stored at -80˚C until analyzed. 
Samples were loaded at 1 x 105 cell equivalents per well in a pre-cast 4-12% Bis-Tris SDS-
PAGE gel (Bio-Rad Laboratories, Inc.). Electrophoresis was run at 120 volts for 100 minutes. 
Transfer was conducted using Trans-Blot Turbo Transfer System (Bio-Rad Laboratories, Inc.). 
Membranes were blocked with 5% milk solids or 5% BSA in 1x TBS-T. Primary and HRP-
conjugated secondary antibody incubation were performed overnight and for 1 hour, respectively, 
in blocking solution. Membranes were washed for 15 minutes three times after each antibody 
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incubation. Membranes were developed using Pierce ECL Western Blotting Substrate or 
SuperSignal West Femto Chemiluminescent Substrate (Thermo Scientific) and imaged using a 
FluorChem E system (Protein Simple). All blots shown in the same figure are from the same 
experiment.  
Antibodies used include anti-NLRP3, mAb (Cryo-2) at 1 to 1000 dilution (AdipoGen), 
anti-ASC, pAb antibody at 1 to 1000 dilution (Enzo Biosciences), anti-HMGB1 antibody 
(HAP46.5, ab12029) at 1:2000 dilution (Abcam), anti-Caspase 1 antibody (14F468) at a 1 to 1000 
dilution (Novus Biologicals), anti-Actin antibody (SC-1615) at 1:5000 dilution (Santa Cruz 
Biotechnologies), Goat-anti Mouse antibody (SC-2005) at 1:5000 dilution (Santa Cruz 
Biotechnologies) and Goat-anti Rabbit antibody (SC-2004) at 1:5000 dilution (Santa Cruz 
Biotechnologies). 
 
3.2.13 Measuring THP1 surface CD11b levels 
THP1 cells, seeded at 1 X 105 cells/well, were stained with 1 ng/μl of APC-conjugated 
anti-CD11b (or isotype control) (Biolegend) in a final volume of 50 μl for 30 min on ice. Cells 
were washed once with 1x PBS + 2% FBS + 0.05% sodium azide (FACS buffer), suspended in 50 
μl of FACS buffer, then analyzed using an LSR-II flow cytometer (Becton, Dickinson, BD).  
 
3.2.14 Evaluating infection assays by flow cytometry 
THP1 infection assays under non-phagocytosing and phagocytosing conditions were 
modified from a previous study [25]. Briefly, GFP-expressing S. aureus Newman and the isogenic 
lukAB-deficient mutant were cultured and normalized to 1.0 X 109 CFU/ml as described above. 
After normalization, bacteria were pelleted and suspended in phenol red-free RPMI with 10 mM 
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HEPES Buffer (RPMI+HEPES) for non-phagocytosing conditions or opsonized with 
RPMI+HEPES supplemented with 20% normal human serum (NHS) for phagocytosing 
conditions. To promote opsonization, bacteria were incubated at 37oC with rotation for 30 min, 
centrifuged and pellet suspended in equivalent volume of RPMI+HEPES. Ninety-six well plates 
used for phagocytosing conditions were first coated with 20% NHS in RPMI+HEPES for 30 min 
at 37oC and subsequently washed with RPMI+HEPES. 
 Prior to infection, THP1 cells were primed with 500 ng/ml of purified S. aureus 
lipoteichoic acid (LTA) for 3 hrs, centrifuged at 1,500 rpm [450 x g] and 4°C then suspended in 
equivalent volume of RPMI+HEPES. THP1 cells, plated at 1 X 105 cells/well, were infected with 
GFP S. aureus Newman or the isogenic lukAB-deficient mutant at an MOI of 10. For 
phagocytosing conditions, THP1 cells and bacteria were centrifuged at 1,500 rpm [450 x g] and 
4°C for 7 min to promote synchronization of phagocytosis. Post-synchronization, cells were 
treated with 2.5 μg/ml of polyclonal anti-LukA antibody affinity purified from rabbit sera along 
and lysostaphin (40 μg/ml; Ambi Products LLC) to reduce effects of extracellular S. aureus and 
LukAB, then incubated at 37°C and 5% CO2 for 45 min. For non-phagocytosing conditions, 
bacteria were incubated at 37°C and 5% CO2 for 120 min. 
 Post-infection, cells were washed 2 times in 200 μl of PBS then stained with a 1:5,000 
dilution of a Fixable Viability Dye (eFluor 450; Affymetrix eBioscience) and a 1:150 dilution of 
FLICA-1 in a final volume of 20 μl for 20 min on ice. Cells were washed 2 times in 200 μL of 
FACS buffer before being suspended in 40 μl of fixing buffer (1 X PBS + 2% paraformaldehyde 
+ 2% FBS + 0.05% sodium azide) and analyzed using an LSR-II flow cytometer to measure GFP 
and eFluor 450 fluorescence.  
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Table 3.1 Staphylococcus aureus strains 
Strain Background Description Designation Reference 
VJT 1.07 Newman WT/pOS1 Newman (p) [20] 
VJT 2.59 USA 200 WT USA 200 [55] 
VJT 2.84 USA 100 WT USA 100 NARSA3 
VJT 2.97 Newman  WT WT or Newman [35] 
VJT 4.79 USA 400 MW2 USA 400 [56] 
VJT 7.09 Newman ΔhlgACB::tet Δhlg [57] 
VJT 8.16 Newman  ΔlukED ΔlukED [20] 
VJT 8.91 Newman ΔlukAB ΔlukAB [20] 
VJT 9.72 Newman ΔlukAB/pOS1 Newman ΔlukAB (p) [20] 
VJT 9.76 Newman ΔlukAB/pOS1-lukAB Newman ΔlukAB (plukAB) [20] 
VJT 10.21 USA 500 USA 500-2395 USA 500 [58] 
VJT 12.61 USA 300 LAC USA 300 [59] 
VJT 15.15 USA 300 pOS1 LAC (p) [20] 
VJT 15.17 USA 300 ΔlukAB/pOS1 LAC ΔlukAB (p) [20] 
VJT 15.18 USA 300 ΔlukAB/pOS1-lukAB LAC ΔlukAB (plukAB) [20] 
VJT 15.19 USA 400 pOS1 MW2 (p) [20] 
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VJT 15.21 USA 400 ΔlukAB/pOS1 MW2 ΔlukAB (p) [20] 
VJT 15.22 USA 400 ΔlukAB/pOS1-lukAB MW2 ΔlukAB (plukAB) [20] 
VJT 21.05 USA 700 WT USA 700 NARSA3 
VJT 21.06 USA 800 WT USA 800 NARSA3 
VJT 21.08 USA 1100 WT USA 1100 NARSA3 
VJT 38.71 Newman pOS1sGFP-PsarA-sod RBS Newman GFP This study 
VJT 38.72 Newman ΔlukAB pOS1sGFP-PsarA-sod RBS Newman ΔlukAB GFP This study 
VJT 38.77 USA 300-BK pOS1sGFP-PsarA-sod RBS USA 300 GFP This study 
VJT 38.78 USA 300 ΔlukAB pOS1sGFP-PsarA-sod RBS USA 300 ΔlukAB GFP This study 
                                                          
3 NARSA, Network of Antimicrobial Resistance in Staphylococcus aureus. 
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3.3 Results 
3.3.1 S. aureus kills human monocytes in a LukAB dependent manner.  
To investigate the ability of S. aureus to kill human monocytes, a variety of live S. aureus 
clinical isolates, representing different clonal lineages, were co-cultured with THP1 cells. Each 
S. aureus strain killed THP1 cells, albeit to varying degrees, as assessed by the amount of 
cytoplasmic lactate dehydrogenase (LDH) released into the culture supernatant (Fig. 3.1A). To 
evaluate the contribution of S. aureus secreted proteins to cell death, culture filtrates were 
collected from log-phase grown S. aureus and used to intoxicate THP1 cells. These culture 
filtrates were all capable of inducing cell death in a dose dependent manner (Fig. 3.1B).  
 To further dissect the role of specific secreted toxins, we selected S. aureus Newman, a 
well-characterized methicillin-sensitive clinical isolate [35] that exhibited potent cellular killing 
[20]. Here, THP1 cells were intoxicated with a titration of culture filtrates from S. aureus 
Newman or individual isogenic mutants deficient of lukAB, hla, hlgACB, or lukED and LDH 
release was evaluated (Fig. 3.1C). Only loss of LukAB had a significant effect on culture filtrate 
cytotoxicity, particularly at concentrations of ≤ 5% v/v. Culture filtrates lacking LukAB had 
residual cytotoxicity at higher concentrations, suggesting that additional factors can contribute to 
THP1 cell death (Fig. 3.1C). Using S. aureus strains lacking multiple toxins and in various 
combinations, we demonstrated that HlgACB and Hla in culture filtrates also contribute to THP1 
killing at these higher concentrations (Fig. 3.1D), consistent with previous reports using murine 
cells [30,31,36]. We also utilized these strains to determine the relative effects of each toxin in 
live S. aureus-mediated killing of THP1 cells (Fig. 3.1E). Similar to our observations with 
culture filtrates, loss of LukAB significantly reduced S. aureus killing of THP1 cells, while the 
loss of the other toxins had little if any additional effect. To further validate the LDH data, we 
used propidium iodide (PI), a membrane-impermeable DNA-intercalating dye to monitor 
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membrane integrity of human monocytes using flow cytometry. In agreement with the LDH 
release data, LukAB was responsible for the propidium iodide staining observed with culture 
filtrates of S. aureus strain Newman (Fig. 3.1F).  
 S. aureus Newman naturally does not encode pvl, thus we next sought to determine 
whether LukAB also contributes to THP1 cell death in methicillin-resistant S. aureus (MRSA) 
strains that produce PVL. We assessed the cytotoxicity of wildtype and LukAB-deficient strains 
LAC (USA 300) and MW2 (USA 400), two representative MRSA clones, towards THP1 cells in 
models of live bacterial infection (Fig. 3.1G). As with Newman, strains LAC and MW2 lacking 
lukAB exhibited reduced cytotoxicity to THP1 cells when compared to the isogenic parental 
strain, a phenotype complemented by expressing lukAB from a plasmid episomally (Fig. 3.1G).  
The impact of LukAB in killing human monocytes was also tested using live bacterial 
infection and culture filtrate intoxication of purified CD14+ primary human monocytes. The 
diminished cytotoxicity of lukAB deficient S. aureus strains seen in THP1 experiments was 
phenocopied in experiments with primary monocytes, as was the complementation of the 
phenotype by lukAB-expressing plasmids (Fig. 3.1H and 3.1I). Thus, these data demonstrate that 
LukAB is the predominant toxin secreted by S. aureus to kill human monocytes. 
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Figure 3.1 Staphylococcus aureus LukAB induces cell death in human monocytic cells. (A) 
THP1 cells were infected with the indicated S. aureus strains at a multiplicity of infection (MOI) 
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of 50 for 2 hours and culture supernatants were analyzed for LDH release as a measurement of 
cell lysis. (B) Culture filtrates, acquired from log-phase growth of S. aureus strains listed, were 
used to intoxicate THP1 cells at the indicated concentrations for 4 hours and LDH release was 
analyzed. (C and D) THP1 cells were intoxicated with culture filtrates from S. aureus Newman 
or the indicated isogenic mutants for 4 hours and LDH release was analyzed. (E) THP1 cells 
were infected with S. aureus Newman or the indicated isogenic mutants at an MOI of 50 and 
LDH release was analyzed after 2 hours. THP1 cells (F) and primary CD14+ human monocytes 
(G) were infected with S. aureus Newman, USA300 (LAC) or USA400 (MW2) or the respective 
lukAB-deficient mutants and complemented strains at an MOI of 50 (F) or 25 (G) and LDH 
release was analyzed after 2 hours. (H) Culture filtrates (1% v/v) from the indicated S. aureus 
strain and isogenic mutants were used to intoxicate primary CD14+ human monocytes for 1 hour 
and LDH release was analyzed. (I) THP1 cells were incubated with propidium iodide and 
intoxicated with culture filtrates from S. aureus Newman, lukAB mutant, or complemented strain 
at 1% (v/v) for 4 hours then analyzed by flow cytometry. Error bars represent the mean ± 
standard error of the mean for at least two independent experiments, each performed in triplicate. 
Experiments with primary cell experiments include at least three independent donors. Asterisks 
indicate significance at a p-value of ≤ 0.05 by Tukey’s multiple comparisons post-test for 1-way 
or 2-way ANOVA, as appropriate. 
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3.3.2 LukAB kills human monocytes by engaging its cellular receptor.  
To determine whether LukAB was sufficient to induce THP1 cell death, and to compare 
its relative cytotoxicity to that of the other bi-component pore forming toxins, THP1 cells were 
intoxicated with purified toxins. LukAB, LukED and HlgAB were all able to induce cytotoxicity 
in THP1 cells, as measured by release of LDH into the culture medium (Fig. 3.2A). In contrast, 
HlgCB and PVL were unable to lyse THP1 cells [29]. Among the toxins tested, LukAB was the 
most potent, capable of lysing THP1 cells at concentrations approximately 8- and 12-fold lower 
than HlgAB and LukED, respectively (Fig. 3.2A).  
 LukAB targets CD11b on human neutrophils to promote cell death [22], so we next 
sought to determine if LukAB-CD11b recognition was also required for LukAB activity towards 
human monocytes. We first utilized a previously characterized LukAB mutant that does not bind 
CD11b, LukAB E323A [24]. This mutant toxin failed to elicit LDH release from THP1 cells, 
indicating that CD11b interaction is required for LukAB-mediated death in this monocytic cell 
line (Fig. 3.2A). To further validate this finding, THP1 cells were transduced to stably express 
short hairpin RNA (shRNA) against CD11b or a non-targeting control (Fig. 3.2B). Knockdown 
of CD11b was confirmed through immunostaining and analysis by flow cytometry (Fig. 3.2B). 
These transduced cells were then intoxicated with purified LukAB, LukED or HlgAB (Fig. 
3.2C). The CD11b shRNA knockdown significantly reduced LukAB-mediated cytotoxicity, but 
not cytotoxicity resulting from HlgAB or LukED intoxication, indicating that LukAB recognizes 
CD11b on human monocytes to induce cell death (Fig. 3.2C). The potency of LukAB in 
mediating THP1 cell permeability to PI paralleled the potency observed for release of LDH from 
target cells. (Fig. 3.2D).  
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We next sought to determine the potency to LukAB, relative to other pore-forming toxins 
in killing CD14+ primary human monocytes. As assessed by PI staining, dose-titrations of each 
toxin demonstrated that LukAB and PVL were the most potent in their ability to kill primary 
monocytes (Fig. 3.2E). Interestingly, primary monocytes exhibited a ten-fold increase in 
susceptibility to LukAB when compared to the THP1 cell line. This difference in toxin 
susceptibility was accentuated in PVL where primary monocytes were susceptible to the toxin 
while THP1 cells were essentially resistant. 
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Figure 3.2 LukAB recognizes CD11b on human monocytes to potently induce cell death. 
(A) THP1 cells were intoxicated with titrations of the indicated purified toxins for 1 hour and 
LDH release was analyzed. (B) THP1 cells were transduced with either non-targeting shRNA or 
shRNA against CD11b and surface CD11b levels were evaluated by flow cytometry. (C) THP1 
cells described in B were intoxicated with titrations of the indicated toxins for 1 hour and LDH 
release was analyzed. (D) THP1 cells were intoxicated with the indicated concentration of 
LukAB for 1 hour and analyzed by flow cytometry for permeability to propidium iodide. (E) 
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Primary CD14+ human monocytes were intoxicated with titrations of the indicated toxins for 1 
hour and analyzed by flow cytometry for permeability to propidium iodide. EC50 values also 
shown. Error bars represent the mean ± standard error of the mean for at least two independent 
experiments, each performed in triplicate. Primary cell experiments include three independent 
donors. Asterisks indicate significance at a p-value of ≤ 0.05 by Tukey’s multiple comparisons 
post-test for 1-way or 2-way ANOVA, as appropriate. 
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3.3.3 LukAB-induced cell death displays necrotic features. 
Traditionally, programmed cell death can be morphologically categorized into necrotic or 
apoptotic phenotypes [37,38]. During necrotic cell death membrane integrity is rapidly lost, 
releasing cytosolic and nuclear contents into the extracellular milieu. Death with necrotic 
features leads to inflammation, as cytosolic contents act as endogenous danger signals triggering 
activation of innate immune signaling. In contrast, apoptosis is relatively immunologically silent 
as cytosolic and nuclear contents are broken down into small membrane bound bodies [39]. To 
further visualize the effect of LukAB on the membrane of THP1 cells, culture filtrates from S. 
aureus Newman or the isogenic lukAB deficient-mutant were used to intoxicate THP1 cells 
which were then examined by transmission electron microscopy (Fig. 3.3A). THP1 cells 
intoxicated with LukAB-containing culture filtrates displayed vacuolation of the cytoplasm, 
substantial plasma membrane compromise, and gross changes in nuclear morphology, all 
suggestive of necrotic cell death. This is in contrast to THP1 cells intoxicated with culture 
filtrates from an isogenic lukAB deficient-mutant or with the media control, where membranes 
were mostly intact and cytoplasmic contents preserved (Fig. 3.3A).  
 Another marker of necrosis is the release of High Mobility Group Box 1 protein 
(HMGB1), a nuclear protein that, when released, acts as a pro-inflammatory danger signal [40]. 
To test whether LukAB induced HMGB1 release, THP1 cells were intoxicated with S. aureus 
culture filtrates or purified LukAB and the culture supernatants were evaluated by immunoblot 
with antibodies specific to HMGB1. We observed that LukAB was necessary and sufficient to 
induce HMGB1 release (Fig. 3.3B and 3.3C).  
 Necrotic cell death paired with secretion of inflammatory cytokines IL-1β and IL-18 is 
termed pyroptosis [41-43]. To determine if LukAB causes THP1 cells to secrete IL-1β and IL-
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18, we analyzed culture supernatants from THP1 cells intoxicated with Newman strain culture 
filtrates (Fig. 3.3D) and purified LukAB (Fig. 3.3E). In this setting, THP1 cells secreted IL-1β, 
IL-18 and TNF-α in response to Newman strain culture filtrates, though deletion of lukAB 
eliminated secretion of IL-1β and IL-18 with no evident effect on TNF-a secretion. THP1 cells 
do not express pro-IL-1β at baseline and thus require priming with a Toll-like receptor ligand 
such as lipoteichoic acid (LTA) prior to intoxication with purified LukAB. LTA induced TNF-α 
secretion, but LukAB was required for secretion of IL-1β and IL-18 (Fig. 3.3E). As with THP1, 
primary CD14+ human monocytes also secreted IL-1β and IL-18 in response to LukAB (Fig. 
3.3F). 
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Figure 3.3 LukAB induces necrotic cell death and secretion of pro-inflammatory cytokines 
IL-1β and IL-18. (A) THP1 cells were intoxicated with culture filtrate from S. aureus Newman 
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(10% v/v), isogenic lukAB mutant or culture media for 1 hour. Cells were collected, prepared and 
imaged by transmission electron microscopy (see methods). (B) THP1 cells were intoxicated 
with 1% (v/v) culture filtrate from S. aureus Newman (1% v/v) and the indicated isogenic 
mutants and after 4 hours supernatants were collected and analyzed by immunoblot for HMGB1 
release. (C) THP1 cells were intoxicated with purified LukAB at the indicated concentrations for 
1 hour and supernatants were analyzed by immunoblot for HMGB1 release. (D) Primary CD14+ 
human monocytes were intoxicated with purified LukAB at the indicated concentrations for 1 
hour and supernatants were analyzed by immunoblot for HMGB1 release. (E) THP1 cells were 
intoxicated with culture filtrates (1% v/v) from the indicated strains and supernatants were 
collected and analyzed for secretion of the indicated cytokines. THP1 cells (F) and primary 
CD14+ human monocytes (G) were primed for production of pro-IL-1β with 500 ng/mL LTA 
for 3 hours followed by intoxication with LukAB (THP1 with 50 ng/mL and CD14+ monocytes 
with 30 ng/mL) for 1 hour then supernatants were analyzed for secretion of the indicated 
cytokines. Error bars represent the mean ± standard error of the mean for at least two 
independent experiments, each performed in triplicate. Primary cell experiments include three 
independent donors. Asterisks indicate significance at a p-value of <=0.05 by Tukey’s multiple 
comparisons post-test for 1-way or 2-way ANOVA, as appropriate. 
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3.3.4 LukAB induces activation of Caspase 1 in human monocytes. 
Pyroptosis depends on the activation of Caspase 1 [39]. To determine if LukAB induced 
Caspase 1 activation, THP1 cells were incubated with purified LukAB and activation of Caspase 
1 assessed using immunoblot analyses. The auto-proteolysis-derived P10 subunit, an indication 
of Caspase 1 activation, was observed in cells treated with purified LukAB (Fig. 3.4A). To 
quantitatively assess Caspase 1 activation, we used a flow cytometry based fluorescent-labeled 
peptide inhibitor of Caspase 1 (660-YVAD-FMK) assay (hereafter FLICA-1) [41]. THP1 cells 
treated with S. aureus culture filtrates demonstrated a marked increase in FLICA-1 fluorescence 
when compared to the isogenic lukAB–deficient mutant or untreated cells (Fig. 3.4B and 3.4C). 
The phenotype of the lukAB-deficient mutant could be complemented to that of the WT strain by 
expressing a plasmid encoding lukAB. As observed by immunoblot (Fig. 3.4A), LukAB 
treatment alone was sufficient to cause enhanced FLICA-1 activation in THP1 cells (Fig. 3.4D). 
Measurable change in FLICA-1 activation in THP1 cells lagged the introduction of toxin by 
approximately five minutes. After the lag period, FLICA-1 activation rapidly increased reaching 
a plateau over approximately 10 minutes after the FLICA-1 signal began to increase.  
 It has previously been reported that Hla and PVL activate Caspase 1 [28,29,36]. We next 
sought to determine the relative potency of each S. aureus leukotoxin in inducing Caspase 1 
activation as measured by FLICA-1 in both THP1 cells (Fig. 3.4F) and primary CD14+ human 
monocytes (Fig. 3.4G). In THP1 cells, LukAB was the most potent FLICA-1 activator (Fig. 
3.4F). Although PVL did not induce cell lysis in THP1 cells (Fig. 3.2A), it did induce FLICA-1 
activation (Fig. 3.4F). In primary human monocytes, LukAB and PVL demonstrated equivalent 
potency in inducing FLICA-1 activation (Fig. 3.4G).  
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Figure 3.4 LukAB is a potent activator of Caspase 1. (A) THP1 cells were intoxicated with 50 
ng/mL LukAB for 1 hour and cell lysates were analyzed by immunoblot for Caspase 1 cleavage, 
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which indicates activation. (B and C) THP1 cells were incubated with FLICA-1 (660-YVAD-
FMK) then intoxicated with culture filtrates (1% v/v) from the indicated S. aureus stains. After 1 
hour, cells were washed, fixed and analyzed by flow cytometry. Panel B shows a representative 
flow plot from one experiment, and panel C shows the corresponding mean florescence 
intensities (MFI). (D) THP1 cells were incubated with FLICA-1, intoxicated with purified 
LukAB for 1 hour (50 ng/mL), then washed, fixed and analyzed by flow cytometry. (E) FLICA-1 
was added to THP1 cells then LukAB was added (50 ng/mL) for time-course samples in 
descending order. All samples were washed and fixed at the same time, corresponding to 
different LukAB incubation times, then analyzed by flow cytometry. THP1 cells (F) and primary 
CD14+ human monocytes (G) were incubated with FLICA-1 and intoxicated with a dose 
titration of the indicated purified S. aureus leukotoxin for 1 hour. Cells were washed, fixed and 
analyzed by flow cytometry. Bars represent the standard error of the mean of triplicate samples. 
Each graph is representative of three experiments. Primary cell experiments include three 
independent donors. Asterisks indicate significance at a p-value of ≤ 0.05 by Tukey’s multiple 
comparisons post-test for 1-way or 2-way ANOVA, as appropriate. 
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3.3.5 NLRP3 and ASC are necessary for LukAB-induced cytokine secretion and necrotic 
cell death. 
The activation of Caspase 1 by S. aureus Hla and PVL depends on host NLRP3 and ASC 
[26,29]. We next sought to determine whether LukAB-mediated Caspase 1 activation, secretion 
of IL-1 and IL-18 and cell death were also dependent on NLRP3 and ASC. To this end, THP1 
cells were transduced to stably express shRNA constructs targeting inflammasome components 
ASC and NLRP3, or a non-targeting shRNA control. Knockdown of ASC and NLRP3 were 
confirmed by immunoblot analyses (Fig. 3.5A). Importantly, knock down of ASC or NLRP3 did 
not reduce levels of the LukAB receptor CD11b (Fig. 3.5B). Knock down of ASC or NLRP3 
resulted in a significant reduction in LukAB-induced Caspase 1 activation (Fig. 3.5C) and 
secretion of the Caspase 1 dependent cytokines IL-1β and IL-18 (Fig. 3.5D). Thus, FLICA-1 is a 
reliable measure of NLRP3 inflammasome activation by LukAB. Moreover, LukAB-induced 
necrotic cell death as measured by LDH release (Fig. 3.5E) and membrane permeability to PI 
(Fig. 3.5F) was essentially eliminated when ASC or NLRP3 were depleted. Knock down of ASC 
or NLRP3 also had a similar effect on IL-1β and IL-18 secretion and cell death in THP1 cells 
intoxicated with Newman culture filtrates (Fig. 3.6). Residual cell death and cytokine release was 
consistently observed in the NLRP3 knock down, a result likely due to incomplete knockdown 
(Fig. 3.5C-F).  
 Activation of the NLRP3 inflammasome involves potassium efflux [42,43], thus we 
evaluated the role of potassium in LukAB-mediated inflammasome activation. THP1 cultures 
supplemented with potassium chloride, but not sodium chloride or choline chloride (Fig. 3.7), 
inhibited LukAB-induced NLRP3-inflammasome activation as assessed by FLICA-1 activation 
(Fig. 3.5G) and cell membrane PI permeability (Fig. 3.5H). Altogether, these results indicate that 
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LukAB activates the NLRP3 inflammasome to initiate Caspase 1-dependent cytokine release and 
necrotic cell death. 
 
 
Figure 3.5 LukAB activates the NLRP3 inflammasome leading to cell death and cytokine 
secretion. (A) THP1 cells were transduced with shRNA against NLRP3, ASC or a non-targeting 
control. Cells lysates were analyzed by immunoblot to confirm knockdown of NLRP3 and ASC. 
(B) Surface CD11b levels were evaluated by flow cytometry. (C) THP1 shRNA cells were 
incubated in the presence of FLICA-1 then intoxicated with LukAB (50 ng/mL) for 1 hour then 
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analyzed by flow cytometry. (D-E) THP1 shRNA cells were primed with 500 ng/mL LTA for 3 
hours followed by intoxication with LukAB (50ng/mL) for one hour. Culture supernatants were 
collected and analyzed for secretion of the indicated cytokines. (F) THP1 shRNA cells were 
intoxicated with LukAB (50 ng/mL) for 1 hour and culture supernatants were collected for 
analysis of LDH release. (G) THP1 shRNA cells were incubated with propidium iodide then 
intoxicated with LukAB (50 ng/mL) for 1 hour then analyzed by flow cytometry. (H and I) 
THP1 cells were incubated in media supplemented with an additional 25 mM NaCl or KCl. Cells 
were incubated with FLICA-1 (H) or propidium iodide (I) then intoxicated with LukAB (50 
ng/mL) for 1 hour and analyzed by flow cytometry. Bars represent the mean ± standard error of 
the mean for at least two independent experiments, each performed in triplicate. Asterisks 
indicate significance at a p-value of ≤ 0.05 by Tukey’s multiple comparisons post-test for 1-way 
or 2-way ANOVA, as appropriate. 
 
 
Figure 3.6 NLRP3 and ASC contribute to S. aureus culture filtrate-mediated cytokine 
secretion and THP1 cell death.  The indicated THP1 shRNA cells were intoxicated with culture 
filtrates (1% v/v) from S. aureus Newman.  Culture supernatants were collected and analyzed for 
secretion of LDH release (A) and IL-1β (B) and IL-18 (C) secretion.  Bars represent the mean ± 
standard error of the mean for at least two independent experiments, each performed in triplicate.  
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Figure 3.7 Media supplementation with KCl inhibits LukAB-mediated FLICA-1 activation 
and cell death.  THP1 cells were incubated in media supplemented with an additional 25 mM 
NaCl, KCL or ChCl. Cells were incubated with FLICA-1 (A) or propidium iodide (B) then 
intoxicated with LukAB (50 ng/mL) for 1 hour and analyzed by flow cytometry. Bars represent 
the mean ± standard error of the mean for at least two independent experiments, each performed 
in triplicate. 
 
3.3.6 Caspase 1 is required for LukAB-induced cytokine secretion.  
The dose-dependent cytotoxic activity exhibited by the different S. aureus pore-forming 
toxins towards primary CD14+ human monocytes (Fig. 3.2E) closely matched the results 
obtained by measuring FLICA-1 activation in these cells (Fig. 3.4G). These data raised the 
question as to whether Caspase 1 was required for cell death, a feature of the pyroptotic 
inflammatory cell death pathway. To test this, we transfected THP1 cells with small interfering 
RNA (siRNA) targeting Caspase 1 or ASC, as a positive control. After 72 hours, Caspase 1 
levels were noticeably reduced as determined by immunoblot analyses (Fig. 3.8A). Loss of 
Caspase 1 had only a slight measurable impact on LukAB-induced PI staining (Fig. 3.8B) but 
nearly eliminated secretion of IL-1  and IL-18 (Fig. 3.8C and 3.8D). Additionally, primary 
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CD14+ human monocytes were also treated with two pharmacologic inhibitors of Caspase 1: 
VX-765, a potent and selective small molecule inhibitor of Caspase 1 [44], and zYVAD-FMK, a 
peptide-based inhibitor of Caspase 1 [45]. Following pretreatment with a dose titration of both 
inhibitors, primary monocytes intoxicated with LukAB showed no difference in cell death (Fig. 
3.8E), but both VX-765 and zYVAD-FMK suppressed IL-18 secretion (Fig. 3.8F). 
 
 
Figure 3.8 Genetic or pharmacologic disruption of Caspase 1 blocks LukAB-induced 
cytokine secretion but not cell death. (A) THP1 cells were transfected with siRNA against 
Caspase 1, ASC or a non-targeting sequence. Cell lysates were collected and analyzed by 
immunoblot to confirm knockdown of pro-Caspase 1 and ASC. (B) THP1 siRNA cells were 
incubated with propidium iodide and intoxicated with 50 ng/mL LukAB for 1 hour then analyzed 
by flow cytometry. (C and D) THP1 siRNA cells were primed with LTA (500ng/mL) (C) or not 
(D) and intoxicated with LukAB (50ng/mL) and culture supernatants were analyzed for cytokine 
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release. (E and F) Primary CD14+ human monocytes were incubated with the indicated 
concentration of z-YVAD-FMK or VX-765 for 30 minutes. Primary monocytes were incubated 
in the presence of propidium iodide (E) then intoxicated with LukAB (50ng/mL) and analyzed 
by flow cytometry. (F) THP1 cells were intoxicated with LukAB (50ng/mL) and culture 
supernatants were collected for cytokine analysis. Propidium iodide staining and IL-18 secretion 
are reported as a fraction of measurement in primary cells not treated with inhibitor. Bars 
represent the mean ± standard error of the mean for at least two independent experiments, each 
performed in triplicate. Asterisks indicate significance at a p-value of <=0.05 by Tukey’s 
multiple comparisons post-test for 1-way or 2-way ANOVA, as appropriate. 
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3.3.7 LukAB promotes S. aureus escape from within human monocytes independent of 
NLRP3 or ASC, but dependent on CD11b. 
We next sought to evaluate the contribution of ASC and NLRP3 in infection models with 
live S. aureus. THP1 cells were first infected with S. aureus Newman and the isogenic lukAB-
deficient mutant, both constitutively expressing GFP, in the absence of opsonization (i.e. 
extracellular infection). Following infection cells were stained with a fixable viability dye eFluor 
450, a membrane damage and cell death marker, then analyzed by flow cytometry to determine 
the extent of THP1 cell death. In agreement with previous experiments using LDH and PI, THP1 
cells infected with S. aureus lacking lukAB showed reduced eFluor 450 staining in comparison to 
THP1 cells infected with the wildtype strain (Fig. 3.9A). In shRNA-transduced cell lines, we 
observed LukAB-dependent cell death (Fig. 3.9B), FLICA-1 staining (Fig. 3.9C), and IL1-β 
release (Fig. 3.9D) in the control shRNA cell line. Each of these LukAB-mediated effects was 
significantly reduced in the CD11b, ASC, and NLRP3 knockdown cell lines (Fig. 3.9B-D). The 
phenotypes observed in this extracellular infection model are consistent with our observations 
using purified toxins and culture filtrates.  
LukAB targets CD11b to promote S. aureus escape from within human neutrophils 
[22,25]. We next sought to determine whether LukAB mediates similar escape from within 
human monocytes, and if NLRP3 or ASC contribute to this process. To evaluate cell death post-
phagocytosis we modified our previously described method [25] to utilize GFP expressing 
strains and flow cytometric analyses. S. aureus Newman and the isogenic lukAB-deficient mutant 
were opsonized with human-serum and centrifuged in co-culture with THP1 cells to promote 
phagocytosis (Fig. 3.9E-9L). Following phagocytosis, lysostaphin, a potent enzyme that kills S. 
aureus by degrading the cell wall [46], was added in combination with anti-LukA neutralizing 
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antibodies to remove any remaining extracellular S. aureus and to block any residual 
extracellular LukAB [25]. We next quantified the proportion of cells that were both GFP positive 
and had maximal incorporation of eFluor® 450, as an indication of THP1 cells terminally 
injured by intracellular S. aureus. We observed that post-phagocytosis, LukAB contributed to S. 
aureus-mediated membrane damage and cell death (Fig. 3.9E). The distribution of GFP 
fluorescence in THP1 cells infected with WT S. aureus or the lukAB-deficient mutant were 
overlapping, indicating equal bacterial burden (Fig. 3.9F). Importantly, ex vivo infections of 
primary CD14+ human monocytes with S. aureus Newman and a PVL+ USA 300 strain revealed 
that LukAB is indeed responsible for cell death (Fig. 3.9G) and FLICA-1 activation (Fig. 3.9H) 
post-phagocytosis in human monocytes.  
 Using this model, we next evaluated the contributions of CD11b, ASC and NLRP3 to S. 
aureus-mediated THP1 cell death. Post-infection, approximately 90% of THP1 cells were GFP-
positive across all cell lines and between S. aureus strains (Fig. 3.9I), indicating equivalent 
phagocytosis. We next quantified the proportion of THP1 cells killed by intracellular S. aureus. 
Remarkably, we observed that S. aureus induced THP1 cell death in a LukAB- and CD11b-
dependent manner, but an ASC- and NLRP3-independent manner (Fig. 3.9J). Furthermore, we 
observed that while death was ASC- and NLRP3-independent, LukAB-mediated FLICA-1 
activation (Fig. 3.9K) and IL-1β release (Fig. 3.9L) occurred through CD11b, ASC, and NLRP3.  
Thus, taken together these results demonstrate that LukAB, when secreted by S. aureus in the 
extracellular milieu, activates the host NLRP3 inflammasome to promote killing. However, when 
secreted from within monocytes, LukAB activates the NLRP3 inflammasome and induces cell 
death independently of NLRP3 or ASC. 
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Figure 3.9 LukAB promotes the kill human monocytes by extracellular or phagocytized S. 
aureus. (A) THP1 cells were infected with S. aureus Newman strains at an MOI of 10 for 120 
min under non-phagocytosing conditions (extracellular infection; see methods), stained with the 
fixable viability dye eFluor 450, a membrane damage and cell death marker, and analyzed by 
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flow cytometry. Representative histogram is shown. (B-D) THP1 shRNA cells were infected S. 
aureus Newman, MOI 10 for 120 min, followed by flow cytometry analysis for maximal eFluor 
450 staining (B) and FLICA-1 activation (C). (D) Culture supernatants were collected from 
intracellular infections and analyzed for IL-1β secretion. (E and F) THP1 cells were infected 
with GFP-expressing S. aureus Newman strains at an MOI of 10 for 45 min under phagocytosing 
conditions (intracellular infection; see methods). (E) THP1 cells were stained with the fixable 
viability dye eFluor 450. After infection, THP1 cells were analyzed by flow cytometry and GFP-
positive THP1 cells were selected, indicative of S. aureus phagocytosis. Maximal eFluor 450 
incorporation was gated among GFP-positive cells, indicative of THP1 death by intracellular S. 
aureus. Very few cells appear in the first plot corresponding to the background autofluorescent 
uninfected cells. Representative plots are shown. (F) Representative histogram of GFP 
fluorescence in S. aureus infected and uninfected THP1 cells is shown. (G-H) Purified primary 
CD14+ human monocytes were infected with S. aureus Newman and USA300-BK18807 strains, 
along with respective isogenic lukAB mutants, at an MOI of 5 for 45 min then stained with 
eFluor 450 (G) or FLICA-1 (H) and analyzed by flow cytometry. Graphs reflect the fraction of 
cells that were GFP positive. (I-L) THP1 shRNA cells were infected with S. aureus Newman, 
MOI 10 for 45 min, and analyzed by flow cytometry for (I) GFP fluorescence indicating 
phagocytosis; (J) maximal eFluor 450 staining indicating cell death; (G) and FLICA-1 activation. 
(L) Culture supernatants were collected and analyzed for IL-1β secretion. Bars represent the 
mean ± standard error of the mean for at least two independent experiments, each performed in 
triplicate. Experiments with primary cell experiments include at least three independent donors. 
Asterisks indicate significance at a p-value of ≤ 0.05 by Tukey’s multiple comparisons post-test 
for 1-way or 2-way ANOVA, as appropriate. 
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3.4 Discussion 
Staphylococcus aureus is a leading global cause of life threatening bacterial infections by 
virtue of its remarkable ability to invade practically all tissues in the human body, evade immune 
clearance, and subsequently proliferate. Its wide arsenal of virulence factors likely enables this 
broad tissue tropism and persistence. With regard to pore-forming toxins, many studies have 
focused on α-toxin (Hla) and Panton-Valentine leukocidin (PVL). Herein, we demonstrate that 
LukAB, the most recently identified S. aureus toxin [20,21], is a predominant cytolytic 
leukotoxin responsible for inducing programmed inflammatory cell death in human monocytes. 
Both purified LukAB and PVL have exquisite potency in activating the NLRP3 inflammasome 
and inducing inflammatory cell death in primary CD14+ human monocytes; a result consistent 
with high selectivity of these toxins toward human cells [3]. The dependency of S. aureus on any 
one toxin for survival and pathogenesis is likely tissue-, cell- and strain-specific. Unlike PVL, 
which is only encoded in about 15% of clinical isolates, LukAB is a part of the core genome of 
S. aureus and found in the vast majority of isolates (data publically available in NCBI sequenced 
S. aureus genomes). Our data points to an important role for LukAB in mediating virulence 
through interacting with CD11b on human monocytes. In fact, during ex vivo infection of 
primary CD14+ human monocytes, LukAB seems to be the main factor produced by S. aureus 
responsible for targeting and killing monocytes. By activating the inflammasome in monocytes, 
LukAB is likely to induce uncontrolled production of pro-inflammatory cytokines such as IL-1β 
and IL-18, thus in theory worsening the outcome of S. aureus infections [23,47]. The presence of 
multiple toxins that activate a common host signaling pathway suggests there is selective 
advantage for S. aureus to activate the NLRP3-inflammasome, at least under some 
circumstances. Alternatively, if activation of the NLRP3-inflammasome is detrimental to S. 
aureus in its host, each of these NLRP3-inflammasome activating toxins must also provide 
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advantages to bacterial survival that are independent and outweigh the negative selective 
pressure inflammasome activation would exert on the organism.  
By using both genetic and pharmacologic approaches, we demonstrate that LukAB-
mediated IL-1β and IL-18 secretion depends on Caspase 1. Consistent with previous reports on 
Caspase 1 activity in programmed necrotic cell death [48], we have found that genetic depletion 
of Caspase 1 by siRNA in THP1 cells and pharmacologic inhibition with zYVAD-FMK and VX-
765 in primary CD14+ human monocytes does not alter LukAB-induced cell death. With these 
data we cannot rule out a role for Caspase 1 in programmed necrotic cell death, either as a longer 
half-life executioner that persists through the time course of siRNA experiments as suggested 
previously [48], or as a highly sensitive executioner resistant to total inhibition. These results 
suggest that LukAB-mediated death shares common features with a pyroptotic mechanism but 
cannot be strictly classified as pyroptosis without further experimentation in human immune 
cells completely lacking Caspase 1, which are currently lacking.  
 In contrast to other S. aureus bi-component pore-forming toxins, which are found as 
water-soluble monomers in solution, LukAB is isolated as a dimer in solution [24,49]. The 
recently solved crystal structure of LukAB identified three salt bridges, unique to LukAB, that 
are involved in dimer formation [49]. While it is tempting to speculate that the “dimeric” nature 
of LukAB accelerates LukAB-mediated Caspase 1 activation and monocyte death, we observed 
similar potencies with PVL, which is not isolated as a dimer in solution [24] nor targets CD11b. 
These results may then suggest that the signals downstream of receptor binding regulate the 
potencies of LukAB and PVL. Indeed, S. aureus pore-forming toxins LukAB, PVL and Hla all 
converge on a single signal transduction pathway in human phagocytes: activation of the 
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NRLP3-inflammasome, which ultimately leads to the generation of mature IL-1β and IL-18 and 
necrotic cell death. 
  Another novel feature of LukAB is the activity of this toxin from within human 
neutrophil phagosomes, which facilitates bacterial escape and promotes cell killing [20,22,25]. 
We show here that this characteristic is also evident in primary CD14+ human monocytes. Using 
THP1 cells as a model, we determined that LukAB-mediated cell death from within monocyte 
phagosomes is CD11b-dependent, but NLRP3 or ASC-independent manner. In contrast, the 
extracellular model of infection revealed that S. aureus LukAB killed monocytic cells in a 
CD11b-, ASC- and NLRP3-dependent manner. Previously, LLO from Listeria monocytogenes 
has been reported to activate S10H3 dephosphorylation in addition to activating the NLRP3-ASC 
inflammasome [50], and escape of L. monocytogenes into the cytoplasm has been shown to cause 
infrequent bacterial lysis leading to AIM2-ASC inflammasome activation [51]. This study, 
however, represents the first of its kind showing an inflammasome-dependent cell death initiated 
by extracellular toxin, but an ASC-containing-inflammasome-independent cell death initiated 
specifically by intracellular toxin. A possible explanation for these observations is that additional 
signaling cascades that lead to cell death are engaged by LukAB-CD11b recognition within the 
phagosome as compared to LukAB-CD11b recognition on the cell membrane. On the contrary, a 
recent report suggested that phagocytosis of S. aureus by murine phagocytes triggers early 
activation of the NLRP3 inflammasome and Caspase 1; an event that is required for bacterial 
clearance [52]. The apparent discrepancy between our results can be attributed to the inability of 
LukAB to lyse murine cells [22,23]. Similarly, we have previously shown that mice lacking 
NLRP3 are protected from S. aureus pneumonia [26]. The magnitude of the detrimental nature of 
NLRP3 activation in human S. aureus infection is likely to be underestimated due to reliance on 
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murine models which are resistant to LukAB-mediated lysis. LukAB binds to human CD11b 
with nearly 1000-fold higher affinity than to mouse CD11b [22], a feature that has led to 
dramatically underestimating the impact of this toxin in murine models [20]. Of note, a recent 
study revealed that children with invasive S. aureus disease exhibit a potent IgG response to 
LukAB [47], highlighting that LukAB is produced in vivo during human infection. These 
findings further support the notion that LukAB influences S. aureus pathophysiology in human 
infections. Ultimately, this study advances our understanding of how LukAB manipulates 
leukocytes, information critical to fully uncover how this virulence factor contributes to S. 
aureus infection.  
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Chapter 4. Novel approaches to studying kinase-dependent regulation of the NLRP3 
inflammasome 
 
4.1 Introduction 
The NLRP3 inflammasome is a critical immune signaling pathway that promotes 
secretion of interleukin-1B (IL-1β) and interleukin-18 (IL-18), and causes necrotic cell death. 
Dysregulation and hyperactivation of the NLRP3 inflammasome can result in hyperinflammatory 
conditions such as Cryopyrin-associated periodic syndromes or exacerbate infection pathology, 
as in S. aureus pneumonia [1].  
Dozens of pathogen- and danger-associated molecules activate the NLRP3 
inflammasome. However, a comprehensive model for inflammation activation and regulation has 
yet to emerge. Post-translational modifications, including phosphorylation, are thought to play a 
major role in regulating the NLRP3 inflammasome.  
Numerous different kinases are required for NLRP3 inflammasome activation under a 
variety of inciting conditions. But little is known about how these kinases control NLRP3 
inflammasome activity. As discussed previously, kinases that regulate the NLRP3 inflammasome 
include Syk [2-8], Jnk/MAPK8/MAPK9 [7,9], Lyn [8], NEK7 [10,11], PKR/EIF2AK2 [12], 
BTK [13], RIPK1/RIPK3/MLKL [14,15], RIPK2 [16], TAK1/MAP3K7 [9], IKKi/CHUK and 
IKKa/IKBKE [17], IRAK1 [18,19], IRAK4 [19] and DAPK [20]. There is also evidence that 
NLRP3 inflammasome regulation is cell type specific. For example, loss of Syk has no effect on 
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nigericin-induced NLRP3 activation in murine dendritic cells [2] but diminishes 
nigericin-induced NLRP3 activation in murine bone marrow derived macrophages [7].   
Multiple putative phosphorylation sites on NLRP3, ASC and pro-Caspase 1 exist. 
Phosphorylation of ASC has been demonstrated in three separate manuscripts. Both Syk and Jnk 
are required for ASC phosphorylation [7] and Syk phosphorylates ASC at Y146 and Y187 [6].  
IKKa/IKBKE interacts directly with ASC in a manner that requires ASC S16 and S193 for 
phosphorylation, though it isn’t clear if IKKa also phosphorylates these sites.  IKKi interacts 
with ASC as well and phosphorylates ASC at S58 [17].  ASC phosphorylation appears to be 
critical for ASC oligomerization, as mutation of phosphorylation sites to alanine diminishes its 
ability to form oligomers in a cell-free system and deletion of Syk blocks Caspase 1 activity in 
cells [6,7,17].   
The mechanisms by which the other identified kinases regulate NLRP3 inflammasome 
activity are less clear.  By in large, their role has been established by showing that genetic 
disruption or pharmacologic inhibition increases or decreases IL-1β secretion or cell death in 
response to NLRP3-dependent stimuli. 
Although direct phosphorylation of NLRP3 has been observed at T233, S387, S436 and 
S728 in phospho-proteome studies, the role of these phosphorylated residues in NLRP3 in 
unstimulated cells is not yet known. Phosphorylation of NLRC4 (a NLR-family protein that 
bypasses ASC to directly activate Caspase 1) by PKCδ at S533 is required for activation of the 
NLRC4 inflammasome in response to Salmonella enterica serovar Typhimurium [21]. A second 
study has found that PKCδ was dispensable for NLRC4-mediated Caspase 1 activation in 
response to Shigella infection [22], suggesting that it may not be a universal requirement. 
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LukAB is a recently identified PFT produced by S. aureus that kills human phagocytic 
cells [23,24] by binding to CD11b [25]. LukAB is one of the most potent toxins of the six S. 
aureus PFTs in activating the NLRP3 inflammasome and killing primary human monocytes [26]. 
When S. aureus is exposed to human polymorphonuclear cells (PMNs), transcription at the 
LukAB promoter increases dramatically, far more than any other toxin promoter. LukAB can 
also be used by S. aureus to escape phagocytosis by PMNs [27].  
To determine whether kinase activity and NLRP3 phosphorylation are involved in 
NLRP3 activation in response to LukAB and possibly other S. aureus PFTs, we initiated a multi-
pronged study to characterize changes in kinases and phosphorylation in response to S. aureus 
LukAB. First, borrowing from cancer kinome research [28], we used multiplexed kinase 
inhibitor bead chromatography and mass spectrometry (MIB/MS) to quantitate changes in 
activity in the THP1 cell kinome. Using this method, activated kinases are affinity purified from 
cell lysates over a column of beads conjugated to promiscuous kinase inhibitors that specifically 
bind activated kinases. After washing several times, purified kinases are eluted, trypsin digested 
and labeled with isobaric tags for mass spectrometry quantitation. 
Guided by a carefully performed time course of LukAB-induced NLRP3 inflammasome 
activation, we compared THP1 cells at different stages of NLRP3 signaling to untreated cells in 
attempt to capture the full picture of kinase activity during NLRP3 inflammasome activation. We 
combined three experimental replicates through inverse variance weighting and found ten 
significant changes across the three time points involving a total of eight kinases. 
Second, we investigated the role of DAPK activity in LukAB-induced NLRP3 
inflammasome activation. Previous research has demonstrated a requirement for DAPK in 
NLRP3 inflammasome activation in response to monosodium urate, nigericin, alum and ATP. 
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When DAPK is overexpressed in THP1 cells, NLRP3 inflammasome activation leads to 
increased IL-1β secretion and knockdown of DAPK by siRNA leads to decreased IL-1β 
secretion [20]. Biochemical assays with recombinant NLRP3 and DAPK in our lab have shown 
that NLRP3 and DAPK interact and DAPK can phosphorylate NLRP3 on S198 and S201. In this 
second part, we used pharmacologic inhibition to show that DAPK is required for LukAB-
induced IL-1β and IL-18 secretion and cell death. 
Third, we investigated the importance of S198 and S201 phosphorylation in NLRP3 
inflammasome activation by using a novel transfection system to overexpress NLRP3 mutants in 
THP1 cells. We show that NLRP3 S201D, a phosphomimetic mutation, leads to spontaneous IL-
18 secretion whereas NLRP3 S198A and S198D did not. 
Overall, this series of studies demonstrates the utility of these novel approaches to 
studying NLRP3 inflammasome regulation and provides a strong foundation for further research 
on kinase-dependent regulation in this system. 
 
4.2 Materials and Methods 
4.2.1 Mammalian cell lines 
THP1 cells (ATCC TIB-202) were maintained in Roswell Park Memorial Institute 
medium 1640 (RPMI) medium (Cellgro) at 37°C with 5% CO2, where culture medium was 
supplemented with 10% heat-inactivated fetal bovine serum (FBS), penicillin (100 U/ml), and 
streptomycin (0.1 mg/ml). Transduced THP1 cells were maintained in 1.3 μg/ml puromycin. All 
experiments utilized cells that 2 days prior reached a density of approximately 0.8 x 106 cells/ml 
before being split 1:2 with fresh media. Prior to infections or intoxications, the desired volume of 
cells was removed, centrifuged and suspended in fresh RPMI media and equilibrated for 1 hr at 
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37°C with 5% CO2. Unless specified, experiments were carried out in either 96-well or 48-well 
flat-bottom tissue culture treated plates. All experiments were conducted within approximately 1 
month of thawing frozen cell stocks.  
 
4.2.2 Purifying LukAB from S. aureus 
A construct to co-purify recombinant LukAB from S. aureus (pOS-1-PlukAB-sslukA-6His-
lukA-lukB) was generated as previously described [29] and transformed into Newman ΔΔΔΔ 
[30] to facilitate purification. LukAB was purified from S. aureus as previously described [29]. 
Briefly, strains were grown in TSB with 10 μg/ml chloramphenicol for 5 h at 37°C, 180 rpm, to 
an optical density at 600 nm (OD600) of approximately 1.5 (which represents 1 x 10
9 CFU/ml). 
The bacteria were then pelleted, and the supernatant was collected and filtered. Nickel-
nitrilotriacetic acid (NTA) resin (Qiagen) was incubated with culture supernatant, washed, and 
eluted with 500 mM imidazole. The protein was dialyzed in 1× Tris-buffered saline (TBS) plus 
10% glycerol at 4°C overnight and then stored at −80°C. 
 
4.2.3 Evaluating cell death by propidium iodide (PI) staining 
THP1 cells, seeded at 1 x 106 cells/mL in 300 μL/well in a 48-well tissue culture plate, 
were intoxicated with LukAB in the presence of propidium iodide (2.5 μg/mL) for 60 minutes. 
Cells were fixed with a combination formaldehyde and methanol solution supplied by 
ImmunoChemistry Technologies. Fluorescence was measured by flow cytometry using an 
Accuri C6 flow cytometer (BD Biosciences). 
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4.2.4 Measuring cytokine secretion by AlphaLISA 
THP1 cells, seeded at 1 x 106 cells/mL in 300uL/well in a 48-well tissue culture plate, 
were intoxicated with LukAB. Culture supernatants were collected and analyzed by AlphaLISA 
for IL-1β, IL-18 and TNF-α according to the manufacturer’s protocol for short incubation 
(Perkin Elmer) with reduced volumes. Briefly, 1uL of each sample or standard was added to a 
separate well in a 384-well plate with 4uL of acceptor beads and cytokine antibody cocktail. 
After a 1-hour incubation at room temperature shielded from light, 5uL of streptavidin-
conjugated donor beads was added to each well for 30 minutes. Luminescence was measured on 
an EnSpire Multimode Plate Reader (Perkin Elmer). 
 
4.2.5 Measuring Caspase 1 Activation with FLICA 
THP1 cells, seeded at 1 x 106 cells/mL in 300uL/well in a 48-well tissue culture plate, 
were intoxicated with LukAB in the presence of the Caspase 1 inhibiting peptide FLICA-FMK 
bound to Alexa Fluor 660 (FLICA-1) (1:100 dilution) for 60 minutes. Cells were washed once 
with 1x PBS and resuspended in 1x PBS plus 8% fixative solution supplied by 
ImmunoChemistry Technologies. Fluorescence was measured by flow cytometry using an 
Accuri C6 flow cytometer (BD Biosciences). 
 
4.2.6 Multiplex Inhibitor Bead Chromatography 
THP1 cells were collected and concentrated to 1 x 107 cells/mL in approximately 60mL 
of media per sample. Each sample was treated with 200ng/mL LukAB for 10, 20 or 40 minutes, 
or left untreated. After experimental treatments, cells are harvested by lysing in detergent-
containing phosphorylation-preserving buffer. Total protein is quantified using a Bradford assay. 
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Roughly 10mg of protein lysates per sample are equilibrated to 1M NaCl and passed through 
columns of broad spectrum inhibitor-conjugated beads, including Bisinodylmaleimide-X, 
SB203580, Lapatinib, Dasatinib, Purvalanol B, VI16832 and PP58, to enrich for protein kinases. 
These inhibitors preferentially bind to the active conformation of kinases which allows us to 
correlated captured kinase abundance with kinase activity. Beads are then washed with high- and 
low-salt buffers and 0.1% SDS-containing solution before elution by boiling in 0.5% SDS-
containing solution. 
 
4.2.7 iTRAQ labeling 
Proteins eluted from the MIB column are then purified using chloroform/methanol 
extraction and resuspended in 50mM HEPES (pH 8) for iTRAQ labeling. Samples are trypsin 
digested overnight at 37°C with sequencing grade modified trypsin. iTRAQ labeling of digested 
peptides is carried out using iTRAQ 4-plex reagent for 2 hours at room temperature in the dark. 
Peptides are fractionated with Mini SCX Spin Columns and cleaned with PepClean C18 Spin 
Columns before separation by a Tempo LC MALDI Spotting System. 
 
4.2.8 Mass spectrometry 
MS data is acquired with a Q Exactive MS/MS and analyzed by ProteinPilot Software 
version 3.0 with a UniProtKB/Swiss-Prot database. Proteins are accepted when >= 1 unique 
peptide is identified at >= 99% confidence. Peptide quantitation by ProteinPilot is performed 
using the Pro Group Algorithm with appropriate normalization to correct for various technical 
biases including batch effect, background correction and unequal mixing of the different labeled 
samples. Standard output for the software includes the protein ratio of test to control samples, the 
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number of peptides used in computing the ratio, and the two-sided p-value, which help assess 
whether the change in protein detection is statistically significant. 
 
4.2.9 Exploratory Statistical Analysis of MIB/MS Results 
As an initial exploratory approach, we used a weighting scheme based on the inverse 
variance of calculated ratios across replicates. Statistically significant kinase identifications are 
declared when the 95% confidence interval of inverse variance weighted ratios does not cross the 
point of equivalence, 1. In order to improve robustness, significant hits were only declared if no 
replicates were weighted less than 20%. Correction for multiple hypotheses was not yet 
performed. 
 
4.2.10 DAPK inhibition experiments 
THP1 cells were cultured as described above for propidium iodide and AlphaLISA 
assays. Cells were treated with 500ng/mL LTA for 2.5 hours then the DAPK inhibitor 
(Calbiochem, CAS 315694-89-4) was added at the appropriate concentration per experiment for 
30 minutes. Then, LukAB was added at 50ng/mL for 1 hour. Cells or culture supernatants were 
collected and analyzed as described above.  
 
4.2.11 Site directed mutagenesis of NLRP3 
NLRP3 mutants were generated from the wildtype sequencing using the QuikChange 
Lightning site-directed mutagenesis kit (Agilent Technologies) according to the manufacturer’s 
protocol. Briefly, primers containing the mutated sequence were used in a PCR reaction to 
mutate and amplify the NLRP3 containing plasmid. DpnI, a restriction enzyme that requires 
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DNA methylation, was used to digest the template plasmid. Beta-mercaptoethanol was added to 
XL10-Gold Ultracompetent E. coli cells that were then transformed with 1.5uL of DpnI-treated 
DNA from the QuikChange reaction. E. coli was then plated overnight. Colonies were isolated 
the subsequent day and analyzed by restriction digest to identify positive transformants. Sanger 
sequencing was used to verify mutagenesis.  
 
 4.2.12 Cloning of NLRP3 mutants into T7 expression vector 
Primers were made to introduce new restriction digest sites at the ends of the mutated 
NLRP3 genes. PCR was performed, followed by restriction digest of the NLRP3 PCR product 
and the T7 promoter-containing vector pUNCH938. The vector was phosphatase treated with 
calf intestine phosphatase and the mutant gene was ligated with the vector. Max Efficiency DH5 
Competent Cells were transformed with the ligation reaction and plated on selecting media 
overnight. Colonies were isolated the subsequent day and analyzed by restriction digest to 
identify clones containing NLRP3. Sanger sequencing was used to verify the sequence of the T7 
promoter and NLRP3. 
 
4.2.13 In vitro transcription of capped and poly-adenylated mRNA 
The mMESSAGE mMACHINE T7 Ultra Kit (Life Technologies) was used for in vitro 
transcription of capped and poly-adenylated mRNA according to the manufacturer’s protocol.  
Briefly, NLRP3-containing plasmids were linearized at the 3’ end of the NLRP3 gene, column 
purified and quantified with UV spectroscopy. Transcription reactions were assembled at room 
temperate and incubated for 2 hours at 37°C. After transcription, reactions were spiked with 1uL 
TURBO DNase for 15 minutes at 37°C. Poly-adenylation was then carried out for 30 minutes at 
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37°C and poly-adenylated mRNA was purified using lithium chloride precipitation. mRNA was 
quantified using UV spectroscopy. 
 
4.2.14 Transfection of mRNA into THP1 cells 
Transfection of mRNA into THP1 cells was carried out using TransIT-mRNA 
Transfection Kit (Mirus). THP1 cells were resuspended in fresh media at a density of 5x10^5 
cells/mL and 500uL of cells were added to a 24-well tissue culture plate. In a separate tube, 50uL 
OptiMEM, an appropriate amount of mRNA, and 1uL of both the boost and transfection reagent 
per sample were combined. After a 3-minute incubation, 50uL was added over the top of the 
THP1 cells with effort to disperse the mixture as much as possible. Transfection of GFP mRNA 
was used as a control and to track protein expression over time. 
 
4.3 Results 
4.3.1 LukAB causes rapid NLRP3 inflammasome activation and cell death 
In order to better understand the kinetics of LukAB-mediated NLRP3 inflammasome 
activation and cell death, we performed a careful time course analysis. THP1 cells were 
incubated separately with fluorescent probes for Caspase 1 activation (FLICA-1), mitochondrial 
polarization (JC-1) and plasma membrane integrity (PI). Then 50ng/mL LukAB was added and 
separate samples were analyzed by flow cytometry at time points ranging from 3 minutes to 100 
minutes depending on the experiment. Additionally, culture supernatants were collected to 
analyze secretion of lactate dehydrogenase (LDH), a second marker of cell death. It is important 
to note that no priming agent was added to these cells. 
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LukAB intoxication caused rapid activation of Caspase 1 starting at 4 minutes that was 
maximal by 12 minutes. Mitochondrial polarization was equivalent to untreated cells at 11 
minutes, but dropped precipitously at 17 minutes and beyond, indicating disruption of 
mitochondrial integrity. Both markers of cell death increased following roughly 30 minutes of 
LukAB treatment, though the increasing PI signal was detectable before measurable levels of 
LDH activity were present in the culture supernatant (Figure 4.1). 
While mitochondrial depolarization has been implicated in NLRP3 inflammasome 
activation in response to other triggers [31], it has not previously been assayed in response to 
LukAB or other S. aureus PFTs. In order to determine the relationship of mitochondrial 
depolarization to NLRP3 inflammasome activation, we measured mitochondrial polarization 
after treating cells with LukAB while using potassium inhibition and shRNA knockdown of 
NLRP3 and ASC to block upstream and downstream processes. We used CCCP as a control that 
should depolarize the mitochondria regardless of the activation of the NLRP3 inflammasome. 
Addition of 25mM KCl, but not 25mM NaCl, blocked LukAB-induced Caspase 1 activation and 
cell death, but had no effect on mitochondrial depolarization. Knockdown of NLRP3 or ASC 
with shRNA also blocked Caspase 1 activation and cell death, but had no effect on mitochondrial 
depolarization (Figure 4.2) 
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Figure 4.1 LukAB intoxication leads to rapid NLRP3 inflammasome activation, 
mitochondrial depolarization and cell death. THP1 cells were incubated separately with 
fluorescent probes for Caspase 1 activation (FLICA-1), mitochondrial polarization (JC-1) and 
cell death (PI).  Cells were then treated with 50ng/mL LukAB and analyzed at various time 
points.  Collected data was transformed to a 0 to 100 scale in order to compare points of maximal 
signal across assays.  The lower right graph is a composite of the other three. 
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Figure 4.2 Mitochondrial depolarization is not blocked by extracellular potassium or 
shRNA-mediated depletion of NLRP3 or ASC. (A) THP1 cells were incubated in regular 
RPMI, or RPMI supplemented with 25mM NaCl or 25mM KCl for 30 minutes.  Fluorescent 
probes to assess Caspase 1 activation (top), cell membrane permeabilization (middle) and 
mitochondrial polarization (bottom) were then added followed by 50ng/mL LukAB for 1 hour.  
Cells were analyzed by flow cytometry.  (B)  THP1 cells containing shRNA constructs targeted 
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at ASC, NLRP3 or a scrambled control, were incubated with fluorescent probes as in (A) then 
treated with 50ng/mL LukAB for 1 hour. CCCP was added as a positive control to depolarize 
mitochondria 15 minutes before analyzing cells.  Cells were analyzed by flow cytometry 
 
4.3.2 MIB/MS identifies 344 kinases expressed in THP1 cells  
 Given that LukAB treatment of THP1 cells causes Caspase 1 activation in approximately 
10 minutes, and cell death at approximately 30 minutes, we decided to assay the THP1 kinome at 
10, 20 and 40 minutes. These time points should correspond to kinases involved in activating the 
NLRP3 inflammasome at 10 minutes, kinases immediately changed in response to NLRP3 
inflammasome activation at 20 minutes and kinases involved in triggering cell death at 40 
minutes. Borrowing from well-established protocols in cancer kinome research [28], we 
compared the kinome of LukAB-treated THP1 cells at these three time points to untreated cells 
by using MIB/MS. 
 In total, between three biological replicates, 344 individual kinases were identified by 
mass spectrometry through identification of at least one unique peptide with >99% confidence in 
all four samples in a replicate. Of these kinases, 180 were identified in all three replicates, 50 
were identified in two replicates, and 114 were identified in only one replicate. Kinases from all 
eleven families [32] were identified. Of the 16 previously mentioned kinases implicated in 
NLRP3 inflammasome regulation, 14 were identified in our survey. 
 
4.3.3 Eight kinases are modulated in response to LukAB intoxication 
 For each kinase identified by MIB/MS, a fold change ratio was calculated based on the 
unique peptides and mass spectrometry probe identified for that kinase and sample. To combine 
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replicates and prioritize candidate kinases based on their likelihood of truly being modulated in 
response to LukAB, the inverse variance weighted mean ratio and a new 95% confidence 
interval were calculated for each kinase. Inverse variance weighting has a propensity to allow 
one replicate with a small sample size and variance to sway the data. To counter this, we 
calculated the variance of the weights themselves for each replicate and used 0.1 as a cutoff that 
appeared to represent well balanced weighting between replicates. 
A total of eight kinases had a 95% confidence interval that did not overlap one, indicating 
that they had changed relative to untreated cells, and met our robustness criteria of relatively 
balanced weights. These kinases included AURKA, CAM2KB, CAM2KD, CSF1R, IRAK1, 
NEK2, ROCK2 and STK17B. Figure 4.3 depicts the fold change ratio at each time point for 
these eight kinases. The data points colored in red are both significant and robust.  
No kinase was changed at the earliest time point, though AURKA and STK17B trended 
close. Also, no significant increases in kinase activity were captured. Only CAM2KD and 
CSF1R were changed at more than one time-point; 20 minutes and 40 minutes. Notably, IRAK1 
has previously been implicated in NLRP3 inflammasome regulation in response to LPS priming.  
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Figure 4.3 Kinome analysis by MIB/MS identifies 344 kinases, 8 of which are significantly 
changed at 10 separate time points. (A) A Venn diagram of the number of kinases identified in 
each biological replicate.  The replicates and the total number of kinases identified are listed 
outside the diagram. (B) A graph depicting the fold change from baseline and 95% confidence 
interval for each of the eight significant kinases at all three time points.  Those colored in red 
meet both significance and robustness criteria. 
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4.3.4 Inhibiting DAPK suppresses LukAB cytotoxicity and IL-1β and IL-18 secretion 
 Building on other data from our lab that showed recombinant DAPK can bind and 
phosphorylate recombinant NLRP3 in vitro (data not shown), we undertook to analyze the 
functional role of DAPK in LukAB-induced NLRP3 inflammasome signaling. Using a 
commercially available DAPK inhibitor, we found that blocking DAPK reduces LukAB-induced 
IL-1β and IL-18 secretion and also blocks cell death (Figure 4.4). 
 
 
Figure 4.4 DAPK inhibition blocks LukAB-mediated IL-1β and IL-18 secretion and cell 
death in THP1 cells. THP1 cells were primed with 500ng/mL lipoteichoic acid for 2.5 hours as 
indicated.  Then DAPK inhibitor was added for 30 minutes at the indicated concentration (μM).  
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Finally, 50ng/mL LukAB was added for 1 hour.  (A) IL-1β and (B) IL-18 secretion were 
analyzed by AlphaLISA and (C) propidium iodide staining was analyzed by flow cytometry. 
 
4.3.5 mRNA transfection of NLRP3 S198D/S201D into THP1 cells causes spontaneous IL-
18 secretion not seen in S198D single mutant 
 In order to determine if phosphorylation at S198 and S201, the sites identified in the in 
vitro recombinant DAPK-NLRP3 phosphorylation assay (data not shown), were necessary or 
sufficient for NLRP3 inflammasome activation, we constructed a series of mutants to both block 
and mimic phosphorylation. Having seen that DAPK inhibition blocks NLRP3 activation, we 
reasoned that if phosphorylation by DAPK was required for NLRP3 inflammasome activity then 
a phosphomimetic mutation, serine to aspartic acid, might be constitutively active when 
overexpressed in THP1 cells leading to Caspase 1 activation and cytokine secretion.  
 Expression of exogenous genes in THP1 cells is challenging because the cells readily 
initiate a cell death process when transfected. Viral transduction has been successful but is slow 
and labor intensive. In order to rapidly test functional consequences of phosphorylation site 
mutations, we utilized in vitro transcription to produce capped and poly-adenylated mRNA 
followed by transfection using the TransIT-mRNA Transfection Kit. We used GFP mRNA in 
initial trials of mRNA transfections in THP1 cells to be able to rapidly determine the transfection 
efficacy. 
 Transfection of GFP mRNA was well tolerated with almost no cell death observed 
(Figure 4.5A). Transfection of GFP mRNA resulted in detectable GFP fluorescence as early as 1-
hour post transfection with approximately 20% of cells being GFP positive by flow cytometry. 
The fraction of GFP positive cells increased across 14 hours reaching a high of approximately 
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85% (Figure 4.5B-C). Beyond 14 hours, the fraction of GFP positive cells remained stable but 
the mean fluorescence intensity (MFI) continued to increase through approximately 48 hours 
post transfection (data not shown). Cells exposed only to the transfection reagents with no GFP 
mRNA failed to produce fluorescence by flow cytometry and microscopy (Figure 4.5D) 
 Upon testing transfection of in vitro transcribed NLRP3, we observed significant toxicity 
within the first 12 hours with the number of viable cells decreasing from 85% to 50%. This 
change was not concomitant with secretion of IL-18 and thus was not thought to be the result of 
NLRP3 inflammasome activation. However, transfection of the NLRP3 double mutant 
S198D/S201D, but not NLRP3 single mutant S198D or S198A led to a substantial increase in 
IL-18 secretion and an enhancement of cell death, consistent with S198D/S201D leading to 
spontaneous NLRP3 activation (Figure 4.6A-B). 
  
 258 
 
 
Figure 4.5 GFP mRNA transfection efficiency is high and well tolerated in THP1 cells. 
THP1 cells were transfected with GFP mRNA using the TransIT-mRNA kit and were monitored 
by flow cytometry for 14 hours.  (A) The fraction of viable cells, as determined by forward and 
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side scatter, is depicted.  (B) The GFP mean fluorescence intensity of viable cells is depicted.  
(C) The fraction of GFP positive cells is depicted.  Note, no change was observed with 
transfection reagent alone and as such this line overlaps with untreated cells.  (D) Transfected 
cells were imaged by fluorescence microscopy at 14 hours post transfection. 
 
 
Figure 4.6 Phosphomimetic mutation of NLRP3 S198 and S201 leads to spontaneous 
NLRP3 inflammasome activity. THP1 cells were transfected with a control mRNA (elongation 
factor a from Xenopus), wildtype sequence NLRP3 or NLRP3 containing the indicated amino 
acid changes.  (A) Cell viability was determined at 13 hours post transfection by flow cytometry.  
(B) Culture supernatants were collected and analyzed by AlphaLISA for IL-18 secretion. 
 
4.4 Discussion 
 S. aureus PFTs all activate the NLRP3 inflammasome and LukAB is one of the most 
potent in killing human cells. Little is known, thus far, about how LukAB activates the NLRP3 
inflammasome except that it requires potassium efflux [26]. In this study, we utilized a variety of 
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complementary strategies to characterize changes in the THP1 cell kinome in response to LukAB 
treatment.  
Initially, we performed a careful time course analysis of NLRP3 inflammasome 
activation, mitochondrial depolarization and cell death. We observed extremely rapid activation 
of Caspase 1, the most proximal step resulting from NLRP3 inflammasome activation, by about 
10 minutes after LukAB exposure. This rapid pace was not dependent on the cells being primed. 
We observed mitochondrial depolarization following NLRP3 inflammasome activation. At 
around 30 minutes, both PI and LDH indicated cells were undergoing necrosis. Both PI and LDH 
transit though holes in the plasma membrane and PI is considerably smaller than LDH, so the 
observation that cells became PI positive slightly before leaking LDH was not surprising. 
While mitochondrial depolarization has been implicated in NLRP3 inflammasome 
signaling from other inciting agents [31], it has not previously been connected to PFT-mediated 
NLRP3 inflammasome signaling. We found that LukAB treatment consistently led to loss of 
mitochondrial polarization. However, LukAB-induced mitochondrial depolarization was not 
inhibited by extracellular potassium or by shRNA-mediated knockdown of NLRP3 or ASC. 
These data suggest that mitochondrial depolarization resulting from LukAB intoxication is either 
initiated upstream of potassium efflux or is a consequence of LukAB intoxication that is 
independent of NLRP3 inflammasome signaling. Although potassium efflux is thought to be a 
direct result of LukAB inserting into the cell membrane, LukAB may also activate secondary 
signaling events unrelated to the permeabilization of host cell membranes. One study has shown 
that LukA or LukB on their own can initiate NF-κB signaling leading to IL-8 production [33]. 
However, in the active kinome analysis, we observed a decrease in activity in members of the 
NF-κB signaling pathway including IRAK1. 
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Our kinome analysis represents the first application of this high throughput screening 
technology to the study of kinases in immune cells. Using a proteomics-based approach, we 
identified 344 unique kinases as being expressed in THP1 cells. While this may not be the full 
complement of kinases in THP1 cells, it is the largest catalog of kinase expression evidence to 
date. Each kinase was identified by at least one peptide that was found across four samples: the 
untreated, and 10, 20 and 40 minute LukAB treatment samples. As a result, we are extremely 
confident in declaring these kinases as expressed in THP1 cells. 
We are also surprised to find many kinases missing from our analysis, most notably, 
DAPK and MLKL. These two kinases have been implicated in inflammasome activation under 
different inciting conditions. However, one limitation of this approach, as with all mass 
spectrometry approaches, is that low abundance kinases can easily be missed. Additionally, 
because peptides had to be identified across all four samples for the peptide to be included, it is 
possible that major changes in kinase activity would be missed because of extremely low activity 
in one sample that fails to register. 
Surprisingly, in the kinome analysis, we observed a decrease in kinase activity far more 
frequently than an increase. The kinases that are decreased in activity may represent basal state 
inhibitors of the NLRP3 inflammasome signaling pathway. A large number of the modulated 
kinases are annotated as being involved in cell cycle regulation and cell division processes. This 
may be a bias in that cell cycle regulation research was one of the earliest areas to focus in on 
kinase signaling, but may also be a true indicator of NLRP3 inflammasome related processes. 
One recent report found that NEK7, a cell cycle regulating kinase, restricted NLRP3 
inflammasome activation to interphase of the cell cycle. NEK7 bound directly to NLRP3 in a 
kinase-independent manner to promote inflammasome formation. Loss of NEK7 decreased IL-
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1β secretion in response to canonical (nigericin, ATP, alum) and non-canonical NLRP3 stimuli 
(E. coli and C. rodentium) [11]. 
It is also possible that changes in kinase activity relate to other signaling events unrelated 
to the NLRP3 inflammasome. For example, a kinase could be involved in mitochondrial 
depolarization in response to LukAB, a phenotype that was not blocked by extracellular 
potassium or knockdown of the NLRP3 inflammasome. Further research will be needed to 
determine the roll of these kinases. 
In the second part of our study, we demonstrated that DAPK is critical for LukAB-
induced NLRP3 inflammasome activation. Also, using mRNA transfections to overexpress 
phosphomimetic mutants, we identified S201 as an important phosphorylation site on NLRP3. 
The S198D mutant did not stimulate IL-18 secretion alone, but the S198D/S201D mutant led to 
robust IL-18 secretion. It is possible that phosphorylation at both S198 and S201 is required for 
activation, rather than just phosphorylation at S201. Future experiments will have to address the 
S201D single mutant. Based on biochemical evidence not shown, recombinant DAPK appears to 
phosphorylate NLRP3 at S198 and S201, but further research is needed to determine if DAPK is 
responsible for the required activity at these sites in cells.  
Transfection of GFP mRNA into THP1 cells was extremely well tolerated.  However, 
transfection of similar amounts of NLRP3 mRNA led to cell death over the same time period. 
We currently believe that this is the result of NLRP3 activating a signaling pathway besides the 
inflammasome that leads to cell death without cytokine secretion. NLRP3 has been observed to 
trigger ASC- and Caspase-8-dependent apoptosis [34], but further investigation is required to 
determine if that is the cause of death in this setting. 
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Stepping back, the application of mRNA transfections to the study of protein signaling in 
THP1 cells is a significant advancement. Viral transduction, a slow and labor-intensive process, 
has been relied on in the past for overexpressing proteins in THP1 cells. Often times, this is so 
challenging that researches have opted to use standard plasmid transfections to reconstitute the 
NLRP3 inflammasome in non-immune cells. One major shortcoming of this approach is that 
regulators of the NLRP3 inflammasome that are present in immune cells may not be present in 
epithelial cells. As such, experiments in the reconstituted system may be misleading about the 
role for endogenous regulators.  
With mRNA transfections, multiple proteins can be cloned, mutated and transfected into 
THP1 cells at a time. Titration of expression can occur through changing the dose of mRNA or 
changing the time at which subsequent evaluation is performed. The drawback of expressing 
mutant proteins over a background of wildtype proteins can be overcome with advanced 
planning to combine siRNA and mRNA transfections in which mutations have been introduced 
to evade siRNA-mediated destruction. Because siRNA-mediated depletion of proteins can take a 
few days and mRNA transfections lead to rapid protein production, we recommend transfecting 
siRNA well in advanced of transfecting mRNA. Ultimately, this technique has the potential to 
open a goldmine of new explorations in THP1 cells that have previously been impossible. For 
example, rapid alanine mutational scanning can now be used to identify critical residues in 
protein-protein interactions or protein signaling networks. 
Overall, the data and techniques emerging from these early studies hold great promise in 
advancing our knowledge of LukAB intoxication and NLRP3 inflammasome signaling. 
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Chapter 5. Concluding thoughts and future directions 
 
 In recent years, our understanding of how Staphylococcus aureus interacts with the innate 
immune system has grown tremendously. Identification of novel PFTs and their receptors on the 
host cell membrane, characterization of their species specificity, and the discovery that the 
NLRP3 inflammasome is central in responding to all PFTs is an important starting foundation for 
understanding the contribution of the PFTs to disease pathogenesis. As the threat of drug 
resistant S. aureus continues to grow, novel strategies will be required for combating infections. 
Targeting S. aureus pore forming toxins may be one such strategy. 
 In the review contained in Chapter 2, I outlined the current scientific research pertaining 
to S. aureus and inflammasome interactions. Thus far, most studies have focused on the 
significance of Hla to disease pathogenesis. With the discovery of LukAB and its demonstrated 
potency in killing human cells, and its failure to kill mouse cells, it is now clear that new animal 
models are required to better capture the full effect of S. aureus PFTs in infection pathogenesis.  
Introducing or replacing mouse PFT receptor genes with human sequences might help 
overcome this resistance, but the large number of toxins and receptor genes makes replacing all 
of them together more difficult. Additionally, the result of chimeric receptor expression on 
immune signaling more generally would be entirely unpredictable. For example, would replacing 
mouse CD11b with human CD11b affect its association with mouse CD18? Or would inclusion 
of both mouse and human CD11b sequences cause competition for CD11b-associated molecules 
that reduces signaling potential? Efforts are currently underway to develop these mice so the 
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opportunity to study LukAB in vivo, and the consequences of humanizing receptors in 
mice, will soon exist. 
An alternative approach would be to develop humanized mouse models through bone 
marrow reconstitution. However, at best, this labor intensive process creates chimeric myeloid 
compartments with variable distribution of human cells to tissues such as the lung. There is also 
evidence that S. aureus virulence factors act on epithelial and endothelial cells which cannot be 
humanized. Mice are generally resistant to S. aureus and even humanized mice require direct 
inoculation with approximately 1 million S. aureus colony forming units to establish infection.  
 Although mice provide the best opportunity for genetic studies, a natural host may be 
more suitable for studies of S. aureus virulence. One such natural host is the domesticated 
chicken, Gallus gallus domesticus. S. aureus naturally causes a wide range of infections in 
chickens that mimic its infectivity in humans; this includes localized abscesses, synovitis, 
osteomyelitis, endocarditis and bacteremia. While most university animal facilities are not 
equipped for housing chickens, S. aureus can also infect the yolk sac, causing omphalitis. As 
such, S. aureus inoculation of chicken eggs may be a viable strategy for investigating S. aureus 
virulence in a natural host. However, many differences between chicken and human immune 
systems exist that would also raise questions about the generalizability and translatability of such 
a model. 
 Without new models that incorporate sensitivity to a wider range of S. aureus virulence 
factors, novel treatments may be misguided and ineffective. 
 In Chapter 3, I highlighted my work on investigating the mechanism of LukAB in killing 
human monocytes. This work demonstrated the significance of LukAB, as compared to the other 
S. aureus PFTs, in activating the NLRP3 inflammasome and killing human monocytes. We were 
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also surprised to find that when S. aureus was phagocytosed, LukAB-mediated bacterial escape 
did not require the NLRP3 inflammasome, even though the NLRP3 inflammasome was being 
activated. Loss of ASC did not diminish LukAB-induced cell death from within the phagosome, 
suggesting that this mode of cell death is not caused by an ASC-containing inflammasome. 
Future research will investigate the role of RIPK1/RIPK3 and Caspase 8 in this cell death 
process. 
 In Chapter 4, I discussed initial experiments characterizing important kinase and 
phosphorylation changes in the response to LukAB. In our data from the MIB/MS analysis, we 
were surprised to see no significant increases in kinase activity despite identifying approximately 
180 kinases in all three replicates. It is possible that kinases that had very low activity in the 
basal state, but were upregulated in response to LukAB, were missed because of their low 
capture rate on the MIB/MS column in the untreated sample. We will have to go further analyze 
the raw mass spectrometry data to see if there are high abundance peptides associated with 
kinases that appear in LukAB-treated samples that were completely absent in untreated cells. We 
will also follow up on the eight kinases that decrease in activity in response to LukAB. By 
depleting each kinase with siRNA, we will test for increased sensitivity or spontaneous activity 
of the NLRP3 inflammasome. I suspect that these kinases, particularly those in the earlier time 
points, are involved in maintaining the off state of the NLRP3 inflammasome. 
 The development I am most excited for is the application of mRNA transfections to 
structure-function analyses in THP1 cells. My demonstration of high efficacy transfection with 
mRNA will allow researchers an opportunity to do broad-scale mutagenesis studies to identify 
critical residues in the proteins in innate immune cells, rather than having to create reconstituted 
systems in epithelial cells. The early product of this new strategy demonstrated that the 
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S198D/S201D NLRP3 mutant has spontaneous inflammasome activity. This is the first direct 
demonstration of a phosphomimetic mutation in NLRP3 with functional consequences. 
Continued research can target all phosphorylation sites to better understand the consequences of 
kinases and phosphorylation in the regulation of the NLRP3 inflammasome. 
 Lastly, having spent considerable time with the literature in the NLRP3 inflammasome 
field, I believe a collaborative effort is needed to systematically address holes and 
generalizability of existing research. Dozens of different activators are used to study NLRP3 
inflammasome activity leading to disparate findings. Cell type differences, species differences, 
unique activators and genetic versus pharmacologic interventions have resulted in a body of 
research that is hard to follow. A systematic and searchable cataloging of what experiments were 
done including the cells, activator, reagents, and results would help provide clarity. Additionally, 
the readouts of NLRP3 inflammasome activation, namely IL-1β and IL-18 secretion and cell 
death, are easily adapted to high throughput analysis. A research core set up to systematically 
compare inhibitors across different activators could also produce a wealth of data to help resolve 
conflicting findings.   
Overall, the data described in this dissertation and the future research questions they 
highlight should continue to sustain a fruitful research program in the area of S. aureus host-
pathogen interactions and NLRP3 inflammasome regulation. 
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Appendix A. Functional amyloid signaling via the inflammasome, necrosome and 
signalosome: new therapeutic targets in heart failure4 
 
A.1 Abstract 
As the most common cause of death and disability globally, heart disease remains an 
incompletely understood enigma. A growing number of cardiac diseases are being characterized 
by the presence of misfolded proteins underlying their pathophysiology, including cardiac 
amyloidosis and dilated cardiomyopathy (DCM). At least nine precursor proteins have been 
implicated in the development of cardiac amyloidosis, most commonly caused by multiple 
myeloma (MM) light chain disease and disease-causing mutant or wildtype transthyretin (TTR). 
Similarly aggregates with PSEN1 and COFILIN-2 have been identified in up to 1/3 of idiopathic 
DCM cases studied indicating the potential predominance of misfolded proteins in heart failure. 
In this review, we present recent evidence linking misfolded proteins mechanistically with heart 
failure and present multiple lines of new therapeutic approaches that target the prevention of 
misfolded proteins in cardiac TTR amyloid disease. These include multiple small molecule 
pharmacological chaperones now in clinical trials designed specifically to support TTR folding 
by rational design, such as tafamidis, and chaperones previously developed for other purposes, 
such as doxycycline and tauroursodeoxycholic acid. Lastly, we present newly discovered non-
                                                          
4 This article previously appeared as an article in the journal Frontiers in Cardiovascular Medicine. The original 
citation is as follows: Parry TL, Melehani JH, Ranek MJ, and Willis MS (2015) Functional amyloid signaling via the 
inflammasome, necrosome, and signalosome: new therapeutic targets in heart failure. Front. Cardiovasc. Med. 
2:25. doi: 10.3389/fcvm.2015.00025 
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pathological “functional” amyloid structures, such as the inflammasome and necrosome 
signaling complexes, which can be activated directly by amyloid. These may represent future 
targets to successfully attenuate amyloid-induced proteotoxicity in heart failure as the 
inflammasome, for example, is being therapeutically inhibited experimentally in autoimmune 
disease. Together, these studies demonstrate multiple novel points in which new therapies may 
be used to primarily prevent misfolded proteins or to inhibit their downstream amyloid-mediated 
effectors, such as the inflammasome, to prevent proteotoxicity in heart failure.  
 
A.2 Introduction 
As the most common cause of death and disability globally, heart disease remains an 
incompletely understood enigma. Despite vast improvements in our understanding of the 
neurohormonal basis of heart failure, current therapies targeting this system have reached a 
plateau for which new therapeutic paradigms might be considered. A great deal of insight has 
recently been achieved by our understanding of the role of protein homeostasis in the heart. The 
role of misfolded proteins, once reserved as the pivotal pathophysiological mechanism in 
neurodegenerative diseases, such as Alzheimer’s disease, Huntington’s disease, and Parkinson’s 
disease, has now been demonstrated to be present in many types of heart failure. 
 
A.3 Misfolded proteins in cardiac disease 
A growing number of cardiac diseases are characterized by misfolded proteins underlying 
their pathophysiology, including cardiac amyloidosis and dilated cardiomyopathy. Cardiac 
amyloidosis represents a broad disease entity characterized by misfolded proteins forming 
insoluble aggregates that are deposited in the heart. While the physical morphology is shared by 
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all amyloid fibrils, the spectrum of affected organs and clinical presentation and prognosis varies 
greatly. The prognosis is often dependent upon the makeup of the amyloid precursor protein and 
its associated pathophysiology throughout the body. At least nine precursor proteins have been 
implicated in the development of cardiac amyloidosis [1]. The most common cause of cardiac 
amyloidosis is multiple myeloma (MM), specifically MM-secreted monoclonal Ig light chain 
disease [1], followed by disease-causing mutant or wildtype transthyretin (TTR) protein [2]. 
Functionally, infiltrative amyloid deposition causes a restrictive cardiomyopathy (diastolic 
dysfunction) and subsequent systolic heart failure. 
The pathophysiology of AL (Ig light chain) cardiomyopathy was hypothesized to be due 
to the extracellular deposition of fibrils, resulting in increased passive stiffness and loss of 
cardiac parenchyma due to cell death [1]. The physiological impairment in diastolic filling in 
amyloid cardiomyopathy patients supported this idea [3,4]. However, evidence for precursor 
toxicity has gained traction with recent correlations of AL cardiomyopathy with ATTR 
cardiomyopathy function with similar degrees of fibril deposition [5]. Surprisingly, patients with 
equal fibril deposition due to AL cardiomyopathy are functionally was worse than ATTR 
patients indicating that the infiltration itself is not completely responsible for the dysfunction [5]. 
Soluble factors found circulating in AL patients may be an additional contributor to the cardiac 
dysfunction. This has been shown in studies where experimental infusion of amyloidogenic light 
chain proteins from patients with severe cardiac involvement into healthy hearts. The infusion of 
amyloidogenic light chain proteins induced diastolic dysfunction in healthy unaffected isolated 
mouse hearts, while infusion of light chains from patients with myeloma and no amyloidosis do 
not [6-9]. The cardiac dysfunction in amyloid cardiomyopathy therefore appears to be related to 
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mechanisms induced by both infiltrative insoluble factors in the heart itself and circulating 
soluble factors from the systemic multiple myeloma. 
Recognition of protein aggregation as a cause of heart failure is likely underestimated. 
Two recent studies illustrate the prevalence of protein aggregation as a cause of heart failure in 
patients that had heart failure clinically characterized by dilated cardiomyopathy. Two new 
sequence variants in the presenilin-1 (PSEN1) gene promoter were identified in nearly 1% 
(3/325) of patients of the idiopathic dilated cardiomyopathy patients investigated [10]. 
Interestingly, PSEN1 mutant patients have cardiac protein aggregates present, along with 
reduced psen1 gene and PSEN1 protein expression [10]. Mechanistically, PSEN1 co-
immunoprecipitates with SERCA2a illustrating one point in which PSEN1 may be affecting 
cardiac function [10]. With the PSEN1 oligomer interacting directly with the Ca2+ channel, it’s 
possible that changes in Ca2+ and heart failure seen in these patients may be mechanistically 
linked by this interaction [10]. Similarly, tangles and plaque-like aggregates made of COFILIN-2 
have been found in other dilated cardiomyopathy cases, estimated to involve nearly 1/3 of the 
cases [11]. Initial studies investigated the aggregate composition of aggregates extracted from 
human idiopathic DCM with Congo red positivity has been found to include COFILIN-2 in a 
high percentage of patients, which was confirmed in a larger cohort of samples (Subramanian, 
2015). Aggregates had COFILIN-2 present, an actin depolymerizing protein known to participate 
in neurodegenerative diseases [12,13]. Understanding COFILIN-2’s role in chronic degenerative 
diseases such as DCM offers a novel therapeutic target [11]. 
Mutations in heat shock proteins (HSPs), a critical component of the cellular “anti-
folding” apparatus, also underlie human cardiac disease. HSP proteins assist protein folding in 
routine maintenance of the cardiomyocyte. However in the context of disease, their recruitment 
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to protein misfolding is critical with acquired conditions such as ischemia/reperfusion injury, or 
because of mutations which can modify protein structures [14]. In Long QT Syndrome 2, 
mutations in KCNH2 (aka human ether-a-go-go related gene/HERG) encoding the rapidly 
activating-delayed rectifier potassium channel Kv11.1 alpha-subunit alter cell repolarization of 
the ventricular action potential [15]. Characterized by prolonged QT interval and ventricular 
tachycardia, syncope, and sudden death, the largest number of HERG mutations (28/34) affect 
protein folding and trafficking [16]. Similarly, the desmin contractile apparatus linking nucleus, 
mitochondria, and sarcolemma is critical to cardiomyocyte function. Desmin deficiency or 
mutations in the chaperone proteins assisting desmin folding (e.g. HSPA/HSP70, HSPH 
(HSP110), DNAJ (HSP40), HSPB (small HSPs), SHPD, HSPE, CCT result in proteotoxicity 
mediated via aggregate formation [14].  
 
A.4 Protein folding, preamyloid oligomers, and aggregation 
In biological systems, multiple physical factors influence protein folding [17], including 
mutations, molecular chaperones, and protein quality control systems (such as the ubiquitin 
proteasome system) that prevent the formation of misfit conformations resulting from 
destabilized protein folding and/or aggregate formation [18,19]. Protein misfolding is driven by 
alterations in the protein sequence (i.e. mutations), malignant post-translational modifications, 
and oxidative stress among other environmental cues (Figure A.1A). These alterations initiate 
pathology through: 1) formation of a destabilized protein; 2) accumulation of intermediates with 
unstable folding, and 3) stabilization of misfolded conformations through the formation of 
aggregates (Figure A.1B-D). While native conformation stability is characterized as having 
achieved the lowest free energy state, this feature may also explain the stability of 
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aggregate/fibril formation in diseases, including heart failure in amyloidosis and non-
amyloidosis-related states.  
 
Figure A.1 Native, non-native, aggregates, and amyloid protein structures and the stressors 
that drive them. (A) Proteins are prone misfolding by direct biological and indirect 
environmental stresses, including alterations in the protein sequence (mutations) and post-
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translational modifications (e.g. those induced by oxidative stress), respectively, creating protein 
aggregates and amyloid. These toxic structures are dangerous to biological systems, driving 
amyloidosis in neurodegenerative and cardiac pathologies. (B) Unfolded protein reside at a high 
entropy state in an unstable “non-native” structure. As they become folded, they move towards a 
lower entropy and move towards stable and favorable “native” structure. (C) Biological and 
environmental stressors initiate alterations in protein sequence (i.e., mutations), forcing 
intermediates into unstable conformations. (D) Destabilized proteins accumulate resulting into 
misfolded protein aggregates and amyloid with more stable conformations. B-D: ©Bentham 
Science. Used with permission. Gomes, 2012 [21]. 
Protein folding is a process through which polypeptide chains wrap themselves to achieve 
optimal stability in their physiological environment (Figure A.1B) [20]. This process results from 
the lower energy “native-like” interactions that are more stable than “non-native-like” 
conformations (Figure A.1C) [21]. As favorable interactions are established, proteins transition 
from a high entropy state to one with a lower entropy structure. Proteins therefore have a range 
of free energies they can move through, inevitably proceeding through a set of conformations 
that narrow as the native state is achieved [22-24]. Typically for small globular proteins, this 
transition has been likened to that of a funnel, where inter- and intra-domain interactions 
cooperatively interact to establish a stable native confirmation [25]. Adverse conditions or 
mutations result in a degeneration of the energetic minimum, resulting in the lowering of barriers 
between native-like conformations (Figure A.1D). The resulting larger distribution results in 
higher energy amyloidogenic conformers in destabilized folding patterns, susceptible to 
degradation or consequent local unfolding that triggers aggregation. These conformers can then 
 278 
 
contribute to the assembly into amorphous organized aggregates into fibrils results from 
interactions between stabilized aggregates (Figure A.1D).  
 
A.5 Protein aggregates, proteotoxicity, and heart failure 
Protein aggregates and their preceding intermediates induced cell death is a process 
described as proteotoxicity (Figure A.2). These designations refer to a protein’s state, not its 
origin as many different types of proteins can form these misfolded proteins. However, most 
familiar examples of aggregates tend to be recognized for their specific sources, such as β-
amyloid (AB) and α-synuclein found in Alzheimer’s and Parkinson’s disease, respectively. 
Misfolded protein aggregation leading to heart failure has been found to be caused by misfolded 
transthyretin and excessive immunoglobulin resulting from aging or mutations and multiple 
myeloma, respectively. Soluble oligomers and aggregated proteins disrupt cellular function by 
interfering with proteasome function, disrupting cell signaling and protein trafficking, and 
directly support signals that induce cell death [26,27]. The accumulation of misfolded protein 
oligomers have been identified in patients with hypertrophic cardiomyopathy, idiopathic dilated 
cardiomyopathy, and Becker’s muscular dystrophy, but not in healthy controls [28]. In dilated 
cardiomyopathy, cytosolic aggregates co-localize with ubiquitin and increased autophagy has 
been identified [29]. Autophagy, a mechanism for removing aggregated proteins, may be one 
way in which the heart clears the pathological buildup of misfolded proteins. 
The link between misfolded proteins, proteotoxicity and heart failure has just recently 
been made. Early correlations between misfolded proteins and heart disease were made in mouse 
models of cardiac hypertrophy, where aggregation of misfolded proteins and aggresomes were 
identified [30]. Further, inhibiting proteasome activity resulted in the accumulation of 
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ubiquitinated protein aggregates and enhanced autophagy [30]. However, it was not until the 
toxic effects of misfolded proteins in the heart were tested directly that the causal link of 
misfolded proteins to proteotoxicity and heart failure was made. In these studies, mouse hearts 
expressing small oligomers prone to misfolding (Poly-Q83) were compared to hearts expressing 
a similar but non-oligomer forming peptide repeat (Poly-Q19) [31]. Mice with cardiac PQ83 
developed heart failure by 5 months of age, whereas the non-aggregating control PQ19’s heart 
function was completely normal [31]. These studies develop a new paradigm by which to 
consider how protein aggregation may contribute to heart failure and ischemic heart disease 
[32,33], as well as genetic diseases associated with protein misfolding and cardiac dysfunction. 
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Figure A.2. Protein aggregate and amyloid stimulate cellular dysfunction. Misfolded protein 
aggregates and amyloid inhibit normal proteasome function, interfere with cellular signaling and 
trafficking, and induced apoptotic cell signaling pathways. All of these perturbations have been 
shown to occur in pathologies, such as hypertrophic cardiomyopathy, idiopathic dilated 
cardiomyopathy, and Becker’s muscular dystrophy.  
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A.6 How endogenous systems prevent protein misfolding 
Cells have adapted mechanisms to counteract the propensity of a protein to misfold, 
particularly in the face of common cellular challenges, such as oxidative stress, and the routine 
post-translational modifications that can accumulate on proteins. The ubiquitous heat shock 
proteins (HSPs) act as molecular chaperones to counteract the stress-induced denaturation of 
other proteins. In the heart, the cardio-protective effect of HSP90, HSP70, TRiC as well as a host 
of small HSPs (αBCrystallin (aka HSPB5), HSP20 (aka HSPB6), HSP22 (aka HSPB8, H11 
kinase, and αCCrystallin), HSP27 (aka HSPB1 and HSPB2), and HSP60) has been described in 
the context of cardiac hypertrophy, heart failure, and ischemia reperfusion disease [34]. Their 
ability to protect the misfolding of specific targets, such as actin, tubulin, desmin, lipid 
membranes, and mediators of cell death (e.g. Bax/Bak) have been implicated to date, though a 
thorough description of their role is just beginning to be elucidated [34].  
Not only do chaperones play a role in maintaining proper protein folding, they have 
overlapping functions that might be useful when thinking about new therapeutic interventions in 
targeting protein misfolding. HSPs have overlapping functions-the integrity of a single protein 
can be maintained by >1 HSP in most cases. Recent studies have provided a proof of concept of 
how this knowledge may be applied therapeutically. Briefly, cultured cardiac cells with disease 
causing mutations in CryAB mediate cell death and dysfunction; as the complementary HSPB1 
is introduced into the cells, both the aggregate formation and associated toxicity is relieved [35]. 
As a consequence of this relationship, overexpressing HSPB1 facilitates the ubiquitination and 
proteasome degradation of protein aggregates induced by multiple CryAB misfolding mutations 
[35] illustrating that increasing HSP expression can help enhance both the solubility and 
degradation of misfolded proteins in cardiomyocytes. Similarly, treatment of the CryABR120G 
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mutant mouse model of desmin-related cardiomyopathy with the drug geranylgeranyl-acetone 
(increasing HSPB8 and HSPB1) significantly reduces heart failure [36]. CryABR120G transgenic 
mice treated with geranylgeranyl-acetone have reduced amyloid oligomer formation, decreased 
fibrosis, and recovery of heart function and overall survival [36]. 
 
A.7 Pharmacological chaperone therapies 
Establishing the role of misfolded proteins in heart failure gives context to the emerging 
development of small molecule pharmacological chaperones [37-39]. Pharmacological 
chaperones are defined as molecules which act specifically on misfolded or destabilized protein 
substrate(s) to specifically refold or stabilize these proteins, respectively [40]. Pharmacological 
stabilization of the protein transthyretin (TTR) and amyloid fibril disruptors are being developed 
for polyneuropathy. More recently, their applicability to amyloid disease in the heart has been 
demonstrated and they are now undergoing clinical trials for cardiac amyloidosis due to 
misfolded TTR. Mutations and aging cause misfolding to result in TTR amyloidosis and 
pharmacological chaperone therapy has successfully been used to treat both forms successfully. 
Initial studies investigating pharmacological chaperone therapy focused on the 
neurological manifestations of TTR amyloidosis. Extracellular deposition of TTR is a hallmark 
of the fatal autosomal dominant neurodegenerative Familial Amyloidotic Polyneuropathy (FAP) 
[41], in which both mutant (familial forms) and wild type (senile/aging forms) aggregate. More 
than 80 different mutations destabilize TTR and prevent formation of the tetramer and promote 
aggregation of misfolded monomers [42]. Misfolded TTR, also known as pre-albumin, is a 
protein synthesized by the liver that forms a soluble homotetramer that acts to transport thyroid 
hormone (T4) and retinol. Extensive screening in aggregate-prone conditions led to the discovery 
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of multiple aromatic small molecules that stabilize mutant TTR [43]. These molecules, including 
specific NSAIDs and naturally-derived flavonoid and xanthones, function by binding to 
thyroxine-binding sites in TTR to stabilize its structure [43]. This led to the development of a 
wide range of compounds from different structural families, including enzoxazoles [44,45]. 
Tafamidis, a derivative enzoxazole, was selected for clinical development based on its ability to 
stabilize mutant TTR in vitro and was later found to have a therapeutic effect in neurological 
disease models [46,47]. While occupying the thyroxine-binding sites, tafamidis’s negative 
cooperativity acts to stabilize the TTR tetramer. 
The first human study of tafamidis for the treatment of polyneuropathy associated with 
TTR mutations was reported in 2012. Patients with the V30M TTR mutation and FAP were 
treated with 20 mg daily for 18 months [46]. The primary objective was to monitor progression 
of neuropathy and evaluate drug safety, while a secondary objective was to determine if 
tafamidis exhibits a stabilizing effect on human V30M TTR. A total of 128 patients were 
randomized to tafamidis or placebo. Significant reduction in neuropathy impairment scores were 
identified as early as 6 months and continued through 18 months [46]. The changes in small 
nerve fiber function scores were attenuated by tafamidis, while allowing significant increases in 
BMI to occur (reflecting less muscle mass loss /atrophy resulting from the disease process) [46]. 
Oral tafamidis is now approved in the EU for the treatment of TTR amyloidosis in adult patients 
with early stage symptomatic polyneuropathy to delay neurologic impairment. In Argentina, 
Japan, and Mexico tafamidis is approved for use in delaying peripheral neurological impairment 
of TTR familial amyloid polyneuropathy [48]. In the US, the FDA has requested a second 
efficacy study before it will grant approval while noting that the data provided internal 
consistency and replication of effect. 
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In addition to neurodegeneration, patients with TTR-FAP develop cardiac disease. At 
least five clinical trials that investigate tafamidis in patients with TTR-related cardiomyopathy 
are active or have been completed (see Table A.1). The first one recently published was a 
randomized crossover study in healthy volunteers that determined tafamidis did not have any 
effect on QTc intervals or serious adverse events in 42 subjects [49]. Inhibition of TTR 
expression using siRNA therapy is yet another therapeutic approach being tested to treat TTR-
related cardiomyopathy (see Table A.1, rows 6-7). 
Pfizer’s tafamidis and its potential to stabilize amyloid cardiomyopathy (TTR) is just the 
tip of the iceberg in the development of pharmacological chaperones for heart disease. Multiple 
other anti-amyloidogenic compounds have been discovered, including: 1) AG10; 2) doxycycline; 
3) tauroursodeoxycholic acid (TUDCA); 4) (-)-epigallocatechin-3-gallate (EGCG); and 5) 
curcumin. High throughput screening for compounds that bind to the T4 pocket of TTR under 
physiological conditions identified AG10, which has higher affinity for TTR and greater 
pharmacokinetic stability while being more selective than tafamidis and diflunisal (a salicylic 
acid derivative) at physiological conditions [50]. In in vitro studies, AG10 was found to 
effectively inhibit the proteotoxicity of V122I-TTR in human cardiomyocytes [50]. AG10 
inhibits aggregation of both wild-type TTR (associated with aging) and V122I-TTR significantly 
better than tafamidis and almost fully stabilizes TTR at 10 μM plasma concentrations [42]. AG10 
is a bivalent molecule and thus able to bind 2 TTR proteins per molecule, allowing it to 
simultaneously occupy adjacent T4 sites in the TTR tetramer [42].
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Table A.1. Clinical studies investigating tafamidis and siRNA TTR in transthyretin-associated (amyloid) cardiomyopathy. 
TTR: Transthyretin. Created from data available at: ClinicalTrials.gov (Accessed 2 February 2015). 
1. TTR Cardiomyopathy 
ClincialTrials.gov NCT01775761 
Estimated enrollment: 42 
Estimated completion: 2013 (For 
Primary Outcome Measure) 
A Study To Determine Any Effect Of 
Tafamidis On Electrocardiographic 
Intervals, Specifically The Rate 
Corrected QT Interval (QTc) 
Endpoint: Safety 
Phase 1 
Randomized, Placebo, and Positive 
Controlled Cross-Over study  
Completed/No study results posted. 
Primary outcome measures: QTc interval 
using Fridericia's correction method 
(QTcF) of tafamidis and placebo (baseline-
adjusted) at each post-dose time.  
Secondary outcome measures: QTcF of 
moxifloxacin and placebo at historical 
moxifloxacin median Tmax of 3 hours. 
 
2. TTR Cardiomyopathy 
ClincialTrials.gov NCT01655511 
Enrollment: 9 
Estimated completion: September 
2012 (For Primary Outcome 
Measure) 
Safety And Pharmacokinetic Assessment 
Of Orally Administered Tafamidis In 
Healthy Volunteers 
Endpoint: Pharmacokinetics of Tafamidis 
>120 mg as an oral solution 
Phase 1 
Randomized, Double-Blind, Cross-over, 
ascending Dose-Tolerance 
 
 
Completed/No study results posted. 
Primary outcome measures: Safety and 
tolerability of orally administered tafamidis 
in healthy volunteers 
Secondary outcome measures: Cmax, 
Tmax, AUC 0-24, AUC last, AUC Inf, T1/2 
plasma decay, TTR blood concentration,  
TTR stabilization 
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Table A.1 Continued 
3. TTR-CM 
ClincialTrials.gov NCT00925002 
Estimated enrollment: 110 
Estimated completion: 2021 
Safety And Efficacy Evaluation Of Fx-
1006a In Patients With V122i Or Wild-
Type Transthyretin (TTR) Amyloid 
Cardiomyopathy 
Endpoint: Safety/Efficacy 
Phase 3 
Non-randomized, open-label evaluation of 
Tafamidis in patients with TTR amyloidosis 
 
 
Active, currently recruiting. 
Primary outcome measures: Long-term, 
open-label safety and efficacy in TTR 
amyloidosis patients (10 years) 
Secondary outcome measures: Provide 
investigation product until market 
availability to ATTR who have completed 
protocol 
4. Cardiomyopathy 
ClincialTrials.gov NCT00694161  
Estimated enrollment: 35 
Estimated completion: 2010 (Final 
data collection for primary outcome 
measure) 
The Effects Of Fx-1006A On 
Transthyretin Stabilization And Clinical 
Outcome Measures In Patients With 
V122I Or Wild-Type TTR Amyloid 
Cardiomyopathy 
Endpoint: Safety/Efficacy 
Phase 2 
Interventional, open label, of TTR 
Stabilization and Clinical outcomes in 
V122I or wildtype TTR amyloid 
cardiomyopathy 
Completed (Has Results, below) 
Primary outcome measures: Participants 
with TTR V122I) and wildtype TTR 
achieved TTR stabilization at Week 6 
(97.1%, N=35). 
Secondary outcome measures: Those 
achieving TTR stabilization continued 
through Month 12 (87.5% with stabilized 
TTR, N=34). 
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Table A.1 Continued 
5. Transthyretin (TTR) Amyloid 
Cardiomyopathy 
Tafamidis 
ClincialTrials.gov NCT01994889 
Estimated enrollment: 400 
Estimated completion: August 2018 
Tafamidis 
Endpoint: Safety /Efficacy 
Phase 3 
Multi-Center, International, Double-blind, 
placebo-controlled, randomized study to 
evaluate efficacy, safety, and tolerability of 
oral dosing of Tafamidis Meglumine in 
TTR-CM 
Recruiting, no study results posted. 
Primary outcome measures: All-cause 
mortality and frequency of CV-related 
hospitalization. 
Secondary outcome measures: 6 min 
walk test, Kansas City Cardiomyopathy 
Questionnaire, CV-related mortality, 
Frequency of CV-related hospitalization, 
All-cause mortality, TTR stabilization at 1 
month. 
 
 
6. TTR-mediated Amyloidosis 
ALN-TTRSC 
ClincialTrials.gov NCT01814839 
Estimated enrollment: 76 
Estimated completion: 2015 
ALN-TTRSC (RNAi) 
Endpoint: Safety 
Phase 1 
Randomized, double-blind, placebo-
controlled, single and multi-dose, dose 
escalating study 
Completed, no study results posted. 
Primary outcome measures: Adverse 
events, serious adverse events, study drug 
discontinuation 
Secondary outcome measures: 
Pharmacokinetics of ALN-TTRSC, Effect 
of ALN-TTRSC on Vitamin A, Effect of 
AL-TTRSC on retinol binding protein 
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Table A.1 Continued 
7. TTR-mediated Amyloidosis 
ALN-TTRSC 
ClincialTrials.gov NCT01981837 
Estimated enrollment: 25 
Estimated completion: January 2015 
ALN-TTRSC (RNAi) 
Endpoint: Safety /Efficacy 
Phase 2 
Open-label trial to evaluate safety, 
pharmacokinetics, pharmacodynamics, and 
Exploratory Clinical Trial of ALLN-TTRSC 
activity in TTR Cardiac Amyloidosis 
Patients 
Active, not recruiting, no study results 
posted. 
Primary outcome measures: AEs, SAEs, 
Study Drug Discontinuation. 
Secondary outcome measures: 
Pharmacokinetics of ALN-TTRSC, Effect 
of ALN-TTRSC on TTR 
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The discovery that tetracycline antibiotics have anti-amyloidogenic activity comes from 
the observation that iododoxorubicin (an anthracycline) is able to reduce amyloid and improve 
end organ damage in amyloid light-chain (AL) amyloidosis [51,52]. Doxycycline was then 
shown to act as a fibril disruptor in vitro, without toxicity [53]. In mouse models of AL 
amyloidosis, doxycycline similarly disaggregated amyloid and improved tissue markers of TTR 
deposition, without effecting pre-fibril aggregates [54]. In combination with the water-soluble 
bile acid tauroursodeoxycholic acid (TUDCA), synergistic clearance of TTR deposits was 
observed [55]. Used in treating cholestasis in liver disease, TUDCA, like doxycycline, is an FDA 
approved drug for other indications. A phase II, open-label study evaluating the efficacy, 
tolerability, safety, and pharmacokinetics of doxycycline and TUDCA in TTR-related 
cardiomyopathy is currently underway (Table A.2). 
Additionally, there are a number of naturally occurring polyphenols that have anti-
amyloidogenic properties, including the polyphenols EGCG and curcumin. EGCG, found in 
green tea, appears to bind amyloidogenic proteins and exert its protective effects by redirecting 
the aggregation process. Specifically, alternate non-pathogenic oligomeric species are instead 
formed which then deplete the formation of pathogenic types [56,57]. In a phase II clinical trial, 
EGCG was effective in preventing the progression of cardiomyopathy over 12 months. Of the 14 
patients completing the study, no significant changes in cardiac mass or wall thickness were 
found when treated with ~500-700 mg EGCG daily [58]. However, wide variation in 
bioavailability following oral EGCG intake is an issue complicating the clinical development of 
this compound [58,59], including suspected hepatic toxicity [60]. Still, at least three clinical 
trials evaluating EGCG for protein misfolding diseases are ongoing, two of which are in cardiac 
amyloidosis (Table A.3). The other polyphenol, curcumin, competes for T4 on TTR to stabilize 
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TTR’s native structure [61], inhibiting amyloid fibril formation in vitro, and disrupting pre-
formed TTR fibrils from generating small oligomers [62]. In vivo studies of transgenic TTR mice 
have demonstrated prevention of cytotoxicity and decreases in TTR deposition [63]. However, 
there are no ongoing clinical trials evaluating curcumin for this therapeutic indication. 
Successful early studies of pharmacological chaperones in pre-clinical and now clinical 
trials of amyloid-based disease have supported the concept that reversing/stabilizing protein 
misfolding is possible and can attenuate and sometimes reverse the pathophysiology, even in the 
heart. The increasing number of clinical trials (both phase 1 and 2) with cardiac indication holds 
promise that we will better understand the efficacy and safety of these drugs in patients with 
heart failure soon. While specific pharmacological chaperones appear to be specific for their 
misfolded substrate (e.g. TTR), it will be interesting to see how applicable these chaperones are 
to other substrates and whether pharmacological chaperones can be created for other substrate(s) 
found in differing causes of heart failure. With limited options for patients with heart failure, this 
class of drug offers a new way to treat an old but common problem. 
Are pharmacological chaperones the only way to think about inhibiting proteotoxicity? It 
is possible that multiple points exist to prevent the proteotoxicity from contributing to heart 
failure, understanding that the formation of pre-amyloid oligomers, aggregates, and amyloids 
itself are a continuum. Like the concept of proteotoxicity itself, some of the answers may come 
from emerging discoveries in neurodegenerative diseases caused by endogenous misfolded 
proteins (e.g. Tau protein in Alzheimer’s disease) or exogenous proteins (e.g. caused by prions). 
Next, we introduce how the concept of altered proteostasis activates large signaling complexes, 
including the inflammasome and necrosome, as well as complexes to prevent misfolded protein-
induced cell death (proteotoxicity), such as the signalosome.
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Table A.2. Clinical studies investigating doxycycline in transthyretin-associated (amyloid) cardiomyopathy. TTR: 
Transthyretin; TUDCA: Tauroursodeoxycholic acid; UDCA: Ursodeoxycholic acid. Created from data available at: 
ClinicalTrials.gov (Accessed 2 February 2015). 
8. Transthyretin Amyloidosis 
Doxycycline + TUDCA 
ClincialTrials.gov NCT01171859 
Estimated enrollment: 40 
Estimated completion: July 2015 
(Final data collection date for 
primary outcome measure) 
Doxycycline + TUDCA 
Endpoint: Safety /Efficacy 
Phase 2 
Single center, non-randomized, open-
label, prospective study followed by 6 
month withdrawal to evaluate efficacy, 
tolerability, safety, pharmacokinetics of 
TUDCA in TTR Amyloidosis 
Active, not recruiting 
Primary outcome measures: Response 
rate to TUDCA (Based in mBMI reduction 
<10%, change in Neurologic Impairment 
Score-Lower Limbs (NIS-LL) <2 and NT-
proBNP <30% (or <300 pg/ml) 
Secondary outcome measures: 
Treatment-emergent adverse events, 
Doxycycline PK, Response in autonomic 
dysfunction, Neuropathy and Visceral 
Organ Involvement, Incidence of patients 
discontinuing from study due to clinical or 
laboratory adverse events 
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Table A.2 Continued 
9. Amyloidosis; Heart 
(Manifestation); Senile Cardiac 
Amyloidosis 
Doxycycline + TUDCA 
ClincialTrials.gov NCT01855360 
Estimated enrollment: 40 
Estimated completion: Sept 2015 
(Final data collection date for 
primary outcome measure) 
Doxycycline + TUDCA 
Endpoint: Safety /Efficacy 
Phase 1/2 
Open-label study of TUDCA in TTR-
cardiomyopathy 
Recruiting 
Primary outcome measures: Rate of 
progression of TTR cardiac amyloidosis 
(Strain echocardiography) 
Secondary outcome measures: Number 
of patients with adverse events to the 
medications over the period of therapy (18 
months), Evaluate general and health 
related QoL in Senile and Familial TTR 
amyloidosis subjects. 
10. Transthyretin Amyloidosis;  
Cardiomyopathy 
Doxycycline + UDCA 
ClincialTrials.gov NCT02016365 
Estimated enrollment: 30 
Estimated completion: June 2015 
(Final data collection date for 
primary outcome measure) 
Doxycycline + UDCA 
Endpoint: Safety /Efficacy 
Phase 2 
Open-label study multi-center study of 
Safety and Efficacy of TUDCA in ATTR 
amyloidosis disease progression 
Active, not recruiting 
Primary outcome measures: efficacy on 
serum NT-proBNP (12 months). 
Secondary outcome measures: Modified 
BMI, Increase in septum thickness, 
neurologic Kumamoto Scale, Number of 
patients with adverse events, blood work 
for potential drug-related adverse events. 
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Table A.3. Clinical studies investigating ECGG in primary cardiac amyloidosis and Alzheimer’s disease. EGCG: 
Epigallocatechin-3-gallete. Created from data available at: ClinicalTrials.gov (Accessed 2 February 2015). 
11. Light Chain (AL) Amyloidosis, 
Cardiac Involvement 
ClincialTrials.gov NCT02015312 
Estimated enrollment: 38 
Estimated completion: Sept 2017 
(Final data collection date for 
primary outcome measure) 
Green Tea Compound EGCG 
Safety/Efficacy 
Phase II  
Randomized, Double-Blind Study of 
Safety/Efficacy 
Recruiting  
Primary outcome measures: 12 month 
change in LV mass. 
Secondary outcome measures: Change in 
QoL, Number of adverse events according 
to CTC criteria, change in cardiac 
biomarkers, hematological improvement, 
organ response (non-heart), overall 
survival. 
12. Alzheimer’s Disease  
ClincialTrials.gov NCT00951834 
Estimated enrollment: 50 
Estimated completion: June 2015 
(Final data collection date for 
primary outcome measure) 
Green Tea Compound Epigallocatechin-
3-gallete 
Efficacy Study 
Phase II/III  
Randomized, Double-Blind Study of 
Efficacy 
Recruiting 
Primary outcome measures: ADAS-
COG (Score 0-70) 
Secondary outcome measures: Safety 
and tolerability, MMSE Score after 18 
months vs. baseline, Time to 
hospitalization and Time to death related 
to AD, brain atrophy via MRI, Baseline 
ADAS-COG and Baseline-MMSE as 
covariates, CIBIC+ and WHO QoL Bref, 
Trail Making Test and MVGT. 
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Table A.3 Continued 
13. Primary (Cardiac) Amyloidosis 
of Light Chain Type  
ClincialTrials.gov NCT01511263 
Estimated enrollment: 86 
Estimated completion: December 
2015 (Final data collection date for 
primary outcome measure) 
Green Tea Compound Epigallocatechin-
3-gallete 
Efficacy 
Phase II  
Open-label, Randomized Study of Dietary 
EGCG 
Recruiting 
Primary outcome measures: Cardiac 
response (Rate of cardiac response 
following chemotherapy in patients with 
AL amyloidosis). Endpoint at 6 months. 
Secondary outcome measures: Rate of 
adverse events, cardiac progression, time 
to cardiac progression, rate of cardiac 
events, time to cardiac events, survival at 6 
months. 
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A.8 Amyloid proteins, heart failure, and activation of the inflammasome 
The inflammasome is a large oligomeric signaling structure that generates a robust pro-
inflammatory response through coordinated necrotic cell death and secretion of IL-1β and IL-18. 
While the composition varies based on the activating signal, the inflammasome generally is 
made up of three proteins, including a cytosolic sensory receptor, an adaptor protein ASC, and a 
Caspase 1 enzyme [64]. The best characterized inflammasome, the NLRP3 inflammasome 
(Figure A.3), is activated by a diverse array of infectious and sterile stimuli, which initiate 
signaling through perturbation of cellular homeostasis – either through mitochondrial disruption, 
ER stress, calcium influx, potassium efflux, or some combination of these mechanisms [65,66]. 
When activated, these proteins come together to form an enormous fibrillar structure that acts as 
a platform for cytokine processing [67-69]. For example, NLRP3 mutations resulting in 
activation cause familial cold-induced inflammatory syndrome 1 (FCIS1), Muckle-Wells 
syndrome (MWS) and chronic neurologic cutaneous and articular syndrome (CINCA), all of 
which are characterized by hyperactive NLRP3 inflammasome signaling and chronic 
inflammation. Disruption of IL-1 signaling, with either the IL-1-receptor antagonist, Anakinra, 
or an anti-IL-1β monoclonal antibody, Canakinumab, provides rapid and dramatic resolution of 
symptoms [70,71].  
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Figure A.3. The NLRP3 inflammasome is an amyloid-like fibrillar cytokine-processing 
platform, which senses amyloid and contributes to worsening heart failure. (A) Amyloid 
fibrils from diverse sources including amyloid-beta, islet amyloid polypeptide, serum amyloid A, 
prions and possibly others, accumulate within cells and tissues. (B) The NLRP3 inflammasome 
can activate in response to these amyloid fibrils, leading to formation of a functional amyloid 
nucleated by NLRP3 and containing long polymeric repeats of ASC, the adaptor protein, and 
pro-Caspase 1. The NLRP3 inflammasome is capable of inducing a pro-inflammatory necrotic 
cell death, termed pyroptosis. Additionally, the proximity of pro-Caspase 1 proteins to one 
another leads to their proteolytic activation and release of active Caspase 1. Active Caspase 1 
then processes pro-IL-1β and pro-IL-18, among other proteins, leading to the secretion of the 
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active form of these pro-inflammatory mediators. (C) Both IL-1β and IL-18 have been shown to 
directly cause cardiac dysfunction and may be targets for pharmacologic intervention as in the 
CANTOS trial. (D) IL-1β and IL-18 also can contribute to systemic inflammatory diseases 
characterized by massive production of acute phase reactants such as serum amyloid A. Serum 
amyloid A can then act as a seed for additional amyloid formation, which is sometimes seen in 
chronic inflammatory diseases such as Muckle-Wells syndrome (MWS) or Rheumatoid arthritis 
(RA). In many resting cells, which do not express components of the NLRP3 inflammasome, 
these components can be upregulated through Toll-like receptor-NF-κB mediated signaling. 
Upon upregulation of inflammasome components, these cells are “primed” for inflammasome 
activation. It still remains to be seen whether inflammasome activation originating in the heart or 
from phagocytes drives the pathogenesis of heart failure. Additionally, studies have yet to tease 
out the role of NLRP3 inflammasome-mediated pyroptosis in cardiac dysfunction. (E) The 
inflammatory IL-1β and IL-18 may contribute to the formation of amyloid in neighboring cells, 
through unclear mechanisms. IL-18 co-localizes with Aβ-plaques and increases the 
hyperphosphorylation of tau-protein [105]. IL-18 enhanced cleavage of serum amyloid-β 
precursor protein experimentally and may be one mechanism, of many remaining to be 
discovered.  
Some patients with activating mutations of NLRP3 develop multi-organ serum amyloid 
A protein (AA)-type amyloidosis - likely the result of persistently elevated levels of this acute 
phase protein in response to chronic inflammation [72]. AA amyloidosis can involve deposits in 
the heart that lead to ventricular hypertrophy, atrial dilatation, and cardiac dysfunction [73-76]. 
Although typically thought of as rare, a recent survey of re-examined autopsy tissues from 369 
rheumatoid arthritis patients found that 30% had evidence of AA amyloid deposits with cardiac 
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amyloid and renal amyloid appearing with equal frequency [77]. In two recent case reports of 
AA amyloidosis, treatment with anti-cytokine therapies reduced chronic inflammation and serum 
amyloid A levels resulting in stabilized or improved cardiac manifestations of the disease 
[78,79], providing further support for the hypothesis that limiting the availability of aggregation-
prone proteins can limit amyloid formation. 
While chronic inflammation can lead to amyloidosis, studies have also shown that the 
NLRP3 inflammasome can be activated in response to different types of amyloid, including 
amyloid-beta, islet amyloid polypeptide, serum amyloid A, prions, and curli fibers, a type of 
amyloid found in the biofilm of E. coli and S. enteric serovar Typhimurium [80 ,81-85]. This 
diverse collection of amyloid that trigger the NLRP3 inflammasome raise the possibility that 
NLRP3 is central in generating an inflammatory response to all amyloids. 
We are just beginning to appreciate the role of the NLRP3 inflammasome in cardiac 
disease. In mice, cardiac-specific overexpression of a constitutively active form of the 
calcineurin A catalytic subunit leads to impaired cardiac function [86] and myocardial 
inflammation characterized by activation of Caspase 1 [87]. In this model, additional deletion of 
NLRP3 or pharmacologic inhibition of IL-1β signaling using the IL-1-receptor antagonist 
significantly reduced left ventricular dilatation and abrogated the progressive decrease in 
fractional shortening (FS) observed in wildtype and saline treated mice, thus implicating the 
NLRP3 inflammasome in this cardiac dysfunction [87].  
In patients with idiopathic dilated cardiomyopathy, increased mRNA levels of NLRP3 
inflammasome components were associated with worsening left ventricular ejection fraction and 
NLRP3 and IL-1β mRNA at the time of admission were independent predictors of 6-month re-
hospitalization [88]. In support of a role for IL-1β signaling in cardiac dysfunction, human atrial 
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trabeculae tissue in an organ bath exhibited compromised systolic and diastolic function when 
exposed to TNF-α and IL-1β individually and had additive effects when combined at low doses 
[89]. Additionally, in patients with rheumatoid arthritis without concurrent cardiovascular 
disease, treatment with anakinra improved noninvasive measures of vascular and left ventricular 
function [90]. 
In 2011, a large multicenter trial called Canakinumab Anti-inflammatory Thrombosis 
Outcomes Study (CANTOS), which planned to enroll 17,200 post myocardial infarction patients, 
was initiated to determine whether IL-1β inhibition can prevent recurrent myocardial infarction, 
stroke and cardiovascular death among stable patients with coronary artery disease who remain 
at high vascular risk [91]. This trial will provide the most comprehensive clinical evaluation to 
date of the inflammatory hypothesis in cardiac disease. 
These studies highlight the emerging and pivotal role that the NLRP3 inflammasome and 
IL-1β signaling plays in the pathogenesis of heart failure. Continued interrogation of the NLRP3 
inflammasome in heart failure is likely to aid in identifying new targets for therapeutic 
intervention, which may act synergistically with pharmacologic chaperones to break the cycle of 
amyloidosis and inflammation. 
 
A.9 Amyloid proteins, heart failure, and activation of “functional amyloid”: Necrosome 
While amyloid has primarily been described as a key mediator of pathological processes, 
it now been recognized that when certain proteins form amyloid, it is part of their physiological 
role. That is, they act as a molecular switch to promote environmental adaptation and act as a 
regulator of intracellular signaling [92]. This includes the receptor-interacting protein kinases 
RIP1 and RIP3, which are found in the heart and activate cell death by forming the necrosome 
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[92]. Activation and assembly resulted from their ability to form a fibrillar complex with 
amyloid properties, which was observed during in vitro and in vivo experimental conditions [93]. 
The RIP homotypic interaction motifs (RHIMs) of RIP1 and RIP3 mediate the assembly of 
heterodimeric filamentous structures, which can trigger downstream signaling and cell death 
[93].  
In the heart, myocardial ischemia induces RIP3 expression, which is sufficient to induce 
necroapoptosis [94]. Conversely, RIP3-/- mice challenged with MI had better function and less 
hypertrophy 30 days post- infarction, accompanied by decreased inflammatory response and 
decreased ROS production [94]. Similarly, inhibiting RIP1 with the small molecule Necrostatin-
1 (Nec-1) prevents necrotic cell death in experimental models of cardiac ischemia [95]. This 
model also displayed less adverse remodeling, evidenced by less dilation, preserved systolic 
function, and reduced inflammation (TNF-α mRNA and ROS) [95]. Taken together, these 
studies illustrate both the importance of the RIP1/RIP3-mediated necrosis in ischemia, offering a 
new direction for therapy to disrupt physiologic amyloid-like proteins that contribute to 
pathology [96].  
 
A.10 The COP9 signalosome enhances protein degradation to reduce the misfolded protein 
burden 
Enhanced protein degradation clinically can be attempted through blockade of the bad 
signaling complexes (e.g. the inflammasome and necrosome), or by activation of the beneficial 
constitutive photomorphogenesis mutant 9 (COP9) signalosome (CSN). Analogous to 
ubiquitination, proteins can be neddylated via a series of enzymatic reactions to conjugate 
NEDD8 to substrate proteins, such as a Cullin-RING-Ligase (CRL) (detailed in Figure A.4), 
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triggering the assembly of a functional CRL. CRLs are the largest family of ubiquitin ligases, 
including the ubiquitin ligases Parkin, Mdm2, Smurf1, and XIAP, in addition to transcription 
factors, such as E2F1, HIF1a, and p53 [97]. 
Only recently has the role of deneddylation been explored. The CSN is a highly 
conserved multiprotein complex composed of eight subunits (CSN1 to 8) to form a ~350 kDa 
complex that deneddylates proteins [98] to regulate the protein degradation by ubiquitin 
proteasome system [99]. CRL deneddylation is essential to disassemble the functional CRL and 
release the ubiquitinated substrate protein for subsequent degradation by the proteasome. The 
CSN crystal structure has two organization centers: 1) A horseshoe-shaped ring created by its six 
PCI domain proteins and a large bundle formed by the carboxy-terminal a-helices of each 
subunit [100]. The CSN5-CSN6 dimer is found at the core of the helical bundle [100]. 
Neddylated CRL binding to CSN is sensed by CSN4, communicated to CSN5 (with CSN6), 
resulting in activation of the deneddylase and regulation of downstream ubiquitin ligases [100].  
Recent studies have demonstrated the COP9 signalosome regulates autophagosome 
maturation in vivo. Mice with a cardiomyocyte-specific deletion of csn8 resulted in striking 
increases in autophagic flux (evidenced by increased LC3-II/LC3I, autophagosomes by TEM) 
and increased p62 protein (a functional amyloid forming protein) [101,102]. CSN appears to 
regulate Rab7, which plays a critical role in autophagosomal formation and may explain its 
regulation of autophagy [102]. Furthermore, the CSN appears to influence proteasomal activity 
by directly interacting with the 26S proteasome and potentially competing with the 19S 
proteasome lid [103,104]. Therefore, it is hypothesized that the overt loss of protein quality 
control due to compromised autophagosome formation and removal paired with reduced 
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functionality of the UPS results in severe cardiomyocyte necrosis, leading to dilated 
cardiomyopathy, heart failure, and death.  
Inducible cardiac CSN8-/- mice demonstrated the role of CSN8 in regulating autophagic 
flux in vivo. The temporal cardiac Cre-LoxP ablation of CSN8 resulted in the accumulation of 
neddylated cullin (and non-cullin) proteins, increased ubiquitinated proteins, and a significant 
decrease in autophagic flux [101]. Autophagosomes were markedly increased, as were oxidized 
proteins and necrotic cardiomyocytes, resulting in a dilated cardiomyopathic phenotype [101]. 
How the COP9 signalosome is activated has not been clearly delineated. An intriguing 
possibility is that, similar to the proteasome, the COP9 signalosome can be regulated by post-
translational modifications. Currently there are no known proteins that post-translationally 
regulate the CSN, however if found, this approach may have great therapeutic potential with 
small pharmacological modulators. 
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Figure A.4. Cullin-RING ubiquitin ligase (CRL) activity is regulated via neddylation and 
deneddylation. Cullin serves as a scaffold protein when neddylated (conjugated with NEDD8), a 
reaction catalyzed by NEDD8 activating enzyme (NAE), ubiquitin conjugating enzyme (Ubc12) 
and a NEDD8-specific ligase (NEDD E3). Cullin neddylation triggers displacement of the 
inhibitory CAND1 (cullin-associated NEDD8-dissociated protein 1), allowing cullin to interact 
with the adapter protein, Skp1, and a F-box protein forming a functional CRL. Next a ubiquitin 
charged E2 and a substrate are brought in close proximity to foster the transfer of ubiquitin to the 
substrate. After substrate ubiquitination, the COP9 Signalosome (CSN) will deneddylate (remove 
NEDD8) from cullin, which triggers the disassembly of the CRL and frees the substrate to be 
degraded by the proteasome. The freed cullin can be neddylated again to initiate another cycle or 
inhibited via CAND1 binding.  
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A.11 Summary and Conclusion 
The formation of amyloids has been observed as a pathological change implicated in 
neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, and 
polyglutamine proteins (Huntington’s disease). Paralleling these pathological findings and 
mechanisms, heart failure has similarly been found to involve these same biological processes 
[31]. This has led to the multiple clinical studies underway testing pharmacological interventions 
to stabilize the common TTR misfolding in cardiac amyloidosis (Tables A.1-3). However, the 
activation of amyloid formation is not only a pathological state; recent evidence suggests critical 
functional processes have similar aggregated states (Table A.4) [92]. Evidence that both the 
necrosome and inflammasome can be inhibited demonstrate the utility of targeting their 
activation when aggregates have already formed, complementing the pharmacological 
chaperones that largely prevent misfolded proteins from forming and possibly 
reversing/removing protein aggregation. Complementary to these three pathways, activation of 
the COP9 signalosome by a yet to be determined pathway, may prove to be another way in 
which misfolded cardiac proteins can be cleared to reduce future aggregate burdens. The 
multiple levels in which heart failure may be targeted illustrates many new opportunities for 
treating the heavy burden of heart failure where limited therapies exist, none of which currently 
target the underlying protein quality control issues outlined in this review (Figure A.5). 
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Figure A.5. Targeting pathological and functional aggregates in heart failure. Alterations 
drive protein unfolding and misfolding, resulting in the formation of misfolded, toxic protein 
aggregates and amyloid. Such misfolded protein structures activate pathological pro-
inflammatory and necrotic signaling complexes such as the inflammasome and necrosome. 
However, protein aggregates can also activate the signalosome to assist in clearing of 
mis/unfolded proteins. The continuum of protein misfolding, to protein aggregation and amyloid 
formation, to activation of large signaling complexes provides multiple levels for potential 
pharmacological therapeutic targeting. (A) Pharmacological chaperones target misfolded and 
unfolded proteins to stabilize protein conformation. Such drugs include tafamidis, doxycycline 
and tauroursodeoxycholic acid. (B) Targeting and inhibiting large signaling structures like the 
inflammasome and necrosome offer new and possibly complementary methods of treating 
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amyloid based diseases. To date, these targets have been inhibited through treatment with an IL-
1 antagonist (inflammasome) and Necrostatin-1 (necrosome). (C) Alternately, the COP9 
signalosome may offer yet another therapeutic target to reduce the amyloidosis burden. 
Increasing activity of the signalosome could function alone or in tandem with other therapies to 
assist in clearance of misfolded protein aggregates and amyloid.  
  
3
0
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Table A.4. Proteins forming amyloid as part of their functional role in cellular responses to the environment. ©2013 Elsevier 
Publishing. Used with permission. From: Furukawa and Nukina, 2013 [92].  
 
                                                          
5 ThT, Thioflavin T; CR, Congo red; EM, Electron microscopy; X-ray, X-ray diffraction.  
Proteins 
 
Species 
 
Roles 
 
Detection methods for aggregates5 
 
Soluble state 
 
Aggregated state 
 
Sup35 Yeast Translation terminator Functional ThT, CR, EM, X-ray, etc. 
Mod5 Yeast tRNA isopentenyltransferase Functional ThT, EM 
CPEB Marine snail Transcriptional 
activator/repressor 
Functional ThT, EM 
Fruit fly 
Pmel17 Human Melanin synthesis Functional ThT, CR, EM, X-ray 
RIP1, RIP3 Human Kinases Functional ThT, CR, EM, X-ray 
p62 Human Sequestosome formation Functional ThT, EM 
GW182 Human P-body formation Functional EM 
RCK/p54 Human P-body formation Functional EM 
TIA-1 Human Stress granule formation Functional ThT, CR, EM 
TDP-43 Human DNA/RNA binding protein Pathological/functional? ThT, CR, EM 
FUS/TLS Human DNA/RNA binding protein Pathological/functional? EM 
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